There's been some chatter about the UK gov't ordering between 2+ years worth of Midazolam last year (March 2020). There is solid evidence both in print and video that Hancock actually did that.. We also have his quote "You stayed at home, to protect the NHS..."

Page 40 on your programs
https://committees.parliament.uk/oralevidence/288/default/

Ok. So you have to be asking yourself, "what's the big deal O?" I'll let you decide. and it's pretty easy to put 2 & 2 together and by the time you finish reading? IT'S A HUGE DEAL.

First off, guess who manufactures Midazolam? Pfizer.!!!!!

Midazolam is a commonly used drug in palliative care and is considered one of the four essential drugs needed for the promotion of quality care in dying patients in the United Kingdom. Think of it as diazepam on steroids.

Midazolam is also a drug that has been used in executions by lethal injection in the USA, combined with two other drugs.

Midazolam acts as a sedative to make the prisoner unconscious. The other drugs then stop the lungs and heart working. However it has been the source of controversy as several prisoners took a long while to die and appeared to be in pain when midazolam was used.

Midazolam can also cause serious or life-threatening breathing problems such as shallow, slowed, or temporarily stopped breathing that may lead to permanent brain injury or death.

According to the US National Library of Medicine, "Midazolam injection may cause serious or life-threatening breathing problems such as shallow, slowed, or temporarily stopped breathing that may lead to permanent brain injury or death. You should only receive this medication in a hospital or doctor’s office that has the equipment that is needed to monitor your heart and lungs and to provide life-saving medical treatment quickly if your breathing slows or stops. Your doctor or nurse will watch you closely after you receive this medication to make sure that you are breathing properly."

Time for some stats.
NHS data shows us that during the height of the “first wave” between April and June 2020 there were 58,005 beds occupied which equated to 62 percent occupancy. This is 30 percent down on the same time frame in the previous year.

-2017, April-June there were on average a total of 91,724 beds occupied which equated to 89.1 percent occupancy.
-2018, April-June there were on average a total of 91,056 beds occupied which equated to 89.8 percent occupancy.
-2019, April-June there were on average a total of 91,730 beds occupied which equated to 90.3 percent occupancy.
-2020, April-June there were on average a total of 58,005 beds occupied which equated to 62 percent occupancy.

It also shows us that Attendances & Emergency Admissions (A&E) attendance during the height of the first wave was 57% down on the previous year.

2018 – April – 1,984,369 attended A&E
2019 – April – 2,112,165 attended A&E
2020 – April – 916,581 attended A&E

Which begs the question of what exactly were we protecting the NHS from? It seems to me that they were actually underwhelmed contrary to our "trusty" media reports.

However, there were 41,627 more deaths than previous 5 year average up to the 1st May 2020, and the vast majority of these occurred in April. An April which saw A&E attendance down 57% compared to the previous year and bed occupancy down 30% compared to the previous year. 33,408 of these excess deaths mentioned Covid-19 on the death certificate, the vast majority of which occurred in those over the age of 85.

Data taken from the Office for National Statistics (ONS) shows us that during April 2020 there were 26,541 deaths that occurred in care homes, an increase of 17,850 on the five-year average. This is half the amount of alleged Covid-19 deaths during the same period.

Why did so many people die in care homes when hospitals were far from overwhelmed? Surely if they have developed serious complications due to Covid-19 they would require urgent medical attention and hospital treatment?

Don’t forget we’re told that serious illness in Covid-19 presents pneumonia and accompanying respiratory insufficiency. Therefore typical symptoms include breathlessness, cough, weakness and fever. We’re also told that people who suffer deteriorating respiratory failure and who do not receive intensive care, develop acute respiratory distress syndrome with severe breathlessness.

Why were these people in care homes and not in hospital?
Hancock gave the order to put them there (2 years worth, no less).. :(
This particular order happened March 19th, 2020 (oddly the same day that Neil Ferguson @ Imp College of London revised his March 16th "covid doom forecast" from 510,000 UK deaths to 25,000 by the end of May 2020. Oh and the same day Public Health England announced that COVID-19 was no longer considered a High Consequence Infectious Disease (HCID) in the UK that the media opted to ignore).. Huh?

The reason he did this "order"? Free up hospital beds - approx 15,000. In fact, between April-June 2020 bed occupancy was down 30% compared to the previous year.

His little order (directive) also meant that people who required medical treatment & attention were put into Care Homes in the thousands.

When Hancock ordered twice the amount in 2020 as he did in 2019, one needs to ask why? And I'm asking why?
https://pharmaceutical-journal.com/article/news/supplies-of-sedative-used-for-covid-19-patients-diverted-from-france-to-avoid-potential-shortages

According to official data in April 2019 up to 21,977 prescriptions for Midazolam were issued, containing 171,952 items, the vast majority being Midazolam Hydrochloride. However in April 2020 45,033 prescriptions for Midazolam were issued, containing 333,229 items, the vast majority being Midazolam Hydrochloride. That is a 104.91% increase in the number of prescriptions issued for Midazolam and a 93.85% increase in the number of items they contained. But these weren’t issued in hospitals, they were issued by GP practices which can only mean one thing, they were issued for end of life care. HOLY SHIT!!!!!

In the below graph, you can see a huge surge in Midazolam prescriptions out of hospital & a huge surge in alleged Covid19 deaths. This is not speculation, this is fact! Moreover, we can now put causation and correlation in the same sentence.

There has also been mention that they were mixing it with morphine.. So what happens if you mix it with morphine? Once again, strap in for this one.

Here's a little study I found from 2015.
"Effects of morphine and midazolam on pharyngeal function, airway protection, and coordination of breathing and swallowing in healthy adults
Conclusion: Morphine and Midazolam in dosages that produce sedation are associated with increased incidence of pharyngeal dysfunction and dis-coordinated breathing and swallowing, a combination impairing airway protection and potentially increasing the risk for pulmonary aspirations."

Back to Midazolam....

For those of you who think this was just a UK issue? Think again. Canada was also in on the game Yup.. But you won't guess who the supplier was? None other than the 1st patent holder of the S1 Spike Protein (1990) Pfizer, which was supplied from both the US and Turkey.. Their first series of orders April 17 (Quebec and Ontario) and their spikes took a huge leap from April 20th onwards then a resupply after Sept 3 where deaths doubled after each week of reporting.

Here's the Health Canada Orders
https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/covid19-interim-order-drugs-medical-devices-special-foods/information-provisions-related-drugs-biocides/list.html

Here's the death relative "Death Graphs" for Canada courtesy of the WHO :(
https://covid19.who.int/region/amro/country/ca

What about the US? As of April 2nd, 2020, they had a shortage which was oddly used for putting C19 patients on VENTILATORS? Remember NYC? Remember that we only heard about the need for Vents? Yeah I remember. At that same time there was also an 51% increase for sedatives, including MIDAZOLAM!!!
https://www.raps.org/news-and-articles/news-articles/2020/4/fda-reports-shortage-of-sedation-drug-used-for-put

So with all of this and the fact that no government on planet earth can provide proof of SARS-CoV-2 isolation or purification and the fact that there is plenty of proof regarding governments ordering what can be consider "end of life" drugs, we have a much bigger issue, or perhaps the real proof that the gov'ts MURDERED people.

For anyone not entirely freaked out by this startling revelation, I'm trying to find the global midazolam sales for 2020, if you can find it, without having to purchase the report? Please add it below.

FYI, they also have a nasal spray.. :(

Arche Echo KT (sent by scyrkot@ualberta.ca)

Sep 18, 2024, 4:53 PM (9 days ago)

Hi Owen, 

Thanks so much for your interest in this study! We appreciate your patience. Our team would be happy to have you participate in a focus group discussion around the guidelines for long COVID, and how best to communicate them to the public. The focus group will be on Zoom and will last between 60-90 minutes. 

Please use the link below to learn more about the study and complete the questionnaire by September 20, 2024. 

https://redcap.ualberta.ca/surveys/?s=t7tuFCpka6g6aGZn

Please do not share this link with others. Note that by clicking the link, reviewing the Study Information Letter and completing the demographic questionnaire, this means that you consent to participate in an online focus group. 

Thanks again for your consideration! Feel free to reach out if you have any questions.

Best wishes,

Samantha C

Health Research Project Lead, ARCHE

Ok. Game on.

I was hoping that this would be a mix of people who were open minded but it turned out to be endless testimonials by people who were adamant of continued “breathing barrier wearing for all”, “social distancing”, promoting more jabs, even though all of them getting continuously sick from thee multiple jabs, although they blamed it on “long-convid”. NO, It’s that your immune systems are screwed from multiple bioweapon injections. Duh.

I’m glad my mic was on mute as I was screaming at my computer at how ludicdrous this was. Like, come on.

You recover, but continue to follow the un-scientifc non-medical countermeasures.. actually, obsessed is a more aprapos term. It was torture listening to them harp on and bash those of us who couldn’t/wouldn’t comply and it was “all our fault” that Novid-19 was still present.

Some were in full panic mode, in particular a young teacher who was married to her breathing barrier and a shrink who wouldn’t allow her patients in unless they wore N-95’s. One person, got sick “with covid” late 2019. Um. How did you know when it wasn’t isolated or purified and there were no tests, nor was even named.. Another was in full paranoia mode which is sad that it has come to this. One was jab injured and questioned it a little but was eventually told otherwise. But as a whole? They all fell for it, hook, line and sinker.

Then it was my turn to speak as I had enough.

I was able to explain my experiences objectively as I started with how my immune system was compromised shortly after birth when my mom’s GP thought it wise to give me an allergy test after my mom and that I was injured from the 2D’s and 2P’s.. , not naming names or freaking out on them but I’ll be honest, it was tough biting my tongue. I got about 20 minutes in and got the hook.

Ok, I do have much to say and only a short time to say it and there was 1 more person to speak. I hoped that she wasn’t like the rest..

So much for that hope.. Flushed down the toilet. :(

Near the end, I intervened on a couple of misconceptions they fell for with context and offered to share my source materials which were in the public record. Then a screaming match directed at me ensued.. The mod “Muted” my mic and the meeting ended shortly after that..

But hey, I get a $25 electronics gift card for putting up this this BS.

So I decided to write the Mod an email..

See below. :)

Samantha Cyrkot <scyrkot@ualberta.ca>
date:Sep 27, 2024, 9:59 PM

subject:Re: Invitation Focus Group #2 - Prevention of Post COVID-19 Condition @ Fri Sep 27, 2024 5pm - 6:30pm (PDT)

Hi Samantha,

I'm not sure if you were the mod for this or not. If you weren't? Please forward this email to her as I honestly can't remember her name.

In any case, I knew I would be walking into a minefield within minutes of this zoom meeting and how it ended was completely uncalled for, but typical as I've had countless debates, discussions, etc with people in this group over the past few years and I always welcome MATURE ADULT DISCUSSION/DEBATE. This is how we learn. At least, this is how it used to be.

To be labelled as "hijacking it"was way out of line. No one in this little group knows me or what I've endured over the past, or  over the last 4+ years. Yet, it was ok, to have a couple of people jump all over me without a chance to defend myself because I was sharing facts and stats which are IN THE PUBLIC RECORD? 

The amount of "group-think" was astounding to say the least. The virtue signalling was nothing new and I've witnessed it frequently. But the anger? LOL.. Well, the truth doesn't need defending and if I've learned anything over my time on this planet, it is to make sure your brain is in gear, before your mouth is in action. The irony in all of this? I have still yet to make a retraction for any of my findings or studies I have shared with others. Odd how that happens.

Yes, we all have stories to share and I have a plethora of stories & studies to share countering the feeble attempts by the gov't to silence the Scientists, Doctors, Nurses, Professors, etc. Their stories are horrific and they are real and they happened. I personally dealt with many Health Care Professionals who were in need of Whistleblower Protection. I also dealt with those who had Whistleblower Protection. I lost count at how many times they tried to hold back their tears because they didn't want to violate their hippocratic oath and I applaud anyone who has the courage to make a stand.

Remember, there are still 0 "clinically relevant" or "statistically significant" findings for ANY of the medical or non-medical countermeasures (breathing barriers, social distancing & lockdowns).

In fact, the shrink you had on this group could have her license pulled for violating her patient's informed consent rights by demanding her "patients wear a N-95". Where is the conclusive evidence to support such a ridiculous request? IF you are too afraid to be around people who are paid to help, you should find another job. Period.

Remember, where this is a potential for harm, and to date, I've found over 80 different issues from covering your face without the proper PPE (Full face respirator for BSL's), the person must get proper INFORMED CONSENT. If you have cancer, or heart disease/heart-related issues, diabetes, auto-immune disorders, renal issues or respiratory issues? You should never cover your face as it will exacerbate those issues. Aside from hypoxia and hypercapnia, I've found at least 80+ issues in which those people should not be covering their faces. A simple spirometry test would prove this.  FIT testing is also important and if a surgeon touches his/her mask during a procedure? The OR nurse removes it and puts another one on him/her. We call this "donning" and "doffing".

One thing I forgot to mention is that I helped my OSHA best buddy create his company pre-2020 and into 2020.

When I was a part of the Global Nurses group, I was tasked with vetting every study before I uploaded it to the site. I have since transferred it to my substack with some updates post Jan 2022. https://owenowenowen.substack.com/p/the-evidence-regarding-potential

FYI, Doctors and Nurses ARE NOT EXPERTS IN PPE. Industrial Hygienists are. The IH's are the ones who do the testing (FIT & Spirometry) on the Health Care Sector, Resource Sector & the Construction Sector (hello N-95 masks which are actually for DUST and last time I checked, a viral particle is a fraction of the size of a dust particle).

Also odd is the note/disclaimer on the boxes "Does not prevent Covid-19"..

When it comes to "asymptomatic transmission"? If people actually reviewed the literature on this, they would notice that it "appeared suddenly" in 2020.. It wasn't a thing for the Spanish Flu, or the plague, or the Hong Kong Flu, or Polio, etc.. Go look in the medical dictionaries over the last few hundred years and you will see what I mean.. The term, itself, was created in the late 1700's by some French Scientist. The WHO knew in the beginning that it didn't work but suddenly said that it did. Huh? Based on what evidence? Still waiting for it. :(

Social distancing? Oh my. I guess many forgot to review the study in which many countries and their media outlets glommed on to which was actually done in 2006, by a 15 year old, Laura Glass as a high school science project using.. wait for it....

 a computer model. However, due to the fact that she was a minor, she wasn't allowed to be the senior author, so her dad, Robert Glass assumed the role.. Now one would hope, or even assume that he would have a background in Science, like Epidemiology but no, he was a "SYSTEMS ANALYST" for a software company. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3372334/

 It was eviscerated by many in the scientific community. I have the link somewhere buried in the 40,000+ links I have but it's pretty damning to say the least and the study should've been retracted asap when it came to what transpired in 2020.

Aside from the little bit on the history of "coronavirus". People should take note as to what happened in 1990 onwards. FYI, the Swine Flu jab was pulled in 1976 because of Guillain Barre Syndrome and under 25 deaths.. Actually, that was when the media still asked the tough questions, unlike the last 4+ years.
In fact, the US CDC has pulled "vaccines", 10 times since the 1955 Cutter Incident for under 50 deaths. https://www.cdc.gov/vaccine-safety/historical-concerns/index.html

So why did they ignore the plethora of safety signals with the C-19 gene therapy products? This is an honest question.

Now back to what's happened since 1990...

1990 - Pfizer patents the spike protein (WO1993023422A1) which targets the heart muscle/tissues in puppies and little baby pigs https://patents.google.com/patent/WO1993023421A1/en

1990's - Lipid Nanoparticle patented by Peter Cullis & Michael Hope.. Both Prof's at UBC whom later created a couple of spin off companies, Acquitas Therapeutics  https://acuitastx.com/ and Arbutus Biopharma https://www.arbutusbio.com/

1999- Fauci tosses a ton of $$$ to Dr. Raplh Baric (UNC-Chapel Hill and the Godfather of Coronaviruses) to weaponize the spike testing it on bunnies.

2000 - Dr. Baric and UNC Chapel Hill sought to patent critical sections of the coronavirus family for their commercial benefit

2002 (April) - The spring before the 1st bioweapon (yes, it's a bioweapon as per the 1975 UN Bioweapons Convention) called SARS-1. Baric et al filed an application -  U.S. Patent 7,279,372 https://patents.google.com/patent/US7279327B2/en  for "a method of producing recombinant coronavirus ". This was in the very 1st sentence of the Patent. In layman's terms they sought to patent a means of producing, “an infectious, replication defective, coronavirus. For those not in the know, "replication defective" means that critical portions of the viral genome have been removed such that a viral vector cannot REPLICATE!!!

2003 - SARS-1 appears out of nowhere as there was nothing in the scientific literature to support its existence between 1999-2002.

2003 - HCQ was found to be very effective to combat this new bioweapon. Countries stockpiled it and did so until "The Great Social Experiment of 2020".. 

2007/08- Conronavirus eradicated as per the WHO.

2014 - Dr. Ralph Baric is up to his old tricks and starts messing with the spike protein again ie Gain of Function.

2015 (March 25/26) Peter Daszak makes this statement at the National Academy of Sciences "until an infectious disease crisis is very real, present, and at an emergency threshold, it is often largely ignored. To sustain the funding base beyond the crisis, he said, we need to increase public understanding of the need for MCMs such as a pan-influenza or pan-coronavirus vaccine. A key driver is the media, and the economics follow the hype. We need to use that hype to our advantage to get to the real issues. Investors will respond if they see profit at the end of process,"

2015 (Nov 19 to be more precise)- Baric publishes a paper "A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence"... https://www.nature.com/articles/nm.3985  Baric's chimeric virus creation in tandem with Wuhan Institute of Virology, while Moderna and NIAID join forces to tackle coronaviruses which were previously eradicated.. Hmm.

2016 - US Patent # US20180000953A1 (Lipid nanoparticle compositions ) filed by modeRNA

2018 - One of the worst influenza seasons in decades. Bioweapon released into flu shots. Panic created by the "Powers-which-shouldn't-be" but the world didn't fall for it. This is important to note for those who allegedly had "Covid-19" in 2019..

2018 (March) US Patent US20180000953A1 from early 2016 assigned to, you guessed it, modeRNA

2018 - Wuhan declared the 1st HUB for 5g . Beat out Italy, Spain, Iran and the US.While I won't get into the many issues with 5G, it is important to note that all biological entities are now exposed to 3,000 different frequencies for the 1st time ever!

2019 (early) - Convid allegedly found in sewage

2019 (March 18) - modeRNA  "vaccine" development BEGINS!!!!!!

2019 (August 7) - Dr. Kary Mullis (inventor of the RT-PCR) suddenly dies of pneumonia.Kary Mullis also said this about his Nobel Prize winning invention.

2019 (Oct 18) - Event 201 aka. a precursor for things to come after the failed pathogen release in 2018. https://archive.org/details/og-event201

2019 (Oct 18-27) - World Military Games Wuhan in which 9,308 athletes for 109 countries attended.

2019 (August 2nd) - Ft. Detrick shut down for a few weeks due to the fact that they had a lab leak every 3 days for 7 years.. I have the actual link to the repeated lab leaks but you can look into the Meningitis Outbreak, Anthrax outbreak and others. But here's the report. https://www.fredericknewspost.com/news/health/fort-detrick-lab-shut-down-after-failed-safety-inspection-all-research-halted-indefinitely/article_767f3459-59c2-510f-9067-bb215db4396d.html

2019 (December) - 1st alleged case of SARS-2. NO AUTOPSY PERFORMED. NO WAY TO DETERMINE IF PATIENT 1 ACTUALLY HAD A "THING" OR NOT.

2020 (Jan 30) The WHO gives this pathogen a name - the 2019 Novel Coronavirus https://iris.who.int/handle/10665/330775

NOVEL? Nope, they planned this pathogenic release for a few years, contrary to what they want you to believe. :(

2020 (Jan) - Study comes out which had 13 alleged Convid "Positive" patients who had "close contacts" with 763 people.. OUTCOME? Not 1 of the 763 people got sick or died. INFECTION REPLICATION DEFECTIVE JUST LIKE BARIC CREATED IN 2015.

2020 (Feb 11) - SARS COV-2 is named in record time (MERS took 3 years to name btw) by the WHO https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it

2020 (Mar) Ft Detrick is allowed to re-open  https://www.fredericknewspost.com/news/politics_and_government/military/fort-detrick-laboratory-restored-to-full-operations-after-being-shut-down-by-cdc/article_fcee204f-1493-52fb-ba9b-f80cb00da727.html

2020 (Mar) - The Great Social Experiment of 2020 commences and humanity is overwhelmed from the fear porn from our gov'ts and the paid media shills. .. Well, most of humanity.

2020 (April) HCQ given EUA approval for treatment of this alleged "thing".

2020 (June) Convid-19 vaccines given EUA to "start" clinical trials.. shortly thereafter, EUA revoked for HCQ as you can't have an EUA for a "vaccine" if other therapies are available.. Coincidence?

2020 (June to late Nov) - 3 phases of clinical trials occurred which is a scientific and ethical no-no as Phase 1 takes 1-2 years/has between 20-80 healthy volunteers, Phase 2 takes 1-2 years/has a couple hundred volunteers which are your target group, and Phase 3 takes 2-3 years which involved a few thousand volunteers. But they merged it under the "Warp Speed" Banner, not testing it for transmission, infection, reduction in hospitalization, ICU admission or DEATH because they were working at the "Speed of $cience"..

2020 (Oct 22) - VRBPAC has a meeting and admits that they are looking at 16 Severe/Serious Adverse Events including DEATH, following the jab group in the clinical trials. Page 17 on your programs  https://www.fda.gov/media/143557/download

2020 (Late fall before the rollout) Pseudourdine added to the ingredient to allegedly stabilize the mRNA. Based on what clinical trial evidence?  Note Pseudouridine is a known CARCINOGEN.

2020 (Dec 14) the experimental gene therapy bioweapon is launched with only 28 days of SAFETY which is in direct contradiction to a majority of every country's rules when it comes to "vaccine development & approval (at least 10 years).

2021 (Jan) Placebo group unblinded for the 3rd time with the excuse that "it was the ethical thing to do". Huh? NO. YOU DON'T UNBLIND A PLACEBO GROUP BASED ON ETHICS AS YOU NEED TO MEASURE THE JABS EFFICACY AGAINST A PLACEBO TO SEE IF IT

1. induces and immune response

2. blocks transmission

3. prevents infection..

2021 (Dec) Cases and deaths skyrocketed vs the alleged Covid Cases and Covid deaths pre jab rollout within the same time frame (1 year).. https://owenowenowen.substack.com/p/the-numbers-from-canada-and-the-rest

2021, 2022, 2023, 2024 - All-cause mortality spikes globally. Check out Ed Dowd' and his groups work on this https://phinancetechnologies.com/HumanityProjects/Projects.htm#Nav_title

What you should be focusing on is not "long covid" but how to rid the body of the mRNA, spike and the other toxic ingredients. I took a look at the MSDS for the ingredients for both the "booster" (still no human trial data) and the ancestral strain. Here's the results. https://owenowenowen.substack.com/p/whats-in-the-new-and-improved-moderna

There are a few treatment options out there and some are having success.  https://covid19criticalcare.com/protocol/i-recover-post-vaccine-treatment/   Remember, as I stated at the end of this fiasco, I do care for humanity. Always have and always will, contrary to what this little group thinks. I have been invited and have appeared in countless zoom meetings, public appearances.

You should also be looking at why igG4 levels have skyrocketed since C-19. Little tip, you want elevated igG3 levels and they are lower by a magnitude of 1, 2 or 3x's.

- Or renal issues. 

- Or antibody enhancement (ADE). 

- Or why cancer rates are imploding. In fact, I've since lost 2 very close friends who were Stage 1 pre=jab and both jump to stage 4 in 8 and 13 days respectively. This is not possible unless you are exposed to something which will hyper-accelerate your cancer. Sadly, the mRNA products do just that. Or maybe you live in a uranium mine.. Or live on top of a cell tower or inside an exposed nuclear power facility.

- Or why healthy children, well, healthy children pre-C19 inoculation are getting myocarditis or pericarditis after they are injected? This also applies to athletes and they are still dropping like flies. In March or May of 2021, I created a FB group called "Covid-19 Vaccine Side Effects, What's Really Going On" in hopes to create an outlet for people to share their stories. I had just under 6,000 members within a couple of days and it grew until it was pulled by the Facebook Stasi.

- Or why women who have been experiencing menopause are now having frequent periods?

I'm still waiting for the safety date for the following:

1. biodiversity

2. genotoxicity

3. carcinogenicity

4. pregnancy, reproductive, menstrual - back in late 2020, Pfizer signed an LOI to perform tests on pregnant and new moms. This never happened before they started injecting innocent moms and moms to be. I know a couple of unjabbed actors who are on set and whenever they are around jabbed actors they are getting their periods 2x-3x's/month

5. multiple comorbidities - excluded from the trials

6. children (all ages) - the worst being the 6months - 4/5yr olds where 2/3's of the participants never got past the 1st or 2nd shot. Remember, there are 20,000,000 children in this age category and they bum rushed the EUA based on sketchy data from 7 kids.

7. lipid nanoparticle distribution (LNP)

8. pharmacokinetic (PK)

9. pharmacodynamic

10. mix and match studies.

11. Shedding/transmission

12. Prior alleged "Covid19" infection.

13. Human studies for the "Booster"

They are not present in the Clinical Trial Results. Why not? What were they hiding?

This website has some of the most comprehensive studies on 95 different therapies used to treat whatever this "novel" this is supposed to be. Many have "statistically significant" outcomes. I suggest you and anyone else still in denial read it

https://c19early.org/

Or perhaps, they should take a look at the studies on the AESI's post jab. I've compiled as much as I could up to Jan 2022 but had to take a break when I had to go back to work as I did all of this research for free. I have added 50-100 more since then but I have a few more thousand to add and I just don't have the time due to other commitments and priorities.
https://owenowenowen.substack.com/p/the-motherload-of-rare-adverse-events

I should also preface my logic for calling the C19 "vaccines" as experimental gene therapy products (bioweapons).. One need look no further than moderna's 2020 10-Q SEC filings and biontech's 2020 FORM 20-F filings. They refer to their products as "gene therapy" and last time I checked, "gene therapy" is a violation of the 1975 UN Bioweapons Convention. I did a substack piece on this and you can find the source links to the above in my source lines (23a and 23b respectively)
https://owenowenowen.substack.com/p/moderna-and-what-did-they-know

Last year, I was invited to share my research in a "Disciplinary Hearing for Dr Daniel Nagase and the BC Colleges of Nurses and Physicians".. This was a huge honour to partake in as it's not every day an ER doctor follows a non-pHD-educated researcher.. Well, the average phD is 60-120 credit hours and to date? I'm over 18,000 with at least 6,000 hours dedicated to the "gene therapy products". Here's the email that was admitted to the College and after they received my evidence submission, mass panic ensued with them. They attempted to adjourn the hearing, not once, but twice.. Why? It's not like this evidence just appeared.. It was IN THE PUBLIC RECORD!
https://owenowenowen.substack.com/p/in-defence-of-dr-daniel-nagase

To date, they still haven't tried to reconvene the hearing and the AHS has since reinstated his license with one caveat - "no written jab exemptions". We had a good laugh and that is in the process of being removed while the BC college is still crapping their pants at what has been presented to them and I am very proud to be a part of this awakening to the College.

In any event, there is soooooo much more to share and add but I would recommend that you allow people who have different "opinions".. ok, I use facts and evidence but you get the idea, to be able to get involved and have the "triggered mafia" take a chill pill as they look like under-educated fools. Do they have their stories? As I mentioned above, they do. But the "how" needs to be questioned and this really hasn't been addressed.

Remember, I have hundreds of thousands.. Actually, over a million emails I and my group had to review from 48 countries and they are all similar. Pre-rollout? The issues were the treatment options - Remdesivir and Ventilators. In some cases, Midazolam  - I have a copy of the 3 purchase orders that Health Canada made which coincide with the alleged "C-19 deaths").. I also have the purchase orders from the UK NHS where they ordered a 2-3 yr supply which was then released to the care homes. So much for saving "granny".. You also have to factor in the cost of looking after seniors and it's not cheap. But they are our family members and deserve the correct care and RESPECT. They received neither and I also have many Care Home Nurses/Aides who can attest to this.

What I find the most troubling is how the Medical and Scientific Community got captured in 2020 onwards. We had world renowned scientists, some of the most published Dr's in their respective fields, former pharmaceutical executives, nurses, doctors, Professors in relevant fields get smeared/fired/de-licensed/etc.  for speaking out.

THIS IS NOT HOW SCIENCE WORKS UNLESS IT HAS BEEN CAPTURED! MOREOVER, ANY PERSON/GROUP SUPPORTING THIS MADNESS NEEDS A REALITY CHECK AS THE AMOUNT OF DAMAGE DONE TO THE PLANET IS IRREVERSIBLE!!!!

I am grateful to have been a part of this focus group but the confirmation bias was ridiculous. This must stop and yes, as we age, we don't like to be exposed to evidence which counters what we've been led to believe. Science doesn't care about ones belief and it's an ongoing process.. Well, when it hasn't been captured.

I doubt that you will review the links I have sent and I doubt that I will ever be invited to participate in one of these focus group as I'm willing to bet a dollar (note, I have yet to lose a dollar bet) that the amount of "complaint emails" from the triggered will create some new policy to ensure that the bias is alive and well.. But at what cost? Remember, the clinical trials are still ongoing and are set to end in 2027. I guess, those who didn't roll up their sleeves are the "placebo group".

Lastly, with regards to "Long Covid", everyone in the focus group, aside from me, had multiple C19 inoculations which means they actually have "Vaccine-induced Long Covid" as they were repeatedly getting "SICK". But it's not a vaccine, it should read "Reactions to Injected Gene Therapy Products" or something to that effect.  There's a reason why they never tested for "transmission" in the Clinical Trials. Well, they also didn't test for infection prevention, ICU admission, increased/decreased hospitalization, Covid-19 infection after injection and reduced deaths.

There is so much more to add and I've been a part of many zoom meetings, focus groups, etc. All of them were constructive. This one? LOL. Not even close and that's pretty sad when I see the fear within their testimonials. No wonder they are constantly getting sick from the incessant "mask" wearing, isolation (we need to be around other humans as we emit frequencies which are actually helpful to our well being), hand sanitizing (they missed the recalls for many of these products by Health Canada as a majority contained methane or ethanol or both).. 

If anyone in this group would like to reach out to me? You have my consent but you may want to share this email with them 1st as it provides more context and the source links are still in the PUBLIC RECORD.

With confidence,

Owen

PS. as someone who was "vaccine-injured" as a child and has suffered the consequences, I'm not "anti-vaxx", I'm "anti-unsafe medical procedures of ANY kind"

Now the real question? Will I get a reply back?

Stay tuned :)

It’s been a while since I did anything here as I’ve been too busy and sadly, all of my predictions regarding the “Great Social Experiment of 2020” have come to fruition.

Of note, I have still yet to make a retractions, even though cancer, heart-related issues, auto-immune disease, anti-dependant enhancement and all-cause mortality are out of control from people still taking the gene therapy bioweapon who are either dropping like flies or getting seriously injured as a result. But not everyone is.. Yet :(

In any event, this article is not on Convid but the latest previously failed scam they once called “Monkeypox” which has changed to “Mpox” because people can’t spell “Money” ;)

I will call it “MONEYPOX 2.0” ;)

Monkeypox, aka Mpox, aka Moneypox virus is a DNA virus in the Orthopoxvirus genus, which also includes viruses such as vaccinia, cowpox, and variola as originally “described” in 1958 in monkeys, rodents were likely to be the natural reservoir of this virus with primates—including humans—being incidental hosts.

Incidental hosts? Sure we were. ;)

What are orthopoxviruses?
”Orthopoxvirus is a genus (grouping) of viruses that cause a raised, bumpy rash. They’re zoonotic diseases, which means they can infect animals and humans. Orthopoxviruses infect mammals like cows, cats and small rodents, but they sometimes spread to people, too. Smallpox — which is eradicated (no longer spreads) — and mpox are the only orthopoxviruses that spread between humans.”
https://my.clevelandclinic.org/health/diseases/orthopoxvirus

So, if smallpox was eradicated, how did moneypox come into play and why did it appear shortly after the Convid-19 Experimental Gene Therapy Bioweapons were released on humanity?

I took a look at the studies I complied from my substack “The Motherload of "rare" adverse events from the Covid-19 Bio Weapons” and this is what I have thus far. Note, I took some time off after early 2022 to focus on work and there are many more to add.

- Anaphylaxis including Cutaneous Adverse Effects (Skin reactions)

Nov 9, 2021 Eosinophilic dermatosis after AstraZeneca COVID-19 vaccination:  https://onlinelibrary.wiley.com/doi/10.1111/jdv.17806

Nov 9, 2021 A case of toxic epidermal necrolysis after vaccination with ChAdOx1 nCoV-19 (AZD1222):  https://onlinelibrary.wiley.com/doi/10.1111/ajd.13742

Oct 28, 2021 Anaphylaxis after Modern COVID-19 vaccine:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8558796/

Oct 26, 2021 Association of self-reported history of high-risk allergy with allergy symptoms after COVID-19 vaccination:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8548941/

Oct 22, 2021 Anaphylactoid reaction and coronary thrombosis related to COVID-19 mRNA vaccine:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8531274/

Oct 17, 2021 Cutaneous adverse reactions of 35,229 doses of COVID-19 Sinovac and AstraZeneca vaccine COVID-19: a prospective cohort study in health care workers:  https://onlinelibrary.wiley.com/doi/10.1111/jdv.17761

Oct 7, 2021 CoronaVac COVID-19 Vaccine-Induced Anaphylaxis: Clinical Characteristics and Revaccination Outcomes: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8504472/

Oct 5, 2021 Varicella zoster virus and herpes simplex virus reactivation after vaccination with COVID-19: review of 40 cases in an international dermatologic registry:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656951/

Oct 1, 2021 Immunization practices and risk of anaphylaxis: a current, comprehensive update of COVID-19 vaccination data:  https://pubmed.ncbi.nlm.nih.gov/34269740/

Sept 21, 2021 Skin reactions after vaccination against SARS-COV-2: a nationwide Spanish cross-sectional study of 405 cases:  https://pubmed.ncbi.nlm.nih.gov/34254291/

Sept 17, 2021 Assessment of Allergic and Anaphylactic Reactions to mRNA COVID-19 Vaccines With Confirmatory Testing in a US Regional Health System:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8449279/

Sept 11, 2021 Increased risk of urticaria/angioedema after BNT162b2 mRNA COVID-19 vaccination in health care workers taking ACE inhibitors:  https://www.mdpi.com/2076-393X/9/9/1011

Sept 10,2021 Clinical and pathologic correlates of skin reactions to COVID-19 vaccine, including V-REPP: a registry-based study:  https://pubmed.ncbi.nlm.nih.gov/34517079/

Sept 4, 2021 COVID-19 mRNA vaccine causing CNS inflammation: a case series:  https://link.springer.com/article/10.1007/s00415-021-10780-7

Sept 1, 2021 Allergic reactions and adverse events associated with administration of mRNA-based vaccines. A health system experience:  https://pubmed.ncbi.nlm.nih.gov/34474708/

Aug 31, 2021 Anaphylaxis reactions to Pfizer BNT162b2 vaccine: report of 3 cases of anaphylaxis following vaccination with Pfizer BNT162b2:  https://www.mdpi.com/2076-393X/9/9/974

Aug 31, 2021 Allergic reactions after COVID-19 vaccination: putting the risk in perspective:  https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2783633

Aug 26, 2021 Reports of anaphylaxis after coronavirus disease vaccination 2019, South Korea, February 26-April 30, 2021:  https://pubmed.ncbi.nlm.nih.gov/34414880/

Aug 18, 2021 A case series of cutaneous COVID-19 vaccine reactions at Loma Linda University Department of Dermatology:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8372465/

Aug 4, 2021 Cumulative adverse event report of anaphylaxis following injections of COVID-19 mRNA vaccine (Pfizer-BioNTech) in Japan: the first month report:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8335977/

July 31, 2021 Biphasic anaphylaxis after first dose of 2019 messenger RNA coronavirus disease vaccine with positive polysorbate 80 skin test result:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8325373/

July 28, 2021 IgE-mediated allergy to polyethylene glycol (PEG) as a cause of anaphylaxis to COVID-19 mRNA vaccines:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8444836/

July 23, 2021 Relationship between pre-existing allergies and anaphylactic reactions following administration of COVID-19 mRNA vaccine:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8220987/

July 22, 2021 Clinical and histopathologic spectrum of delayed adverse skin reactions after COVID-19 vaccination: https://onlinelibrary.wiley.com/doi/10.1111/cup.14104

July 19, 2021 An academic hospital experience assessing the risk of COVID-19 mRNA vaccine using patient’s allergy history:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8288228/

July 19, 2021 Delayed cutaneous reactions after the administration of mRNA vaccines against COVID-19: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8288253/

June 18, 2021 The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach. : https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8248554/

June 14, 2021 Elevated rates of anaphylaxis after vaccination with Pfizer BNT162b2 mRNA vaccine against COVID-19 in Japanese healthcare workers; a secondary analysis of initial post-approval safety data:  https://academic.oup.com/jtm/article/28/7/taab090/6298507

July 8, 2021 Bullous drug eruption after the second dose of COVID-19 mRNA-1273 (Moderna) vaccine: Case report:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264280/

June 6, 2021  Biphasic anaphylaxis after exposure to the first dose of the Pfizer-BioNTech COVID-19 mRNA vaccine COVID-19: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8242856/

May 29, 2021 Biphasic anaphylaxis after exposure to the first dose of Pfizer-BioNTech COVID-19 mRNA vaccine COVID-19:  https://onlinelibrary.wiley.com/doi/10.1002/jmv.27109

May 6, 2021 Sex differences in the incidence of anaphylaxis to LNP-mRNA vaccines COVID-19:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8101867/

April 28, 2021 Anaphylaxis Associated with COVID-19 mRNA Vaccines: Approach to Allergy Research:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080508/

April 27, 2021 Cutaneous adverse effects of available COVID-19 vaccines:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8076732/

April 21, 2021 Allergy to Polyethilenglicole of Anti-SARS CoV2 Vaccine Recipient: A Case Report of Young Adult Recipient and the Management of Future Exposure to SARS-CoV2:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8143141/

April 19, 2021 Practical handling of allergic reactions to COVID-19 vaccines: A position paper from German and Austrian Allergy Societies AeDA, DGAKI, GPA and OGAI. https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8054127/

April 14, 2021 Anaphylaxis following Covid-19 vaccine in a patient with cholinergic urticaria:  https://academic.oup.com/milmed/advance-article/doi/10.1093/milmed/usab138/6225467

April 9, 2021 Polyethylene glycol (PEG) is a cause of anaphylaxis to Pfizer / BioNTech mRNA COVID-19 vaccine:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251011/

April 7, 2021 Skin reactions reported after Moderna and Pfizer’s COVID-19 vaccination: a study based on a registry of 414 cases:  https://pubmed.ncbi.nlm.nih.gov/33838206/

April 6, 2021 Anaphylactic reactions to COVID-19 mRNA vaccines: a call for further studies:  https://europepmc.org/article/PMC/PMC8023205

April 2, 2021 Prolonged anaphylaxis to Pfizer 2019 coronavirus disease vaccine: a case report and mechanism of action:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8021358/

April 1, 2021 Allergic reactions to COVID-19 vaccines: statement of the Belgian Society of Allergy and Clinical Immunology (BelSACI):  https://www.tandfonline.com/doi/abs/10.1080/17843286.2021.1909447

March 22, 2021 Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin disease: practical recommendations. An ETFAD position statement with external experts:  https://onlinelibrary.wiley.com/doi/10.1111/jdv.17237

March 8, 2021 Acute allergic reactions to COVID-19 mRNA vaccines:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7941251/

March 3, 2021 Allergenic components of the mRNA-1273 vaccine for COVID-19: possible involvement of polyethylene glycol and IgG-mediated complement activation:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8013891/

Feb 28, 2021 Allergic reactions, including anaphylaxis, after receiving the first dose of Modern COVID-19 vaccine – United States, December 21, 2020 to January 10, 2021:  https://onlinelibrary.wiley.com/doi/10.1111/ajt.16517

Feb 28, 2021 Allergic reactions, including anaphylaxis, after receiving the first dose of Pfizer-BioNTech COVID-19 vaccine – United States, December 14 to 23, 2020:  https://onlinelibrary.wiley.com/doi/10.1111/ajt.16516

Feb 24, 2021 Severe Allergic Reactions after COVID-19 Vaccination with the Pfizer / BioNTech Vaccine in Great Britain and the USA: Position Statement of the German Allergy Societies: German Medical Association of Allergologists (AeDA), German Society for Allergology and Clinical Immunology (DGAKI) and Society for Pediatric Allergology and Environmental Medicine (GPA): LOTS OF CONFLICTS ON INTEREST: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7903024/

Feb 16, 2021 COVID-19 vaccines increase the risk of anaphylaxis: (Norwegian): https://tidsskriftet.no/2021/02/debatt/covid-19-vaksiner-gir-okt-risiko-anafylaksi https://pubmed.ncbi.nlm.nih.gov/33685103/  (no abstract available)

Feb 12, 2021 Reports of anaphylaxis after receiving COVID-19 mRNA vaccines in the U.S.-Dec 14, 2020-Jan 18, 2021:  https://jamanetwork.com/journals/jama/fullarticle/2776557

FEB 5, 2021 Allergic reactions and anaphylaxis to LNP-based COVID-19 vaccines:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862013/

Feb 1, 2021 COVID-19 vaccine-associated anaphylaxis: a statement from the Anaphylaxis Committee of the World Allergy Organization:.  https://www.worldallergyorganizationjournal.org/article/S1939-4551(21)00011-9/fulltext

Jan 29, 2021 Allergic reactions, including anaphylaxis, after receiving first dose of Modern COVID-19 vaccine – United States, December 21, 2020-January 10, 2021:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7842812/

Jan 21, 2021 Allergic reactions, including anaphylaxis, after receiving the first dose of the Pfizer-BioNTech COVID-19 vaccine:  https://jamanetwork.com/journals/jama/fullarticle/2775646

Jan 15, 2021 Allergic reactions, including anaphylaxis, after receiving the first dose of Pfizer-BioNTech COVID-19 vaccine – United States, December 14-23, 2020:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7808711/

Jan 5, 2021 Severe allergic reactions to the COVID-19 vaccine – statement and practical consequences (6 OF THE 7 AUTHORS ARE ALSO LISTED IN THE FEB 24TH STUDY): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7787363/

Jan 1, 2021 Pfizer Vaccine Raises Allergy Concerns:  https://ui.adsabs.harvard.edu/abs/2021Sci...371...10D/abstract

Dec 15, 2020 Allergic reactions to the first COVID-19 vaccine: a potential role of polyethylene glycol:  https://onlinelibrary.wiley.com/doi/10.1111/all.14711

And this..

- Cutaneous/Keratolysis/Dermatosis/Bullous/Sweet’s Syndrome/etc (Skin Related)

Jan 17, 2022 Sweet syndrome after severe acute respiratory syndrome coronavirus 2 mRNA vaccine: A case report and literature review: https://onlinelibrary.wiley.com/doi/10.1111/1346-8138.16309

Dec 1, 2021 Bilateral immune-mediated keratolysis after immunization with SARS-CoV-2 recombinant viral vector vaccine:  https://journals.lww.com/corneajrnl/Abstract/2021/12000/Bilateral_Immune_Mediated_Keratolysis_After.23.aspx

Nov 25, 2021 A case of generalized Sweet’s syndrome with vasculitis triggered by recent vaccination with COVID-19:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8612751/

Oct 7, 2021 Hematuria, a generalized petechial rash and headaches after Oxford AstraZeneca ChAdOx1 nCoV-19 vaccination:  https://casereports.bmj.com/content/14/10/e245440.long

Oct 4, 2021 Herpes-like skin lesion after AstraZeneca vaccination for COVID-19: A case report:  https://onlinelibrary.wiley.com/doi/10.1002/ccr3.4883

Sept 29, 2021 Sweet’s syndrome after Oxford-AstraZeneca COVID-19 vaccine (AZD1222) in an elderly woman:  https://onlinelibrary.wiley.com/doi/10.1111/dth.15146

Sept 12, 2021 Recurrent herpes zoster after COVID-19 vaccination in patients with chronic urticaria on cyclosporine treatment – A report of 3 cases:  https://onlinelibrary.wiley.com/doi/10.1111/jocd.14437

Sept 7, 2021 Case report: Pityriasis rosea-like rash after vaccination with COVID-19:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8452904/

Aug 25, 2021 Cutaneous Adverse Reactions to COVID-19 Vaccines: Insights from an Immuno-Dermatological Perspective: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8470727/

Aug 23, 2021 Exacerbation of plaque psoriasis after COVID-19 inactivated mRNA and BNT162b2 vaccines: report of two cases:  https://onlinelibrary.wiley.com/doi/10.1111/dth.15110

Aug 7, 2021 Rare cutaneous adverse effects of COVID-19 vaccines: a case series and review of the literature:  https://onlinelibrary.wiley.com/doi/10.1111/jdv.17578

Aug 4, 2021 Onset / outbreak of psoriasis after Corona virus ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca / Covishield): report of two cases:  https://onlinelibrary.wiley.com/doi/10.1111/dth.15085

Aug 3, 2021 Petechiae and peeling of fingers after immunization with BTN162b2 messenger RNA (mRNA)-based COVID-19 vaccine:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8413049/

July 21, 2021 Bullous drug eruption after second dose of mRNA-1273 (Moderna) COVID-19 vaccine: Case report: https://www.sciencedirect.com/science/article/pii/S1876034121001878

July 8, 2021 Vesiculobullous cutaneous reactions induced by COVID-19 mRNA vaccine: report of four cases and review of the literature:  https://onlinelibrary.wiley.com/doi/10.1111/ced.14835

July 3, 2021 Sweet syndrome induced by SARS‐CoV‐2 Pfizer‐BioNTech mRNA vaccine https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8441847/

June 18, 2021 Sweet syndrome induced by SARS-CoV-2 Pfizer-BioNTech mRNA vaccine: https://onlinelibrary.wiley.com/doi/full/10.1111/all.14981

June 6, 2021 Dermatologic manifestations and complications of COVID-19: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7274995/

May 26, 2021 Coronavirus 19 presenting with atypical Sweet's syndrome: https://onlinelibrary.wiley.com/doi/10.1111/jdv.16662

May 24, 2021 Petechial rash associated with CoronaVac vaccination: first report of cutaneous side effects before phase 3 results:  https://ejhp.bmj.com/content/early/2021/05/23/ejhpharm-2021-002794.long

Weird that a majority of these studies came before “Moneypox 1.0”.. That’s a pretty significant coincidence if you ask me.

Before I get into the clinical trial debauchery let’s look at some facts about Moneypox, shall we.

This is what I found from my local health authority on the topic and it’s pretty much “copy & paste” to the Provincial Health Authority and our National Health Authority.. All complete bs..

"Mpox is a disease caused by the mpox virus. It is endemic in parts of west and central Africa, where transmission has primarily been from infected animals to humans, with very limited human-to-human transmission.

Vaccination against mpox

Experience of other jurisdictions shows early use of vaccines among groups who are at the highest risk of spread, along with case and contact tracing efforts by Public Health, can reduce transmission, prevent severe illness and limit risk to the wider population. Vaccine is not recommended or available for the general public.

Eligibility:

Eligible individuals are Two-Spirit and transgender people and cisgender males who self-identify as belonging to the gay, bisexual and other men who have sex with men community and answer yes to any of the criteria below:

- Has sex with more than one partner, or

- Has sex with a partner who has more than one partner, or

- Has casual sex (e.g. cruising), or

- Engages in sex work or plans to, either as a worker or a client.

The vaccine cannot be administered to people who have symptoms that could be due to mpox......

The vaccine is not available to individuals of any gender who are not part of the community of gay, bisexual and other men who have sex men, unless they have been identified as a close contact of a confirmed case.

Vaccine is not recommended or available for the general public.

How mpox is spread

The mpox virus does not spread easily from person to person the way some viruses do, such as the virus that causes COVID-19. In this global outbreak of mpox the primary mode of transmission is via close, sexually-associated skin-to-skin contact. "

Source? Fraser Health Authority (BC, Can)- https://www.fraserhealth.ca/health-topics-a-to-z/immunizations/diseases-and-immunizations/mpox

Basically, if you are trans, gay or CIS, this virus is for you. But, but, you could be achimp-to-matic and not even know it.. Sure..

To Fraser Health and every other “Health Authority/Agency”, why are you pushing an alleged "vaccine".

Based on what evidence please? .

1. Where is the human trial data?

2. Were clinical trials performed in Canada? If so, where? How many Canadians were enrolled/involved in the clinical trials?

3. How many phases were completed in Canada?

4. How many years were spent with each phase?

5. What are/were the sides effects/safety signals?

6. What are all of the ingredients of these jabs?

7. Aside from the obvious similarities to shingles and herpes, why are the 7 symptoms the same as countless other illness/diseases?

8. Why is this effecting those who have had prior C-19 Gene Therapy shots?

9. Are you going to be dumb enough to push any mandates for mass inoculation if the Fed or Provincial Puppet Masters tell you to even though these alleged issues only effects the above you listed on your site?

10. Why was the name changed from monkeypox to mpox?

But what does it look like? It was a little difficult finding CURRENT images of this alleged killer poxvirus.

But first, please check out this link for 36 different types of skin rashes - https://lifepathdoc.com/rashes/

Here’s a small sample and sadly, the image doesn’t show all 36 so you will have to click on the above link.

Below. High school student Julian Glenn was believed to have contracted the monkeypox virus from his pet prairie dog, John, in this file photo taken in 2003. Wait what? 2003?

Looks like chickenpox + flea bites + acne to me.

Here’s a shot of a little baby with chickenpox from 2016.

More chickenpox

The last shot above is from an adult with Chickenpox. Remember this one.

Vs. Some dude in Cali who took a selfie back in August 2022..

Hmmmm.. Still looks like chickenpox or a drug allergy but this was from 2022 when the jab injuries continued to pour in globally.

Also from 2022 from the Congo which looks like the Adult Chicken Pox pic I shared above or shingles which I have below. Why does it look different from the one above?

What about 2024? August 23,2024 to be more precise.

I’m still not convinced.

What about Shingles/Herpes Zoster?

I firmly believe that this was created to cover up pox-like side effects from the bioweapon and so does one of my favourite humans, Dr. David E. Martin.

https://rumble.com/v5c4icj-monkeypox-a-cover-for-covid-injection-side-effects-warns-dr.-david-martin.html

CLINICAL TRIALS

I took a look at clinicaltrials.gov website looking over the moneypox jab trials and their subsequent trial results and was alarmed at what i found..

As of this writing there are only 4 Phase 1 Clinical Trials which have “monkeypox” listed. However, only 1 is focused on this alleged new killer virus and it’s still recruiting. WTAF? Are they not currently injecting people with a Moneypox jab?

CLINICAL TRIAL EVDIENCE. Or lack thereof. Here’s the current list with “Monkeypox” or “Mpox” listed on clinicaltrials.gov - https://clinicaltrials.gov/search?cond=monkeypox&term=MPOX

A whopping 41 entries.. Ok.. it’s new.. Right? Nope. Are the trials RCT? Nope.

Phase 1 Clinical Trials? 4.. with 3 of them listed as "completed".. Ok.. So how many people were enrolled and what were the human trial results?

NCT00728689 - "A Phase I Randomized, Double-Blind, Crossover, Exploratory Study of the Pharmacokinetics of a Single Oral Dose of Form I Versus Form V Capsules of the Anti-Orthopoxvirus Compound ST-246® in Fed Normal Healthy Volunteers"
Enrolment? 12 people. Conditions? Orthopoxviral Disease, Smallpox, Monkey Pox. Why the other 2 conditions? Moreover, where is the "placebo control group" to see if the interventions are superior to the placebo?
Hmm.. 2 different intervention periods but 1-3 days and 11-13 days is pretty pathetic considering that there is 0 followup mentioned within this study for reactions after 13 days.

The exclusionary criteria is concerning even though it's an alleged Phase 1 trial which is supposed to have between 18-80 HEALTHY VOLUNTEERS. We don't have many "healthy people left".

What's really alarming? The date of the original study 2008-08-01.. Wait. What?

It gets worse. In this original trial 1 of the 6 people died during the washout period (Days 4-10).. Um. Ok, How & Why?
https://clinicaltrials.gov/study/NCT00728689?cond=monkeypox&term=MPOX&aggFilters=phase:1&rank=2

NCT05976100- "Study of the Safety, Tolerability, Pharmacokinetics of NIOCH-14 in Volunteers Aged 18-50 Years"
Enrolment? 90. Start date? 2020-09-04 End Date?2022-03-09. Study Type? Interventional .
https://clinicaltrials.gov/study/NCT05976100?cond=monkeypox&term=MPOX&aggFilters=phase:1&rank=3
NO DOUBLE BLIND PLACEBO CONTROLLED RCT. Next..

NCT05762523 - "Safety and Tolerability Study of the VAC∆6 Vaccine in Volunteers Aged 18-40 Years".. 60 volunteers.
This study is an open-label, controlled, parallel-group clinical trial. The study included 60 healthy volunteers of both sexes aged 18-40 years who had not been vaccinated against smallpox, had no vaccine marks and anti-smallpox virus neutralizing antibodies in their sera as well as those who met the inclusion criteria and did not have any exclusion criteria.

Another interventional study with no placebo group.. Started 2019-05-18 Ended - 2020-01-27. Huh What was going on in 2019 and 2020 for them to have to do this study?
https://clinicaltrials.gov/study/NCT05762523?cond=monkeypox&term=MPOX&aggFilters=phase:1&rank=4
Next..

The above 3 trials have "Moneypox" listed as 1 of the "conditions. Others listed? Cowpox, Smallpox or Orthopoxviral Disease

Come on.. There must be at least 1 Phase 1 Clinical Trial which is solely for Moneypox..

AND HERE IT IS..

NCT05988203 - “A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines”

Has it started? Nope. Still recruiting. 64 people but it's also not a Double Blind Placebo Control RCT.. WTF? Guess who the manufacturer is? Biontech.. Lovely :( But important note? Mark this down and watch it gain traction as a possible treatment for C-19 gene therapy jabs. BNT166a

Sponsored by NIAID.. :(

https://clinicaltrials.gov/study/NCT05988203?cond=monkeypox&term=MPOX&aggFilters=phase:1&rank=1

That’s it, ONE Phase 1 study which is still recruiting. How pathetic.

What about Phase 2? A whopping 6 studies. :(

NCT05512949 - ‘Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox Vaccine”
Study Start Date? 2022-09-09
Study Completion Date? 2023-10-19
Enrolment- 229 suckers.
”This study is a Phase 2 randomized, open-label, non-placebo controlled, multi-site clinical trial that will evaluate two intradermal (ID) regimens for Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine compared to the standard subcutaneous (SC) regimen in healthy, vaccinia-naïve adults 18 to 50 years of age, inclusive. At least 210 participants will be enrolled and randomized to one of three study arms.”

Wait, 210? What happened to the other 19 people? Valid question.
At first glance, this Phase 2 Trial doesn’t have a Phase 1 Trail Associated with it which is a problem as you need the Phase 1 to ensure that your healthy volunteers do not have any issues.. Hmm.. Moreover, they are using a SMALLPOX drug (JYNNEOS) to see it will be effective for this alleged Moneypox 2.0 thing. LOL. Yeah, that totally makes sense as they are no way similar except that they are both part of the orthopoxvirus family. That’s like comparing avian flu to CONVID FFS.

Bavarian Nordic A/S JYNNEOS's initial approval for mpox use was based on survival data from lethal mpox virus challenge studies (FDA's Animal Rule) in non-human primates. Actually, it started in 2019 based on the SMALLPOX Virus which was eradicated years ago but who cares about facts or dates? ;) You may want to review this blurb on Bavarian Nordic and how many 2-dose jabs they provided to the world in 2022-2023 - 15million doses.. Hmmm.. My bullshit detector just redlined. You provide a shot which has sketchy trial data behind it, if any, release it to populations and hope that it doesn’t give you the “thing”.. Yeah, that’s totally wise.. LOL.

At any rate, back to this ridiculous clinical trial..

Once again, the exclusionary criteria is problematic as this is supposed to be include your target group.

However, if you:
- Had close contact of anyone known to have monkeypox in the 3 weeks prior to signing Informed Consent Form (ICF)…
- Were immunocompromised,
- Are PREGNANT OR BREASTFEEDING,
- Have any history of MONKEYPOX, cowpox, or vaccinia infection,
- Received or plans to receive any other vaccine in the 2 weeks prior to signing ICF through Day 43 (Cough, cough, CONVID SHOTS),
- Received experimental therapeutic agent or vaccine in the 3 months prior to signing ICF.
- Have tattoos, scars, or other marks which would, in the opinion of the investigator, interfere with assessment of the vaccination site.
- Have any medical disease or condition that, in the opinion of the participating site Principal Investigator (PI) or appropriate sub-investigator, precludes study participation. This includes acute, subacute, intermittent, or chronic medical disease or condition that would place the participant at an unacceptable risk of injury, render the participant unable to meet the requirements of the protocol, or may interfere with the evaluation of responses or the participant's successful completion of this trial.

……Then you can’t be in the clinical trials. LOL.

Of the 229, oops 210 which survived, who enrolled, 49% were “CIS MALE” and 48% were “CIS FEMALE”, 2.2% NON BINARY, 0.4% GENDER NON-CONFORMING, 0.4% GENDERQUEER, 0.4% TRANS, MAN, 0.4% TRANS WOMAN, & 0.4% DECLINED TO STATE.

Umm. what’s “CIS”? ;) Just kidding. Actually, why are you including those who are not part of the alleged “at risk” group in these sketchy clinical trials?

Where are the NON-NONE OF THE ABOVE if they want the masses to blindly roll up their sleeves?

I can’t take this anymore but here’s the study.

https://clinicaltrials.gov/study/NCT05512949?cond=monkeypox&term=MPOX&aggFilters=phase:2&rank=4

NCT05846243 - “Study on Immunogenicity, Reactogenicity and Safety of the VACΔ6 Vaccine in Volunteers Aged 18-60 Years” PHASE 2/3
Start Date? 2021-10-01
Completion Date? 2022-04-01
Enrolment? 344.. (that’s a pretty small sample size for a merged CT)
”This is a Double-blind, Comparative, Randomized, Placebo-controlled Study on Immunogenicity, Reactogenicity and Safety of Live Cell-Based Vaccine Against Smallpox and Other Orthopoxvirus Infections (VAC∆6 Vaccine) Based on Vaccinia Virus in 18-60-year-old Volunteers.”

Wait, did they actually mention “Placebo”? Ok, I’ll bite.

”Of the 4 different groups which have a total of 272 volunteers
- The study included 334 healthy volunteers of both sexes aged 18-60 years who met the inclusion criteria and had no exclusion criteria.

The study was carried out in two stages:

The first stage is an open comparative study of the safety, reactogenicity, immunological activity and protective efficacy of VAC∆6 vaccine in parallel groups of 30 volunteers aged 18 to 60 who met the inclusion criteria. Volunteers were divided into two groups:

• Group 1: 15 volunteers who received a single intradermal VAC∆6 dose of 1x10⁷ PFU. Live smallpox vaccine was administered by scarification 2 months after the vaccination.

• Group 2: 15 volunteers who received two intradermal VAC∆6 doses of 1x10⁶ PFU (given 28 days apart). Live smallpox vaccine was administered by scarification one month after the full vaccination series.

The second stage is a Double-blind, Comparative, Randomized, Placebo-controlled study on Immunogenicity, Reactogenicity, and Safety of the VAC∆6 Vaccine in Parallel Groups. Randomization was carried out using the envelope method. The sealed opaque envelopes included in the Investigator's File were distributed to the clinical sites in the required quantity prior to the start of the study.

A total of 304 volunteers aged 18-60 took part in the second stage of the clinical study, of which 158 were men and 146 were women, who met the inclusion criteria and had no exclusion criteria. The volunteers were assigned to study sites as follows:

1. FGBUZ MSCH-163, FMBA Russia - 272 volunteers randomized into four groups:

   • Group 3: 76 volunteers who received two intradermal VAC∆6 doses of 10⁶ PFU/0.2 ml (given 28 days apart);

   • Group 4: 76 volunteers who received two intradermal placebo doses of 0.2 ml (given 28 days apart);

   • Group 5: 60 volunteers who received a single intradermal VAC∆6 dose of 10⁷ PFU/0.2 ml;

   • Group 6: 60 volunteers who received a single intradermal placebo dose of 0.2 ml.

2. State Budgetary Health Institution of the Novosibirsk Region "Municipal Infectious Disease Clinical Hospital No. 1" - 32 volunteers randomized into two groups:

   • Group 7: 16 volunteers who received a single intradermal VAC∆6 dose of 10⁷ PFU/0.2 ml;

   • Group 8: 16 volunteers who received a single intradermal placebo dose of 0.2 ml.

     • Before applying for a state license to the Ministry of the Russian Federation on May 4, 2022, the VACΔ6 vaccine was renamed to OrthopoxVac.
       

NO RESULTS POSTED YET, EVEN THOUGH THE STUDY WAS COMPLETED BACK IN APRIL 1, 2024. WHY NOT?

PHASE 2 Studies
Not yet recruiting - NCT06549530,
Recruiting - NCT05559099, NCT05698082,
Active, Not Recruiting - NCT05740982

You will have to check out the “Exclusionary Criteria” as it’s too long to list here..
https://clinicaltrials.gov/study/NCT05846243?cond=monkeypox&term=MPOX&aggFilters=phase:2&rank=6

Not looking good, so let’s look at the PHASE 3 Clinical Trials

Completed? NCT05846243 which I mentioned above and not only covers “Moneypox 2.0” but Smallpox and Cowpox. WTF?
Active, Not Recruiting - NCT06223919, NCT02977715
Recruiting - NCT05597735, NCT05534165, NCT05698082

What about Stage 4. You know the ones which happen after Phase 1 (1-2 years), Phase 2 (1-2 years) and Phase 3 (2-3 years) which based on Moneypox 1.0 should be happening either in 2025, 2026 or 2027.

Completed - NCT05734508
Recruiting - NCT06156566
Not Yet Recruiting - NCT05745987

OH boy. So the alleged “Completed” Trial is a joke. 500 total participants. THIS SHOULD BE IN POPULATION-WIDE LEVELS and the sample size is embarrassing. 500 people? RUFKM? In no way, shape or form can this be classified as a Phase 4 trial. Ok. It’s not a Clinical Trial, it’s an “Observational Study” to monitor and assess the safety profile of the MVA-BN vaccine among staff and study personnel of the PALM-007 study in the Democratic Republic of the Congo. The main questions it aims to answer are:
-To estimate the incidence of serious adverse events (SAEs) in all individuals vaccinated with the MVA-BN vaccine
-To estimate the incidence of adverse events (AEs) after each dose of MVA-BN vaccine.

Well so much for actual Clinical Trial evidence. :(

Back in Sept. 5th, 2022, Professor Gregory A. Poland published this in The Lancet - “Prevention of monkeypox with vaccines: a rapid review” and started his fear porn article with this ridiculous and unfounded statement, “The largest outbreak of monkeypox in history began in May, 2022, and has rapidly spread across the globe ever since.”

Really? HAHAHAHAHAHAHAHAHA.. His paper is more about smallpox, than Moneypox and using smallpox “vaccines” to treat/prevent the latest scam.

Well done, dunderhead but you should really focus on the isolation/purification of this alleged new killer virus, what tests were used to determine if you had a thing or not because the over-amplified PCR test, which failed miserably during Novid is not an acceptable testing format, nor should it be a “gold standard” test.. Kerry Mullis is still rolling in his grave. :(

There was one part of his Rapid Review which has me questioning when the Moneypox jab started
”The USA currently has two licensed smallpox vaccines: ACAM2000 (Emergent Product Development Gaithersburg, MD, USA), and JYNNEOS (Bavarian Nordic, Hellerup, Denmark). ACAM2000 is only licensed to prevent smallpox, whereas JYNNEOS was approved for the prevention of smallpox and monkeypox in 2019. Both have been evaluated for protection against infection with monkeypox virus in animals.”

2019? Ok, I’m so confused right now and wish they could make up their minds when this thing was a thing.. Was it 1958? 2003? 2019, 2021? or 2024?

I welcome any additional info you can share in the comments and I will keep my eyes out for more images and updates to these BS clinical trials.

Bottom Line? It’s another scam created to incite fear in the lemmings.. Don’t fall for this crap!

May 22, 2026

UPDATE.. After 3 years, I have found the actual ingredients/chemical compounds for the MODIFIED mRNA . STRAP IN, It’s going to get rough. :(

The mRNA in both the Pfizer-BioNTech and Moderna COVID-19 vaccines are nucleoside-modified, specifically using 1-methylpseudouridine …….

Wait a sec.

There was a ton of chatter on the lastone.. 1-methypseudouridine.

Recent research highlights a potential oncological risk associated with its use in 100% modified mRNA:

• Tumour Promotion: Computer modelling and melanoma models suggest that substituting all uridines with N1-methylpseudouridine can stimulate cancer growth and metastasis by suppressing the type I interferon response and innate immune surveillance.

• Immune Suppression: High levels of this modification may inhibit essential immune pathways, potentially creating conditions favourable for rapid tumour progression or “turbocancer.”

• Therapeutic Balance: For cancer vaccines, lower percentages of N1-methylpseudouridine are recommended to maintain adequate innate immune stimulation for anti-tumour immunity, whereas its use in infectious disease vaccines aims to minimize harmful inflammatory responses”
  
  https://www.sciencedirect.com/science/article/abs/pii/S0141813024022323
  
  HOLY CRAP!!!!
  
  In any case back to the rest of the blurb..
  
  …… to increase stability and reduce immune detection. This genetic material encodes the SARS-CoV-2 spike (S) glycoprotein (aka. synthetic, self-assembling spike protein) and contains proline substitutions to stabilize the protein structure.

The core structural components of the mRNA molecule include:

• 5′ Cap: A cap structure (Cap1 for Pfizer, enzymatically capped for Moderna) essential for ribosome recognition and stability.

• 5′ Untranslated Region (UTR): Sequences that facilitate ribosome binding; Pfizer uses human $\alpha$-globin and AES motifs, while Moderna uses an undisclosed 5′ UTR.

• Coding Sequence: The genetic code for the spike protein, which is GC-rich and codon-optimized for efficient expression.

• 3′ Untranslated Region (UTR): Sequences aiding mRNA stability; Pfizer uses mtRNR1 motifs, while Moderna uses a human $\beta$-globin gene-based sequence.

• Poly(A) Tail: A tail of adenosine ribonucleotides that regulates translation; Pfizer’s tail consists of 30 adenosine residues, 10-nucleotide linkers, and 70 adenosine residues (totalling 110 units), while Moderna’s tail length is undisclosed.

It was a bitch to find the chemical compositions but I found them..

5’ Cap
Doesn’t have an MSDS per se, but the chemical ingredients do.

1. The 7-Methylguanosine 5'-diphosphate sodium salt (CAS: 104809-16-7) Safety Data Sheet indicates it does not contain substances with occupational exposure limits and has no data available for acute toxicity, skin corrosion, or carcinogenicity.

From the MSDS
Relevant identified uses: For R&D use only. Not for medicinal, household or other use.”

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity -No data available
Skin corrosion/irritation - No data available
Serious eye damage/eye irritation- No data available
Respiratory or skin sensitisation - No data available
Germ cell mutagenicity - No data available
Carcinogenicity - IARC: No component of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity - No data available
Specific target organ toxicity - single exposure - No data available
Specific target organ toxicity - repeated exposure - No data available
Aspiration hazard - No data available

https://www.chemicalbook.com/msds/7-methylguanosine-5-diphosphate-sodium-salt.htm

Yikes. What about the other chemicals?

"Triophosphate bridge”. Not listed but one of the main chemicals,

Sodium Tripolyphosphate (STPP)
1.2 Relevant identified uses of the substance or mixture and uses advised against Identified uses : Laboratory chemicals, Industrial & for professional use only.

SECTION 11: Toxicological information

11.1 Information on toxicological effects Acute toxicity LD50 Oral - rat - male and female - > 2.000 mg/kg (OECD Test Guideline 401) LC50 Inhalation - rat - male and female - 4 h - > 0,39 mg/l LD50 Dermal - rabbit - 4.640 mg/kg Skin corrosion/irritation Skin - rabbit Result: No skin irritation (OECD Test Guideline 404)
Serious eye damage/eye irritation Eyes - rabbit Result: No eye irritation (OECD Test Guideline 405)
Respiratory or skin sensitisation Page 4 of 6 in vivo assay - mouse Result: Did not cause sensitisation on laboratory animals. (OECD Test Guideline 429)
Germ cell mutagenicity in vitro assay S. typhimurium Result: negative rat - male Result: negative
Carcinogenicity IARC: No component of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity no data available
Specific target organ toxicity - single exposure no data available
Specific target organ toxicity - repeated exposure no data available
Aspiration hazard - no data available

Additional Information RTECS: YK4570000 Gastrointestinal disturbance,

To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.

https://www.cdhfinechemical.com/images/product/msds/101_621840591_SodiumTripolyphosphate-CASNO-7758-29-4-MSDS.pdf

2. mRNA Cap Analogs. Still looking into this one but the one closest mentioned “For general laboratory use.”
https://www.jenabioscience.com/nucleotides-nucleosides/nucleotides-by-application/in-drug-discovery/mrna-modification/nu-855-m2-7-3-ogp3g-arca-cap-analog-solid

Ok. Now on to the 2nd ingredient of this “WELL TESTED MODIFIED mRNA” scam

5′ Untranslated Region (UTR):
The 5′ Untranslated Region (5′ UTR) is not composed of chemical “ingredients” or additives, but is a natural segment of messenger RNA (mRNA) consisting of a sequence of ribonucleotides.

These nucleotides are made of three core chemical components:

• Ribose sugar: A five-carbon sugar that forms the backbone of the RNA strand.

• Phosphate groups: Link the ribose sugars together to form the phosphodiester backbone.

• Nitrogenous bases: Specifically Adenine (A), Cytosine (C), Guanine (G), and Uracil (U), which encode regulatory information.

The 1st 2 above do not have any MSDS affixed to them BUT.. the nitrogen bases do.

Adenine (A)
Recommended Use Laboratory chemicals. Uses advised against Food, drug, pesticide or biocidal product use.

11. Toxicological information
Inhalation Avoid breathing dust or spray mist. May be harmful if inhaled. Ingestion May be harmful if swallowed. Eyes Avoid contact with eyes. Skin Avoid contact with skin.
Toxicologically Synergistic Products No information available
(b) skin corrosion/irritation; No data available
(c) serious eye damage/irritation; No data available
(d) respiratory or skin sensitization; Respiratory No data available Skin No data available (
e) germ cell mutagenicity; No data available
(g) reproductive toxicity; No data available
(h) STOT-single exposure; No data available
(i) STOT-repeated exposure; No data available Target Organs No information available
Other Adverse Effects The toxicological properties have not been fully investigated.
Symptoms / effects,both acute and delayed No information available.
Other Adverse Effects The toxicological properties have not been fully investigated.

https://www.fishersci.com/store/msds?partNumber=AC147440250&productDescription=ADENINE+25GR&vendorId=VN00032119&countryCode=US&language=en

Cytosine (Cytosine (CAS 71-30-7, Formula C4H5N3O)
Classified with a Warning signal word and poses hazards including skin irritation (H315), serious eye irritation (H319), and respiratory irritation (H335) )
Wonderful :(

Relevant identified uses : For R&D use only. Not for medicinal, household or other use.

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity - No data available
Skin corrosion/irritation - No data available
Serious eye damage/eye irritation - No data available
Respiratory or skin sensitisation - No data available
Germ cell mutagenicity - No data available
Carcinogenicity IARC: No component of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity - No data available
Specific target organ toxicity - single exposure No data available
Specific target organ toxicity - repeated exposure No data available Aspiration hazard - No data available
Additional Information RTECS: UW7350150 To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.

https://www.chemicalbook.com/msds/cytosine.pdf

Guanine (G)
Relevant identified uses: For R&D use only. Not for medicinal, household or other use.

SECTION 11: Toxicological information

Information on toxicological effects
Acute toxicity - No data available
Inhalation - No data available
Skin corrosion/irritation - No data available
Serious eye damage/eye irritation- No data available
Respiratory or skin sensitisation- No data available
Carcinogenicity - IARC: No component of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity- No data available
Specific target organ toxicity - single exposure
Specific target organ toxicity - repeated exposure - No data available
Aspiration hazard - No data available

Additional Information
RTECS: MF8260000- To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.

https://www.chemicalbook.com/msds/guanine.htm

Uracil (U)
Relevant identified uses : For R&D use only. Not for medicinal, household or other use.

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity LD50 Oral - Rat - > 6.000 mg/kg
Skin corrosion/irritation No data available
Serious eye damage/eye irritation No data available
Respiratory or skin sensitisation No data available
Germ cell mutagenicity No data available
Carcinogenicity IARC: No component of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity No data available
Specific target organ toxicity - single exposure No data available
Specific target organ toxicity - repeated exposure No data available Aspiration hazard - No data available
Additional Information RTECS: YQ8650000 To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.

https://www.chemicalbook.com/msds/uracil.pdf

I’ll finish off the rest later. My brain is reeling from all of the similar “Recommended Uses” and the lack of data/information under the Sec. 11 Toxicological Information sections.


Now back to my original stack from 2023.

With the announcement from our alleged Top Doc, Dr. Tam(pon) earlier, I decided to get some answers from our "trusty" health agencies here in Cana-dope..

My questions:
1. What were the trial identifier #'s for the recent modeRNA booster shots?
2. Were they conducted in cana-dope?
3. If they were, how many canadians were enrolled?
4. How long were the trials?
5. What were the safety signals?
6. If there were trials conducted in Cana-duh, which phases were completed?

The answers from PHAC, Health Canadope, Health BC were very revealing.. They had NOTHING!!!!!

I, however, had. everything and kept those pricks on the phone for at. least 4 hours and they all got schooled.. :)

So, I called the Office of Clinical Trials but after 6 rings the line is disconnected with no option for voicemail..

My last call was to Research Ethics Board (REB) as I gained an ally back in late 2021 who, not only agreed with me but is doing everything possible to help with on my quest.. Oh, this person is also a manager with a PhD so no peons and NO I WILL NOT PROVIDE THE NAME AS I WANT THIS PERSON TO KEEP THEIR JOB!

We were talking about the latest round of BS, the lack of human trial data, safety signals, etc. which got me looking at Health Canada's website on the "new & improved" BOOSTER.. lol..

Oh boy..

Here’s the source link from Health Cana-duh’s website - https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/vaccines/moderna.html

Clinical trials showed that beginning 2 weeks after the second dose, the Moderna Spikevax® COVID vaccine was:

94.1% effective in protecting trial participants aged 18 and above against COVID-19
100% effective in trial participants 12 to 17 years old
as effective in trial participants 6 to 11 years old as in young adults (18 to 25 years old)
37% effective in trial participants 2 to 5 years old
51% effective in trial participants 6 to 23 months old

Notice the low "efficacy" in the kids (6 months to 5 years old)? Yet, they want to still push these on your kids? Um. No.

It gets worse. Further down the page I stumbled upon..

"Mixed-dose schedules
A different vaccine may be offered for your second dose. For example, you may have received Pfizer-BioNTech Comirnaty® as your first dose and be offered Moderna Spikevax® as your second. This is known as a mixed vaccine series.

The National Advisory Committee on Immunization (NACI) recommends an mRNA vaccine (Pfizer-BioNTech Comirnaty® or Moderna Spikevax®) should be offered for your second dose."

Um. THERE ARE NO STUDIES ON MIX AND MATCH AND BOTH PFIZZZZEERRR. & MODERNA MENTIONED THIS IN THEIR CLINICAL TRIALS AND PMA'S..

What about the ingredients? NON-mRNA
LIPIDS
DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine)
Lipid SM-102
PEG2000-DMG (1,2-dimyristoyl-rac-glycerol,methoxy-polyethyleneglycol)
Cholesterol

BUFFERS & SALTS
Acetic acid
Sodium acetate trihydrate
Sucrose
Trometamol
Trometamol hydrochloride
Water for injection

So let’s see how these chemicals look like compared to their predecessors. This time I’m assembling it alphabetically..

ACETIC ACID

Recommended Use - Laboratory chemicals.
Uses advised against - Food, drug, pesticide or biocidal product use.”

Label Elements
Signal Word - Danger

Hazard Statements - Flammable liquid and vapor
Causes severe skin burns and eye damage

Engineering Measures Use only under a chemical fume hood. Use explosion-proof electrical/ventilating/lighting equipment. Ensure that eyewash stations and safety showers are close to the workstation location. Ensure adequate ventilation, especially in confined areas.

11. Toxicological information
Irritation - Causes severe burns by all exposure routes
Sensitization- No information available
Carcinogenicity The table below indicates whether each agency has listed any ingredient as a carcinogen.
IARC NTP ACGIH OSHA Mexico
Not listed Not listed Not listed Not listed Not listed

Mutagenic Effects Not mutagenic in AMES Test
Reproductive Effects No information available.
Developmental Effects No information available.
Teratogenicity No information available.
STOT - single exposure None known
STOT - repeated exposure None known
Aspiration hazard - No information available
Symptoms / effects,both acute and delayed
Ingestion causes severe swelling, severe damage to the delicate tissue and danger of perforation: Symptoms of overexposure may be headache, dizziness, tiredness, nausea and vomiting
Endocrine Disruptor Information - No information available
Other Adverse Effects The toxicological properties have not been fully investigated.

12. Ecological information
Ecotoxicity - Do not empty into drains.
Bioaccumulation/ Accumulation - No information available.

SOURCE - FISHER SCI . Original publish date? 2009. Last revision date? Dec 26, 2021. Total Revisions? 6

Well, the above sure looks safe to me.. So glad they oped to keep this one in the mix with all of the “No information available” sections.. What could possibly go wrong? :(

CHOLESTEROL

For this one, I’m going to use to different MSDS sheets as Fischer Sci (who also was one of the big dogs in the RT-PCR sweepstakes is up to something with this one)

Thermo Fisher Scientific

Recommended Use - Laboratory chemicals.
Uses advised against - Food, drug, pesticide or biocidal product use.

2. Hazard(s) identification
This chemical is not considered hazardous by the 2012 OSHA Hazard Communication Standard (29 CFR 1910.1200)

WAIT WHAT? Hmm.. something stinks here.. let’s see what CHEMICAL BOOK HAS TO SAY..

SECTION 2: Hazards identification

GHS Label elements, including precautionary statements

• Symbol(GHS)

• Signal word - Danger

Precautionary statements
P201 Obtain special instructions before use.
P261 Avoid breathing dust/fume/gas/mist/vapours/spray.
P305+P351+P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.
P308+P313 IF exposed or concerned: Get medical advice/attention.
P403+P233 Store in a well-ventilated place. Keep container tightly closed.

Hazard statements
H302 Harmful if swallowed
H315 Causes skin irritation
H319 Causes serious eye irritation
H331 Toxic if inhaled
H336 May cause drowsiness or dizziness
H351 Suspected of causing cancer
H372 Causes damage to organs through prolonged or repeated exposure

HOUSTON WE HAVE A PROBLEM.

Let’s see what else Thero Fisher Scientific has to say for the rest of the doc.

SECTION 10: Stability and reactivity
Reactive Hazard None known, based on information available

11. Toxicological information
Toxicologically Synergistic Products - No information available
Irritation No information available
Sensitization No information available
Carcinogenicity The table below indicates whether each agency has listed any ingredient as a carcinogen.
IARC NTP ACGIH OSHA Mexico
Not listed Not listed Not listed Not listed Not listed

Mutagenic Effects - No information available.
Reproductive Effects - No information available.
Developmental Effects - No information available.
Teratogenicity - No information available.
STOT - single exposure - None known
STOT - repeated exposure - None known
Aspiration hazard - No information available
Symptoms / effects,both acute and delayed - No information available
Endocrine Disruptor Information - No information available
Other Adverse Effects - The toxicological properties have not been fully investigated.

Here’s what CHEMICALBOOK has to say about toxicity at the bottom of Sec 11.
”Toxicity - Present in all parts of the animal body; concentrated in spinal cord, brain, skin secretions, and gallstones. An unsaturated, unsaponifiable alcohol (m.p. 149℃). It is synthesized in the body from ethanoate units; its metabolism is regulated by a specific set of enzymes. It is the parent compound of many other steroids and its presence in high concentrations in the blood is suspected as being a contributory factor in cardiovascular disease.”

Back to Fisher Sci’s section
12. Ecological information
Ecotoxicity - Do not empty into drains.
Persistence and Degradability - No information available
Bioaccumulation/ Accumulation - No information available.
Mobility - No information available.

SOURCES - FISHER SCI (Revision Date 24-Dec-2021 Revision Number 4) & CHEMICALBOOK (2023-09-02 Revision Number:1)

DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine) (Lipids in the ancestral jabs but they added the DSPC anagram)

Recommended use of the chemical and restrictions on use - For research use only. Not intended for diagnostic or therapeutic use.

11. TOXICOLOGICAL INFORMATION
Information on likely routes of exposure
Inhalation - No data available.
Eye contact - No data available.
Skin Contact - No data available.
Ingestion - No data available.
Information on toxicological effects
Symptoms - No information available.
Delayed and immediate effects as well as chronic effects from short and long-term exposure
Chronic Toxicity No information available.
Numerical measures of toxicity - Product Information
Unknown acute toxicity 100% of the mixture consists of ingredient(s) of unknown toxicity

12. ECOLOGICAL INFORMATION
Ecotoxicity - May cause long lasting harmful effects to aquatic life

100% of the mixture consists of components(s) of unknown hazards to the aquatic environment.

Persistence and degradability - No information available.
Bioaccumulation - No information available.
Mobility - No information available.

SOURCE - Santa Cruz Biotechnology Inc (May 2, 2017)

Lipid SM-102

Application of the substance / the mixture
This product is for research use - Not for human or veterinary diagnostic or therapeutic use.

2 Hazard(s) identification

· Classification of the substance or mixture (sorry I couldn’t add the little icons)
Flam. Liq. 2 H225 - Highly flammable liquid and vapor.
Acute Tox. 4 H302 - Harmful if swallowed.
Skin Irrit. 2 H315 - Causes skin irritation.
Eye Irrit. 2A H319 - Causes serious eye irritation.
Signal word - Danger
Hazard statements
H225 Highly flammable liquid and vapor.
H302 Harmful if swallowed.
H315 Causes skin irritation.
H319 Causes serious eye irritation.
· Precautionary statements
P210 Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P233 Keep container tightly closed.
P240 Ground/bond container and receiving equipment.
P241 Use explosion-proof electrical/ventilating/lighting/equipment.
P242 Use only non-sparking tools.
P243 Take precautionary measures against static discharge.
P264 Wash thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P280 Wear protective gloves/protective clothing/eye protection/face protection.
P301+P312 If swallowed: Call a poison center/doctor if you feel unwell.
P330 Rinse mouth.
P321 Specific treatment (see on this label).
P303+P361+P353 If on skin (or hair): Take off immediately all contaminated clothing. Rinse skin with water/shower.
P305+P351+P338 If in eyes: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P332+P313 If skin irritation occurs: Get medical advice/attention.
P362+P364 Take off contaminated clothing and wash it before reuse.
P337+P313 If eye irritation persists: Get medical advice/attention.
P370+P378 In case of fire: Use CO2, powder or water spray to extinguish.
P501 Dispose of contents/container in accordance with local/regional/national/international regulations.

3 Composition/information on ingredients
· Chemical characterization: Mixtures
· Description: Mixture of the substances listed below with nonhazardous additions.
· Dangerous components:
CAS: 64-17-5 - RTECS: KQ6300000 ethanol 90.0%
CAS: 2089251-47-6 SM-102 10.0%

Wait a second. There is ETHANOL PRESENT IN THIS INGREDIENT?

10 Stability and reactivity
· Reactivity - No further relevant information available.
· Chemical stability
· Thermal decomposition / conditions to be avoided: No decomposition if used according to specifications.
· Possibility of hazardous reactions No dangerous reactions known.
· Conditions to avoid No further relevant information available.
· Incompatible materials: No further relevant information available.
· Hazardous decomposition products: No dangerous decomposition products known.

11 Toxicological information
LD/LC50 values that are relevant for classification:
ATE (Acute Toxicity Estimate)
Oral LD50 5,000 mg/kg
64-17-5 ethanol
Oral TDLO 1.14 ml/kg (man)
LD50 7,060 mg/kg (rat)
TDLO 650 (man)
Dermal. LD50 40,000 mg/kg (rat)
Inhalative TCLO 1,800 (hmn)
LC50 10 h - 20,000 mg/m³ (rat)
LD50 Inhalation TCLO 1,800 mg/m³/30m (hmn)
Irritation of skin TDLO 1,800 mg/kg (wmn)

· Primary irritant effect:
· on the skin: Irritant to skin and mucous membranes.
· on the eye: Irritating effect.
· Sensitization: No sensitizing effects known.
· Additional toxicological information:
The product shows the following dangers according to internally approved calculation methods for preparations:
Harmful
Irritant

· Carcinogenic categories
IARC (International Agency for Research on Cancer) 64-17-5 ethanol

SOURCE - CAYMEN CHEMICAL (Printing date 06/07/2022)

PEG2000-DMG (1,2-dimyristoyl-rac-glycerol,methoxy-polyethyleneglycol)

PEG-lipid is used to control the particle size and act as a steric barrier to prevent aggregation during storage.
1.2 Relevant identified uses of the substance or mixture and uses advised against
Identified uses: Laboratory chemicals, Synthesis of substances.

10. STABILITY AND REACTIVITY
10.1 Reactivity - No data available.
10.2 Chemical stability - Stable under recommended storage conditions.
10.3 Possibility of hazardous reactions - No data available.
10.4 Conditions to avoid - No data available.
10.5 Incompatible materials - Strong acids/alkalis, strong oxidising/reducing agents.
10.6 Hazardous decomposition products - Under fire conditions, may decompose and emit toxic fumes.
Other decomposition products - no data available

12. ECOLOGICAL INFORMATION
12.1 Toxicity - No data available.
12.2 Persistence and degradability - No data available.
12.3 Bioaccumlative potential - No data available.
12.4 Mobility in soil - No data available.
12.5 Results of PBT and vPvB assessment - PBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted. (WHY NOT?)
12.6 Other adverse effects - No data available.

Source - Med Chem Express (Revision Date: Apr.-20-2023)

SODIUM ACETATE TRIHYDRATE (commonly used in heat packs)

1.2. RECOMMENDED USE AND RESTRICTIONS ON USE:
USE OF THE SUBSTANCE/MIXTURE: FOR LABORATORY AND MANUFACTURING USE ONLY.
RECOMMENDED USE: LABORATORY CHEMICALS
RESTRICTIONS ON USE: NOT FOR FOOD, DRUG OR HOUSEHOLD USE

SECTION 10: STABILITY AND REACTIVITY 
10.1. REACTIVITY: NO ADDITIONAL INFORMATION AVAILABLE
10.3. POSSIBILITY OF HAZARDOUS REACTIONS: NOT ESTABLISHED.
10.4. CONDITIONS TO AVOID: DIRECT SUNLIGHT. EXTREMELY HIGH OR LOW TEMPERATURES.
10.5. INCOMPATIBLE MATERIALS: STRONG ACIDS. STRONG BASES. STRONG OXIDIZERS.
10.6. HAZARDOUS DECOMPOSITION PRODUCTS:
FUME. CARBON MONOXIDE. CARBON DIOXIDE.

SECTION 11: TOXICOLOGICAL INFORMATION 
11.1. INFORMATION ON TOXICOLOGICAL EFFECTS:
ACUTE TOXICITY (ORAL): NOT CLASSIFIED
ACUTE TOXICITY (DERMAL): NOT CLASSIFIED
ACUTE TOXICITY (INHALATION): NOT CLASSIFIED
SKIN CORROSION/IRRITATION: NOT CLASSIFIED
PH: 8.9 1M SOLUTION
SERIOUS EYE DAMAGE/IRRITATION: NOT CLASSIFIED
PH: 8.9 1M SOLUTION
RESPIRATORY OR SKIN SENSITIZATION: NOT CLASSIFIED
GERM CELL MUTAGENICITY: NOT CLASSIFIED
CARCINOGENICITY: NOT CLASSIFIED
REPRODUCTIVE TOXICITY: NOT CLASSIFIED
STOT-SINGLE EXPOSURE: NOT CLASSIFIED
STOT-REPEATED EXPOSURE: NOT CLASSIFIED
ASPIRATION HAZARD: NOT CLASSIFIED
VISCOSITY, KINEMATIC: NO DATA AVAILABLE
LIKELY ROUTES OF EXPOSURE: INHALATION. SKIN AND EYE CONTACT.
POTENTIAL ADVERSE HUMAN HEALTH EFFECTS AND SYMPTOMS:
BASED ON AVAILABLE DATA, THE CLASSIFICATION CRITERIA ARE NOT MET (OH BOY :( )

SECTION 12: ECOLOGICAL INFORMATION 
12.1. TOXICITY: NO ADDITIONAL INFORMATION AVAILABLE
12.2. PERSISTENCE AND DEGRADABILITY:
SODIUM ACETATE, TRIHYDRATE (6131-90-4):
PERSISTENCE AND DEGRADABILITY: NOT ESTABLISHED.
12.3. BIOACCUMULATIVE POTENTIAL:
SODIUM ACETATE, TRIHYDRATE (6131-90-4):
BIOACCUMULATIVE POTENTIAL: NOT ESTABLISHED.
12.4. MOBILITY IN SOIL: NO ADDITIONAL INFORMATION AVAILABLE
12.5. OTHER ADVERSE EFFECTS:
OTHER INFORMATION: AVOID RELEASE TO THE ENVIRONMENT.

Source - Grainger (ISSUE DATE: 12/10/2013 REVISION DATE: 11/24/2020)

Sorry for all of the caps. Sadly, this is how it presented when I copied it. :(

However, what does CHEMICAL BOOK have to say about this one?
Relevant identified uses of the substance or mixture and uses advised against
Relevant identified uses - For R&D use only. Not for medicinal, household or other use.

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity LD50 Oral - Rat - 3.530 mg/kg Remarks: (anhydrous substance) (RTECS)
LC50 Inhalation - Rat - male and female - 4 h - > 5,6 mg/l (OECD Test Guideline 403) Remarks: (anhydrous substance)
LD50 Dermal - Rabbit - female - > 20.000 mg/kg (OECD Test Guideline 402)
Remarks: (anhydrous substance)
Skin corrosion/irritation
Respiratory or skin sensitization - No data available
Germ cell mutagenicity - No data available
Reproductive toxicity No data available
Specific target organ toxicity - single exposure - No data available
Specific target organ toxicity - repeated exposure - No data available
Aspiration hazard - No data available
Toxicity - LD50 orally in Rabbit: 3530 mg/kg LD50 dermal Rabbit > 10000 mg/kg

Source - CHEMICAL BOOK (Revision Date:2023-05-06 Revision Number:1)

SUCROSE

In my original MDSD/Ingredient Substack I didn’t really spend much time on this one as it’s supposed to be sugar. Big mistake. Read on.

Relevant identified uses: For R&D use only. Not for medicinal, household or other use. (SUGAR, REALLY? ;) )

Information on toxicological effects
Acute toxicity
LD50 Oral - Rat - 29.700 mg/kg
Remarks: Behavioral: Somnolence (general depressed activity). Cyanosis
Diarrhea, Inhalation

Skin corrosion/irritation - No data available
Serious eye damage/eye irritation- No data available
Respiratory or skin sensitization- No data available
Carcinogenicity - No data available
Reproductive toxicity - No data available
Specific target organ toxicity - single exposure - No data available
Specific target organ toxicity - repeated exposure - No data available
Aspiration hazard - No data available
Toxicity - LD50 orally in Rabbit: 29700 mg/kg (POOR BUNNIES)

SECTION 12: Ecological information
Toxicity - No data available
Persistence and degradability - No data available
Bioaccumulative potential - No data available
Mobility in soil - No data available

Source - CHEMICAL BOOK (Revision Date:2023-09-09Revision Number:1)

TROMETAMAL

1.2 Relevant identified uses of the substance or mixture and uses advised against Identified uses: For research use only, not for human or veterinary use.

10 STABILITY & REACTIVITY
10.1 Reactivity - No data available.
10.3 Possibility of hazardous reactions - No data available.
10.4 Conditions to avoid - No data available.
10.5 Incompatible materials - Strong acids/alkalis, strong oxidising/reducing agents. 10.6 Hazardous decomposition products - Under fire conditions, may decompose and emit toxic fumes.
Other decomposition products - no data available.

11 TOXICOLOGICAL INFORMATION
11.1 Information on toxicological effects - The toxicological effects of this product have not been thoroughly studied.
Carcinogenicity: NTP? No    IARC Monographs? No    OSHA Regulated? No   ACGIH? No

SOURCE - ABMOLE (I HAVE NO IDEA WHEN THIS WAS CREATED)

(NOTE: When reviewing other MSDS sheets for Trometamol there are sections which have additional Toxicological Effects such as, Thermo Fisher Sci’s MSDS
Toxicologically Synergistic Products - No information available

Delayed and immediate effects as well as chronic effects from short and long-term exposure (EMPHASIS ADDED)

Irritation - No information available
Sensitization No information available
Mutagenic Effects- No information available
Reproductive Effects - No information available.
Developmental Effects - No information available.
Teratogenicity - No information available.
STOT - single exposure - None known
STOT - repeated exposure - None known
Aspiration hazard - No information available
Symptoms / effects,both acute and delayed - No information available
Endocrine Disruptor Information - No information available
Other Adverse Effects - The toxicological properties have not been fully investigated.

SOURCE - THERMO FISHER SCIENTIFIC (Creation Date 15-Dec-2011 Revision Date 24-Dec-2021 Revision Number 4)

TROMETAMOL HYDROCHLORIDE aka TRIS HYDROCHLORIDE

Recommended Use - Laboratory chemicals
Uses advised against - Food, drug, pesticide or biocidal product use

10. Stability and reactivity
Reactive Hazard - None known, based on information available

11. Toxicological information
Acute Toxicity
Product Information - No acute toxicity information is available for this product
Irritation - Irritating to eyes, respiratory system and skin
Sensitization No information available
Carcinogenicity - NO RESULTS (as per table).. Hmmmmm
Mutagenic Effects - No information available
Reproductive Effects - No information available.
Developmental Effects - No information available.
Teratogenicity - No information available.
STOT - single exposure - None known
STOT - repeated exposure - None known
Aspiration hazard - No information available
Symptoms / effects,both acute and delayed - No information available
Endocrine Disruptor Information - No information available
Other Adverse Effects - The toxicological properties have not been fully investigated.

SOURCE - THERMO FISHER SCIENTIFIC (Creation Date 26-Sep-2009 Revision Date 24-Dec-2021 Revision Number 7

So what are the chemical differences in the Lipids, Salts & Buffers compared to the ancestral shots for modeRNA? They added “DPSC” to the 1,2-distearoyl-sn-glycero-3-phosphocholine which I believe is the actual term for it & replaced Sodium Acetate with Sodium acetate “trihydrate”..

The “trihydrate” addition is the presence of water molecules (3 per formula unit), lower melting point and more soluble. Oh it can crystallize when exposed to heat which is why it’s used in heat packs in conjunction with Sodium Acetate..

I don’t know what in the hell our health authorities/regulators are on.. Probably glue as every single one of these chemicals are not “intended for humans or animals”.

Plus the amount of “no data available” or “no information available” is great cause for concern. No wonder we are seeing issues across the board.

WAKEY WAKEY.. :(

James Roguski

Project In Humanity

Last updated: April 24, 2026…

Read more

7 months ago · 184 likes · 93 comments · James Roguski

I’m taking a little pause from my Covid research to address the BS coming from the gov’t.. regarding the climate issue a la Directed Energy Weaponry (DEW) , High-frequency Active Auroral Research Program (HAARP) and those long-lasting “contrails” way up in the skies aka. Chemtrails/Solar Radiation Management/Geo-engineering trails/etc.

Actually, “Chemtrails” should be called “Stratospheric Aerosol Management” aka SAI.

Tesla was the original patent holder of DEW until it expired and Bernard Eastlund picked up the torch with one of his 23 patents being US 4686605A - "Method and apparatus for altering a region in the earth's atmosphere, ionosphere, and/or magnetosphere"...

In layman’s terms? A natural gas powered antenna array in Gakona, Alaska, covering a 33 acre area with the ability to generate billions of watts of power and use it a a death ray, of sorts.

Here’s an excellent report from 1995 which has some eerie predictions from physicist, Dr. Patrick Flanagan @ the 6 minute mark but the denial from the site manager is quite telling. The fact that a news outlet ran this story is impressive.

What about DEW Patents? Do they exist? YES. :(

I did a simple search in Brave for “Directed Energy Patents”.. This is what it gave me..

”The provided search context highlights several key directed energy weapon patents, primarily focusing on RF directed energy, fiber lasers, and electron beams.

US8049173B1 (2011) covers a dual use RF directed energy weapon and imager, utilizing a generator to provide a first beam of RF electromagnetic energy directed to an object.

US10337841B2 (2019) and WO2016024265A1 describe directed energy weapons based on fiber lasers, comprising a plurality of laser units in a gimbaled housing for use against targets.

US7282727B2 (2007) details an electron beam directed energy device, often located in outer space, where individual beams are focused on distant targets to destroy missiles, overcoming Coulomb repulsion.

Raytheon Company holds multiple related patents, including WO2007022339A2 (2007) and US7490538B2 (2009) for weapons with lethal and non-lethal directed-energy portions, as well as US7784390B1 (2010) for a solid-state non-lethal directed energy weapon.

Other notable patents include US7126477B2 (2006) by Raytheon for a millimeter-wave area-protection system and US6799499B2 (2004) by Canada for a landmine neutralizer using a high-power microwave device.”

Then I did a search for “Is HAARP Directed Energy”
”Yes, the High Frequency Active Auroral Research Program (HAARP) is fundamentally a directed energy system, specifically designed to transmit high-frequency radio waves into the ionosphere…..”

The funny thing is how they try to downplay it to make sure they remain in the shadows.. Not cool.

As mentioned in the above vid, HAARP was to be completed in 1997. Here’s where it gets weird. Guess what happened in 1998?

”Nine of the top 10 warmest years on record for the contiguous 48 states have occurred since 1998, and 2012 and 2016 were the two warmest years on record.”

• source EPA Climate Change Indicators: U.S. and Global Temperature

Fun. Well, not if it's your house or a certain couple of towers which used to stand in one of the US's most populated cities... Hint? Spires don't evaporate during an implosion.

So why am I typing all of this? Well, I just stumbled upon this video.

DEWs (Directed Energy Weapons) IN ACTION

The 1st couple of minutes are from some dudes cell phone in the US. The rest? From a documentary but still worth your time, especially the public admission from the US govt.

The 7:42 mark is from captured footage from a couple of years ago shot from a few miles away and, once again, further validation to the claim that they exist and CAN START FOREST FIRES IN A MATTER OF MINUTES!!!!.

HOLY CRAP!!!!!!

It gets better. 8:19 mark when DEW takes out a 5g tower. There is a slight argument that this could be a lightening bolt but it's minimal. This one I actually support and for a few thousand hours of research on the dangers on 5g alone and a decade in the "g" industry. My acoustic neuroma as a parting gift is a ringing which will never go away as a result. Thanks big Cell for not having any bioscientists on staff and thanks CRTC & FCC for also not having any bioscientists on staff.. While I'm at it, thanks also Big Cell for not being able to get your Cell Towers insured. Hmm.. Now why could that be? Oh yeah, like the nuclear power plants, you can't insure towers which emit RADIATION!!!! Ugh.

Back to the video, @ the 9:48/49 mark, we see the DEW zap at a warehouse in Beirut a couple of years ago. It was labelled as a “bomb” which went off in an industrial building at a wharf and the news went off stating it was a bomb. After watching the recent footage? I beg to differ.

10:28? You guessed it. Another DEW zap but this time somewhere in Asia. Where? No clue but eerily similar to the previous video.

10:44 - 11:07. Same type of DEW zap as the last 2. This one sliced a skyscraper with relative ease.. Remember that little bit above where I mentioned Eastlund's 40sq mile antenna array? Except for the missing first couple of seconds of the strike, this one is crazy insane. Just think. If this was an apartment bldg? Anyone in the building is instantly toasted. Notice how it turned to dust? Remember when a couple of towers turned into dust under the guise of "planes" and "thermite"?

11:13. This one is from Mexico and I do recall watching this one before. The "bluish" colour of the zaps can't be lightening as we don't see the bolts.. Just balls, of sorts. The secondary reddish-orange flashes are either building or utility explosions as an after effect of the DEW zaps.

12:00. Kauiai, HI. Holy beams in the sky batman!!!! I haven't really spent anytime on the recent "fires" in Hawaii as my gut told me it was DEW and I've been a little preoccupied. Like many DEW zap attacks, some of the trees seem to be impervious to "fire" even though the houses/buildings are completely destroyed. Kinda reminds of Lyton when I drove through there a few months back. It was like a perfect barrier between the trees and the town and tress in the town.

Here’s additional footage of the Circle of Fire which perfectly surrounded Lahaina City plus video of boats catching on fire both on the docks and boats in the harbour which were NOT tied to the dock. This makes no sense whatsoever.

Qui bono?

I mentioned SAI’s above briefly and here’s my hypothesis. I have noticed a spike in the barium and aluminum oxide levels in our well water between 2 water test reports from the mid 2000’s and in 2015. What I really didn’t know was how toxic and flammable barium was until I looked into it.

From the MSDS sheet

Product identifier

• Product name: Barium

• CBnumber: CB0854186

• CAS: 7440-39-3

• EINECS Number: 231-149-1

• Synonyms: barium,BARIUM STANDARD SOLUTION

Relevant identified uses of the substance or mixture and uses advised against

• Relevant identified uses: For R&D use only. Not for medicinal, household or other use.

It gets worse.

SECTION 2: Hazards identification

GHS Label elements, including precautionary statements

• Symbol(GHS)

Signal word Danger

Precautionary statements
P210 Keep away from heat/sparks/open flames/hot surfaces. — No smoking.
P223 Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P231+P232 Handle under inert gas. Protect from moisture.
P240 Ground/bond container and receiving equipment.
P280 Wear protective gloves/protective clothing/eye protection/face protection.
P335+P334 Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P370+P378 In case of fire: Use … for extinction.
P402+P404 Store in a dry place. Store in a closed container.

Hazard statements
H228 Flammable solid
H261 In contact with water releases flammable gas

Indication of any immediate medical attention and special treatment needed

No data available (????????????????)

To add more insult to injury, the “Toxicological” & “Ecological” sections should have you freaking out and it’s not due to the “No Data Available” sections .. Ok, I lied. It is that serious.

Then we have Aluminum Oxide. Here’s the MSDS Sheet.

“Product identifier

• Product name: Aluminum oxide

• CBnumber: CB9853056

• CAS: 1344-28-1

• EINECS Number: 215-691-6

• Synonyms: ALUMINUM OXIDE,Al2O3

Relevant identified uses of the substance or mixture and uses advised against

• Relevant identified uses: For R&D use only. Not for medicinal, household or other use.

SECTION 2: Hazards identification

GHS Label elements, including precautionary statements

• Symbol(GHS)

Signal word Danger

Precautionary statements
P210 Keep away from heat/sparks/open flames/hot surfaces. — No smoking.
P240 Ground/bond container and receiving equipment.
P241 Use explosion-proof electrical/ventilating/lighting/…/equipment.
P251 Pressurized container: Do not pierce or burn, even after use.
P261 Avoid breathing dust/fume/gas/mist/vapours/spray.
P301+P330+P331 IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P303+P361+P353 IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P305+P351+P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.
P331 Do NOT induce vomiting.
P405 Store locked up.
P410+P412 Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.

Hazard statements
H222 Extremely flammable aerosol
H225 Highly Flammable liquid and vapour
H226 Flammable liquid and vapour
H304 May be fatal if swallowed and enters airways
H314 Causes severe skin burns and eye damage
H318 Causes serious eye damage
H319 Causes serious eye irritation
H333 May be harmful if inhaled
H336 May cause drowsiness or dizziness

The “lack of data” in Sections 9-12 is alarming!

Both of these chemicals are being sprayed daily with the gov’t playing dumb and blaming it on “Climate Change”. I beg to differ.

The folks at “Natural Society” have a decent article on these 2 dangerous and higly flammable chemicals plus some info on Strontium here. Don’t forget to read the comments as this is not new.

I find it too convenient that the gov’t is blaming “climate change” on anything that’s on fire when they are allowing fire accelerants to be sprayed from the skies with the potential to be triggered by DEW or HAARP or DEW & HARRP.

Dane Wigington has spent many years looking into geo-engineering and has quite the resource section on this and “Engineering Wildfires”

In any event, I opted to do my civic duty and reach out to all of the Provincial & Federal Environmental Ministers regarding the situation in the skies. Feel free to copy and paste, edit to your liking and email them.

TO:
ministre-minister@ec.gc.ca, ENV.Minister@gov.bc.ca, DM.ENV@gov.bc.ca, aep.minister@gov.ab.ca, env.minister@gov.sk.ca, minec@manitoba.ca, minister.mecp@ontario.ca, ministre@environnement.gouv.qc.ca, elg/egl-info@gnb.ca, minister.environment@novascotia.ca, samyersMinister@gov.pe.ca, ecc-minister@gov.nl.ca, nils.clarke@yukon.ca, Shane_thompson@gov.nt.ca

Subject: Environmental Emergency (reply requested)

Stephen,

I've included all of the provincial ministers in this convo as I've got friends and family across the country.

As a former voter and lifelong citizen of this once wonderful country. I, along with millions of Canadians, are now politically marooned due to the incompetence and complete denial of those Dr's and Scientists who came forward since 2020 which is a completely different convo. 

I have lost all faith in our "democratic" system.

But does my vote count? Does my voice count? Based on the amount of outside influence, I doubt it.

In any event, here are some questions in which we want answers for if you continue to push this "climate change" issue.. Well, man induced climate change via the current available tech.

Let's start with a simple, yet alarming quote by LBJ back in the early 60's

"There will come a day when man controls the weather and he who controls the weather, controls the WORLD"
https://archive.org/details/he-who-controls-the-weather-will-control-the-world-lyndon-b-johnson

Let that sink in for a minute or until you clue in.

Before you start labelling me, stop. I actually do care about our environment but I draw the line when it is politicized for the wrong reasons and to date, I have yet to see any politician actually address the elephant in the room regarding "climate change" - the human influence regarding the tech used to create/adjust weather and the results created from this influence.

Aside from what's happening in our skies on a daily basis, it seems that every province in this country has an issue when it comes to the root cause of the problem. Why would this be? Could it be that, like the Health Ministers, a majority of "Environment" ministers are appointed without any relevant work experience? Yes, you have staff which may have a clue or 2 but where are they getting their info from and at what cost?

Our land is being polluted daily by large chemical corps who would rather take the risk of petty fines of their millions of $$$ of toxic waste/chemicals which are being dumped into our water systems, our land and even the skies. THIS MUST CHANGE. As elected and appointed officials, you are responsible for the air we breathe, the water we drink and to ensure that our crops are free of chemical influence. Thus far, you all have failed us. As an example, organic fertilizers using class A bacteria and other organic elements can not only reduce the reliance on chemical fertilizers and enrich the soil. How do I know this? I co-owned a company a decade ago which did this and also did bio/soil remediation. Hell, I could clean up oil spills in a fraction of the time using our products and still can. Moreover, the price point pales in comparison to those who think chemicals in our soil/water and thus food is more cost effective. Bullshit. Organics cut the reliance and over time, cost-effective and enrich the soil with oxygen that the chemical fertilizers fail to do.

Please don't blame former administrations as it's in the past. We need to look at the present and the future if we are to survive.

Now regarding the "wild fires" that are currently affecting our ability to breathe. Please note that any videos I use are to demonstrate what was captured at the time. As a disclaimer, I do not endorse any political or religious opinions they may have.

Why or how could so many fires which are many miles/km's away from one another in different provinces all start simultaneously or within seconds/minutes of one another?

https://www.bitchute.com/video/uV1dSuEY1Aw3/

Could it be from people dropping their smokes/joints/camp fires/pyro's? Perhaps..

Could it be DEW (directed energy weaponry)/HAARP? High probability.

DEW - 
https://publications.gc.ca/collections/collection_2023/cnrc-nrc/NR16-419-2023-eng.pdf
https://www.lockheedmartin.com/en-us/capabilities/directed-energy.html
https://climateviewer.com/2018/08/02/weather-control-directed-energy-weapons-fires-rage-worldwide/

HAARP-
https://pubs.aip.org/physicstoday/article/68/12/72/415022/HAARP-the-most-powerful-ionosphere-heater-on

HAARP in action -

HAARP Open House 2022 -

Angels Don't Play This HAARP -
https://archive.org/details/angels-still-dont-play-this-haarp

The book - https://www.alachuacounty.us/Depts/epd/EPAC/Angels%20Dont%20Play%20This%20HAARP%20by%20Nick%20Begich%201997.pdf

Could it be a combo of geoengineering and DEW? See my above answer regarding DEW.
https://www.bitchute.com/video/7mbMGog16dLw/

With all of the $ that this govt is taking from us in "carbontax", we have yet to see any accounting or results for this ridiculous cash grab. As an additional slap in the face, now you want to increase the tax to combat their "cause".. Why? Where will the $ go and to whom? When we will see results?

To add more insult, planes were spraying yesterday above the existing smoke from the fires which I saw when the skies cleared at nite. Sadly, it was too dark to take pictures.
Weather modification tech: How cloud seeding increases rainfall

Lots of jobs in this field.
https://duckduckgo.com/?q=weather+modificaiton+jobs&t=newext&atb=v368-1&ia=web

Are you aware of Canada's Weather Modification Act? https://laws-lois.justice.gc.ca/eng/acts/W-5/index.html

We have the ability to create weather and the patents for this go back to the late 1800's. Don't believe me? Check out the patents for said topic and learn something and do something positive for a change.
https://climateviewer.com/2014/03/24/geoengineering-weather-modification-patents/

Remember the LBJ speech I shared at the beginning? There's a reason why I shared it. During the Cold War days, MAD (mutually assured destruction) was never an option as it went against the actual purposes of war:

-  take over the country, instill your dogma, steal resources, etc.. it's impossible to do this if a country has been nuked back to the stone age.

This is why we haven't had a nuclear war. However, using weather modification as a weapon is better alternative, well, that's if you support war. Imagine if troops were moving along a mountain. You need to stop them. Create enough rainfall to flood out the roads, thus stopping them in their tracks and then you could bomb them or allow the result of the heavy rainfall to wash out the roads or create rockslides via DEW.

So, if we the ability to create weather, why is it that we can't create rain to stop these fires? It's a very simple and honest question which I pose to all of you included in this email. Using this principal, we could end drought in areas which need it, improve the quality of life globally. Yet, we use this tech as a weapon or claim complete ignorance. Tesla is rolling in his grave right now.

It's time to do something about this and if you can't? Please resign asap as your policies and decisions are counterproductive, regardless of what your "beliefs" are..

In closing, I do expect all of you to review the literature and evidence I have shared. I will be calling you all next week and will continue to do so.

FEB 13, 2025 UPDATE - As of July 2024, the BC College of Surgeons & Physicians DROPPED their case against Dr. Nagase.

NEVER GIVE UP THE FIGHT!!!

Now back to the story and evidence.

Over the last 3+ years, my life has taken more spins and turns than the craziest rollercoaster.

Just a little over 6 months ago, I had the privilege in meeting Dr. Daniel Nagase at a rally we we both speaking at. What started as an innocent intro has developed into a pretty incredible friendship. Not only were we both able to obtain both a pfizer covid-19 vial but 2 moderna syringes which he took to a lab for independent analysis. The results? Well, let’s just say that they are consistent with what we’ve seen on the net and I still have to sit down with him and go over all of the images for clarification for an over-due substack piece which has been waiting patiently.

In any event, the cool thing about speaking with a doctor who doesn’t have his head buried in the sand is the fact that no topics are off-limits and there is plenty of incredible dialogue. In fact, I don’t think that we have not seen eye-to-eye on any subject material.

Our calls last for hours and good thing neither of us are charging one another ;)

A few weeks ago I got a call from him regarding an email he received from Dr. Trevor Corneil who was assigned by the BC College of Physicians and Surgeons to review his speeches and anything else he spoke out about since the “Great Social Experiment of 2020” reared it’s toxic bioweapon-infested head. Aside from the first few pages of alleged credentials, the majority of his 71 page report was laughable at best and littered with very questionable statements.

On the first pass, I couldn’t get past the 1st 5 or 6 pages as I was in shock how biased and uninformed Dr. Corneil really was when it came to Ivermectin or anything else he wasted 4 months on .. Yes 4 months.

Dr. Nagase was given 3 weeks to form a rebuttal.

Can anyone say “Kangaroo Court is now in session”?

Fortunately, my new friend accepted the challenge and also invited me to participate in this fiasco..

My email will be used as evidence for part of his defence.. However, I was given less then 24 hours to complete it with a laptop which goes on auto-scroll mode “up” or “down” it doesn’t discriminate against me but is s serious pain in the ass, especially when I have to add or edit something.. :(

In any event here’s my email..

To trevor.corneil@ubc.ca RachelNoble@ngariss.org gkeirstead@CPSBC.CA lisa@ngariss.org andrea@ngariss.org dhammell@CPSBC.CA RIrvine@CPSBC.C Ajenkinsonv@gmail.com KBracken@CPSBC.CA

Monday, February 13th, 2023 at 5:35 PMMonday, February 13th, 2023 at 5:35 PM

SUBJECT - These materials are for presentation for the defense of Dr. Daniel Nagase

Trevor et al,

Unlike you getting 4months to prepare a 71 page doc, Dr. Nagase got 3 weeks for his rebuttal and I have under 24 hours. Oh how I l love the 2023 version of preparing for a Kangaroo Court. Yes, I'm going there.

At any rate, I am an independent researcher with well over 35 years of experience covering a variety of subject matter. I was born during the Hong Kong Flu and was "vaccine injured" as a child. After my 2D's and 2P's, I developed asthma, severe anaphylaxis, hypertension and ADHD even though I skipped 2-1/2 grades in 3 months. The school system couldn't keep up with me so I was the 1st child in NS to be put on Ritalin in the mid 70's. What I didn't know was they cut the ritalin with cocaine. Officially I was a lab rat and spent 3-4 days a week in a Dr's office or hospital until I was 18.

Aside from being the "Murphy's Law Poster Boy for Accidents" from 1991 - 1993, 1995, 2002 (L5 disc) and a mini stroke in 2009, I've been relatively healthy as I eat as healthy as possible due to the overwhelming amount of side effects from meds I was on during my "pain years'..

My last hospital visit happened in 2015 when I ate something which put me in emerg with welts all over my body and given the fact that anaphylaxis is listed on both the Oct 22,2020 and Feb 2021 VRBPAC list of "Working List of Possible Adverse Event Outcomes" when these "vaccines" were given "Interim Order Approval" I paid close attention.

Since then? The only time I have been sick was when I wasn't getting enough sleep and my immune system took me out for a total of 6 days (2 days/year) over the last 3 years. Based on my medical history, I should've been a prime target for what ever this "thing" is, which after 211 FOIA requests for proof of isolation/purification still has "no records found"..
https://www.fluoridefreepeel.ca/fois-reveal-that-health-science-institutions-around-the-world-have-no-record-of-sars-cov-2-isolation-purification/

Pay close attention to the amount of Canadian groups their are and which ones. Aside from the RCMP, there are 51 other entities which should have conclusive proof..

Oh, don't forget the "Drosten Paper" but did you read the rebuttal? https://www.covid19reader.com/did-faulty-science-lead-to-lockdowns-examining-the-drosten-paper/

Now I don't want to play the germ vs terrain theory game as this is neither the time, nor place for it.

Since March 2020, I have devoted well over 13,000 hours of independent research when deemed "non-essential". To date, I deal with well over 250,000 medical and scientific experts in 48 countries for which I am eternally grateful for. Many of these wonderful humans are either whistleblowers or want to come forward but are continuously being silenced, coerced or threatened if they go against the narrative? Why? Is this what the "scientific method" is supposed to stand for? Open debate? Challenges? Replication of evidence? Odd how everyone of them have dealt with patients during the last 3+ years vs those who hide behind policy or bureaucracy or "modelling" data.

Dr. Daniel Nagase is one of the above medical and scientific experts not on the government payroll who has enriched not only my life and countless others. I had the pleasure of sharing the same stage at a rally we both spoke at earlier in 2022 and unlike those who you and others brand as right-wing, tin-foil hat, anti-science, god-loving, trumpers, I don't play politics nor religion. I do not base my speeches on "freedom". Instead, my speeches are littered with facts, evidence, data and stats which is entirely source-based upon request or compiled in my substack.

If you have a question or need clarification on a medically-related matter? He has yet to let me down. He is very detailed, well researched and actually answers questions in a timely manner. His expertise is top notch. Dr. Nagase has opened my eyes to an experimental med which was used in the hospital he worked at during this alleged pandemic (sorry, but when you have an IFR lower than the seasonal flu). You know this, I know this and many others also know this. Our phone calls last 2-4 hours and every call is very educational and fascinating.

Now he has to defend himself, it's bad enough that you, ok not literally, took his family away from him because he opted to draw a line in the sand but this current fiasco is where I draw the line.

IF this "great social experiment of 2020" was as lethal as 1st advertised, the entire planet would've been locked down, all stores would be closed, people would be locked in their houses with their windows sealed shut and the only way that you could get food would be from the military which would deliver your food to your front door which had a decontamination chamber affixed to it..

Problem is? We never came close to that. The population was duped by a faulty model from Neil Ferguson and the folks at Imperial College of London..

Did you notice how the deaths increased in the same period of time post rollout? Don't even get me started on all-cause mortality as I find it odd how instead of being beaten down with daily updates for over a year, the gov't opted to move to a weekly reporting scheme, all the while still pushing fear.. Cortisol levels LOVE fear (sarcasm intended).

If I want to get really picky, the numbers pre-jab are also questionable if you add in the fact that the PCR had a 97.1% false positive rate due to the over-cycling (40-45 in Canada) and the other fact that PCR was not a "Covid-only" test.

That's a slight problem if you want to convince people that there is a killer pandemic happening. What about EMR/EMF, WIFI, cell phone, environmental exposures, constant exposure from 80 years of Nuclear testing, poor diets, etc.?

How is it that not 1 alleged health "expert" in the western hemisphere ever spoke -about looking after our immune systems by-eating health organic foods, drinking properly filtered water (sorry tap water doesn't cut it and that's with over a decade in the industry),taking properly sourced vitamins and minerals, and exercise

Shall I repeat it again? If so, re-read it again and look at their model I included within my substack piece above.

It's bad enough that the only approved "treatment" happened to have a 53.1% kill rate in the Ebola Trials and an 88.6 kill rate once exposed to the people.

https://rupreparing.com/news/2022/1/6/remdesivir-a-world-divided-amp-serious-questions

Then we have another issue, the CICP database in which 98 of the 100 people reported using this toxic drug DIED. Take your pick on which report you want to review and do a word search for "Remdesivir" . The numbers don't lie. https://www.hrsa.gov/cicp/cicp-data#table-1

Another issue lies with ventilator abuse and the cash cow it turned into. I'm baffled at the fact that people who still had open airways were put on vents. Also baffled from the fact that a majority of nurses and other health care professionals didn't have the proper training for vents. I have 1st hand evidence from nurses in the US who had to turn down the "volume" on the vents when the started their shifts in many hospitals which patients were coding. We even have the study for further proof.

Then there is another drug which Dr. Nagase mentioned which was used in his hospital in AB - baricitinib..
https://www.drugs.com/sfx/baricitinib-side-effects.html

Meanwhile, other off-label or repurposed drugs were ignored or scorned by the alleged "experts'.. Have you actually read any trials which weren't skewed?

"COVID-19 early treatment: real-time analysis of 2,495 studies - Analysis of 48 COVID early treatments, approvals in 80 countries, database of 2,287 treatments" https://c19early.org/

Aside from the fact that 2 of the drugs were low cost, with one coming off patent, the other given an EUA in the US from March 28-June 15 https://www.fda.gov/media/136537/download

Don't forget the study which The Lancet was forced to retract regarding HCQ - https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2820%2931180-6/fulltext

There's another reason why HCQ was pulled. The alleged "Vaccine" aka "Experimental Gene Therapy Bioweapon" clinical trials started and if these drugs and other therapies were allowed to continue, there would be NO NEED OF ANY CLINICAL TRIALS.

However, aside from the Nobel Prize winning "Horsepaste" getting its fair share of smear campaigns, HCQ was used for SARS-1 with incredible success and stockpiled for years.. Is there evidence to support this? You decide.. https://pubmed.ncbi.nlm.nih.gov/16115318/

THE COVID-19 "Vaccine" Clinical Trials.

This is what I've learned about Coronaviruses over the years, assuming they are properly isolated or purified. They have 2 inherent problems which is why funding has always been a problem.

1. they resolve themselves over time. Where did SARS-1, MERS, Avian, Swine, etc all go?
2. variants, may be more transmissible but are NEVER as lethal as the ancestral strain.

Odd how we never saw a "vaccine" for any of the coronaviruses listed in #1 above. Why not? SARS-1 had a higher IFR than SARS Cov-2 but the world was not put on a 2+ year pause.

Years ago, I was taught that "vaccines" are:

• supposed to induce an immune response

• block transmission

• prevent infection

• have a weakened live viral fragment from patient 0 or 1 (depending on which country you live in)..

Yet, none of the Interim Order approved "vaccines" do any of the above.

After the rollout, I started calling I have called PHAC, Health Canada, OCC, REB, NRCan, CIHR, Health BC, BCCDC, Fraser/Coast/Island/Interior Health in which I have asked all of them for the trial data for Canadians involved in the original trials for the ancestral C19 strain. Not one of the aforementioned agencies could provide me any source links or data. I have recorded about 300 hours of my calls.

Since you are an expert with a couple of decades of experience under your belt, short of slapping you with a FOIA request, kindly provide me any data for Canadians involved in any of the original trials. I reviewed the clinical trials for Pfizer, Moderna, J&J and AZ with AZ still not approved under EUA in the US and Canada is no where to be found.. Well, unless you want to bring up the LNP issue aka LNP Providence (Artbutus, Aquitas & UBC)... Hello violation of the 1985 Competition Act.

The fact that Canada never participated in ANY of the ancestral trials is concerning and is potentially violates Health Canada's phrase that "vaccines" take at least 10 years" before they get approved".

Here's the link for Immunize BC and it's littered with issues when it comes to vaccine testing and approval. I've added the last paragraph as this was never the case for the C19 shots.

"No safety steps are skipped in these cases, and the vaccine still has to meet all the same safety requirements. An example is COVID-19 vaccines. " https://immunizebc.ca/ask-us/questions/how-long-does-it-take-vaccine-be-tested-and-approved-use-canada

Moreover, how can ANY alleged "Health Official" actually have the gall to stand behind any decision passed down from our Chief Health Officer, or an alleged group of experts who have potential conflicts of interest if 0 Canadians were part of the original trials for the ancestral strain which would be rendered useless once the alleged Delta strain appeared in Aug 2020?

How many of the manufactures adjusted their formulations during the clinical trials once the new variants appeared out of nowhere? The answer? 0

With that said, how could you support? authorize? promote? a gene therapy product which has a history or wiping out the animals in their trials once they are expose to a wild-type virus? Did you even have a chance to review any of the Manufacturing Agreements (1) (2)? Ignorance of the facts are no longer an excuse.

How can you, in good conscience allow a product to be administered into the arms of people which was promoted as an "intramuscular" injection when we are finding evidence of the spike throughout the blood and organs?

Back in late Dec 2021, a friend sent me a link to 1,000 studies pertaining to AESI's or S/SAE's (severe/serious adverse events) including death. To be frank? It was a mess, I found 400 links which were either dead links or blank abstracts which isn't good enough. So I took it upon myself to fix it, put them in alphabetical and chronological order which is one of the largest on planet earth not affiliated with any medical/scientific journal. However, the source links are from the Lancet, BMJ, NEJM, MCPI, NIH, JAMA, Springer, etc..

I stopped at approx 1,600 as it was taking a toll on me and have added a few more from time to time.

Shortly, thereafter, I decided to look at the chemical ingredients compared to their respective MSDS sheets and found that 70% of the Lipids, Buffers and Salts contained the terms "Not for HUMAN or ANIMAL Use, for lab or chemical use only".. It gets worse when you look at the lack of data for reproductive, carcinogenicity, etc..

Yet, this little important fact missed the entire scientific community. I'm currently doing the same for the alleged "boosters" which, when you can find the MSDS sheets which were not corrupted post rollout they also have the same 70% problem affixed to it. Yet there is another issue with the "Boosters". Aside from changing the formulation, last time I checked, if you change the ingredients of a thing and call it a booster, can it legally or scientifically be called as such? It seems the mice (yeah, finally trial on animals) didn't agree.. https://owenowenowen.substack.com/p/if-the-boosters-never-worked-on-mice

You are probably asking yourself, "why is this person calling these "safe & effective vaccines" bioweapons? Glad you asked, it's because they are. I took a deep dive into the patents, SEC filings, various medical journals/papers and even the media to find this out..

Aside from Dr. David Martin (1) (2) and Dr. Richard Fleming extensive research into this topic, this was sent to me a couple of days ago and should make you think twice next time you want to see these bioweapons injected into innocent human beings.. Katherine Watt who has done some incredible research into the bioweapons and other relevant issues pertaining to present day. (1) , (2) , (3)

She also does an excellent piece on the Ventavia (Pfizer) whistleblower, Brook Jackson in which the BMJ published.

I have too many studies, links, etc to share on the above Bioweapon topic but now I want to address the missing portions of the clinical trials when it comes to short, mid and long-term safety studies.

Remember that group of Canadian Agencies I mentioned way above? Well, I also reached out to them for the following info with regards to any safety data..

1. biodiversity

2. genotoxicity

3. carcinogenicity

4. pregnancy, reproductive, menstrual - back in late 2020, Pfizer signed an LOI to perform tests on pregnant and new moms. This never happened before they started injecting innocent moms and moms to be. I know a couple of unjabbed actors who are on set and whenever they are around jabbed actors they are getting their periods 2x-3x's/month

5. multiple comorbidities - excluded from the trials

6. children (all ages) - the worst being the 6months - 4/5yr olds where 2/3's of the participants never got past the 1st or 2nd shot. Remember, there are 20,000,000 children in this age category and they bum rushed the EUA based on sketchy data from 7 kids.

7. lipid nanoparticle distribution (LNP)

8. pharmacokinetic (PK)

9. pharmacodynamic

10. mix and match studies.

11. Shedding/transmission

12. Prior alleged "Covid19" infection.

13. Human studies for the "Booster"

Here's the link for Pfizer's "landmark study"

https://media.tghn.org/medialibrary/2020/11/C4591001_Clinical_Protocol_Nov2020_Pfizer_BioNTech.pdf

So, if Pfizer never tested for any of the above or excluded certain "groups" for their trials, how can you or anyone else in your position stand by these products?

What about modeRNA?

Phase 1 study.

https://clinicaltrials.gov/ct2/show/NCT04283461

Phase 2

https://clinicaltrials.gov/ct2/show/NCT04470427

Phase 3

https://clinicaltrials.gov/ct2/show/NCT04470427?term=mRNA-1273&recrs=e&draw=2&rank=2

The "exclusionary criteria" in all 3 phases of modeRNA's trials are a masterpiece (sarcasm also noted)

Moreover, why were the animals trials skipped before these bioweapons were released to the masses? Are you actually ok with skipping these trials for an ongoing experiment on humans? I'm not, nor is any other medical profession who truly values their hippocratic oath.

A little bit on the "Booster" and mice

From Dec 20, 2022.

"Extended SARS-CoV-2 RBD booster vaccination induces humoral and cellular immune tolerance in mice"

"The repetitive applications of vaccine boosters have been brought up in face of continuous emergence of SARS-CoV-2 variants with neutralization escape mutations, but their protective efficacy and potential adverse effects remain largely unknown."

NOTE. of course their efficacy and potential AE's are largely unknown if you don't study them in the trials or study them ,find out that there are safety signals, etc.. Remember, THERE WERE NO HUMANS INVOLVED IN THE BOOSTER CLINICAL TRIALS!.. Yet there are those who took the 1st round of shots continue to take them.

Why?

What are the benefits?

-You won't get sick? Nope. You still will.

- You won't get hospitalized? Nope. Still happens

- You won't wind up in the ICU? Nope.. You will with the potential of other issues triggered from the product you allowed to be injected into your deltoid muscle which was goes throughout your blood stream and organs and penetrates your blood barrier

- You won't die? Well, we all eventually die but this also exacerbates your chances of death..

These products are hurting your immune system and your body, in general and studies go back as early as April 2021

"Highlights

• IL-10 overproduction compromises NSC survival, leading to hippocampal neurogenesis reduction in adulthood.

• IL-10 overproduction results in spatial learning and memory impairment.

• IL-10 overproduction increases microglial CD200R expression and reduces microglial CX3CR1 expression in the hippocampus.

• Effects by IL-10 overproduction resemble those produced by physiological aging.

5. Conclusions

This work shows the importance of the microenvironment on microglial cells and their relationship with neurogenesis. Interestingly, we have demonstrated that chronic anti-inflammatory IL-10 overproduction has a similar effect to physiological aging on the hippocampus. Specifically, in transgenic animals and WT with normal aging, hippocampal neurogenesis and memory are impaired together with alterations in the microglia-neuron communication. Likely, IL-10 overexpression modifies microglial receptors involved in neuronal communication, resulting in reduced neurogenesis. This study emphasizes the variety of possibilities that a specific cytokine can exert depending on the moment and the time in which it is expressed. Thus, we describe new properties of IL-10 in hippocampal neurogenesis in vivo."

https://www.sciencedirect.com/science/article/pii/S0889159121006577

Back to the Dec study..

"Multiple vaccine boosters after the conventional vaccination course significantly decreased RBD-specific antibody titers and serum neutralizing efficacy against the Delta and Omicron variants, and profoundly impaired CD4+ and CD8+T cell activation and increased PD-1 and LAG-3 expressions in these T cells. Mechanistically, we confirmed that extended vaccination with RBD boosters overturned the protective immune memories by promoting adaptive immune tolerance. Our findings demonstrate potential risks with the continuous use of SARS-CoV-2 vaccine boosters, providing immediate implications for the global COVID-19 vaccination enhancement strategies."

- Boosters vs Primary series and not real "vaccines". Moreover, RBD's (receptor binding domains) are a key part of a virus located on its ‘spike’ domain that allows it to dock to body receptors to gain entry into cells and lead to infection. These are also the primary targets in the prevention and treatment of viral infections. These RBD's are turning on the body and attacking your immune system. The fact that the body initially accepts the synthetic self-assembling spike protein then turns on the spike once it realizes that it's an imposter is too late. The damage has been done and will continue to do as such to the point that you WILL wind in the hospital, ICU and potentially die quicker. :(

CD4 and CD8 are important for immunity protection and they are now impaired after the shots.. Don't forget. These shots don't promote/provide mucosal immunity which is paramount for fighting upper respiratory viruses, well the ones that they have proof of isolation/purification, of which SARS CoV-2 did either..

These shots are hurting your immune system and removing your antibodies. FACT. Therefore the manufactures and their paid govt and health shills are lying through their teeth..

The study authors are also hinting that the jabs are a risk and should be stopped based on my interpretation.

"Since late 2021, the SARS-CoV-2 Omicron variant has overtaken the global dominance and epidemiology studies have identified substantial levels of vaccine breakthrough infections and reinfections"

- These alleged 1st series of "vaccines" were allegedly developed for the alleged ancestral strain and NOT THE VARIANTS (delta, omnicron, etc).

"Accumulating evidence showed that the use of the first vaccine booster dose was safe and effective, and it could produce high titers of neutralizing antibodies with improved efficacy against Omicron variants "

- Sure it was. If anything more people got sick, hospitalized, wound up in the ICU or died as a direct result of the rollout which I pointed out in one of my latest substack pieces - https://owenowenowen.substack.com/p/the-numbers-from-canada-and-the-rest

"However, the serum protection after one booster vaccination was shown to decline with time, which again rendered the immunized individuals prone to continuous risk from newly emerged SARS-CoV-2 variants. Thus, the administration of a second booster vaccine or, possibly, routine vaccination with boosters was brought to light, for which scarce information was available. More information was needed to properly address relevant questions in the practical field of COVID-19 prophylaxis, such as the recommended condition for the use of additional booster vaccines, the suggested number of enhancement shots to be given and the potential adverse effects of continues administration of booster vaccines."

- Imagine my surprise? It never had any protection to begin with. Yet another fact.

"One of the major concerns associated with continuous immunization with booster vaccines is the relative limited response window of systematic immunity to the same stimuli. It has been reported that foreign antigen stimulation can induce immune tolerance, which is manifested as inability or low efficiency to produce antigen-specific antibodies and to activate effector T cells"

- Remember my point above when I mentioned that the fake spike tricks the body then attacks it? I hate being right.. ;)

"Presently, it is unclear whether extended administration of RBD vaccine boosters can re-establish protective immunity or is prone to induce immune tolerance."

- I beg to differ

"We found that the conventional immunization course could stimulate sustained levels of neutralizing antibodies and promote the antigen specific CD4+ and CD8+T cell reactivity. However, continued vaccination promoted the formation of a prominent adaptive immune tolerance and profoundly impaired the established immune response with the conventional course, evidenced by significant reductions in antigen specific antibody and T cell response, a loss of immune memory and form of immunosuppression micro-environment. Our findings demonstrated the potential risks associated with an extended vaccine booster course of SARS-CoV-2 vaccination, with immediate implications for the strategic use of homology booster vaccines."

- The 1st part of this is debatable but the rest is "statistically significant" enough to warrant a full stop.

"Results

“Extended immunization did not enhance RBD specific antibody production in mice
Extended immunization reduced serum neutralizing antibody responses"
Extended immunization inhibited the production of RBD-specific memory B cells"
Extended immunization suppressed the formation of the germinal center"
Extended immunization inhibited the activation of CD4+T cell immune responses"
Extended immunization inhibited CD8+ T cell-mediated immune response"

- So if it doesn't work in mice, how can it work in humans?https://www.sciencedirect.com/science/article/pii/S2589004222017515

Then we have a serious issue with IgG4 levels increasing instead of IgG3 after the shot - https://www.rintrah.nl/the-trainwreck-of-all-trainwrecks-billions-of-people-stuck-with-a-broken-immune-response/

Why are you ignoring "Net Harm"

""To assess the appropriateness of booster mandates in this age group, we combine empirical risk-benefit assessment and ethical analysis. To prevent one COVID-19 hospitalisation over a 6-month period, we estimate that 31,207–42,836 young adults aged 18–29 years must receive a third mRNA vaccine. " https://jme.bmj.com/content/medethics/early/2022/12/05/jme-2022-108449.full.pdf

5-11

uTobian

What is the Number Needed to Vaccinate (NNTV) to prevent a single COVID-19 fatality in kids 5 to 11 based on the Pfizer EUA application?

NNTV, the standard policy tool that Pharma, the FDA, & CDC no longer want to talk about A funny thing happened this afternoon. Not funny as in “haha”. More like funny as in, “ohhhhh that’s how the FDA rigs the process.” I was reading the CDC’s “Guidance for Health Economics Studies Presented to the Advisory Committee on Immunization Practices (ACIP), 20…

Read more

5 years ago · 230 likes · 186 comments · Toby Rogers

"Independent report

Appendix 1: estimation of number needed to vaccinate to prevent a COVID-19 hospitalisation for primary vaccination, booster vaccination (3rd dose), autumn 2022 and spring 2023 booster for those newly in a risk group"

Updated 27 January 2023

PAY ATTENTION TO ALL OF THE TABLES

https://www.gov.uk/government/publications/covid-19-vaccination-programme-for-2023-jcvi-interim-advice-8-november-2022/appendix-1-estimation-of-number-needed-to-vaccinate-to-prevent-a-covid-19-hospitalisation-for-primary-vaccination-booster-vaccination-3rd-dose-au

Pfizer leaks/Court Ordered PMA data

Last year, Pfizer lost it's court battle with ICAN for the purpose of withholding their PMA data from the public for 75 years. Thankfully, the US Supreme Court Judge was not on Pfizers payroll. The FDA took 118 days to review a few hundred thousand pages of data which is now available to the public. I suggest you spend some time reviewing it please.

Pay close attention to Page 7 where you see the amount of AESI's in the "Case Outcomes". Of the 42,086 people enrolled in the trials, a staggering 1,223 people died. What's additionally troubling is the line about "not recovered at the time of report" - 11,361 and the lack of data/follow up/etc from the unknown section - 9,400

Pages 16-24 mention the AESI's they were looking into but with minimal follow up. Why? Wouldn't this be concerning enough?

Pages 30-38 - "APPENDIX 1. LIST OF ADVERSE EVENTS OF SPECIAL INTEREST" of which there are 1,291 different AESI's. My "motherload of rare adverse events.." substack only lists a fraction of these but people are having at least 1 of the 1,291 listed and more.
https://icandecide.org/wp-content/uploads/2022/04/REDACTED-5.3.6-postmarketing-experience.pdf

The entire Pfizer data dump can be found here no thanks to NACI, PHAC or Health Canada.
https://phmpt.org/pfizers-documents/

Then we have this little gem

"Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults" from Science Direct.

Interesting quote from the study

"Combined, the mRNA vaccines were associated with an excess risk of serious adverse events of special interest of 12.5 per 10,000 vaccinated.."
https://www.sciencedirect.com/science/article/pii/S0264410X22010283

So much for 1 in a million.. Based on this data? We are looking at 1 in 800. Can you now admit that this is actually "statistically significant" and should warrant a full stop on this experiment before it's too late?

Back in 2010/2011 the CDC gave Harvard-Pilgram $1,000,000 to review their VAERS system. What they found will make your head spin.

"Adverse events from drugs and vaccines are common, but underreported. Although 25% of ambulatory patients experience an adverse drug event, less than 0.3% of all adverse drug events and 1-13% of serious events are reported to the Food and Drug Administration (FDA). Likewise, fewer than 1% of vaccine adverse events are reported. Low reporting rates preclude or slow the identification of “problem” drugs and vaccines that endanger public health."
https://digital.ahrq.gov/sites/default/files/docs/publication/r18hs017045-lazarus-final-report-2011.pdf

The "1-13%" is criminal. Remember, up until about 6-8 months ago, CDC Wonder (VAERS System) only had 50 employees. By August of 2021, they were already 6 months behind and factoring in the numbers from VAERS or Open VAERS those numbers are still off..

Here's the info on OPEN VAERS - https://openvaers.com/covid-data

"Comparing our estimate with the CDC-reported VMR (0.002%) suggests VAERS deaths are underreported by a factor of 20, consistent with known VAERS under-ascertainment bias. Comparing our age-stratified VMRs with published age-stratified coronavirus infection fatality rates (IFR) suggests the risks of COVID vaccines and boosters outweigh the benefits in children, young adults and older adults with low occupational risk or previous coronavirus exposure"
https://www.researchgate.net/publication/355581860_COVID_vaccination_and_age-stratified_all-cause_mortality_risk

There are concerns not only with the under-reporting but the fact that an experimental gene therapy bioweapon NEVER tested on the masses before, was allowed to continue considering the fact that there are at least 10 occasions since the 1955 Cutter Incident where jabs were pulled off market due to deaths (under 50) or AESI's (Bells Palsy, paralysis, cancer, MS, GBS, etc.)
https://www.cdc.gov/vaccinesafety/concerns/concerns-history.html

Fast forward to Dec 2020/Jan 2021-ish with the FOIA emails from Bonnie Henry. I'm dumbfounded that she allowed these shots to continue and yes their was immense pressure and control from NACI. Bonnie Henry is responsible to the people of BC and I couldn't give a rat's ass about NACI after uncovering their funding conflicts or other conflicts of interest they tried. Note, I'm still working on this one for my substack along with another 14 articles. http://docs.openinfo.gov.bc.ca/Response_Package_HTH-2021-13807.pdf

Is any of the above getting through to any of you? Do you not understand that your lack of attention to detail is causing more harm than good? Do you also understand that by promoting these bioweapons that you are in direct violation of at least 10 articles of the 1975 Bioweapons Convention?

You should re-acquaint yourselves with the Declaration of Helsinki please https://www.wma.net/what-we-do/medical-ethics/declaration-of-helsinki/

While you are at it, don't forget the 1967 ICCPR -https://www.ohchr.org/en/instruments-mechanisms/instruments/international-covenant-civil-and-political-rights

And our Provincial Informed Consent Laws as every single doctor or other person injecting these products into peoples arms without proper informed consent is in direct violation of our PICL. How can anyone give informed consent when the insert sheets are left intentionally blank? How can any patient receive the dangers of the ingredients, potential side effects or the 1,300+ AESI's? Based on this informed consent would last hours to days.. But it is not. Why not? Because PHAC, NACI or Health Canada said it was "safe and effective"? Or because it alleged prevents infection or blocks transmission? Nope. They never even tested for this in the clinical trials that Canada was NEVER a part of.

There's another elephant in the room. Reporting AESI's or deaths from the jab.. Based on the data, a majority of the AESI's or deaths happened within the first 72 hours but people weren't considered "vaccinated" or "fully vaccinated" until 14 days. Great way to pad your covid-19 stats by the way. (sarcasm intended).

More insult? According to the FDA's fact sheet, the mRNA shots comprised of 2 doses with 1 shot for the viral vector shots. Then it changed, even though there is 0 data to support this. Boosters? Come on. In the 54 years on this planet, I've witnessed lots of insanity when it came from the mouths of gov't officials and even health authorities but to take multiple shots for an alleged "killer" virus which resolves themselves over time before the "get out of hospital free card then call a covid-19 vaccine" is beyond absurd. If you can't understand this, I suggest you all resign immediately.

Here's how I see it and before you start labelling myself or others as "anti-vaxxers" or "science deniers".. Stop.. We are neither. In fact, we are "anti-unsafe medical procedures of any kind" and very "pro-science", well, when it's not politicized which is what's been going on for the last 3+ years. Actually, governments and their complicit/captured Health Authorities are Pro-$cience.

You had 0 evidence to support population-wide masking.

You had 0 evidence to support people standing on a magic circle in a store.

You had 0 evidence to support locking us down..

You had 0 evidence to support the mass inoculation of this province

Yet, there is an abundance of evidence to prove harm for all of the statements I just made.

Still waiting for the "Risk Benefit Analysis" that should've been provided in 2020.. Or an RBA for the jabs.. Nope.. Just sketchy $cience on your websites promoting FRAUD..

If you are offended by anything in which I have shared? Leave your egos at the door please as enough is enough. Unlike you, I've had to report over 100+ deaths and 1000+AESI's to Pfizer US as it's next to impossible to report them in Canada, let alone BC. Sure there is a number you can call but the follow-up is dreadful.

Here's a sad, but related story for you. Aug 2020, my partners Aunt suffered a stroke. As a parting gift, she was also diagnosed with Diabetes and Renal Failure (both of which were not aggressively studied during the original clinical trials). She was recovering somewhat but made the stupid decision (based on her own fears and her Dr's advice) to get a Pfizer shot on April 1, 2021..

On April 15th, she suffered a blood clot in her left leg and the next day, said leg was amputated. She passed 2 months later as the spike was eating her from the inside..

Aside from the issues the Lipids, Buffers and Salts, the Spike is a major problem. It is not naturally re-occurring but a synthetic self-assembling spike protein in which the body can't recognize when it's injected in the deltoid where it doesn't stay.

Sadly, these "spikes' or the shots are producing an Inflammo-Thrombotic response from both the mRNA and the viral vector shots. Research goes back to the mid 1990's on this and is still relevant today - https://www.flemingmethod.com/_files/ugd/659775_e6a31598cb7f4ffd993f02a7d710d8e9.pdf

There's yet another problem with this shots - pseudouridine which is present in the shots..

"Pseudouridine (Ψ) is the most abundant post-transcriptional RNA modification and is widespread in multiple RNA species. Ψ impacts various aspects of RNA biology, conferring distinct structural and functional properties to the RNA molecules that it decorates. However, aberrant pseudouridylation contributes to a variety of human diseases, including cancer and genetic disorders. Dysregulation of the Ψ epitranscriptome can arise from mutations and abnormal expression of pseudouridylation machinery, impacting protein translation and other cellular processes. With advancing understanding of Ψ roles in health and disease, efforts are now invested in developing therapeutic and diagnostic approaches targeting Ψ. Emerging reports indicate that Ψ and its installation machinery could be potential pharmacological targets for therapeutic development and may serve as biomarkers for human diseases."
https://www.cell.com/trends/pharmacological-sciences/fulltext/S0165-6147(22)00058-X

As I mentioned earlier, I have devoted 13,000+ hours to this "Great Social Experiment of 2020" and 3,000+ hours have been spent on Covid-19 "Vaccines" vs. how many hours med students spend studying "vaccines" in medical school.

You and the rest who are pushing a narrative littered with harm will have your day but first you have to deal with the 3rd wave of jab injuries as 2021 was the year of heart-related issues, 2022 was heart and increased cancer (I had a friend who went from Stage 1 cancer to Stage 4 in 8 DAYS!).. the next fastest was 2 weeks to a couple of months and all of them had at least 1-3 shots.. 2023 we will see ADE rearing its ugly head in which I predicted in mid 2020 during the trials. I hope I'm wrong but to date, I have yet to make a retraction on ANYTHING i have posted or published.

In closing, I think this whole fiasco with Dr. Nagase is not only a waste of time but it's not based on anything relevant or remotely scientific.. This is a witch hunt. Last I checked this was 2023 and we are more open to debate. Perhaps I am wrong in making this assessment but I do have hope.

To be honest, life was pretty wonderful before I was deemed non-essential but when you took my life away, instead of becoming violent which solves nothing, you lit a fire under my ass to do everything in my power to prove you all wrong. That's on all of you..

If you require sources to any of the above statements I mentioned, please ask but I'm confident that what I provided will suffice.

With confidence,

Owen

PS. You should've hired me 3 years ago as I could've save the province a ton of money and embarrassment. I bill out at $850/hour.

PSS. My computer keyboard has a "scrolling" issue due to the fact that I've made close to 4 million keystrokes since March 2020 so if you see a dead link or something that is misspelled or out of place? That's the reason.

PSSS. Please confirm that you have received this email.

Slight update..

Now back to my findings.

Back on Jan 5th, 2022 I did a speech in front of CTV in support of a pretty huge Vancouver Convoy Protest in support of Truckers standing up for the end of all mandates. I was looking into the data provided by Neil “I can’t provide a relevant model to save my life” Ferguson but got a little sidetracked with life.

With today being the last day of the ridiculous Canadian Trucker Convoy Inquiry which has been nothing short of a massive coverup, it was time to finish this puppy up and get your “civic caps” on as all levels of Gov’t need to be reminded of the actual facts before they all line up for Unemployment due to their blatant ignorance.

The world went apeshit over Neil’s sketchy and unfounded model and this isn’t the 1st time he has been wrong or even close. In fact, since the early 2000’s, he’s never been remotely close to his forecasts.

Need proof of his past blunders? Of course you do.
- Neil] was behind the disputed research that sparked the mass culling of eleven million sheep and cattle during the 2001 outbreak of foot-and-mouth disease. He also predicted that up to 150,000 people could die. There were fewer than 200 deaths. . . .

- In 2002, Ferguson predicted that up to 50,000 people would likely die from exposure to BSE (mad cow disease) in beef. In the U.K., there were only 177 deaths from BSE.

- In 2005, Ferguson predicted that up to 150 million people could be killed from bird flu. In the end, only 282 people died worldwide from the disease between 2003 and 2009.

- In 2009, a government estimate, based on Ferguson’s advice, said a “reasonable worst-case scenario” was that the swine flu would lead to 65,000 British deaths. In the end, swine flu killed 457 people in the U.K.

Fast foward to 2020, Ferguson admitted that his Imperial College model of the COVID-19 disease was based on undocumented, 13-year-old computer code that was intended to be used for a feared influenza pandemic, rather than a coronavirus. Ferguson declined to release his original code so other scientists could check his results. He only released a heavily revised set of code last week, after a six-week delay.

This is/was the 1st time in history that we allowed a faulty computer model to all governments of the world to do any of the following:
- shut down economies, businesses,
- murdered people in hospitals, care homes, long term care facilities
- denied surgeries for those in need by creating the fear of “overflowing” hospitals
- ruined the family dynamic, friendships
- violated our Charter of Rights, Bill of Rights, 1975 UN Bioweapons Convention,
- violated regional or national informed consent laws or the 1967 IICPR for both medical and non-medical countermeasures
- threatened Doctors, Nurses and other HCP’s with pulling their licenses or firing them if they spoke out against the narrative as they actually witnessed what was really happening in hospitals, care homes, etc..
- forced Health Care Professionals or Experts to violate their Hippocratic Oath or for Doctors to violate the 1964 Declaration of Helsinki
- ignored the “Scientific Method” which we learned in Science Class
To name just a few.

One would think that to be a Prof at Imperial College of London and to continue as a Prof, he/she would have to be pretty intelligent and provide relevant . I beg to differ. The same Neil Ferguson has a Bachelor of Arts in Physics and a PhD in Philosophy in Theoretical Physics. Hmmm.. Where’s his actual training in Epidemiology? Virology? Oh, he did attend a lecture by Robert May on modelling the HIV epidemic, which together with the death of a friend's brother from AIDS, interested him in pursuing the mathematical modelling of infectious diseases.. EXPERT LEVEL ACHIEVED!!!! (sarcasm intended).

Why is any of the above important to what I’m about to share with you? Context people, context.

DATES & NUMBERS OF THE GREAT SOCIAL EXPERIMENT OF 2020

March 11 - Canada’s 1st alleged deathMarch 16, 2020 - Imperial College of London publishes their model of doom. Media outlets glom onto this globally to commence the largest Fear-Porn campaign in modern history.

March 26 - Neil’s model made available to the world. Here’s the Microsoft Excel appendix file to Imperial College’s Report #12,

Nothing to see here, right? ;) Well, except for the little part regarding 326,322 Can deaths by May 12, 2020 (2.2mill US, 510k UK, 90k+ Sweden) that EVERY MEDIA OUTLET & GOVERNMENT WENT BONKERS OVER!!

Gimme an “F”, Gimme and “E”, Gimme an “A”, Gimme an “R”, Gimme a “P”, Gimme an “O”, Gimme an “R”, Gimme a “N”.. WHAT DO YOU GET? FEARPORN..

I decided to review 14 different countries. For reference purposes, I will use the “2.4, Unmitigated” section as I’m in a giving mood today. See below.

There are a few glaring issues with the above info and no they are not typos.. Look at the “actual deaths” and the “over-estimated percentages” based on Neil’s trusty model. Neil you deserve the Nobel Prize for STUPIDITY!

57 days - the time elapsed from said model of doom

5,724 - assumed deaths/day based on model of doom (CANADA)

435,096 alleged deaths by end of may 2020 based on the 5,724 modelled deaths/day

7,295 - actual alleged convid deaths by the end of May 2020. However, there is a slight problem with this number as we find out later in the year from the CDC and others globally as we later found out that between 96-99.1% - depending on the reporting country, these were the percentages of people with multiple comorbidities.

292 - based on the above percentiles? the actual # of alleged C19 deaths without any comorbidities.

March 26 - 39 total deaths

MIDAZOLAM and it’s sinister role in alleged COVID-19 Use

Lots of people were talking about this and some provided varied level of proof, but where was Health Canada during this? Simple, they were ordering just like that moron Matt Hancock was in the UK and yes the US was also ordering it.
Note, Midazolam which is used on those on Vents and is also listed on Health Canada’s website under the category of Appendix C: End of life care formulary. (NOTE, THIS LINK IS NOW DEAD. Thanks for that Health Cana-duh)
WTAF???? Here’s the entire list of EVERYTHING to do with Midazolam with regards to Health Canada pre-convid and to present day

Now for the relevant ones.
March 27 2020 - 1st purchase of Midazolam on Health Can Website which was scrubbed. I had it opened on another tab months ago and should’ve taken a screen shot. 

March 29, 2020 - Deaths @ 60
April 16, 2020 - deaths at 1,195 .. Whoa.. that’s a pretty substantial increase but still no where near the original daily death forecast (combined) based on Ferguson’s Model of Doom.
April 17, 2020 . 4 different Midazolam purchases on Health Canada’s site (3 by pfizer PQ) and 1 by Fresenius Kabi Canada Ltd. (Germany HQ, and presence in 51 other countries). Ironically enough, a majority of their countries had a bulk of the alleged C-19 deaths) HUH?
June 9th More Midazolam  2 orders (JAMP Pharma based in Langley, BC) Deaths @ 7,897..
Sept 3, 2020 - 1 order by Laboratoire Riva Inc. (Quebec) Deaths @ 9,135..

Hmmmmm..

What’s super interesting about this above list? Well, a couple of things, they have more orders since my original research and a few in 2022. Another issue? Why did Health Canada add the term “cancelled” on some of the orders from 2020? Hmmmm

Remdesivir and it’s role in Canada pre-jab rollout and another possible connection to the real reason for deaths during 2020.

Remdesivir (brand name Veklury) that wonder drug from Flip Flop Fauci which had a 53.1% FATALITY RATE IN THE EBOLA TRIALS?
April 25, 2020 - Chloroquine and hydroxychloroquine can have serious side effects. These drugs should be used only under the supervision of a physician.

July 27, 2020 Health Canada authorizes it for use 12+ for those with C19, pneumonia requiring supplementary O2.
July 28, 2020 Public advisory Remdesivir authorized with conditions for the treatment of patients in Canada with severe COVID-19 symptoms
Aug 12, 2020. Health Canada sends out a “Dear Healthcare Professional Letter’
Sept 22, 2020 - Government of Canada signs new agreements to secure additional vaccine candidate and treatment for COVID-19 .. Another 150,000 vials of this toxic crap orded
Sept 22, 2020, Castanet mentions 150,000 vials to be delivered at month end. Deaths at 9,234
Nov 26, 2020. Health Canada goes against the WHO’s advice states that they are following the FDA (probably with a little Flip Flop influence) and the European Medical Agency. Deaths at 11,894

Jab Rollout

Dec 14, 2020. 1st experimental gene therapy bio weapon administered. Deaths to date? 13,431(Dec 13,2020 as there is no data for Dec 14)..
277 - the number of days from the 1st death to the day before the Jab rollout.
0 - the number of clinical trials for any alleged approved C-19 injection in Canada based on the original trials for any of the mRNA jabs pre-rollout
5 - the number of countries who participated in the original bastardized clinical trials (Pfizer)

277 part 2. since the jab rollout to Sept 17, 2021 - 27,370 deaths 

16,563 more deaths since the rollout if you don’t factor in the false positive PCR issue or comorbs or the drugs.

However, for discussion purposes, let’s factor in remdesivir and midazolam to the equation and the 96% comorbids.. 537 without any comorbids.

Houston we have a massive problem.

RANDOM NUMBERS TO MAKE YOU GO HUH?


40-160% increase in all cause mortality in 2021 (US)
40% decrease in condom sales globally in 2021

89% recent report from OZ deaths from double and triple-jabbed
98-100% what nurses and other HCP’s in 48 different countries have told me. 

1 in 500 kids hospitalized from the Covid shots

From the Renz Law DMED Data Spikes in Vaccine Injuries (Partial, what the actual reporting date is still yet to be mentioned)
2181% SPIKE in Hypertension

1048% SPIKE in the Nervous System 

968.3% in diseases and injuries

680% SPIKE in Multiple Sclerosis 

664% SPIKE in Malignant Neoplasms 

551% SPIKE in Guillain-Barre Syndrome 

487% SPIKE in Breast Cancer 

471% SPIKE in Female Infertility 

369% SPIKE in Testicular Cancer 

468% SPIKE in Pulmonary Embolism

452% SPIKE in Migraines

437% SPIKE in Ovarian Dysfunction 

350% SPIKE in Male Infertility 

302% SPIKE in Tachycardia 

291% SPIKE in Bell’s palsy 

279% SPIKE in Miscarriages

269% SPIKE in Myocardial infarction 

155% SPIKE in Birth Defects

These numbers are only partial reports and will only grow as the time passes. However, based on the Imperial College of Londons BS Faulty Model? There was no justified reason for the world to freak out like it did. If anything, all health authorities, governments and media outlets who pushed this crap should be tried and found guilty of TREASON and dealt with accordingly..

- Stefan Oelrich (Bayer): mRNA vaccines are Gene Therapy - World Health Summit, October 2021

Dangers of mRNA vaccines Ind Psychiatry J. 2021 Oct; 30(Suppl 1): S291–S293.
Published online 2021 Oct 22. doi: 10.4103/0972-6748.328833
“Necessity is the mother of invention:” An adage was brought to life with the emergence of the mRNA vaccine against the backdrop of the foreboding and mercurial COVID-19 pandemic. Considering a negligible adverse-effect profile and a break-neck manufacturing speed, it shone bright as the ideal vaccine candidate. However, “all that glitters is not gold,” as was evidenced by the significant reactogenicity, a host of multi-systemic side-effects, that are being reported by the vaccine recipients; which is palpably resulting in a shift of emotions for the vaccine, accounting for vaccine hesitancy. Anaphylaxis, antibody-dependent enhancements, and deaths, comprise the most serious side-effects, albeit occurring in sparing numbers. Storage and transportation require fastidious temperatures, rendering it substantially inaccessible to a country like India. The biggest jolt, however, was the unfolding of the biases in reporting vaccine efficacy, as only the attractively high numbers of the relatively equivocal relative risk reduction were reported while keeping at bay the meager numbers of the more forthright absolute risk reduction.”

Many at the time didn’t know that modeRNA was not a vaccine manufacturer, they were a chemotherapy company for cancer. modeRNA (appropriately listed in NASDAQ as “MRNA” ;) ) founded by Flagship Pioneering in 2010 and utilizes mRNA molecules to cause a recipient’s own cells to express targeted proteins for a desired therapeutic effect. modeRNA claims that such therapies can be used to treat a wide range of conditions beyond infectious diseases such as COVID-19. They never had a vaccine ever or patent for a vaccine until 2019 which they filed in 2016.

FYI? Patent approval usually takes 22-24 months or longer depending on the complexity. Prioritized examination for plant & utility patents (Track One) is between 6-12 months (maybe). So, how did US Patent 10,720,600 get approval in 4 months and 1 week. Filed Feb 28th, 2020, approved July 7th, 2020. (1)

modeRNA and its investors have spent billions of dollars (2) on mRNA research and modeRNA has sought and obtained hundreds of patents (3) in the United States, Europe, Japan, and other jurisdictions to protect that technology, with several hundred patent applications pending. modeRNA has identified at least seven U.S. patents (4) that it alleges protect the subject mRNA-1273 technology, and has numerous patent applications pending, including dozens (5) in the United States alone.

On March 28, 2019, modeRNA, the poster child of the mRNA supposed vaccine, lodged an amendment to a previously multi-rejected patent. Included in that amendment were the following words: “Because of a concern for re-emergence or a deliberate release of the SARS coronavirus, vaccine development was initiated.”(6) These words and other factors indicate modeRNAwas aware of the planned release of the weaponized SARS-COV-2. Of the 210 vaccines which were part of Warp Speed, modeRNA was #1. They filed their 1st patent in 2010 with a goal to turn the human cell into it’s own pharma co. As mentioned above, their primary focus was Chemo drugs. However, their core tech came from a National Science Foundation grant and was published Aug 2009, 1 year before modeRNA filed its 1st patent.

Of the 140+ patents assigned to Moderna & 150+ patent applications which they initiated or conducted, they never produced a drug during since their inception in 2010. WHY? BECAUSE EVERYTHING THEY PRODUCED WAS NOT SAFE!!!! Moreover, they are violating the 1980 Bayh-Dole act in all of their patents and have been operating illegally since their inception.

Since 2005, DARPA gave $1.7billion for BioWeapons & Bio Preparedness through Fauci’s NIAID with the majority of that going to modeRNA. Fauci also put many non−compete and appropriated grants in which modeRNA received non−competing funds. In a nutshell they don′t have to prove or do any thing or even tell you what the thing is being used for. Think blank check.

Speaking of DARPA and modeRNA, one particular patent (7) assigned to modeRNA concerns methods and compositions that can be used specifically against coronaviruses, including COVID-19. The patent names a modeRNA scientist and a former modeRNA scientist as inventors, both of which acknowledged performing work under the DARPA awards in two academic papers.

WHAT ABOUT THE TRIALS?

• Phase 1 = 21% adverse reactions.. From a global perspective? this would be the US population

• Low Dose Group = 6% adverse reactions = 28million

• 2nd dose group = 100% reaction of some form.

95% efficacy? Where’s the raw data please. “Meanwhile modeRNA says 95 of 30,000 volunteers in its ongoing trial got covid-19: 90 on placebo versus 5 receiving the vaccine, leading both companies to claim around 95% efficacy.” (8) It doesn’t take a math whiz to figure out that we have been played. I did a little breakdown of the 95% efficacy here .

“The modeRNA COVID-19 Vaccine is a vaccine and may prevent you from getting COVID-19. There is no U.S. Food and Drug Administration (FDA) approved vaccine to prevent COVID-19.” (9)

modeRNA actually claims that their devices are “gene therapy” and actually qualify, like Pfizer, as deceptive practices of making medical claims without clinic trial proof. 15 US Code Section 41 of the Trade Commission act, is the law on deceptive practices. The lack of completed human trials also puts these mRNA products at odds with 15 U.S. Code Section 41. Per this law,(10,11) it is unlawful to advertise “that a product or service can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made.”

As of 2018, they were a Gene Therapy Company and still are. (12)

mRNA ‘Vaccines’ Fulfill None of the Criteria for a Vaccine Definition of Vaccine (13)

• Immunity: Protection from an infectious disease. If you are immune to a disease, you can be exposed to it without becoming infected.

• Vaccine: A product that stimulates a person’s immune system to produce immunity to a specific disease, protecting the person from that disease. Vaccines are usually administered through needle injections, but can also be administered by mouth or sprayed into the nose.

That’s the medical definition. The legal definition, in the few cases where it has been detailed, is equally unequivocal:

• Iowa code (14) — “Vaccine means a specially prepared antigen administered to a person for the purpose of providing immunity.”

• Washington state code(15,16) — “Vaccine means a preparation of a killed or attenuated living microorganism, or fraction thereof …” The statute also specifies that a vaccine “upon immunization stimulates immunity that protects us against disease …”

These definitions, both medical and legal, present problems for mRNA “vaccines,” since:

• mRNA injections do not impart immunity. modeRNA and Pfizer both admit that their clinical trials aren’t even looking at immunity. As such they do not fulfill the medical and/or legal definition of a vaccine.

• They do not inhibit transmissibility of SARS-CoV-2 infection. As such they do not fulfill the medical and/or legal definition of a vaccine.

mRNA Therapy Doesn’t Satisfy Public Health Measure Directive. There is another issue of whether a gene therapy can be mandated and this may hinge on it being accepted as a vaccine. Many will TRY and cite the 1905 Jacobsen case but this has been misinterpreted, it was about a $5 FINE FOR REFUSING THE JAB. Uninformed legal experts have argued that it’s acceptable for some individuals to be harmed by a public health directive as long as it benefits the collective.

Since mRNA therapies do not render the immunized person immune, and do not inhibit transmission of the virus, they cannot qualify as a public health measure capable of providing collective benefit that supersedes individual risk, and therefore cannot be mandated.

However, if vaccination is a public health measure meant to protect and benefit the collective, then it would need to accomplish two things:

• Ensure that the vaccinated person is rendered immune from the disease.

• Inhibit transmission of the disease from the vaccinated person to other individuals.

Back to the original problem that mRNA therapies for COVID-19 do not accomplish either of these things. Since these gene therapies do not render the person immune, and do not inhibit transmission of the virus, they cannot qualify as a public health measure capable of providing collective benefit that supersedes individual risk.

On the contrary, the only one benefiting from an mRNA “vaccine” is the individual receiving the gene therapy, since all they are designed to do is lessen clinical symptoms associated with the S-1 spike protein.

In other words, they won’t keep you from getting sick with SARS-CoV-2; they are only supposed to lessen your infection symptoms if or when you do get infected. So, getting vaccinated protects no one but yourself. Since you’re the only one who will reap a benefit (less severe COVID-19 symptoms upon infection), the justification to accept the risks of the therapy “for the greater good” of your community is blatantly irrational.

Here’s the problem: the primary end point in the COVID-19 “vaccine” trials is not an actual vaccine trial end point because, again, vaccine trial end points have to do with immunity and transmission reduction. Neither of those was measured.

Another problem : key secondary end points in modeRNA’s trial include prevention of severe COVID-19 disease (defined as need for hospitalization) and prevention of infection by SARS-CoV-2, regardless of symptoms.(17,18) However, modeRNA did not actually measure rate of infection, stating that it was too “impractical” to do so.

That means there’s no evidence of this gene therapy having an impact on infection, for better or worse. And, if you have no evidence, you cannot fulfill the U.S. Code requirement that states you must have “competent and reliable scientific evidence … substantiating that the claims are true.”

Making matters worse, both Pfizer and modeRNA eliminated their control groups by offering the real vaccine to any and all placebo recipients who want it.(19) The studies are supposed to go on for a full two years, but by eliminating the control group, determining effectiveness and risks is going to be near impossible.

What is Gene Therapy? Per MedlinePlus.gov’s page. (20)

• “Gene therapy is an experimental technique that uses genes to treat or prevent disease … Researchers are testing several approaches to gene therapy, including: … Introducing a new gene into the body to help fight a disease …

  Although gene therapy is a promising treatment option for a number of diseases (including inherited disorders, some types of cancer, and certain viral infections), the technique remains risky and is still under study to make sure that it will be safe and effective. Gene therapy is currently being tested only for diseases that have no other cures.”

The fact that there are many different treatments which have shown to fight off Covid-19, proves that it doesn’t qualify as a disease that has no cure. So why do we need a gene therapy jab? Short answer, we don’t.

But here’s what the FDA defines “gene therapy” (21)
“Human gene therapy seeks to modify or manipulate the expression of a gene or to alter the biological properties of living cells for therapeutic use. Gene therapy is a technique that modifies a person’s genes to treat or cure disease.

Gene therapies can work by several mechanisms:

• Replacing a disease-causing gene with a healthy copy of the gene

• Inactivating a disease-causing gene that is not functioning properly

• Introducing a new or modified gene into the body to help treat a disease”

mRNA are molecules that contain genetic instructions for making various proteins. mRNA “vaccines” deliver a synthetic version of mRNA into your cells that carry the instruction to produce the SARS-CoV-2 spike protein, the antigen, that then activates your immune system to produce antibodies. Then there’s modeRNA’s trial website,(22) where they describe their technology thus:

• “Typical vaccines for viruses are made from a weakened or inactive virus, but mRNA-1273 is not made from the SARS-CoV-2 virus. It is made from messenger ribonucleic acid (mRNA), a genetic code that tells cells how to make protein, which help the body’s immune system make antibodies to fight the virus.”

modeRNA describes its product not as a vaccine, but as ‘gene therapy technology’ in SEC filings. This is because neither modeRNA nor Pfizer make any claims about their products creating immunity or preventing transmission.” Additionally, modeRNA’s SEC filings specifically state that “Currently, mRNA is considered a gene therapy product by the FDA,” as well. (23a)

Here’s the 2020 SEC 10F filings for Biontech in which “gene therapy” is mentioned 22 times (23b)

Back in Feb 2021, MIT Technology Review looked into the history of mRNA tech with a particular interest in modeRNA, stating (24)

• “Vaccines were not their focus. At the company’s founding in 2010, its leaders imagined they might be able to use RNA to replace the injected proteins that make up most of the biotech pharmacopoeia, essentially producing drugs inside the patient’s own cells from an RNA blueprint. ‘We were asking, could we turn a human into a bioreactor?’ says Noubar Afeyan, the company’s cofounder …”

Aug 2020 - Bloomberg reported that the modeRNA vaccine would seek to transform your body into “a vaccine-making machine”. (25)

May 2020 - NY Times reported that “Researchers at 2 Harvard-affiliated hospitals are adapting a proven form of gene therapy to develop a coronavirus vaccine” (26) I’ll say it sllllooowweeeerrr - A proven form of GENE THERAPY”.

To summarize: The definition of “genetic” is something relating to genes, and the definition of “therapy” is the medical treatment of a disease. The definition of “gene therapy” is the process of modifying or manipulating the expression of a gene, or altering the biological properties of living cells.

mRNA are snippets of genetic code that instructs cells to produce proteins. mRNA COVID-19 therapies “deliver genetic instructions into your cells,” thereby triggering your body to produce a fragment of the virus (the spike protein). So, mRNA vaccines ARE gene therapy. There’s simply no way around this. They fulfill all the definitions of gene therapy and none of the definitions for a vaccine.

So, why all of the misrepresentation? Easy. Experimental gene therapies do not have financial liability protection from the governments, but pandemic vaccine do, even in the experimental stage, as long as they have an EUA!!!!!!

The governments supporting this need a huge kick in the balls!!!!

SOURCES

(1) https://www.modernatx.com/sites/default/files/US10702600.pdf

(2) https://investors.modernatx.com/news-releases/news-release-details/statement-moderna-intellectual-property-matters-during-covid-19

(3) https://www.modernatx.com/mrna-technology/modernas-intellectual-property

(4) https://www.modernatx.com/patents

(5) http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.html&r=0&p=1&f=S&l=50&Query=an%2Fmoderna&d=PG01

(6) https://www.freepatentsonline.com/y2019/0240317.html

(7) http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=10,702,600.PN.&OS=PN/10,702,600&RS=PN/10,702,600

(8) https://blogs.bmj.com/bmj/2021/02/05/clarification-pfizer-and-modernas-95-effective-vaccines-we-need-more-details-and-the-raw-data/

(9) https://www.fda.gov/media/144638/download

(10) https://www.law.cornell.edu/uscode/text/15/chapter-2/subchapter-I

(11) https://www.ftc.gov/system/files/warning-letters/covid-19-letter_to_american_chinese_medicine_association_clinic.pdf

(12) https://www.modernatx.com/about-mrna

(13) https://www.cdc.gov/vaccines/vac-gen/imz-basics.htm

(14) https://rules.iowa.gov/Notice/Details/4096C

(15) https://www.sos.wa.gov/_assets/elections/initiatives/finaltext_2141.pdf

(16) https://www.sos.wa.gov/_assets/elections/initiatives/finaltext_1984.pdf

(17) https://www.modernatx.com/sites/default/files/mRNA-1273-P301-Protocol.pdf

(18) https://www.cidrap.umn.edu/news-perspective/2020/07/phase-3-trial-moderna-covid-19-vaccine-begins-amid-us-summer-surge

(19) https://www.npr.org/2021/02/17/968760642/long-term-covid-19-vaccine-studies-hampered-as-placebo-recipients-get-real-shot

(20) https://medlineplus.gov/genetics/understanding/therapy/genetherapy/

(21) https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/what-gene-therapy

(22) https://www.modernatx.com/cove-study

(23a) https://www.sec.gov/Archives/edgar/data/1682852/000168285220000017/mrna-20200630.htm

(23b) https://www.sec.gov/Archives/edgar/data/1776985/000177698522000019/bntx-20211231.htm

(24) https://www.technologyreview.com/2021/02/05/1017366/messenger-rna-vaccines-covid-hiv/

(25) https://www.bloomberg.com/features/2020-moderna-biontech-covid-shot/

(26) https://archive.is/oDB2T#selection-595.12-599.1

However, I wasn’t a fan of the layout - no dates, no categories, dead links, duplicate links etc. I was hoping that they would compare it to the FDA VRBPAC meetings which were supposed to be on the manufacturers asses to ensure that safety would still be a “thing” since we skipped animals trials, merged the trial phases and unblinded the “placebo group”.. Speaking of the placebo group, am I the only one who finds it strange that so many people in said group were experiencing such a wide array of adverse events? Isn’t supposed to be saline? If so, how could so many people have an adverse to saline? Perhaps I’ll do a deep dive into that someday.

In any event, back to the matter at hand - the lack of safety for these bioweapons. At first, I thought it would take a couple of days correcting errors, adding a few newer studies or missed groups, etc. Big mistake, like HUGE MISTAKE. I had no idea how severe it really was, nor did I realize the amount of rabbit holes and cross-referencing I would get myself in.

Additional links and categories were added to make this the MOTHERLOAD. I made it as current as possible and will upload more when they become available.

Thanks to Danny Davies for sharing this with me. Actually screw that, you owe me a bottle of tequila or scotch dude ;)

I dedicate this, to those who have lost someone from the bioweapons or who have been injured as a result of the bioweapons.

This may be my final research effort and it is the most important “FU” to the “Health Powers Which Shouldn’t Be” who have not only violated informed consent for those who thought it wise to get injected/were forced to get injected/those who are around those who got injected/etc. Yes, shedding is a “thing” and has been for a few decades. Remember, just because you haven’t been injured or died, yet, doesn’t mean it won’t happen sooner because “you were doing your part”. The animals from past Rona trials would agree but they are all dead. :( VAERS is an absolute joke and allegedly they only have 50 people looking after the millions - hundreds of millions of Severe/Serious Adverse events. Yes, you read that correctly.

OK OWEN» FOCUS» ;)

The following, along with my research into the ingredients of the mRNA jabs, the negative-efficacy issue and other research I will eventually post here, should end the debate and put an immediate stop to the madness. I need your help getting this out.

As a reminder, I’ve included the FDA’s VRBPAC Meetings since Oct 22, 2020 onward for reference. Don’t freak out when you see how many studies/reports/etc. were mentioned as far back as Oct 22, 2020

Source Page 17 https://www.fda.gov/media/143557/download

THEN FEB 2021

THEN JUNE 2021

I just found this little gem which should have you scratching your heads.. From 2014, no less. :(

source

Looks like the lipid nanoparticle (LNP) has some explaining to do. I wonder how many issues below are linked with the above pic?

There are a couple of questions you must be asking yourself if you read the above.
1. What condition does not cause a serious/severe adverse event if you take the bioweapon?
2. Why would a positive “convid test" potentially cause an S/SAE?
3. Why would there be manufacturing issues when the standards are so high? ok this one is meant to be sarcastic but come on..

Let us take a look at the actual evidence now, shall we? These are a mixture of peer-reviewed studies, expert opinions, expert commentary with a special surprise admission from the “4-eyed little wizard behind the curtain himself buried somewhere below.

Acute Coronary Syndrome

Nov 18, 2021 ACS Risk Biomarkers Significantly Increase After mRNA COVID-19 Vaccine: https://www.thecardiologyadvisor.com/home/topics/acs/acute-coronary-syndrome-acs-biomarkers-mrna-covid19-vaccine/

Nov 8, 2021 Mrna COVID vaccines dramatically increase endothelial inflammatory markers and risk of Acute Coronary Syndrome as measured by PULS cardiac testing: a caution:  https://www.ahajournals.org/doi/10.1161/circ.144.suppl_1.10712

Acute myelitis 

July 31, 2021 Acute myelitis and ChAdOx1 nCoV-19 vaccine: coincidental or causal association:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325554/

Alopecia Areata 

Dec 15, 2021 Alopecia areata after SARS-CoV-2 vaccination: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8673931/

Nov 6, 2021 Recurrence of alopecia areata after covid-19 vaccination: a report of three cases in Italy:  https://onlinelibrary.wiley.com/doi/10.1111/jocd.14581

Sept 24, 2021 Alopecia areata after ChAdOx1 nCoV-19 vaccine (Oxford/AstraZeneca): a potential triggering factor? https://onlinelibrary.wiley.com/doi/full/10.1111/jocd.14459

Anaphylaxis including Cutaneous Adverse Effects (Skin reactions)

Nov 9, 2021 Eosinophilic dermatosis after AstraZeneca COVID-19 vaccination:  https://onlinelibrary.wiley.com/doi/10.1111/jdv.17806

Nov 9, 2021 A case of toxic epidermal necrolysis after vaccination with ChAdOx1 nCoV-19 (AZD1222):  https://onlinelibrary.wiley.com/doi/10.1111/ajd.13742

Oct 28, 2021 Anaphylaxis after Modern COVID-19 vaccine:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8558796/

Oct 26, 2021 Association of self-reported history of high-risk allergy with allergy symptoms after COVID-19 vaccination:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8548941/

Oct 22, 2021 Anaphylactoid reaction and coronary thrombosis related to COVID-19 mRNA vaccine:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8531274/

Oct 17, 2021 Cutaneous adverse reactions of 35,229 doses of COVID-19 Sinovac and AstraZeneca vaccine COVID-19: a prospective cohort study in health care workers:  https://onlinelibrary.wiley.com/doi/10.1111/jdv.17761

Oct 7, 2021 CoronaVac COVID-19 Vaccine-Induced Anaphylaxis: Clinical Characteristics and Revaccination Outcomes: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8504472/

Oct 5, 2021 Varicella zoster virus and herpes simplex virus reactivation after vaccination with COVID-19: review of 40 cases in an international dermatologic registry:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656951/

Oct 1, 2021 Immunization practices and risk of anaphylaxis: a current, comprehensive update of COVID-19 vaccination data:  https://pubmed.ncbi.nlm.nih.gov/34269740/

Sept 21, 2021 Skin reactions after vaccination against SARS-COV-2: a nationwide Spanish cross-sectional study of 405 cases:  https://pubmed.ncbi.nlm.nih.gov/34254291/

Sept 17, 2021 Assessment of Allergic and Anaphylactic Reactions to mRNA COVID-19 Vaccines With Confirmatory Testing in a US Regional Health System:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8449279/

Sept 11, 2021 Increased risk of urticaria/angioedema after BNT162b2 mRNA COVID-19 vaccination in health care workers taking ACE inhibitors:  https://www.mdpi.com/2076-393X/9/9/1011

Sept 10,2021 Clinical and pathologic correlates of skin reactions to COVID-19 vaccine, including V-REPP: a registry-based study:  https://pubmed.ncbi.nlm.nih.gov/34517079/

Sept 4, 2021 COVID-19 mRNA vaccine causing CNS inflammation: a case series:  https://link.springer.com/article/10.1007/s00415-021-10780-7

Sept 1, 2021 Allergic reactions and adverse events associated with administration of mRNA-based vaccines. A health system experience:  https://pubmed.ncbi.nlm.nih.gov/34474708/

Aug 31, 2021 Anaphylaxis reactions to Pfizer BNT162b2 vaccine: report of 3 cases of anaphylaxis following vaccination with Pfizer BNT162b2:  https://www.mdpi.com/2076-393X/9/9/974

Aug 31, 2021 Allergic reactions after COVID-19 vaccination: putting the risk in perspective:  https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2783633

Aug 26, 2021 Reports of anaphylaxis after coronavirus disease vaccination 2019, South Korea, February 26-April 30, 2021:  https://pubmed.ncbi.nlm.nih.gov/34414880/

Aug 18, 2021 A case series of cutaneous COVID-19 vaccine reactions at Loma Linda University Department of Dermatology:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8372465/

Aug 4, 2021 Cumulative adverse event report of anaphylaxis following injections of COVID-19 mRNA vaccine (Pfizer-BioNTech) in Japan: the first month report:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8335977/

July 31, 2021 Biphasic anaphylaxis after first dose of 2019 messenger RNA coronavirus disease vaccine with positive polysorbate 80 skin test result:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8325373/

July 28, 2021 IgE-mediated allergy to polyethylene glycol (PEG) as a cause of anaphylaxis to COVID-19 mRNA vaccines:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8444836/

July 23, 2021 Relationship between pre-existing allergies and anaphylactic reactions following administration of COVID-19 mRNA vaccine:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8220987/

July 22, 2021 Clinical and histopathologic spectrum of delayed adverse skin reactions after COVID-19 vaccination: https://onlinelibrary.wiley.com/doi/10.1111/cup.14104

July 19, 2021 An academic hospital experience assessing the risk of COVID-19 mRNA vaccine using patient’s allergy history:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8288228/

July 19, 2021 Delayed cutaneous reactions after the administration of mRNA vaccines against COVID-19: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8288253/

June 18, 2021 The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach. : https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8248554/

June 14, 2021 Elevated rates of anaphylaxis after vaccination with Pfizer BNT162b2 mRNA vaccine against COVID-19 in Japanese healthcare workers; a secondary analysis of initial post-approval safety data:  https://academic.oup.com/jtm/article/28/7/taab090/6298507

July 8, 2021 Bullous drug eruption after the second dose of COVID-19 mRNA-1273 (Moderna) vaccine: Case report:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264280/

June 6, 2021  Biphasic anaphylaxis after exposure to the first dose of the Pfizer-BioNTech COVID-19 mRNA vaccine COVID-19: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8242856/

May 29, 2021 Biphasic anaphylaxis after exposure to the first dose of Pfizer-BioNTech COVID-19 mRNA vaccine COVID-19:  https://onlinelibrary.wiley.com/doi/10.1002/jmv.27109

May 6, 2021 Sex differences in the incidence of anaphylaxis to LNP-mRNA vaccines COVID-19:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8101867/

April 28, 2021 Anaphylaxis Associated with COVID-19 mRNA Vaccines: Approach to Allergy Research:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080508/

April 27, 2021 Cutaneous adverse effects of available COVID-19 vaccines:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8076732/

April 21, 2021 Allergy to Polyethilenglicole of Anti-SARS CoV2 Vaccine Recipient: A Case Report of Young Adult Recipient and the Management of Future Exposure to SARS-CoV2:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8143141/

April 19, 2021 Practical handling of allergic reactions to COVID-19 vaccines: A position paper from German and Austrian Allergy Societies AeDA, DGAKI, GPA and OGAI. https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8054127/

April 14, 2021 Anaphylaxis following Covid-19 vaccine in a patient with cholinergic urticaria:  https://academic.oup.com/milmed/advance-article/doi/10.1093/milmed/usab138/6225467

April 9, 2021 Polyethylene glycol (PEG) is a cause of anaphylaxis to Pfizer / BioNTech mRNA COVID-19 vaccine:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251011/

April 7, 2021 Skin reactions reported after Moderna and Pfizer’s COVID-19 vaccination: a study based on a registry of 414 cases:  https://pubmed.ncbi.nlm.nih.gov/33838206/

April 6, 2021 Anaphylactic reactions to COVID-19 mRNA vaccines: a call for further studies:  https://europepmc.org/article/PMC/PMC8023205

April 2, 2021 Prolonged anaphylaxis to Pfizer 2019 coronavirus disease vaccine: a case report and mechanism of action:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8021358/

April 1, 2021 Allergic reactions to COVID-19 vaccines: statement of the Belgian Society of Allergy and Clinical Immunology (BelSACI):  https://www.tandfonline.com/doi/abs/10.1080/17843286.2021.1909447

March 22, 2021 Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin disease: practical recommendations. An ETFAD position statement with external experts:  https://onlinelibrary.wiley.com/doi/10.1111/jdv.17237

March 8, 2021 Acute allergic reactions to COVID-19 mRNA vaccines:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7941251/

March 3, 2021 Allergenic components of the mRNA-1273 vaccine for COVID-19: possible involvement of polyethylene glycol and IgG-mediated complement activation:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8013891/

Feb 28, 2021 Allergic reactions, including anaphylaxis, after receiving the first dose of Modern COVID-19 vaccine – United States, December 21, 2020 to January 10, 2021:  https://onlinelibrary.wiley.com/doi/10.1111/ajt.16517

Feb 28, 2021 Allergic reactions, including anaphylaxis, after receiving the first dose of Pfizer-BioNTech COVID-19 vaccine – United States, December 14 to 23, 2020:  https://onlinelibrary.wiley.com/doi/10.1111/ajt.16516

Feb 24, 2021 Severe Allergic Reactions after COVID-19 Vaccination with the Pfizer / BioNTech Vaccine in Great Britain and the USA: Position Statement of the German Allergy Societies: German Medical Association of Allergologists (AeDA), German Society for Allergology and Clinical Immunology (DGAKI) and Society for Pediatric Allergology and Environmental Medicine (GPA): LOTS OF CONFLICTS ON INTEREST: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7903024/

Feb 16, 2021 COVID-19 vaccines increase the risk of anaphylaxis: (Norwegian): https://tidsskriftet.no/2021/02/debatt/covid-19-vaksiner-gir-okt-risiko-anafylaksi https://pubmed.ncbi.nlm.nih.gov/33685103/  (no abstract available)

Feb 12, 2021 Reports of anaphylaxis after receiving COVID-19 mRNA vaccines in the U.S.-Dec 14, 2020-Jan 18, 2021:  https://jamanetwork.com/journals/jama/fullarticle/2776557

FEB 5, 2021 Allergic reactions and anaphylaxis to LNP-based COVID-19 vaccines:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862013/

Feb 1, 2021 COVID-19 vaccine-associated anaphylaxis: a statement from the Anaphylaxis Committee of the World Allergy Organization:.  https://www.worldallergyorganizationjournal.org/article/S1939-4551(21)00011-9/fulltext

Jan 29, 2021 Allergic reactions, including anaphylaxis, after receiving first dose of Modern COVID-19 vaccine – United States, December 21, 2020-January 10, 2021:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7842812/

Jan 21, 2021 Allergic reactions, including anaphylaxis, after receiving the first dose of the Pfizer-BioNTech COVID-19 vaccine:  https://jamanetwork.com/journals/jama/fullarticle/2775646

Jan 15, 2021 Allergic reactions, including anaphylaxis, after receiving the first dose of Pfizer-BioNTech COVID-19 vaccine – United States, December 14-23, 2020:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7808711/

Jan 5, 2021 Severe allergic reactions to the COVID-19 vaccine – statement and practical consequences (6 OF THE 7 AUTHORS ARE ALSO LISTED IN THE FEB 24TH STUDY): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7787363/

Jan 1, 2021 Pfizer Vaccine Raises Allergy Concerns:  https://ui.adsabs.harvard.edu/abs/2021Sci...371...10D/abstract

Dec 15, 2020 Allergic reactions to the first COVID-19 vaccine: a potential role of polyethylene glycol:  https://onlinelibrary.wiley.com/doi/10.1111/all.14711

Antibody Dependent Enhancement (ADE)

Jan19, 2022 - Defective immunity and COVID-19 antibody dependent enhancement in Alberta, Canada: https://drjessesantiano.com/defective-immunity-and-covid-19-antibody-dependent-enhancement-in-alberta-canada/

Jan 6, 2022 57 Top Scientists And Doctors Release Shocking Study On COVID Vaccines And Demand Immediate Stop To All Vaccinations: https://fort-russ.com/2022/01/57-top-scientists-and-doctors-release-shocking-study-on-covid-vaccines-and-demand-immediate-stop-to-all-vaccinations/

Oct 10, 2021 A review: Antibody-dependent enhancement in COVID-19: The not so friendly side of antibodies: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8512237/

Sept 14, 2021 Antibody dependent enhancement: Unavoidable problems in vaccine development: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8438590/

June 3, 2021 Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8175044/

Feb 24, 2021 Two Different Antibody-Dependent Enhancement (ADE) Risks for SARS-CoV-2 Antibodies: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7943455/

THEY WARNED US LONG BEFORE THE RELEASE DURING THE TRIALS

Sept 9, 2020 Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies: https://www.nature.com/articles/s41564-020-00789-5

Aug 12, 2020 COVID 19 Vaccines: Should we fear ADE?: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7454712/

June 5, 2020 Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures: https://www.nature.com/articles/s41587-020-0577-1

Fauci’s Admittance on ADE from March 26, 2020 - (notice the problems in his response) https://www.c-span.org/video/?c4864114/user-clip-fauci-speaks-vaccine-induced-disease-enhancement

Aphasia (Brain Disorders)

June 24, 2021 Aphasia seven days after the second dose of an mRNA-based SARS-CoV-2 vaccine. Brain MRI revealed an intracerebral hemorrhage (ICBH) in the left temporal lobe in a 52-year-old man. : https://www.sciencedirect.com/science/article/pii/S2589238X21000292#f0005

Appendicitis

Nov 3, 2021 Appendicitis as a possible safety signal for the COVID-19 vaccines: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8565092/

Aug 18, 2021 Appendicitis as a presentation of COVID-19: A case report: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8372448/

June 11, 2021 A Case of COVID-19 Mimicking Acute Appendicitis in Multi-System Inflammatory Syndrome: https://www.cureus.com/articles/54331-a-case-of-covid-19-mimicking-acute-appendicitis-in-multi-system-inflammatory-syndrome

Arthritis/Polyarthralgia/Myalgia/Still’s Disease(Syndrome)

Nov 29, 2021 Immunogenicity of the COVID-19 mRNA vaccine in adolescents with juvenile idiopathic arthritis on treatment with TNF inhibitors. : https://ard.bmj.com/content/early/2021/11/28/annrheumdis-2021-221607.long

Nov 19, 2021 An outbreak of Still’s disease after COVID-19 vaccination in a 34-year-old patient:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8602986/

Oct 15, 2021  Arthritis following COVID-19 vaccination: report of two cases: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8516724/

Sept 7, 2021 Safety and tolerability of the COVID-19 mRNA-vaccine in adolescents with juvenile idiopathic arthritis on treatment with TNF-inhibitors: https://onlinelibrary.wiley.com/doi/10.1002/art.41977

Aug 23, 2021 Polyarthralgia and myalgia syndrome after vaccination with ChAdOx1 nCOV-19:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8405407/

May 25, 2021 Reactive arthritis after COVID-19 vaccination:  https://www.tandfonline.com/doi/full/10.1080/21645515.2021.1920274

March 30, 2021  Flare of rheumatoid arthritis after COVID-19 vaccination: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8009616/

Asthma

Oct 19, 2021 Acute asthma exacerbation after SARS-CoV-2 vaccine (Sinovac®): a case report: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8562397/

Sept 20, 2021 COVID vaccination and asthma exacerbation: might there be a link? : https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8450144/

Auto-Immune Disorders (excluding Guillain–Barré syndrome)

2024 Multiple sclerosis and optic neuritis triggered by COVID-19 mRNA
https://www.sciencedirect.com/science/article/pii/S2667257X23000360

March 18, 2023 New Onset Multiple Sclerosis Post-COVID-19 Vaccination and Correlation With Possible Predictors in a Case-Control Study
https://www.cureus.com/articles/137279-new-onset-multiple-sclerosis-post-covid-19-vaccination-and-correlation-with-possible-predictors-in-a-case-control-study#!/

Feb 14, 2023 Case report: First manifestation of multiple sclerosis temporally correlated with COVID-19 vaccination
https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2023.1097799/full

August 19, 2022 Multiple sclerosis relapse after COVID-19 vaccination: A case report-based systematic review
https://www.jocn-journal.com/article/S0967-5868(22)00331-9/fulltext

May 18, 2022 Severe disease exacerbation after mRNA COVID-19 vaccination unmasks suspected multiple sclerosis as neuromyelitis optica spectrum disorder: a case report
https://link.springer.com/article/10.1186/s12883-022-02698-y

March 16, 2022 SARS-CoV-2 Infection and Vaccination Outcomes in Multiple Sclerosis
https://pmc.ncbi.nlm.nih.gov/articles/PMC9208419/

Nov 15, 2021 A rare presentation of undiagnosed multiple sclerosis after the COVID-19 vaccine
https://www.tandfonline.com/doi/full/10.1080/20009666.2021.1979745


Oct 6, 2021 Humoral Response Induced by Prime-Boost Vaccination with the ChAdOx1 nCoV-19 and mRNA BNT162b2 Vaccines in a Teriflunomide-Treated Multiple Sclerosis Patient:  https://www.mdpi.com/2076-393X/9/10/1140

Oct 5, 2021 Immune-mediated hepatitis with the Moderna vaccine is no longer a coincidence but confirmed:  https://www.sciencedirect.com/science/article/pii/S0168827821020936

Sept 22, 2021 Severe autoimmune hemolytic anemia after receipt of SARS-CoV-2 mRNA vaccine:  https://onlinelibrary.wiley.com/doi/10.1111/trf.16672

Sept 7, 2021 Two cases of Graves’ disease after SARS-CoV-2 vaccination: an autoimmune / inflammatory syndrome induced by adjuvants:  https://www.liebertpub.com/doi/10.1089/thy.2021.0142?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed

Aug 29, 2021 Hepatitis C virus reactivation after COVID-19 vaccination: a case report:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8412816/

Aug 10, 2021 Severe relapse of multiple sclerosis after COVID-19 vaccination: a case report:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8382847/

July 28, 2021 Autoimmune hepatitis triggered by vaccination against SARS-CoV-2:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8316013/

July 22, 2021 Induction and exacerbation of subacute cutaneous lupus erythematosus erythematosus after mRNA- or adenoviral vector-based SARS-CoV-2 vaccination:  https://onlinelibrary.wiley.com/doi/10.1111/ced.14858

July 17, 2021 ANCA-associated vasculitis after Pfizer-BioNTech COVID-19 vaccine:  https://www.sciencedirect.com/science/article/pii/S0272638621007423

July 15, 2021 Acute autoimmune-like hepatitis with atypical antimitochondrial antibody after vaccination with COVID-19 mRNA: a new clinical entity:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279947/

July 13, 2021 Collection of complement-mediated and autoimmune-mediated hematologic conditions after SARS-CoV-2 vaccination:  https://ashpublications.org/bloodadvances/article/5/13/2794/476324/Autoimmune-and-complement-mediated-hematologic

July 3, 2021 Autoimmune hepatitis after COVID vaccine:  https://www.sciencedirect.com/science/article/abs/pii/S0896841121000962?via%3Dihub

June 22, 2021 Autoimmune hepatitis developing after ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca):  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8219312/

May 31, 2021 ANCA glomerulonephritis following Modern COVID-19 vaccination:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8166044/

April 29, 2021 Immune-mediated disease outbreaks or recent-onset disease in 27 subjects after mRNA/DNA vaccination against SARS-CoV-2:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8146571/

April 20, 2021 Autoimmune hepatitis developing after coronavirus disease vaccine 2019 (COVID-19): causality or victim?:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8056822/

Bell’s Palsy/Facial Nerve Palsies

Nov 4, 2021 Left Bell’s palsy after the first dose of mRNA-1273 SARS-CoV-2 vaccine: case report:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8566211/

Oct 28, 2021 Adverse event reporting and Bell's palsy risk after COVID-19 vaccination: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8550908/

Oct 28, 2021 Adverse event reporting and Bell's palsy risk after COVID-19 vaccination: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8550921/

Sept 26, 2021 Bell’s palsy after inactivated vaccination with COVID-19 in a patient with a history of recurrent Bell’s palsy: case report:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8462203/

Sept 4, 2021 Facial nerve palsy following administration of COVID-19 mRNA vaccines: analysis of self-report database:  https://www.sciencedirect.com/science/article/pii/S1201971221007049

Sept 1, 2021 Adverse event reporting and risk of Bell’s palsy after COVID-19 vaccination:  https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00646-0/fulltext

Aug 31, 2021 Bilateral facial nerve palsy and COVID-19 vaccination: causality or coincidence:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8425028/

August 16, 2021 Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study https://pubmed.ncbi.nlm.nih.gov/34411532/

Aug 16, 2021 The association between COVID-19 vaccination and Bell’s palsy:  https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00467-9/fulltext

Aug 4, 2021 Transient oculomotor paralysis after administration of RNA-1273 messenger vaccine for SARS-CoV-2 diplopia after COVID-19 vaccine:  https://pubmed.ncbi.nlm.nih.gov/34369471/  (no abstract) https://journals.lww.com/jneuro-ophthalmology/Citation/9000/Transient_Oculomotor_Palsy_Following_the.98655.aspx

Aug 1, 2021 COVID-19 vaccination association and facial nerve palsy: A case-control study:  https://pubmed.ncbi.nlm.nih.gov/34165512/

July 29,2021 Bell’s palsy after COVID-19 vaccination with high antibody response in CSF:  https://link.springer.com/article/10.1007%2Fs10072-021-05496-5

July 22, 2021 Bell’s palsy after COVID-19 vaccination: case report:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8295024/

July 19 - Sequential contralateral facial nerve palsies following COVID-19 vaccination first and second doses: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8291314/

July, 17, 2021 A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after ChAdOx1 nCoV-19 vaccine:.  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8285283/

June 26, 2021 Bell’s palsy after 24 hours of mRNA-1273 SARS-CoV-2 mRNA-1273 vaccine:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8312995/

June 24, 2021 Association of COVID-19 Vaccination and Facial Nerve Palsy A Case-Control Study: https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2781367

June 7, 2021 Bell’s palsy and SARS-CoV-2 vaccines: an unfolding story:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184125/

May 25, 2021 Bell’s palsy after a single dose of vaccine mRNA. SARS-CoV-2: case report: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8143982/

May 24, 2021 Acute abducens nerve palsy after COVID-19 vaccination:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8142812/

May 20, 2021 Bell’s palsy after Ad26.COV2.S COVID-19 vaccination:  https://academic.oup.com/qjmed/article/114/9/657/6278926

May 11, 2021 Acute facial paralysis as a possible complication of SARS-CoV-2 vaccination:  https://pubmed.ncbi.nlm.nih.gov/33975372/ or https://www.thieme-connect.de/products/ejournals/pdf/10.1055/a-1501-0470.pdf

April 2, 2021 Type I interferons as a potential mechanism linking COVID-19 mRNA vaccines with Bell’s palsy:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8016545/

March 23, 2021 Peripheral facial nerve palsy after vaccination with BNT162b2 (COVID-19):  https://ima-files.s3.amazonaws.com/268773_455e40fd-d140-410f-b1e3-e640b3ee158d.pdf or https://pubmed.ncbi.nlm.nih.gov/33734623/ (no abstract available)

Feb 24, 2021 Bell's palsy and SARS-CoV-2 vaccines: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7906673/

Feb 19, 2021 Reported orofacial adverse effects from COVID-19 vaccines: the known and the unknown:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8013400/

Feb 10,2021 Bell’s palsy after the second dose of the Pfizer COVID-19 vaccine in a patient with a history of recurrent Bell’s palsy:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7874945/

Feb 3, 2021 Bell’s palsy following COVID-19 vaccination https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897359/

Blood Clots/DVT/PE/Other Bleeding Disorders

Nov 27, 2021 Unusual site of deep vein thrombosis after vaccination against coronavirus mRNA-2019 coronavirus disease (COVID-19):  https://www.jstage.jst.go.jp/article/circj/advpub/0/advpub_CJ-21-0882/_article

Nov 17, 2021 COVID-19 vaccine in patients with hypercoagulability disorders: a clinical perspective:  https://pubmed.ncbi.nlm.nih.gov/34786893/

Nov 15, 2021 Isolated pulmonary embolism after COVID vaccination: 2 case reports and a review of acute pulmonary embolism complications and follow-up:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8604520/

Oct 14, 2021 Deep venous thrombosis after vaccination with Ad26.COV2.S in adult males:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8516572/

Oct 9, 2021 An unusual presentation of acute deep vein thrombosis after Modern COVID-19 vaccine: case report:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8576696/

Oct 8, 2021 BNT162b2 and ChAdOx1 SARS-CoV-2 Post-vaccination Side-Effects Among Saudi Vaccinees: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531069/

Oct 6, 2021 Coagulopathies after SARS-CoV-2 vaccination may derive from a combined effect of SARS-CoV-2 spike protein and adenovirus vector-activated signaling pathways: https://www.mdpi.com/1422-0067/22/19/10791

Aug 2, 2021 Three cases of acute venous thromboembolism in females after vaccination for coronavirus disease 2019:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327605/

July 14, 2021 Pulmonary embolism, transient ischemic attack, and thrombocytopenia after Johnson & Johnson COVID-19 vaccine:  https://casereports.bmj.com/content/14/7/e243975.long

June 23, 2021 Blood clots and bleeding episodes after BNT162b2 and ChAdOx1 nCoV-19 vaccination: analysis of European data:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8220408/

April 29, 2021 Deep venous thrombosis more than two weeks after COVID-19 vaccination:  https://tidsskriftet.no/en/2021/04/kort-kasuistikk/deep-vein-thrombosis-more-two-weeks-after-vaccination-against-covid-19

March 9, 2021 Deep venous thrombosis (DVT) occurring shortly after second dose of SARS-CoV-2 mRNA vaccine:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940863/

“Breakthrough Cases” ie. Those who have been jabbed. LOL.. Yeah, I find it funny.

Dec 14, 2021 “SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact”
https://www.nature.com/articles/s41577-021-00662-4

June 14, 2021 - “Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals” https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8363499/

Cancer (non-lymph)

June 2026 - "Lipid nanoparticle used in mRNA vaccine promotes tumor metastasis in mouse model via mtDNA-induced neutrophil activation and NETosis'“
https://www.sciencedirect.com/science/article/abs/pii/S1748013226000666

Feb 12, 2026 - Case report examines potential cancer risks after mRNA vaccination
https://www.news-medical.net/news/20260212/Case-report-examines-potential-cancer-risks-after-mRNA-vaccination.aspx

Jan 3, 2026 - ”COVID vaccination and post-infection cancer signals: Evaluating patterns and potential biological mechanisms”
https://www.oncotarget.com/article/28824/text/

Dec 2025 - “Synthetic messenger RNA vaccines and transcriptomic dysregulation: Evidence from new-onset adverse events and cancers post-vaccination”
https://www.wjgnet.com/2220-315X/full/v15/i4/113869.htm

Oct 2025 - “Case Report Open Access Genomic Integration and Molecular Dysregulation in Aggressive Stage IV Bladder Cancer Following COVID-19 mRNA Vaccination”
https://ijirms.in/index.php/ijirms/article/view/2130

2025 - “COVID-19 vaccination, all-cause mortality, and hospitalization for cancer: 30-month cohort study in an Italian province”
https://www.excli.de/vol24/2025-8400/2025-8400.htm

April 2024 - “Increased Age-Adjusted Cancer Mortality After the Third mRNA-Lipid Nanoparticle Vaccine Dose During the COVID-19 Pandemic in Japan”
https://www.cureus.com/articles/196275-increased-age-adjusted-cancer-mortality-after-the-#!/

April 2022 - “Humoral Responses After SARS-CoV-2 mRNA Vaccination and Breakthrough Infection in Cancer Patients”
https://www.mcpiqojournal.org/article/S2542-4548(21)00173-9/pdf

Feb 5, 2022 “Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line”
https://www.mdpi.com/1467-3045/44/3/73

Dec 7, 2021 - Humoral Responses after SARS-CoV-2 mRNA Vaccination and Breakthrough Infection in Cancer Patients: https://www.mcpiqojournal.org/article/S2542-4548(21)00173-9/pdf

Oct 6, 2021 Squamous cell carcinoma of the lung with hemoptysis following vaccination with tozinameran (BNT162b2, Pfizer-BioNTech):  https://onlinelibrary.wiley.com/doi/10.1111/1759-7714.14179

Aug 16, 2021 Safety of administration of BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 vaccine in youths and young adults with a history of acute lymphoblastic leukemia and allergy to PEG-asparaginase. 
https://onlinelibrary.wiley.com/doi/10.1002/pbc.29295

June 23, 2021 The BNT162b2 mRNA COVID-19 vaccine in adolescents and young adults with cancer: A monocentric experience.:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8220943/

Cardiomyopathy/ Encephalopathy 

Nov 3, 2021 Takotsubo cardiomyopathy after vaccination for coronavirus disease 2019 in a patient on maintenance hemodialysis: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8564792/

Sept 6, 2021 Acute hyperactive encephalopathy following COVID-19 vaccination with dramatic response to methylprednisolone: a case report:  https://www.sciencedirect.com/science/article/pii/S2049080121007536

July 3, 2021 Spectrum of Suspected Cardiomyopathy Due to COVID-19: A Case Series.  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8254392/

Central Nervous System (CNS) demyelination 

Nov 9, 2021 A systematic review of cases of CNS demyelination following COVID-19 vaccination:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8577051/

Oct 29, 2021  Acute CNS demyelination in a subject with cerebellar ataxia following the first dose of COVID-19 mRNA vaccine; a case report: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8567291/

Sept 4, 2021 COVID-19 mRNA vaccination leading to CNS inflammation: a case series:https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8417681/

Cerebral Venous Thrombosis (CVT), AVT, VT. etc. 

Nov 15, 2022 Cerebral venous sinus thrombosis following intracerebral hemorrhage after COVID-19 AstraZeneca vaccination: A case report https://onlinelibrary.wiley.com/doi/full/10.1002/ccr3.6505

Dec 24, 2021 Cerebral venous sinus thrombosis after ChAdOx1 nCov-19 vaccination with a misleading first brain MRI:  https://svn.bmj.com/content/6/4/668

Nov 23, 2021 Cerebral venous sinus thrombosis and thrombotic events after vector-based COVID-19 vaccines: systematic review and meta-analysis:  https://n.neurology.org/content/97/21/e2136.long

Nov 22,2021 Case report: Take a second look: Cerebral venous thrombosis related to Covid-19 vaccination and thrombotic thrombocytopenia syndrome:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8645635/

Nov 18, 2021 Cerebral venous sinus thrombosis (CVST) associated with SARS-CoV-2 vaccines: clues for an immunopathogenesis common to CVST observed in COVID-19:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8600336/

Nov 16, 2021 Cerebral venous sinus thrombosis after mRNA-based COVID-19 vaccination:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593397/

Nov 15, 2021 Endovascular treatment for vaccine-induced cerebral venous sinus thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19: report of three cases:  https://jnis.bmj.com/content/early/2021/11/15/neurintsurg-2021-018238.long

Nov 1, 2021 Age- and sex-specific incidence of cerebral venous sinus thrombosis associated with Ad26.COV2.S COVID-19 vaccination:  https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2785610

Oct 27, 2021 Cerebral venous sinus thrombosis following vaccination with ChAdOx1: the first case of definite thrombosis with thrombocytopenia syndrome in India:  https://casereports.bmj.com/content/14/10/e246455.long

Oct 11, 2021 CAd26.COV2-S vaccination may reveal hereditary thrombophilia: massive cerebral venous sinus thrombosis in a young man with normal platelet count:  https://www.mp.pl/paim/issue/article/16114/

Oct 5, 2021 Cerebral venous thrombosis developing after vaccination. COVID-19: VITT, VATT, TTS and more:  https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0041-1736168

Oct 5, 2021 Case report: cerebral sinus vein thrombosis in two patients with AstraZeneca SARS-CoV-2 vaccine:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8491181/

Oct 14, 2021 - Cerebral Venous Sinus Thrombosis After BNT162b2 mRNA COVID-19 Vaccination: https://www.cureus.com/articles/73542-cerebral-venous-sinus-thrombosis-after-bnt162b2-mrna-covid-19-vaccination

Sept 29, 2021 Clinical and biological features of cerebral venous sinus thrombosis after vaccination with ChAdOx1 nCov-19: https://jnnp.bmj.com/content/early/2021/09/29/jnnp-2021-327340

Sept 28, 2021 Characteristics and outcomes of patients with cerebral venous sinus thrombosis in thrombotic immune thrombocytopenia induced by SARS-CoV-2 vaccine:  https://jamanetwork.com/journals/jamaneurology/fullarticle/2784622

Sept 25, 2021 Cerebral venous sinus thrombosis after vaccination: the United Kingdom experience:  https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01788-8/fulltext

Sept 24, 2021 Cerebral Venous Sinus Thrombosis, Pulmonary Embolism, and Thrombocytopenia After COVID-19 Vaccination in a Taiwanese Man: A Case Report and Literature Review: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8498326/

Sept 17, 2021 Cerebral venous sinus thrombosis following vaccination with Pfizer-BioNTech COVID-19 (BNT162b2):  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8490890/

Sept 14, 2021 Report of the International Cerebral Venous Thrombosis Consortium on cerebral venous thrombosis after SARS-CoV-2 vaccination:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8652852/

Sept 3, 2021 Central venous sinus thrombosis with subarachnoid hemorrhage after COVID-19 mRNA vaccination: are these reports merely coincidental:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422566/

Aug 28, 2021 Cerebral venous thrombosis and myeloproliferative neoplasms: A three-center study of 74 consecutive cases: https://onlinelibrary.wiley.com/doi/10.1002/ajh.26336

Aug 23, 2021 Cerebral venous thrombosis associated with COVID-19 vaccine in Germany:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8427115/

Aug 10, 2021 Massive cerebral venous thrombosis and venous watershed infarction as late complications of COVID-19: a case report: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8352747/

Aug 7, 2021 [Cerebral vein/venous sinus thrombosis with thrombocytopenia syndrome after COVID-19 vaccination]:  https://pubmed.ncbi.nlm.nih.gov/34373413/

Aug 6, 2021 Cerebral venous sinus thrombosis after vaccination: the UK experience:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8346246/

Aug 4, 2021 Cerebral venous sinus thrombosis following vaccination against SARS-CoV-2: an analysis of cases reported to the European Medicines Agency:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8444640/

Aug 1, 2021 Cerebral venous sinus thrombosis associated with vaccine-induced thrombotic thrombocytopenia:  https://pubmed.ncbi.nlm.nih.gov/34333995/

July 30, 2021 Vaccine-induced immune thrombotic thrombocytopenia causing a severe form of cerebral venous thrombosis with a high mortality rate: a case series:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8363077/

July 29, 2021 Cerebral venous sinus thrombosis after COVID-19 vaccination : Neurological and radiological management:  https://pubmed.ncbi.nlm.nih.gov/34327553/

July 29, 2021 Cerebral venous sinus thrombosis after COVID-19 vaccination: neurologic and radiologic management:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8320717/

July 21, 2021 Cerebral venous thrombosis after COVID-19 vaccination: is the risk of thrombosis increased by intravascular administration of the vaccine:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8294245/

July 19, 2021 Cerebral venous thrombosis associated with the covid-19 vaccine in Germany:  https://onlinelibrary.wiley.com/doi/10.1002/ana.26172

July 18, 2021 Cerebral venous thrombosis following BNT162b2 mRNA vaccination of BNT162b2 against SARS-CoV-2: a black swan event:  https://pubmed.ncbi.nlm.nih.gov/34133027/

July 10, 2021 Acute cerebral venous thrombosis and pulmonary artery embolism associated with the COVID-19 vaccine:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8344576/

July 8, 2021 A rare case of a middle-aged Asian male with cerebral venous thrombosis after AstraZeneca COVID-19 vaccination:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265178/

July 1, 2021 Vaccination against COVID-19: insight from arterial and venous thrombosis occurrence using data from VigiBase: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8051185/

June 24, 2021 Anti-PF4 antibody negative cerebral venous sinus thrombosis without thrombocytopenia following immunization with COVID-19 vaccine in an elderly non-comorbid Indian male, managed with conventional heparin-warfarin based anticoagulation: https://www.sciencedirect.com/science/article/pii/S1871402121002046

June 22, 2021 US case reports of cerebral venous sinus thrombosis with thrombocytopenia after vaccination with Ad26.COV2.S (against covid-19), March 2 to April 21, 2020:  https://pubmed.ncbi.nlm.nih.gov/33929487/

June 17, 2021 Adverse effects reported after COVID-19 vaccination in a tertiary care hospital, focus on cerebral venous sinus thrombosis (CVST):  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8220435/

July 15, 2021 Massive cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8561270/

June 12, 2021 59-year-old woman with extensive deep venous thrombosis and pulmonary thromboembolism 7 days after a first dose of Pfizer-BioNTech BNT162b2 mRNA vaccine COVID-19: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212841/

June 8, 2021 Cerebral venous sinus thrombosis in the U.S. population after SARS-CoV-2 vaccination with adenovirus and after COVID-19:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8186447/

June 8, 2021 Cerebral venous sinus thrombosis 2 weeks after first dose of SARS-CoV-2 mRNA vaccine:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8186353/

May 25, 2021 Cerebral venous thrombosis after BNT162b2 mRNA SARS-CoV-2 vaccine: https://www.strokejournal.org/article/S1052-3057(21)00309-8/fulltext

May 25, 2021Cerebral venous thrombosis induced by SARS-CoV-2 vaccine: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8148433/

May 25, 2021 Cerebral venous thrombosis after the BNT162b2 mRNA SARS-CoV-2 vaccine: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8148614/

May 24, 2021 Cerebral venous thrombosis and vaccine-induced thrombocytopenia.a. Oxford-AstraZeneca COVID-19: a missed opportunity for a rapid return on experience: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141689/

May 10, 2021 The importance of recognizing cerebral venous thrombosis following anti-COVID-19 vaccination:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8108377/

May 10, 2021 Cerebral venous thrombosis following COVID-19 vaccination:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8108371/

May 6, 2021 Diagnostic-therapeutic recommendations of the ad-hoc FACME expert working group on the management of cerebral venous thrombosis related to COVID-19 vaccination:  https://www.sciencedirect.com/science/article/pii/S0213485321000839

May 5, 2021 Arterial events, venous thromboembolism, thrombocytopenia and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population-based cohort study: https://www.bmj.com/content/373/bmj.n1114.long

May 2, 2021 Cerebral venous thrombosis after COVID-19 vaccination in the UK: a multicentre cohort study:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8346241/

April 20, 2021 Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination: report of two cases in the United Kingdom:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8056834/

April 15,2021 Management of cerebral and splanchnic vein thrombosis associated with thrombocytopenia in subjects previously vaccinated with Vaxzevria (AstraZeneca): position statement of the Italian Society for the Study of Hemostasis and Thrombosis (SISET):  https://www.bloodtransfusion.it/articolo.aspx?idart=003388&idriv=000162&idart=003388&idriv=000162

April 12, 2021 Cerebral venous sinus thrombosis associated with thrombocytopenia after COVID-19 vaccination:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039796/

April 8, 2021 A Rare Case of Cerebral Venous Thrombosis and Disseminated Intravascular Coagulation Temporally Associated to the COVID-19 Vaccine Administration:  https://www.mdpi.com/2075-4426/11/4/285

April 8, 2021 Cerebral venous thrombosis and thrombocytopenia after COVID-19 vaccination:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8028600/

Cutaneous/Keratolysis/Dermatosis/Bullous/Sweet’s Syndrome/etc (Skin Related)

Jan 17, 2022 Sweet syndrome after severe acute respiratory syndrome coronavirus 2 mRNA vaccine: A case report and literature review: https://onlinelibrary.wiley.com/doi/10.1111/1346-8138.16309

Dec 1, 2021 Bilateral immune-mediated keratolysis after immunization with SARS-CoV-2 recombinant viral vector vaccine:  https://journals.lww.com/corneajrnl/Abstract/2021/12000/Bilateral_Immune_Mediated_Keratolysis_After.23.aspx

Nov 25, 2021 A case of generalized Sweet’s syndrome with vasculitis triggered by recent vaccination with COVID-19:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8612751/

Oct 7, 2021 Hematuria, a generalized petechial rash and headaches after Oxford AstraZeneca ChAdOx1 nCoV-19 vaccination:  https://casereports.bmj.com/content/14/10/e245440.long

Oct 4, 2021 Herpes-like skin lesion after AstraZeneca vaccination for COVID-19: A case report:  https://onlinelibrary.wiley.com/doi/10.1002/ccr3.4883

Sept 29, 2021 Sweet’s syndrome after Oxford-AstraZeneca COVID-19 vaccine (AZD1222) in an elderly woman:  https://onlinelibrary.wiley.com/doi/10.1111/dth.15146

Sept 12, 2021 Recurrent herpes zoster after COVID-19 vaccination in patients with chronic urticaria on cyclosporine treatment – A report of 3 cases:  https://onlinelibrary.wiley.com/doi/10.1111/jocd.14437

Sept 7, 2021 Case report: Pityriasis rosea-like rash after vaccination with COVID-19:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8452904/

Aug 25, 2021 Cutaneous Adverse Reactions to COVID-19 Vaccines: Insights from an Immuno-Dermatological Perspective: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8470727/

Aug 23, 2021 Exacerbation of plaque psoriasis after COVID-19 inactivated mRNA and BNT162b2 vaccines: report of two cases:  https://onlinelibrary.wiley.com/doi/10.1111/dth.15110

Aug 7, 2021 Rare cutaneous adverse effects of COVID-19 vaccines: a case series and review of the literature:  https://onlinelibrary.wiley.com/doi/10.1111/jdv.17578

Aug 4, 2021 Onset / outbreak of psoriasis after Corona virus ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca / Covishield): report of two cases:  https://onlinelibrary.wiley.com/doi/10.1111/dth.15085

Aug 3, 2021 Petechiae and peeling of fingers after immunization with BTN162b2 messenger RNA (mRNA)-based COVID-19 vaccine:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8413049/

July 21, 2021 Bullous drug eruption after second dose of mRNA-1273 (Moderna) COVID-19 vaccine: Case report: https://www.sciencedirect.com/science/article/pii/S1876034121001878

July 8, 2021 Vesiculobullous cutaneous reactions induced by COVID-19 mRNA vaccine: report of four cases and review of the literature:  https://onlinelibrary.wiley.com/doi/10.1111/ced.14835

July 3, 2021 Sweet syndrome induced by SARS‐CoV‐2 Pfizer‐BioNTech mRNA vaccine https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8441847/

June 18, 2021 Sweet syndrome induced by SARS-CoV-2 Pfizer-BioNTech mRNA vaccine: https://onlinelibrary.wiley.com/doi/full/10.1111/all.14981

June 6, 2021 Dermatologic manifestations and complications of COVID-19: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7274995/

May 26, 2021 Coronavirus 19 presenting with atypical Sweet's syndrome: https://onlinelibrary.wiley.com/doi/10.1111/jdv.16662

May 24, 2021 Petechial rash associated with CoronaVac vaccination: first report of cutaneous side effects before phase 3 results:  https://ejhp.bmj.com/content/early/2021/05/23/ejhpharm-2021-002794.long

DEATH

June 21, 2024 A Systematic REVIEW of Autopsy findings in deaths after covid-19 vaccination
https://www.sciencedirect.com/science/article/pii/S0379073824001968

Jan 14, 2024 Autopsy findings in cases of fatal COVID-19 vaccine-induced myocarditis
https://onlinelibrary.wiley.com/doi/10.1002/ehf2.14680

Apr 15, 2023 A Case Report of Creutzfeldt-Jakob Disease after mRNA
COVID-19 Vaccine
https://www.anncaserep.com/open-access/a-case-report-of-creutzfeldt-jakob-disease-after-mrna-covid-19-vaccine-9619.pdf

Dec 5, 2022 Fatal Post COVID mRNA-Vaccine Associated Cerebral Ischemia
https://pmc.ncbi.nlm.nih.gov/articles/PMC10091442/

Nov 27, 2022 Autopsy-based histopathological characterization of myocarditis after anti-SARS-CoV-2-vaccination
https://link.springer.com/article/10.1007/s00392-022-02129-5

Nov 8, 2022 Clinically suspected lethal viral myocarditis combined with encephalitis: a COVID-19 vaccine complication
https://onlinelibrary.wiley.com/doi/10.1002/ehf2.14229

Sept 9, 2022 Do Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines Change Creutzfeldt-Jakob Disease Prognosis?
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9469682/

Feb 22, 2022 Autopsy Histopathologic Cardiac Findings in Two Adolescents Following the Second COVID-19 Vaccine Dose https://pubmed.ncbi.nim.nih.gov/35157759/

Jan 11, 2022 A fatal case of COVID-19 breakthrough infection due to the delta variant
https://onlinelibrary.wiley.com/doi/10.1002/ccr3.5232

Jan 19, 2022 POST COVID-19 VACCINE DEATHS - SINGAPORE’S EARLY EXPERIENCE:
https://www.sciencedirect.com/science/article/pii/S0379073822000299

Dec 15, 2021 Autopsy Findings and Causality Relationship between Death and COVID-19 Vaccination: A Systematic Review: https://www.mdpi.com/2077-0383/10/24/5876

Nov 27, 2021 Fatal systemic capillary leak syndrome after SARS-COV-2 vaccination in a patient with multiple myeloma:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8544977/

Nov 15, 2021 Worldwide Bayesian Causal Impact Analysis of Vaccine Administration on Deaths and Cases Associated with COVID-19: A BigData Analysis of 145 Countries:
https://www.researchgate.net/publication/356248984_Worldwide_Bayesian_Causal_Impact_Analysis_of_Vaccine_Administration_on_Deaths_and_Cases_Associated_with_COVID-19_A_BigData_Analysis_of_145_Countries

Nov 6, 2021 An Insight into the Role of Postmortem Immunohistochemistry in the Comprehension of the Inflammatory Pathophysiology of COVID-19 Disease and Vaccine-Related Thrombotic Adverse Events: A Narrative Review: 
https://www.mdpi.com/1422-0067/22/21/12024

Oct 11, 2021 Brain death in a vaccinated patient with COVID-19 infection:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8502685/

Oct 9, 2021 Lethal vaccine-induced immune thrombotic immune thrombocytopenia (VITT) following announcement 26.COV2.S: first documented case outside the U.S.: 
https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8501343/

Sept 30, 2021 Post-mortem investigation of deaths after vaccination with COVID-19 vaccines: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8482743/

Aug 18, 2021 Deaths associated with recently launched SARS-CoV-2 vaccination:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8372443/

Aug 12, 2021 Fatal exacerbation of ChadOx1-nCoV-19-induced thrombotic thrombocytopenia syndrome after successful initial therapy with intravenous immunoglobulins: a rationale for monitoring immunoglobulin G levels:  https://haematologica.org/article/view/haematol.2021.279509

Aug 11, 2021 COVID-19: lessons from the Norwegian tragedy should be taken into account in planning for vaccine launch in less developed/developing countries:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8359902/

Aug 2, 2021 Intracerebral Hemorrhage due to Thrombosis with Thrombocytopenia Syndrome after Vaccination against COVID-19: the First Fatal Case in Korea:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8352786/

Aug 1, 2021 Post-mortem findings in vaccine-induced thrombotic thrombocytopenia:  https://haematologica.org/article/view/haematol.2021.279075

July 14 ,2021 Over 5,200 post deaths reported following COVID-19 vaccination in Europe: https://www.precisionvaccinations.com/european-agency-confirms-covid-19-vaccine-fatalities

July 10, 2021 Myocarditis-induced sudden death after BNT162b2 COVID-19 mRNA vaccination in Korea: case report focusing on histopathological findings:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8524235/

June 23, 2021 Vaccine-induced immune thrombotic thrombocytopenia with disseminated intravascular coagulation and death after ChAdOx1 nCoV-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34171649/

May 26, 2021 COVID-19 vaccine and death: causality algorithm according to the WHO eligibility diagnosis: https://www.mdpi.com/2075-4418/11/6/955

May 19, 2021 Nursing home deaths after COVID-19 vaccination: https://tidsskriftet.no/en/2021/05/originalartikkel/nursing-home-deaths-after-covid-19-vaccination

May 13, 2021 Fatal cerebral venous sinus thrombosis after covid-19 vaccination:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8117129/

April 29, 2021 Fatal cerebral hemorrhage after COVID-19 vaccine:  https://tidsskriftet.no/en/2021/04/kort-kasuistikk/fatal-cerebral-haemorrhage-after-covid-19-vaccine

April 17, 2021 Deaths associated with the recently launched SARS-CoV-2 vaccination (Comirnaty®):  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8052499/

April 16, 2021 First case of postmortem study in a patient vaccinated against SARS-CoV-2: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8051011/

Jan 15, 2021 Covid-19: Norway investigates 23 deaths in frail elderly patients after vaccination: https://www.bmj.com/content/372/bmj.n149.long

Encephalitis /Myelitis/Encephalomyelitis/Meningoencephalitis/ Meningitis/Encepholapthy

Nov 30, 2021 Autoimmune encephalitis after ChAdOx1-S SARS-CoV-2 vaccination:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8630512/

Nov 4, 2021 Acute disseminated encephalomyelitis (ADEM) following recent Oxford/AstraZeneca COVID-19 vaccination: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8567127/

Sept 6, 2021 Post-COVID-19 vaccine acute hyperactive encephalopathy with dramatic response to methylprednisolone: A case report: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8420261/

Aug 13, 2021 Post-vaccinal encephalitis after ChAdOx1 nCov-19:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8426979/

July 21, 2021 Acute disseminated encephalomyelitis following vaccination against SARS-CoV-2:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8294707/

May 30, 2021 COVID-19-associated acute disseminated encephalomyelitis (ADEM): https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7260459/

May 20, 2021 Acute disseminated encephalomyelitis-like presentation after an inactivated coronavirus vaccine: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8136261/

May 20, 2021 Acute relapse and impaired immunization after COVID-19 vaccination in a patient with multiple sclerosis treated with rituximab:  https://www.tandfonline.com/doi/full/10.1080/21645515.2021.1928463

Gastroparesis (delayed gastric emptying)

Nov 1, 2021 Gastroparesis after Pfizer-BioNTech COVID-19 vaccination:  https://journals.lww.com/ajg/Citation/2021/11000/Gastroparesis_After_Pfizer_BioNTech_COVID_19.27.aspx

Guillain Barre Syndrome

Dec 27, 2021 Guillain-Barré syndrome associated with COVID-19 vaccination:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8632191/

Dec 1, 2021 Clinical variant of Guillain-Barré syndrome with prominent facial diplegia after AstraZeneca 2019 coronavirus disease vaccine:  https://pubmed.ncbi.nlm.nih.gov/34808658/ OR https://journals.lww.com/jcnmd/Citation/2021/12000/Clinical_Variant_of_Guillain_Barre_Syndrome_With.11.aspx

Nov 22, 2021 A case of sensory ataxic Guillain-Barre syndrome with immunoglobulin G anti-GM1 antibodies after first dose of COVID-19 BNT162b2 mRNA vaccine (Pfizer):  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8690109/

Nov 22, 2021 Guillain-Barré syndrome after SARS-CoV-2 vaccination in a patient with previous vaccine-associated Guillain-Barré syndrome:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8608454/

Nov 18, 2021 Guillain-Barré syndrome after the first dose of SARS-CoV-2 vaccine: a temporary occurrence, not a causal association:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8601771/

Nov 12, 2021 Guillain-Barre syndrome after COVID-19 mRNA-1273 vaccine: case report:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8586608/

Nov 11, 2021 Guillain-Barre syndrome after the first dose of COVID-19 vaccination: case report: https://actamedica.lfhk.cuni.cz/media/pdf/am_2021064030183.pdf

Oct 26, 2021 COVID-19 adenovirus vaccines and Guillain-Barré syndrome with facial palsy:  https://onlinelibrary.wiley.com/doi/10.1002/ana.26258

Oct 14, 2021 Guillain-Barre syndrome presenting with facial diplegia following vaccination with COVID-19 in two patients:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8522664/

Oct 7, 2021 Association of receipt association of Ad26.COV2.S COVID-19 vaccine with presumed Guillain-Barre syndrome, February-July 2021:  https://jamanetwork.com/journals/jama/fullarticle/2785009

Oct 7, 2021 Guillain-Barre syndrome after COVID-19 vaccination in an adolescent:  https://www.pedneur.com/article/S0887-8994(21)00221-6/fulltext

Sept 28, 2021 Guillain-Barre syndrome following SARS-CoV-2 vaccination in 19 patients:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8478139/

Sept 26, 2021 Guillian-Barre syndrome with axonal variant temporally associated with Modern SARS-CoV-2 mRNA-based vaccine:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8546902/

Sept 21, 2021 A rare variant of Guillain-Barré syndrome after vaccination with Ad26.COV2.S:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8529941/

Sept 20, 2021 A case of Guillain-Barré syndrome after Pfizer COVID-19 vaccine:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8462911/

Sept 17, 2021 AstraZeneca COVID-19 vaccine and Guillain-Barré syndrome in Tasmania: a causal link:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8447540/

Sept 15, 2021 Guillain-Barré syndrome in an Australian state using mRNA and adenovirus-vector SARS-CoV-2 vaccines:  https://onlinelibrary.wiley.com/doi/10.1002/ana.26218

Sept 14, 2021 A rare case of Guillain-Barré syndrome after COVID-19 vaccination:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8523377/

Sept 1, 2021 Rate of recurrent Guillain-Barré syndrome after COVID-19 BNT162b2 mRNA vaccine:  https://jamanetwork.com/journals/jamaneurology/fullarticle/2783708

Aug 30, 2021 SARS-CoV-2 vaccines are not safe for those with Guillain-Barre syndrome following vaccination:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8405530/

Aug 30,2021 Guillain-Barre syndrome after vaccination with mRNA-1273 against COVID-19:  https://pubmed.ncbi.nlm.nih.gov/34477091/ OR https://ugeskriftet.dk/videnskab/guillian-barres-syndrom-efter-mrna-1273-covid-19-vaccine

Aug 30, 2021 COVID-19 vaccine causing Guillain-Barre syndrome, an uncommon potential side effect:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8405530/

Aug 28, 2021 SARS-CoV-2 vaccines can be complicated not only by Guillain-Barré syndrome but also by distal small fiber neuropathy:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8397486/

Aug 13, 2021 Guillain-Barré syndrome after AstraZeneca COVID-19 vaccination: causal or casual association: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360997/ 

Aug 13, 2021 A novel case of bifacial diplegia variant of Guillain-Barré syndrome after vaccination with Janssen COVID-19:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8395825/

Aug 8, 2021 Sensory Guillain-Barré syndrome after ChAdOx1 nCov-19 vaccine: report of two cases and review of the literature:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349403/

Aug 7, 2021 Guillain-Barré syndrome presenting as facial diplegia after vaccination with COVID-19: a case report:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8346349/

Aug 4, 2021 Guillain-Barre syndrome after BNT162b2 COVID-19 vaccine:  https://link.springer.com/article/10.1007%2Fs10072-021-05523-5

July 30, 2021 A variant of Guillain-Barré syndrome after SARS-CoV-2 vaccination: AMSAN:  https://elitmed.hu/en/publications/clinical-neuroscience/a-variant-of-guillain-barre-syndrome-after-sars-cov-2-vaccination-amsan

July 25, 2021 Facial diplegia: a rare and atypical variant of Guillain-Barré syndrome and the Ad26.COV2.S vaccine:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8381448/

July 17, 2021 A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy following ChAdOx1 nCoV-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34272622/

July 15, 2021 Guillain-Barré syndrome after ChAdOx1 nCoV-19 COVID-19 vaccination: a case series:  https://onlinelibrary.wiley.com/doi/10.1111/ncn3.12537

July 14, 2021 Bilateral facial weakness with a variant of paresthesia of Guillain-Barre syndrome after Vaxzevria COVID-19 vaccine:  https://jnnp.bmj.com/content/early/2021/07/13/jnnp-2021-327027

June 30, 2021 Guillain-Barre syndrome after the first injection of ChAdOx1 nCoV-19 vaccine: first report:  https://www.sciencedirect.com/science/article/pii/S0035378721005853?via%3Dihub

June 10, 2021 Guillain-Barre syndrome after ChAdOx1-S / nCoV-19 vaccination: https://onlinelibrary.wiley.com/doi/10.1002/ana.26143

June 10, 2021 Variant Guillain-Barré syndrome occurring after SARS-CoV-2 vaccination:  https://onlinelibrary.wiley.com/doi/10.1002/ana.26144

June 5, 2021 COVID-19, Guillain-Barré and vaccineA dangerous mix:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8179060/

April 30, 2021 Guillain-Barre syndrome after the first dose of SARS-CoV-2 vaccine: a temporary occurrence, not a causal association:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8086372/

April 22, 2021 Guillain-Barré syndrome after the first injection of ChAdOx1 nCoV-19 vaccine: first report: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8070856/

Feb 18, 2021 Neurological complications of COVID-19: Guillain-Barre syndrome after Pfizer COVID-19 vaccine:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7978140/

Jan 13, 2021 GM1 ganglioside antibody and COVID-19-related Guillain Barre syndrome: case report, systemic review, and implications for vaccine development:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7805391/

Hailey Hailey Disease

Aug 25, 2021 Hailey-Hailey disease exacerbation after SARS-CoV-2 vaccination:  https://www.medicaljournals.se/acta/content/html/10.2340/00015555-3907

Headache

Sept 17, 2021 Delayed headache after COVID-19 vaccination: a warning sign for vaccine-induced cerebral venous thrombosis:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8446734/

Sept 15, 2021 Vaccine-induced thrombocytopenia with severe headache:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8522796/

Sept 5, 2021 Vaccine-induced thrombocytopenia with severe headache: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8522796/

July 27, 2021 Headache attributed to COVID-19 (SARS-CoV-2 coronavirus) vaccination with the ChAdOx1 nCoV-19 (AZD1222) vaccine: a multicenter observational cohort study:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8314854/

Hearing Loss

Nov 30, 2021 Sudden sensorineural hearing loss after covid-19 vaccine; A possible adverse reaction? https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8629793/

Oct 17, 2021 Sudden sensorineural hearing loss after COVID-19 vaccination:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8520501/

Aug 25, 2021 Sudden Sensorineural Hearing Loss Following the Second Dose of COVID-19 Vaccine: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8462391/

July 9, 2021 - Otologic Manifestations After COVID-19 Vaccination: The House Ear Clinic Experience: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8443418/

Hematuria

April 28, 2021 A case of gross hematuria and IgA nephropathy flare-up following SARS-CoV-2 vaccination:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8079938/

March 24, 2021 Gross hematuria after severe acute respiratory syndrome coronavirus 2 vaccination in 2 patients with IgA nephropathy:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7987498/

Hemichorea-Hemiballismus Syndrome 

Acute hemichorea-hemibalismus after COVID-19 (AZD1222) vaccination:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8661968/

Hemorrhage / Hemorrhagic Stroke Menstrual Bleeding/Vasculitis(any)

Jan 1, 2022 Cutaneous lymphocytic vasculitis after administration of the second dose of AZD1222 (Oxford-AstraZeneca) Severe acute respiratory syndrome Coronavirus 2 vaccine: chance or causality: https://journals.lww.com/amjdermatopathology/Fulltext/2022/01000/Cutaneous_Lymphocytic_Vasculitis_After.19.aspx

Dec 24, 2021 Peduncular, symptomatic cavernous bleeding after immune thrombocytopenia-induced SARS-CoV-2 vaccination:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8443534/

Dec 5, 2021 Retinal hemorrhage after SARS-CoV-2 vaccination:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8658415/ 

Nov 30, 2021 Reactivation of IgA vasculitis after vaccination with COVID-19:  https://casereports.bmj.com/content/14/11/e247188.long

Nov 24, 2021 Flares of mixed cryoglobulinaemia vasculitis after vaccination against SARS-CoV-2: https://ard.bmj.com/content/early/2021/11/23/annrheumdis-2021-221248.long

Nov 22, 2021  Repeated Cardioembolic Stroke after COVID-19 mRNA Vaccination: A Case Report: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8606267/

Nov 16, 2021 Intracerebral hemorrhage due to vasculitis following COVID-19 vaccination: case report:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8594320/

Nov 14, 2021 IgA vasculitis following COVID-19 vaccination in an adult:  https://onlinelibrary.wiley.com/doi/10.1111/cup.14168

Nov 11, 2021 Case report: anti-neutrophil cytoplasmic antibody-associated vasculitis with acute renal failure and pulmonary hemorrhage can occur after COVID-19 vaccination:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8632021/

Nov 10, 2021 Leukocytoclastic vasculitis after exposure to COVID-19 vaccine:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8578015/

Nov 9, 2021 Recurrent ANCA-associated vasculitis after Oxford AstraZeneca ChAdOx1-S COVID-19 vaccination: a case series of two patients:  https://onlinelibrary.wiley.com/doi/10.1111/nep.13993

Nov 1, 2021 Intracerebral hemorrhage associated with vaccine-induced thrombotic thrombocytopenia after ChAdOx1 nCOVID-19 vaccination in a pregnant woman:  https://haematologica.org/article/view/haematol.2021.279407

Nov 1, 2021 Imaging in vascular medicine: leukocytoclastic vasculitis after COVID-19 vaccine booster: https://journals.sagepub.com/doi/10.1177/1358863X211055507?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

Oct 28, 2021 Lobar hemorrhage with ventricular rupture shortly after the first dose of an mRNA-based SARS-CoV-2 vaccine:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8553377/

Oct 28, 2021 Leukocytoclastic vasculitis after coronavirus disease 2019 vaccination:  https://onlinelibrary.wiley.com/doi/10.1111/1346-8138.16212

Oct 27, 2021 Possible case of COVID-19 mRNA vaccine-induced small-vessel vasculitis:  https://onlinelibrary.wiley.com/doi/10.1111/jocd.14568

Oct 24, 2021 Induction of cutaneous leukocytoclastic vasculitis after ChAdOx1 nCoV-19 vaccine:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8609955/

Oct 13, 2021 Ischemic stroke as a presenting feature of immune thrombotic thrombocytopenia induced by ChAdOx1-nCoV-19 vaccination:  https://jnnp.bmj.com/content/92/11/1247.long

Oct 12, 2021 Characterizing menstrual bleeding changes occurring after SARS-CoV-2 vaccination: https://www.medrxiv.org/content/10.1101/2021.10.11.21264863v1

Oct 9, 2021 Cutaneous leukocytoclastic vasculitis induced by Sinovac COVID-19 vaccine:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8501511/

Oct 2, 2021 Occurrence of de novo cutaneous vasculitis after vaccination against coronavirus disease (COVID-19):  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8487223/

Sept 30, 2021 Possible triggers of thrombocytopenia and/or hemorrhage by BNT162b2 vaccine, Pfizer-BioNTech:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8514746/

Sept 30, 2021 Cutaneous vasculitis following COVID-19 vaccination:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8483649/

Sept 30, 2021 Case report: ANCA-associated vasculitis presenting with rhabdomyolysis and crescentic Pauci-Inmune glomerulonephritis after vaccination with Pfizer-BioNTech COVID-19 mRNA:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8514980/

Sept 27, 2021 Incidence of acute ischemic stroke after coronavirus vaccination in Indonesia: case series: https://www.eurekaselect.com/article/118179

Sept 23, 2021 Rare case of COVID-19 vaccine-associated intracranial hemorrhage with venous sinus thrombosis:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8461674/

Sept 21, 2021 Leukocytoclastic vasculitis as a cutaneous manifestation of ChAdOx1 corona virus vaccine nCoV-19 (recombinant):  https://onlinelibrary.wiley.com/doi/10.1111/dth.15141

Sept 17, 2021 Case of immunoglobulin A vasculitis after vaccination against coronavirus disease 2019:  https://onlinelibrary.wiley.com/doi/10.1111/1346-8138.16167

Sept 16, 2021 Cutaneous small vessel vasculitis after COVID-19 vaccine:  https://onlinelibrary.wiley.com/doi/10.1111/jocd.14452

Sept 16, 2021 Cutaneous vasculitis after severe acute respiratory syndrome coronavirus 2 vaccine:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8452996/

Sept 16, 2021 First description of immune complex vasculitis after COVID-19 vaccination with BNT162b2: case report:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8443965/

Sept 9, 2021 IgA vasculitis in adult patient after vaccination with ChadOx1 nCoV-19:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8427903/

Sept 8, 2021 Vasculitis and bursitis on [18F]FDG-PET/CT following COVID-19 mRNA vaccine: post hoc ergo propter hoc?;  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8424403/

Sept 3, 2021 Reactivation of IgA vasculitis after COVID-19 vaccination:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8260100/

Sept 1, 2021 Intracerebral hemorrhage and thrombocytopenia after AstraZeneca COVID-19 vaccine: clinical and diagnostic challenges of vaccine-induced thrombotic thrombocytopenia:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8486363/

Aug 31, 2021 Association between ChAdOx1 nCoV-19 vaccination and bleeding episodes: large population-based cohort study:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8406020/

Aug 30, 2021 Intracerebral hemorrhage twelve days after vaccination with ChAdOx1 nCoV-19:  https://pubmed.ncbi.nlm.nih.gov/34477089/

Aug 17, 2021 A case of ANCA-associated vasculitis after AZD1222 (Oxford-AstraZeneca) SARS-CoV-2 vaccination: victim or causality?:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8372491/

Aug 8, 2021 COVID-19 vaccine-induced urticarial vasculitis:  https://onlinelibrary.wiley.com/doi/10.1111/dth.15093

July 31, 2021 Propylthiouracil-Induced Antineutrophil Cytoplasmic Antibody-Associated Vasculitis after COVID-19 Vaccination:  https://www.mdpi.com/2076-393X/9/8/842

July 30, 2021 Cutaneous lymphocytic vasculitis after administration of COVID-19 mRNA vaccine:  https://onlinelibrary.wiley.com/doi/10.1111/dth.15076

July 26, 2021 Varicella-zoster virus-related small-vessel vasculitis after Pfizer-BioNTech COVID-19 vaccination:  https://onlinelibrary.wiley.com/doi/10.1111/jdv.17550

July 26, 2021 Small-vessel vasculitis following Oxford-AstraZeneca vaccination against SARS-CoV-2:  https://onlinelibrary.wiley.com/doi/10.1111/jdv.17547

July 24, 2021 Secondary thrombocytopenia after SARS-CoV-2 vaccine: Report of a case of hemorrhage and hematoma after minor oral surgery: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8310415/

July 17, 2021 Large hemorrhagic stroke after vaccination against ChAdOx1 nCoV-19: a case report:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8444739/

July 17, 2021 ANCA-associated vasculitis after Pfizer-BioNTech COVID-19 vaccine:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8285210/

July 15, 2021 Intracerebral hemorrhage associated with vaccine-induced thrombotic thrombocytopenia after ChAdOx1 nCOVID-19 vaccination in a pregnant woman:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8561298/

July 14, 2021 Cutaneous small-vessel vasculitis after vaccination with a single dose of Janssen Ad26.COV2.S:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8302840/

July 10, 2021 Nephrotic syndrome and vasculitis after SARS-CoV-2 vaccine: true association or circumstantial:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8344645/

July 9, 2021 New-onset leukocytoclastic vasculitis after COVID-19 vaccine:  https://onlinelibrary.wiley.com/doi/10.1111/ijd.15777

July 5, 2021 Granulomatous vasculitis after AstraZeneca anti-SARS-CoV-2 vaccine:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8256676/

July 1, 2021 A case of leukocytoclastic vasculitis after vaccination with a SARS-CoV2 vaccine: case report:  https://onlinelibrary.wiley.com/doi/10.1002/art.41910

June 24, 2021 Neurosurgical considerations regarding decompressive craniectomy for intracerebral hemorrhage after SARS-CoV-2 vaccination in vaccine-induced thrombotic thrombocytopenia-VITT:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8269113/

June 11, 2021 Asymmetric cutaneous vasculitis after COVID-19 vaccination with unusual preponderance of eosinophils:  https://onlinelibrary.wiley.com/doi/10.1111/ced.14797

May 11, 2021 Acral hemorrhage after administration of the second dose of SARS-CoV-2 vaccine. A post-vaccination reaction: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8112292/

April 30, 2021 Outbreak of leukocytoclastic vasculitis after COVID-19 vaccine:  https://onlinelibrary.wiley.com/doi/10.1111/ijd.15623

April 29, 2021 Coronavirus disease vaccine 2019 (COVID-19) in systemic lupus erythematosus and neutrophil anti-cytoplasmic antibody-associated vasculitis:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8084413/

Henoch-Schönlein Purpura ( aka Immunoglobulin A vasculitis (IgAV)

Sept 25, 2021 Henoch-Schönlein purpura following the first dose of COVID-19 viral vector vaccine: case report:  https://www.mdpi.com/2076-393X/9/10/1078

Sept 8, 2021 A rare case of Henoch-Schönlein purpura after a case report of COVID-19 vaccine:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8425851/

June 30, 2021 Henoch-Schönlein purpura occurring after vaccination with COVID-19:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8241653/

Immune-mediated Diseases (IMD) including IMRD, IMID

Jan 17, 2022 - Guidelines on COVID-19 vaccination in patients with immune-mediated rheumatic diseases: a Brazilian Society of Rheumatology task force: (Survey which was a joke, bias much?) https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8762982/

Jan 15, 2022 - COVID-19 vaccination uptake among individuals with immune-mediated inflammatory diseases in Ontario, Canada between December 2020 and October 2021: a population-based analysis: https://www.jrheum.org/content/early/2022/01/10/jrheum.211148

Aug 27, 2021  COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses: https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(21)00247-2/fulltext

May 6, 2021 The BNT162b2 mRNA vaccine against SARS-CoV-2 reprograms both adaptive and innate immune responses: https://www.medrxiv.org/content/10.1101/2021.05.03.21256520v1

April 29, 2021 Immune-mediated disease outbreaks or new-onset disease in 27 subjects after mRNA/DNA vaccination against SARS-CoV-2:  https://www.mdpi.com/2076-393X/9/5/435

Kawasaki Disease 

Jan 16, 2022 Atypical Kawasaki Disease after COVID-19 Vaccination: A New Form of Adverse Event Following Immunization: https://pubmed.ncbi.nlm.nih.gov/35062787/

Feb 24, 2021 Post-COVID-19 Outbreak of Severe Kawasaki-like Multisystem Inflammatory Syndrome in Children: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7909350/

Kidney

Aug 3, 2021 Acute kidney injury with macroscopic hematuria and IgA nephropathy after COVID-19 vaccination:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8329426/

July 7, 2021 Minimal change disease with severe acute kidney injury after Oxford-AstraZeneca COVID-19 vaccine: case report:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8260495/

July 6, 2021 Nephrotic syndrome after ChAdOx1 nCoV-19 vaccine against SARScoV-2:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8257404/

May 31, 2021 ANCA glomerulonephritis following Modern COVID-19 vaccination:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8166044/

May 15, 2021 Minimal change disease and acute kidney injury following the Pfizer-BioNTech COVID-19 vaccine: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8123374/

May 13, 2021 An Additional Case of Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8116318/

April 8, 2021 Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8028833/

Kounis Syndrome

Jan 10, 2022  Kounis syndrome must be considered in the differential diagnosis of myocardial infarction following COVID-19 vaccination: https://academic.oup.com/qjmed/advance-article-abstract/doi/10.1093/qjmed/hcac001/6501457?redirectedFrom=fulltext

May 7, 2021 Kounis syndrome type 1 induced by inactivated SARS-COV-2 vaccine:  https://pubmed.ncbi.nlm.nih.gov/34148772/

Lipschütz Ulcers (You don’t want to know.. )

Aug 2, 2021 Lipschütz ulcers after AstraZeneca COVID-19 vaccination: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8327554/

Lung Disease

Sept 11, 2021 Vaccine-induced interstitial lung disease: a rare reaction to COVID-19 vaccine:  https://thorax.bmj.com/content/77/1/9.long

Lymphadenopathy / Adenopathy/Other Lymph-related issues

Nov 25, 2021 Rapid progression of angioimmunoblastic T-cell lymphoma after BNT162b2 mRNA booster vaccination: case report:  https://www.frontiersin.org/articles/10.3389/fmed.2021.798095/

Nov 17, 2021 Subclinical axillary lymphadenopathy associated with COVID-19 vaccination on screening mammography:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8595349/

Nov 8, 2021 Axillary lymphadenopathy in patients with recent Covid-19 vaccination: a new diagnostic dilemma:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8628154/

Nov, 2021 Lessons of the month 3: Haemophagocytic lymphohistiocytosis following COVID-19 vaccination (ChAdOx1 nCoV-19): https://www.rcpjournals.org/content/clinmedicine/21/6/e677

Oct 26, 2021 COVID-19 vaccine-related axillary lymphadenopathy in breast cancer patients: case series with literature review:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8547943/

Oct 26, 2021 COVID-19 vaccine-related axillary and cervical lymphadenopathy in patients with current or previous breast cancer and other malignancies: cross-sectional imaging findings on MRI, CT and PET-CT:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8628159/

Oct 16, 2021 COVID-19 vaccine-induced unilateral axillary adenopathy: follow-up evaluation in the USA:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8520081/

Oct 14, 2021 Rare case of contralateral supraclavicular lymphadenopathy after vaccination with COVID-19: computed tomography and ultrasound findings:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8516346/

Oct 11, 2021 Regional lymphadenopathy after COVID-19 vaccination: review of the literature and considerations for patient management in breast cancer care:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8502686/

Oct 2, 2021 Massive cervical lymphadenopathy following vaccination with COVID-19: https://journals.sagepub.com/doi/10.1177/01455613211048984?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

Oct 2021 Axillary adenopathy associated with COVID-19 vaccination: imaging findings and follow-up recommendations in 23 women:  https://www.ajronline.org/doi/10.2214/AJR.21.25651

Sept 16, 2021 Cervical lymphadenopathy after coronavirus disease vaccination 2019: clinical features and implications for head and neck cancer services:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8476898/

Aug 25, 2021 COVID-19 post-vaccination lymphadenopathy: report of fine-needle aspiration biopsy cytologic findings:  https://onlinelibrary.wiley.com/doi/10.1002/dc.24863

Aug 18, 2021 Hemophagocytic lymphohistiocytosis after vaccination with ChAdOx1 nCov-19:  https://onlinelibrary.wiley.com/doi/10.1002/jmv.27279

Aug 16, 2021 Rituximab-induced acute lympholysis and pancytopenia following vaccination with COVID-19: https://onlinelibrary.wiley.com/doi/10.1002/ccr3.4517

July 24, 2021 Unilateral axillary lymphadenopathy related to COVID-19 vaccine: pattern on screening breast MRI allowing benign evaluation:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8302478/

July 22, 2021 Incidence of axillary adenopathy on breast imaging after vaccination with COVID-19:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299355/

July 9, 2021 Unilateral axillary adenopathy in the setting of COVID-19 vaccination: follow-up:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8268700/

June 26, 2021 Coronavirus disease vaccine 2019 mimics lymph node metastases in patients undergoing skin cancer follow-up: a single-center study:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8233908/

June 11, 2021 Lymphadenopathy associated with COVID-19 vaccination on FDG PET/CT: distinguishing features in adenovirus-vectored vaccine:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8411598/

June 10, 2021 COVID-19 vaccination-induced lymphadenopathy in a specialized breast imaging clinic in Israel: analysis of 163 cases:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8189756/

June 6, 2021 Biphasic anaphylaxis after exposure to the first dose of Pfizer-BioNTech COVID-19 mRNA vaccine COVID-19:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8242856/

June 5, 2021 Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow-up by ultrasonography:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8178535/

May 16, 2021 A case of cervical lymphadenopathy following COVID-19 vaccination:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8204135/

May 3, 2021 Evolution of bilateral hypermetabolic axillary hypermetabolic lymphadenopathy on FDG PET/CT after 2-dose COVID-19 vaccination:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8575109/

May 1, 2021 Lymphadenopathy after COVID-19 vaccination: review of imaging findings:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8088218/

April 30,2021 COVID-19 vaccine-induced axillary and pectoral lymphadenopathy in PET:  https://www.sciencedirect.com/science/article/pii/S1930043321002612

April 21, 2021 COVID-19 vaccination and lower cervical lymphadenopathy in two-week neck lump clinic: a follow-up audit:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057932/

April 1, 2021 COVID-19 mRNA vaccination-induced lymphadenopathy mimics lymphoma progression on FDG PET / CT:  https://journals.lww.com/nuclearmed/Abstract/2021/04000/COVID_19_mRNA_Vaccination_Induced_Lymphadenopathy.18.aspx

March 27, 2021 Hypermetabolic lymphadenopathy after administration of BNT162b2 mRNA vaccine Covid-19: incidence assessed by [ 18 F] FDG PET-CT and relevance for study interpretation:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8003894/

March 26, 2021 Adverse events of COVID injection that may occur in children. Acute-onset supraclavicular lymphadenopathy coincident with intramuscular mRNA vaccination against COVID-19 may be related to the injection technique of the vaccine, Spain, January and February 2021:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7953532/

March 11, 2021 Acute-onset supraclavicular lymphadenopathy coincident with intramuscular mRNA vaccination against COVID-19 may be related to the injection technique of the vaccine, Spain, January and February 2021:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7953532/

March 4, 2021 Oxford-AstraZeneca COVID-19 vaccination induced lymphadenopathy on [18F] choline PET / CT, not just an FDG finding:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7930521/

March 4, 2021 Unilateral lymphadenopathy after COVID-19 vaccination: a practical management plan for radiologists of all specialties:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7931722/

Feb 24, 2021 Adenopathy after COVID-19 vaccination:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7909073/

Feb 24, 2021 Lymphadenopathy in COVID-19 vaccine recipients: diagnostic dilemma in oncology patients:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7909072/

Feb 24, 2021 Evolution of lymphadenopathy on PET/MRI after COVID-19 vaccination:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7909070/

Feb 23, 2021 Lymphadenopathy associated with the COVID-19 vaccine:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7994368/

Feb 15, 2021 Supraclavicular lymphadenopathy after COVID-19 vaccination: an increasing presentation in the two-week wait neck lump clinic:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7883701/

Microscopic Polyangitis

July 12, 2021 Relapse of microscopic polyangiitis after COVID-19 vaccination: case report:  https://onlinelibrary.wiley.com/doi/10.1002/jmv.27192

Miller Fisher syndrome 

Nov 30, 2021 Miller-Fisher syndrome and Guillain-Barré syndrome overlap syndrome in a patient after Oxford-AstraZeneca SARS-CoV-2 vaccination:  https://casereports.bmj.com/content/14/11/e246701.long

Nov 24, 2021 Miller Fisher syndrome after Pfizer COVID-19 vaccine:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8611397/

Nov 18, 2021 Miller Fisher syndrome after 2019 BNT162b2 mRNA coronavirus vaccination:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8598937/

Multi-system Inflamatory Syndrome (MIS-A or MIS-C)

Dec 1, 2021 Post-vaccination multisystem inflammatory syndrome in adults without evidence of prior SARS-CoV-2 infection:  https://pubmed.ncbi.nlm.nih.gov/34852213/

Nov 22, 2021 Multisystem Inflammatory syndrome following COVID-19 vaccination- ignored and underdiagnosed: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8690108/

Nov 18, 2021 Autoantibody Release in Children after Corona Virus mRNA Vaccination: A Risk Factor of Multisystem Inflammatory Syndrome?  https://www.mdpi.com/2076-393X/9/11/1353

Nov 5, 2021 Multisystem Inflammatory Syndrome in an Adult after COVID-19 Vaccination: a Case Report and Literature Review: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8608920/

Oct 7, 2021 Multisystem inflammatory syndrome in a male adolescent after his second Pfizer-BioNTech COVID-19 vaccine.  https://onlinelibrary.wiley.com/doi/10.1111/apa.16141

July 29, 2021 Multisystem inflammatory syndrome in an adult following the SARS-CoV-2 vaccine (MIS-V): https://casereports.bmj.com/content/14/7/e243888

July 27, 2021 Multisystem Inflammatory Syndrome after SARS-CoV-2 Infection and COVID-19 Vaccination: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8237872/

May 19, 2021 Characteristics Associated With Multisystem Inflammatory Syndrome Among Adults With SARS-CoV-2 Infection: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2779957

April 2, 2021 Adult multisystem inflammatory syndrome in apatient who recovered from COVID-19 postvaccination: https://casereports.bmj.com/content/bmjcr/14/4/e242060.full.pdf

Myocarditis/Pericarditis/Cardiomyopathy/Myopericarditis/Myocardial Infarction

July 20, 2023 - Sex-specific differences in myocardial injury incidence after COVID-19 mRNA-1273 Booster Vaccination https://onlinelibrary.wiley.com/doi/epdf/10.1002/ejhf.2978

Aug 22, 2022, Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.122.059970?rfr_dat=cr_pub++0pubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org

Dec 25, 2021 Eosinophilic Myocarditis Following Coronavirus Disease 2019 (COVID-19) : https://www.jstage.jst.go.jp/article/circj/advpub/0/advpub_CJ-21-0935/_article

Dec 22. 2021 mRNA Coronavirus-19 Vaccine-Associated Myopericarditis in Adolescents: A Survey Study.  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8691954/

Dec 21, 2021 T2 mapping should be utilised in cases of suspected myocarditis to confirm an acute inflammatory process:  https://europepmc.org/article/MED/34931681

Dec 17, 2021 Should T2 mapping be used in cases of recurrent myocarditis to differentiate between the acute inflammation and chronic scar?  https://www.jpeds.com/article/S0022-3476(21)01232-4/fulltext

Dec 16, 2021Myocarditis after vaccination against covid-19.  https://www.bmj.com/content/375/bmj.n3090.long

Dec 14. 2021 Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection.  https://www.nature.com/articles/s41591-021-01630-0

Dec 9, 2021 Recurrence of myopericarditis following mRNA COVID-19 vaccination in a male adolescent:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8656213/

Dec 6, 2021 Clinically Suspected Myocarditis Temporally Related to COVID-19 Vaccination in Adolescents and Young Adults:  https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.121.056583?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

Dec 5, 2021 Epidemiology of myocarditis and pericarditis following mRNA vaccines in Ontario, Canada: by vaccine product, schedule, and interval:  https://www.medrxiv.org/content/10.1101/2021.12.02.21267156v1

Dec 4, 2021 Chest pain with abnormal electrocardiogram redevelopment after injection of COVID-19 vaccine manufactured by Moderna:  https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_8711-21/_article

Dec 4, 2021 Definite Acute Myocarditis After Coronavirus Disease 2019 mRNA Vaccination:  https://www.jstage.jst.go.jp/article/circj/advpub/0/advpub_CJ-21-0840/_html/-char/en

Dec 3 Acute myocarditis associated with COVID-19 vaccination: report of a case:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8639400/

Dec 3, 2021 Features of Inflammatory Heart Reactions Following mRNA COVID-19 Vaccination at a Global Level: https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.2499

Dec 2, 2021 Hypersensitivity Myocarditis and COVID-19 Vaccines:  https://journals.viamedica.pl/kardiologia_polska/article/view/KP.a2021.0166/64903

Dec 1, 2021 Association of myocarditis with the BNT162b2 messenger RNA COVID-19 vaccine in a case series of children:  https://pubmed.ncbi.nlm.nih.gov/34374740/

Dec 1, 2021 Myocarditis associated with COVID-19 vaccination in three adolescent boys:  https://www.mp.pl/paim/issue/article/16160/

Nov 30, 2021 Multimodality imaging and histopathology in a young man presenting with fulminant lymphocytic myocarditis and cardiogenic shock after vaccination with mRNA-1273:  https://casereports.bmj.com/content/14/11/e246059

Nov 28, 2021 Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination:  https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciab989/6445179

Nov 27, 2021Myocarditis Following a COVID-19 Messenger RNA Vaccination: A Japanese Case Series: https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_8731-21/_article

Nov 26, 2021 Myocarditis and pericarditis in adolescents after first and second doses of COVID-19 mRNA vaccines:.  https://academic.oup.com/ehjqcco/advance-article/doi/10.1093/ehjqcco/qcab090/6442104

Nov 24, 2021 Perimyocarditis after vaccination with COVID-19:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8637777/

Nov 22, 2021 Acute myocarditis in a young adult two days after vaccination with Pfizer:  https://www.giornaledicardiologia.it/archivio/3689/articoli/36746/

Nov 22, 2021 Myocardial infarction, stroke, and pulmonary embolism after BNT162b2 mRNA COVID-19 vaccine in persons aged 75 years or older:  https://jamanetwork.com/journals/jama/fullarticle/2786667

Nov 8, 2021  68Ga-DOTATOC digital-PET imaging of inflammatory cell infiltrates in myocarditis following COVID-19 vaccination:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8572651/

Nov 8, 2021 Acute pericarditis and cardiac tamponade after vaccination with Covid-19:  http://www.smj.org.sg/sites/default/files/CCF-2021-216-epub.pdf

Nov 6, 2021 Young male with myocarditis after mRNA-1273 coronavirus disease-2019 (COVID-19) mRNA vaccination:  https://www.jstage.jst.go.jp/article/circj/advpub/0/advpub_CJ-21-0818/_html/-char/en

Nov 5, 2021 Myocarditis after COVID-19 vaccination: magnetic resonance imaging study:  https://academic.oup.com/ehjcimaging/advance- article/doi/10.1093/ehjci/jeab230/6421640

Nov 3, 2021 Myocarditis Following Coronavirus Disease 2019 mRNA Vaccine: A Case Series and Incidence Rate Determination:  https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab926/6420408

Nov 2, 2021 Population-based Incidence of Myopericarditis After COVID-19 Vaccination in Danish Adolescents: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8658061/

Nov 1, 2021 Myocarditis Following mRNA COVID-19 Vaccine:  https://journals.lww.com/pec-online/Abstract/2021/11000/Myocarditis_Following_mRNA_COVID_19_Vaccine.9.aspx

Nov 1, 2021 Acute myocarditis after 2019 coronavirus disease vaccination:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8575404/

Nov 2021 COVID-19 Vaccination Associated with Myocarditis in Adolescents:  https://publications.aap.org/pediatrics/article/148/5/e2021053427/181357/COVID-19-Vaccination-Associated-Myocarditis-in

Oct 30, 2021 Myocarditis and pericarditis in association with COVID-19 mRNA vaccination: cases from a regional pharmacovigilance center:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8587334/

Oct 29, 2021 Case report: acute fulminant myocarditis and cardiogenic shock after messenger RNA coronavirus vaccination in 2019 requiring extracorporeal cardiopulmonary resuscitation:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8586196/

Oct 28, 2021 Myocarditis and pericarditis after COVID-19 vaccination: inequalities in age and vaccine types: https://www.mdpi.com/2075-4426/11/11/1106

Oct 27, 2021 Cardiac MRI Findings of Myocarditis After COVID-19 mRNA Vaccination in Adolescents.  https://www.ajronline.org/doi/10.2214/AJR.21.26853

Oct 24, 2021 Acute myocardial infarction within 24 hours after COVID-19 vaccination: is Kounis syndrome the culprit:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8541841/

Oct 19, 2021 Acute myocarditis after COVID-19 vaccination: case report:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8523482/

Oct 19, 2021 Myocarditis in the setting of a recent COVID-19 vaccination:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8548171/

Oct 18, 2021 Acute myocarditis after administration of the second dose of BNT162b2 COVID-19 vaccine:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8599115/

Oct 15, 2021 Shedding the Light on Post-Vaccine Myocarditis and Pericarditis in COVID-19 and Non-COVID-19 Vaccine Recipients:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8541143/

Oct 12, 2021 Case report: probable myocarditis after Covid-19 mRNA vaccine in a patient with arrhythmogenic left ventricular cardiomyopathy:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8545905/

Oct 12, 2021 Myocarditis following vaccination with COVID-19 messenger RNA: a Japanese case series:  https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_8731-21/_pdf/-char/en

Oct 11, 2021 The very low risk of myocarditis and pericarditis after mRNA COVID-19 vaccination should not discourage vaccination.  https://smw.ch/article/doi/smw.2021.w30087

Oct 6, 2021 Myocarditis after Covid-19 Vaccination in a Large Health Care Organization: https://www.nejm.org/doi/full/10.1056/NEJMoa2110737

Oct 6, 2021 Myocarditis following BNT162b2 mRNA Covid-19 mRNA vaccine in Israel:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8531987/

Oct 5, 2021 A case series of acute pericarditis after vaccination with COVID-19 in the context of recent reports from Europe and the United States:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8491922/

Oct 4, 2021 Acute myocarditis after vaccination with COVID-19 mRNA in adults aged 18 years or older: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2784800

Oct 3, 2021 Biventricular systolic dysfunction in acute myocarditis after SARS-CoV-2 mRNA-1273 vaccination:  https://academic.oup.com/ehjcimaging/advance-article/doi/10.1093/ehjci/jeab206/6380644

Oct 1, 2021 A report of myocarditis adverse events in the U.S. Vaccine Adverse Event Reporting System. (VAERS) in association with COVID-19 injectable biologics:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8483988/

Oct 1. A Case Report for Myopericarditis after BNT162b2 COVID-19 mRNA Vaccination in a Korean Young Male:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8506415/

Oct 2021 Transient cardiac injury in adolescents receiving the BNT162b2 mRNA COVID-19 vaccine:  https://journals.lww.com/pidj/Fulltext/2021/10000/Transient_Cardiac_Injury_in_Adolescents_Receiving.1.aspx

Sept 30, 2021 Myocardial infarction and azygos vein thrombosis after vaccination with ChAdOx1 nCoV-19 in a hemodialysis patient: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8489656/

Sept 30, 2021 A case of acute encephalopathy and non-ST-segment elevation myocardial infarction after vaccination with mRNA-1273: possible adverse effect:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8511584/

Sept 29,2021 Acute myocardial infarction and myocarditis after COVID-19 vaccination:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8522388/

Sept 27, 2021 STEMI mimicry: focal myocarditis in an adolescent patient after COVID-19 mRNA vaccination:. https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8469220/

Sept 24, 2021 Case report: symptomatic pericarditis post COVID-19 vaccination:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8522432/

Sept 21, 2021 Severe myocarditis associated with COVID-19 vaccine: zebra or unicorn?: https://www.internationaljournalofcardiology.com/article/S0167-5273(21)01477-7/fulltext

Sept 21, 2021 Myocarditis after COVID-19 mRNA vaccines:  https://academic.oup.com/qjmed/article/114/10/741/6373418

Sept 20, 2021 Myocarditis following COVID-19 vaccination.  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8450283/

Sept 20, 2021 Acute myopericarditis after COVID-19 vaccination in adolescents:.  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8476255/

Sept 16, 2021 COVID-19 mRNA vaccination and development of CMR-confirmed myopericarditis:  https://www.medrxiv.org/content/10.1101/2021.09.13.21262182v1.full?s=09

Sept 11, 2021 A Late Presentation of COVID-19 Vaccine-Induced Myocarditis.  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8504680/

Sept 9, 2021 Cardiovascular magnetic resonance findings in young adult patients with acute myocarditis following mRNA COVID-19 vaccination: a case series.  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8425992/

Sept 8, 2021 Myocarditis associated with SARS-CoV-2 mRNA vaccination in children aged 12 to 17 years: stratified analysis of a national database:  https://www.medrxiv.org/content/10.1101/2021.08.30.21262866v1

Sept 8, 2021 Myocarditis associated with SARS-CoV-2 mRNA vaccination in children aged 12 to 17 years: stratified analysis of a national database:  https://www.medrxiv.org/content/10.1101/2021.08.30.21262866v1

Sept 7, 2021 Lymphohistocytic myocarditis after vaccination with COVID-19 Ad26.COV2.S viral vector:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8421108/

Sept 6, 2021 Biopsy-proven lymphocytic myocarditis after first COVID-19 mRNA vaccination in a 40-year-old man: case report:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419377/

Sept 4, 2021 Myocarditis following COVID-19 vaccination – A case series.  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8416687/

Sept 1, 2021 COVID 19 vaccine for adolescents. Concern for myocarditis and pericarditis:  https://www.mdpi.com/2036-7503/13/3/61

Sept 1, 2021 Acute symptomatic myocarditis in seven adolescents after Pfizer-BioNTech COVID-19 vaccination:  https://pediatrics.aappublications.org/content/early/2021/06/04/peds.2021-052478

Sept 1, 2021 Symptomatic Acute Myocarditis in 7 Adolescents after Pfizer-BioNTech COVID-19 Vaccination:  https://pediatrics.aappublications.org/content/148/3/e2021052478

Sept 1, 2021 Clinical Guidance for Young People with Myocarditis and Pericarditis after Vaccination with COVID-19 mRNA:  https://www.cps.ca/en/documents/position/clinical-guidance-for-youth-with-myocarditis-and-pericarditis

Aug 31, 2021 Reply to “Letter to the editor: Myocarditis should be considered in those with a troponin rise and unobstructed coronary arteries following PfizerBioNTech COVID-19 vaccination”.  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8499842/

Aug 31, 2021 Myocarditis should be considered in those with a troponin rise and unobstructed coronary arteries following Pfizer-BioNTech COVID-19 vaccination.  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8499841/

Aug 28, 2021  Insights From a Murine Model of Coronavirus Disease 2019 (COVID-19) mRNA Vaccination-Induced Myopericarditis: Could Accidental Intravenous Vaccine Injection Induce Myopericarditis? https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab741/6359059

Aug 25, 2021 Myocarditis associated with COVID-19 vaccination: echocardiographic, cardiac tomography, and magnetic resonance imaging findings:  https://www.ahajournals.org/doi/10.1161/CIRCIMAGING.121.013236

Aug 25, 2021 Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting: https://www.nejm.org/doi/full/10.1056/NEJMoa2110475

Aug 25, 2021 Myocarditis associated with COVID-19 vaccination: echocardiographic, cardiac CT, and MRI findings:.  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8478100/

August 18, 2021 Fulminant myocarditis and systemic hyper inflammation temporally associated with BNT162b2 COVID-19 mRNA vaccination in two patients:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8372420/

Aug 18, 2021 Myocarditis following immunization with Covid-19 mRNA:  https://www.nejm.org/doi/full/10.1056/NEJMc2109975

Aug 18, 2021 Fulminant myocarditis and systemic hyperinflammation temporally associated with BNT162b2 COVID-19 mRNA vaccination in two patients:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8372420/

Aug 18, 2021 Intravenous Injection of Coronavirus Disease 2019 (COVID-19) mRNA Vaccine Can Induce Acute Myopericarditis in Mouse Model: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab707/6353927?s=09

Aug 16, 2021 Be alert to the risk of adverse cardiovascular events after COVID-19 vaccination:  https://www.xiahepublishing.com/m/2472-0712/ERHM-2021-00033 

August 16, 2021 Temporal association between COVID-19 vaccine Ad26.COV2.S and acute myocarditis: case report and review of the literature:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8364889/

Aug 16, 2021 mRNA COVID vaccine and myocarditis in adolescents.  https://www.hkmj.org/system/files/hkmj215120.pdf

Aug 16, 2021 Epidemiology and clinical features of myocarditis/pericarditis before the introduction of COVID-19 mRNA vaccine in Korean children: a multicenter study:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8369310/

Aug 13, 2021 COVID-19 Vaccination-Associated Myocarditis in Adolescents.  https://publications.aap.org/pediatrics/article/148/5/e2021053427/181357/COVID-19-Vaccination-Associated-Myocarditis-in

Aug 10, 2021 (accepted) Myocarditis associated with COVID-19 vaccination in adolescents:  https://publications.aap.org/pediatrics/article/148/5/e2021053427/181357

Aug 10, 2021 Myocarditis with COVID-19 mRNA vaccines:  https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.121.056135

Aug 10, 2021 Association of myocarditis with COVID-19 mRNA vaccine in children: (Original article removed from JAMA, however, “COVID-19 vaccine-associated myocarditis may have a benign short-term course in children; however, the long-term risks remain unknown”. https://clinicalnews.org/2021/08/10/association-of-myocarditis-with-mrna-covid-19-vaccine-in-children/

Aug 10, 2021 Association of myocarditis with COVID-19 messenger RNA vaccine BNT162b2 in a case series of children:  https://jamanetwork.com/journals/jamacardiology/fullarticle/2783052

Aug 9, 2021 Epidemiology and clinical features of myocarditis/pericarditis before the introduction of COVID-19 mRNA vaccine in Korean children: a multicenter study  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369310/

Aug 9, 2021 Acute perimyocarditis after the first dose of COVID-19 mRNA vaccine:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8422910/

Aug 9, 2021 Myocarditis after SARS-CoV-2 mRNA vaccination, a case series:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8349733/

Aug 8, 2021 Myocarditis after mRNA vaccination against SARS-CoV-2, a case series:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349733/

Aug 8, 2021 Myocarditis and pericarditis after vaccination with COVID-19 mRNA: practical considerations for care providers:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349442/

Aug 6, 2021 Cardiac imaging of acute myocarditis after vaccination with COVID-19 mRNA:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369314/

Aug 4, 2021 Case report: acute myocarditis following the second dose of mRNA-1273 SARS-CoV-2 vaccine. https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8422333/

Aug 4, 2021 Perimyocarditis following first dose of the mRNA-1273 SARS-CoV-2 (Moderna) vaccine in a healthy young male: a case report: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8334333/

Aug 4, 2021 Myocarditis and pericarditis after COVID-19 vaccination:  https://jamanetwork.com/journals/jama/fullarticle/2782900

Aug 3, 2021 Myocarditis Following COVID-19 Vaccination.  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8369878/

Aug 2, 2021 Acute myocarditis after Comirnaty (Pfizer) vaccination in a healthy male with previous SARS-CoV-2 infection:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326008/

Aug 2, 2021 Myocarditis, pericarditis, and cardiomyopathy following COVID-19 vaccination:  https://www.heartlungcirc.org/article/S1443-9506(21)01156-2/fulltext

July 31, 2021 Myocarditis, pericarditis and cardiomyopathy after COVID-19 vaccination:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8324414/

July 31, 2021 Occurrence of acute infarct-like myocarditis after COVID-19 vaccination: just an accidental coincidence or rather a vaccination-associated autoimmune myocarditis?: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325525/

July 30, 2021 Myopericarditis after messenger RNA Coronavirus Disease 2019 Vaccination in Adolescents 12 to 18 Years of Age.  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8321962/

July 30, 2021 Myopericarditis after Pfizer mRNA COVID-19 vaccination in adolescents: https://pubmed.ncbi.nlm.nih.gov/34339728/ OR https://www.sciencedirect.com/science/article/pii/S002234762100665X

July 29, 2021 Important Insights into Myopericarditis after the Pfizer mRNA COVID-19 Vaccination in Adolescents: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8440228/

July 29, 2021 Myocarditis after BNT162b2 vaccination in a healthy male:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8238643/

July 28, 2021 Perimyocarditis in adolescents after Pfizer-BioNTech COVID-19 vaccine:  https://academic.oup.com/jpids/advance-article/doi/10.1093/jpids/piab060/6329543

July 27, 2021 Risk of Myocarditis from COVID-19 Infection in People Under Age 20: A Population-Based Analysis: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8328065/

July 24, 2021 Acute myocarditis after SARS-CoV-2 vaccination in a 24-year-old man: (nurse): https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8302854/

July 23, 2021 Unusual presentation of acute perimyocarditis after modern SARS-COV-2 mRNA-1237 vaccination: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381757/

July 21, 2021 Myopericarditis in a previously healthy adolescent male after COVID-19 vaccination: Case report:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8441784/

July 20, 2021 Myocarditis with covid-19 mRNA vaccines:  https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.056135

July 20, 2021 Myocarditis associated with vaccination with COVID-19 mRNA:  https://pubs.rsna.org/doi/10.1148/radiol.2021211430

Jul 18, 2021 Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination: What Do We Know So Far?  https://www.mdpi.com/2227-9067/8/7/607

July 16, 2021 Weighing the Risks of Perimyocarditis With the Benefits of SARS-CoV-2 mRNA Vaccination in Adolescents: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8344506/

July 16, 2021 Pericarditis after administration of BNT162b2 mRNA COVID-19 mRNA vaccine:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8282480/ OR https://www.sciencedirect.com/science/article/pii/S1885585721002218

July 16, 2021 Myocarditis / pericarditis associated with COVID-19 vaccine: “This report builds on the expert discussion, summarizes scientific knowns and uncertainties, and suggests priority areas for consideration.” Later in the article “The benefits of vaccination, including prevention of COVID-19 infection and transmission as well as post-COVID complications such as long-COVID and MIS-C, outweigh the potential risk of vaccine-associated myocarditis and pericarditis but active monitoring and research are needed to understand and prevent vaccine-associated cardiac damage, now and in the future”. BULLSHIT. How can they make assumptions like this?  https://science.gc.ca/eic/site/063.nsf/eng/h_98291.html

July 14, 2021 Acute myocarditis after SARS-CoV-2 mRNA-1273 mRNA vaccination:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8278869/

July 13, 2021 The new COVID-19 mRNA vaccine platform and myocarditis: clues to the possible underlying mechanism:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8275472/

July 12, 2021 COVID-19 vaccine and myocarditis: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8272967/

July 12, 2021 Acute myocardial infarction within 24 hours after COVID-19 vaccination:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8272970/

July 10, 2021 Myocarditis and Other Cardiovascular Complications of the mRNA-Based COVID-19 Vaccines: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8270057/

July 10, 2021 COVID-19 vaccine-induced myocarditis: Case report with literature review: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270733/

July 10, 2021 Myocarditis-induced Sudden Death after BNT162b2 mRNA COVID-19 Vaccination in Korea: Case Report Focusing on Histopathological Findings: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8524235/

Jul 9, 2021 Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices – United States, June 2021: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8312754/

July 3, 2021 Acute myocardial injury after COVID-19 vaccination: a case report and review of current evidence from the Vaccine Adverse Event Reporting System database:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8255555/

July 3, 2021 Myopericarditis after Pfizer messenger ribonucleic acid coronavirus coronavirus disease vaccine in adolescents:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8253718/

July 1, 2021 Acute myocarditis after the second dose of SARS-CoV-2 vaccine: serendipity or causal relationship: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274899/

June 29, 2021 Myocarditis after immunization with COVID-19 mRNA vaccines in members of the US military. This article reports that in “23 male patients, including 22 previously healthy military members, myocarditis was identified within 4 days after receipt of the vaccine”:  https://jamanetwork.com/journals/jamacardiology/fullarticle/2781601

June 29, 2021 Myocarditis following vaccination with BNT162b2 in a healthy male:  https://pubmed.ncbi.nlm.nih.gov/34229940/ 

https://www.sciencedirect.com/science/article/pii/S0735675721005362

June 29, 2021 Myocarditis occurring after immunization with COVID-19 mRNA-based COVID-19 vaccines:  https://jamanetwork.com/journals/jamacardiology/fullarticle/2781600

June 29, 2021 Patients with acute myocarditis after vaccination withCOVID-19 mRNA:  https://jamanetwork.com/journals/jamacardiology/fullarticle/2781602

June 28, 2021 Self-limited myocarditis presenting with chest pain and ST-segment elevation in adolescents after vaccination with the BNT162b2 mRNA vaccine:  https://www.cambridge.org/core/journals/cardiology-in-the-young/article/abs/selflimited-myocarditis-presenting-with-chest-pain-and-st-segment-elevation-in-adolescents-after-vaccination-with-the-bnt162b2-mrna-vaccine/22579D1974BCD41E9CECC545A1119F6D#

June 26, 2021 COVID-19 vaccines and myocarditis: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233865/

June 22, 2021 Recurrence of acute myocarditis temporally associated with receipt of coronavirus mRNA disease vaccine 2019 (COVID-19) in a male adolescent:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216855/

June 17, 2021 Acute myocarditis after a second dose of COVID-19 mRNA vaccine: report of two cases:  https://www.clinicalimaging.org/article/S0899-7071(21)00265-5/fulltext

June 16, 2021 Myocarditis temporally associated with COVID-19 vaccination:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8340723/

June 16, 2021 Possible Association Between COVID-19 Vaccine and Myocarditis: Clinical and CMR Findings:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8245050/

June 16, 2021 Acute myocarditis following administration of BNT162b2 vaccine https://pubmed.ncbi.nlm.nih.gov/34189042/

June 16, 2021 In-depth evaluation of a case of presumed myocarditis after the second dose of  COVID-19 mRNA vaccine:  https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.056038

June 16, 2021 A series of patients with myocarditis after vaccination against SARS-CoV-2 with mRNA-1279 and BNT162b2:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8219373/

June 16, 2021 Acute myocarditis after administration of BNT162b2 vaccine:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8220234/

June 16, 2021 Myopericarditis in a previously healthy adolescent male following COVID-19 vaccination: A case report.  https://onlinelibrary.wiley.com/doi/10.1111/acem.14322

June 14, 2021 COVID-19 mRNA vaccination and myocarditis:  https://pubmed.ncbi.nlm.nih.gov/34268277/

June 12, 2021 Pericarditis after administration of the BNT162b2 mRNA vaccine COVID-19:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8196309/

June 10, 2021 Myocarditis and other cardiovascular complications of COVID-19 mRNA-based COVID-19 vaccines: https://www.cureus.com/articles/61030-myocarditis-and-other-cardiovascular-complications-of-the-mrna-based-covid-19-vaccines 

June 9, 2021 Myocarditis after SARS-CoV-2 vaccination: a vaccine-induced reaction?:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8187737/

May 31, 2021 Acute myocarditis associated with anti-COVID-19 vaccination:  https://ecevr.org/DOIx.php?id=10.7774/cevr.2021.10.2.196

May 28, 2021 Myocarditis following COVID-19 mRNA vaccination: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8162819/

May 18, 2021 Myocarditis following COVID-19 vaccination: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8130498/

April 27, 2021 Acute myocarditis after administration of BNT162b2 vaccine against COVID-19:  https://www.revespcardiol.org/en-acute-myocarditis-after-administration-bnt162b2-articulo-S188558572100133X

March 31, 2021 Temporal relationship between the second dose of BNT162b2 mRNA Covid-19 vaccine and cardiac involvement in a patient with previous SARS-COV-2 infection:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8011690/

March 2, 2021 Premature myocardial infarction or side effect of COVID-19 vaccine:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8012173/

Jan 4, 2021 Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase:  https://www.mdpi.com/2076-393X/9/1/19

Myositis (muscles)

Sept 23, 2021 Inflammatory myositis after vaccination with ChAdOx1:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8460178/

July 3, 2021 COVID-19 and Myositis: What We Know So Far https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8254439/

Feb 27, 2021 COVID-19 vaccine-related myositis https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7989152/

Necrosis

Dec 1, 2021 Acute retinal necrosis due to varicella zoster virus reactivation after vaccination with BNT162b2 COVID-19 mRNA: https://www.tandfonline.com/doi/abs/10.1080/09273948.2021.2001540?journalCode=ioii20

Nov 28, 2021 Genital necrosis with cutaneous thrombosis following vaccination with COVID-19 mRNA:  https://onlinelibrary.wiley.com/doi/10.1111/jdv.17837

July 29, 2021 Cutaneous thrombosis associated with cutaneous necrosis following Oxford-AstraZeneca COVID-19 vaccination:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8444634/

Nephrotic Syndrome 

Jan 4, 2022 A young adult with nephrotic syndrome following COVID-19 vaccination: https://europepmc.org/article/PMC/PMC8723818

July 28, 2021 New-onset nephrotic syndrome after Janssen COVID-19 vaccination: case report and literature review:  https://pubmed.ncbi.nlm.nih.gov/34342187/

July 10, 2021 Nephrotic syndrome and vasculitis following SARS-CoV-2 vaccine: true association or circumstantial? https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8344645/

May 15, 2021 Minimal change disease and acute kidney injury following the Pfizer-BioNTech COVID-19 vaccine: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8123374/

May 6, 2021 COVID-19-associated nephritis: early warning for disease severity and complications?: https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(20)31041-2.pdf

April 8, 2021 Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8028833/

Neurological/Neuromuscular/Neurodegenerative Diseases/Neuromyelitis/CNS

Nov 19, 2021 Spectrum of neuroimaging findings in post-CoVID-19 vaccination: a case series and review of the literature:  https://www.mdpi.com/2035-8377/13/4/61

Nov 8, 2021 Neurological side effects of SARS-CoV-2 vaccines:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8653194/

Oct 31 2021 Spectrum of neurological complications after COVID-19 vaccination:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8557950/

Oct 26, 2021 Cardiovascular, neurological, and pulmonary events after vaccination with BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: an analysis of European data:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8547775/

Oct 25, 2021 Neurological complications after the first dose of COVID-19 vaccines and SARS-CoV-2 infection:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8629105/

Oct 19, 2021 Neurological autoimmune diseases after SARS-CoV-2 vaccination: a case series:  https://onlinelibrary.wiley.com/doi/10.1111/ene.15147

Oct 13, 2021 In-hospital observational study of neurological disorders in patients recently vaccinated with COVID-19 mRNA vaccines:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8511874/

Sept 14, 2021 Neuromyelitis optica in a healthy woman after vaccination against severe acute respiratory syndrome coronavirus 2 mRNA-1273:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8516014/

Sept 14, 2021 Reporting of acute inflammatory neuropathies with COVID-19 vaccines: subgroup disproportionality analysis in VigiBase:  https://www.mdpi.com/2076-393X/9/9/1022

Sept 6, 2021 Neurological symptoms and neuroimaging alterations related to COVID-19 vaccine: cause or coincidence:  https://www.clinicalimaging.org/article/S0899-7071(21)00355-7/fulltext

Sept 4, 2021 COVID-19 mRNA vaccine causing CNS inflammation: a case series:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8417681/

Aug 23, 2021 Nerve and muscle adverse events after vaccination with COVID-19: a systematic review and meta-analysis of clinical trials:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402736/

July 28, 2021 Amyotrophic Neuralgia secondary to Vaxzevri vaccine (AstraZeneca) COVID-19:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8316086/

June 29, 2021 Beware of neuromyelitis optica spectrum disorder after vaccination with inactivated virus for COVID-19:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8241205/

June 1, 2021 Unique imaging findings of neurologic phantosmia after Pfizer-BioNtech COVID-19 vaccination: a case report:  https://journals.lww.com/topicsinmri/Fulltext/2021/06000/Unique_Imaging_Findings_of_Neurologic_Phantosmia.2.aspx

Pancreatic Issues

Nov 12, 2021 Pancreas allograft rejection after ChAdOx1 nCoV-19 vaccine:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8586722/

Nov 2, 2021 -  Association between Acute Pancreatitis and COVID-19: Could Pancreatitis Be the Missing Piece of the Puzzle about Increased Mortality Rates? https://www.tandfonline.com/doi/full/10.1080/08941939.2020.1833263

June 1, 2021 Pancreatic Injury after COVID-19 Vaccine—A Case Report: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8228266/

April 28, 2021 Acute Pancreatitis: A Possible Side Effect of COVID-19 Vaccine: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8163516/

Parsonage-Turner Syndrome 

Dec 22, 2021 Parsonage-Turner Syndrome After COVID-19 Vaccination: A Case Report: https://pubmed.ncbi.nlm.nih.gov/34936579/

Dec 13, 2021 Parsonage-Turner syndrome following coronavirus disease 2019 immunization with ChAdOx1-S vaccine: a case report and review of the literature: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8667016/

Sept 24, 2021  Parsonage-Turner Syndrome After SARS-CoV-2 BNT162b2 Vaccine: A Case Report: https://pubmed.ncbi.nlm.nih.gov/34559695/

June 15, 2021 Parsonage-Turner syndrome associated with SARS-CoV-2 or SARS-CoV-2 vaccination. Comment on: “Neuralgic amyotrophy and COVID-19 infection: 2 cases of accessory spinal nerve palsy” by Coll et al. Articular Spine 2021; 88: 10519:  https://pubmed.ncbi.nlm.nih.gov/34139321/

Pneumonia (any)

Nov 9, 2021 Interstitial pneumonitis after COVID-19 vaccination: A report of three cases: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8576592/

Oct 21, 2021 Acute eosinophilic pneumonia associated with anti-COVID-19 vaccine AZD1222:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8604432/

Pregnancy Issues

Jan 24, 2024 Transplacental Transmission of the COVID-19 Vaccine mRNA: Evidence from Placental, Maternal and Cord Blood Analyses Post-Vaccination:
https://www.ajog.org/article/S0002-9378(24)00063-2/pdf

Sept 28, 2022 COVID-19 Vaccines: The Impact on Pregnancy Outcomes
and Menstrual Function: https://www.jpands.org/vol28no1/thorp.pdf

Jan 13 2022 The effect of maternal SARS-CoV-2 infection timing on birth outcomes: a retrospective multicentre cohort study: https://www.thelancet.com/journals/landig/article/PIIS2589-7500(21)00250-8/fulltext

Sept 8, 2021 Spontaneous Abortion Following COVID-19 Vaccination During Pregnancy: https://jamanetwork.com/journals/jama/fullarticle/2784193

June 10, 2021 Adverse effects of COVID-19 messenger RNA vaccines among pregnant women: a cross-sectional study on healthcare workers with detailed self-reported symptoms: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8189739/

April 21, 2021 Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8117969/

Prion Disease

Jan 18, 2021 COVID-19 RNA-based vaccines and the risk of prion disease:  https://dundasvalley.files.wordpress.com/2021/03/covid19-rna-based-vaccines-and-the-risk-of-prion-disease-1503.pdf

Psychiatric Conditions

June 2025 -“Association Between COVID-19 Vaccination and Neuropsychiatric Conditions”
https://ijirms.in/index.php/ijirms/article/view/2090/1487

Retinopathy/Neuroretinopathy/Ocular

Sept 25, 2021 Central retinal vein occlusion after vaccination with SARS-CoV-2 mRNA: case report:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8597478/

Sept 24, 2021 Ocular adverse events following COVID-19 vaccination:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8477588/

Sept 2, 2021 Association of Ocular Adverse Events With Inactivated COVID-19 Vaccination in Patients in Abu Dhabi: https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2783653?widget=personalizedcontent&previousarticle=2782394

July 21, 2021 Bilateral acute macular neuroretinopathy after SARS-CoV-2 vaccination:  https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2782394

June 12, 2021 Acute-onset central serous retinopathy after immunization with COVID-19 mRNA vaccine:.  https://www.sciencedirect.com/science/article/pii/S2451993621001456

Rhabdomyolysis

Aug 25, 2021 COVID-19 mRNA vaccine induced rhabdomyolysis and fasciitis:  https://link.springer.com/article/10.1007/s00415-021-10768-3

June 15, 2021 COVID-19 vaccine-induced rhabdomyolysis: case report with literature review:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205294/

Schamberg Disease

July 8, 2021 Generalized purpura annularis telangiectodes after SARS-CoV-2 mRNA vaccination:  https://onlinelibrary.wiley.com/doi/10.1111/jdv.17497

Seizures

Dec 1, 2021 - A Seizure After COVID-19 Vaccination in a Patient on Clozapine: https://journals.lww.com/psychopharmacology/Citation/2021/11000/A_Seizure_After_COVID_19_Vaccination_in_a_Patient.16.aspx

June 21, 2021 COVID-19 vaccination in patients with epilepsy: First experiences in a German tertiary epilepsy center: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8216683/

June 7 2021 New-onset refractory status epilepticus after ChAdOx1 nCoV-19 vaccination:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8182981/

May 8, 2021 Focal onset non-motor seizure following COVID-19 vaccination: A mere coincidence? https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8105133/

Splenic Infarction

Dec 7, 2021 Occurrence of splenic infarction due to arterial thrombosis after vaccination with COVID-19: https://casereports.bmj.com/content/14/12/e243846.long

Mar 23, 2021 COVID-19 as a trigger for splenic infarction in a patient with sickle cell trait: A case report: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7986315/

Systemic Capillary Leak Syndrome

Aug 6, 2021 Systemic capillary leak syndrome after ChAdOx1 nCOV-19 (Oxford–AstraZeneca) vaccination: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8432311/

June 15, 2021 Severe Exacerbations of Systemic Capillary Leak Syndrome After COVID-19 Vaccination: A Case Series: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8252024/

Takotsubo Syndrome (stress cardiomyopathy)

Nov 3, 2021 Takotsubo cardiomyopathy after coronavirus 2019 vaccination in patient on maintenance hemodialysis:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8564792/

Oct 8, 2021 Takotsubo (stress) cardiomyopathy after vaccination with ChAdOx1 nCoV-19:  https://casereports.bmj.com/content/14/10/e246580.long

Sept 15, 2021 Takotsubo syndrome after COVID-19 vaccination:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8440167/

July 15, 2021 Takotsubo cardiomyopathy after vaccination with mRNA COVID-19:  https://www.sciencedirect.com/science/article/pii/S1443950621011331

Thrombocytopenia 

Jan 1, 2022 ChAdOx1 nCoV-19 vaccine-associated thrombocytopenia: three cases of immune thrombocytopenia after 107,720 doses of ChAdOx1 vaccination in Thailand:  https://journals.lww.com/bloodcoagulation/Abstract/2022/01000/ChAdOx1_nCoV_19_vaccine_associated.10.aspx

Nov 17, 2021 Relapse of immune thrombocytopenia after covid-19 vaccination in young male patient:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8595970/

Oct 30,2021 Immune thrombocytopenia after immunization with Vaxzevria ChadOx1-S vaccine (AstraZeneca), Victoria, Australia:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8556135/

Oct 29, 2021 Case report of immune thrombocytopenia after vaccination with ChAdOx1 nCoV-19:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8575766/

Oct 27, 2021 Severe immune thrombocytopenic purpura after SARS-CoV-2 vaccine:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8565691/

Oct 23, 2021 A Case of Idiopathic Thrombocytopenic Purpura After Booster Dose of BNT162b2 (Pfizer-Biontech) COVID-19 Vaccine:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8607313/

Oct 7, 2021 Severe immune thrombocytopenia following COVID-19 vaccination: report of four cases and review of the literature:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8494992/

Sept 30, 2021 Relapse of immune thrombocytopenia after COVID-19 vaccination:  https://onlinelibrary.wiley.com/doi/10.1111/ejh.13713

Sept 18, 2021 Prevalence of thrombocytopenia, anti-platelet factor 4 antibodies, and elevated D-dimer in Thais after vaccination with ChAdOx1 nCoV-19:  https://onlinelibrary.wiley.com/doi/10.1002/rth2.12580

Sept 14, 2021 Transient thrombocytopenia with glycoprotein-specific platelet autoantibodies after vaccination with Ad26.COV2.S: case report:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8500336/

Aug 26, 2021 Immune thrombocytopenia after vaccination during the COVID-19 pandemic: (download pdf) https://haematologica.org/article/view/haematol.2021.279442

Aug 22, 2021 Newly diagnosed immune thrombocytopenia in a pregnant patient after coronavirus disease 2019 vaccination:  https://obgyn.onlinelibrary.wiley.com/doi/10.1111/jog.14978

Aug 20, 2021 Immune-mediated thrombocytopenia associated with Ad26.COV2.S vaccine (Janssen; Johnson & Johnson):  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8415511/

Aug 19, 2021  Comment on: Thrombocytopenia in a teen with sickle cell disease following COVID‐19 vaccination: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8441642/

Aug 4, 2021 Immune-mediated thrombocytopenic purpura after Pfizer-BioNTech COVID-19 vaccine in an elderly woman:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8414938/

Aug 4, 2021 Immune thrombocytopenia associated with Pfizer-BioNTech’s COVID-19 BNT162b2 mRNA vaccine:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8336989/

July 31, 2021 Thrombocytopenia in an adolescent with sickle cell anemia after COVID-19 vaccination:  https://onlinelibrary.wiley.com/doi/10.1002/pbc.29271

July 30, 2021 Immune thrombocytopenic purpura and acute liver injury after COVID-19 vaccination:  https://casereports.bmj.com/content/14/7/e242678

July 27, 2021 Thrombocytopenia after COVID-19 vaccination:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313538/

June 30, 2021 Secondary immune thrombocytopenia (ITP) associated with ChAdOx1 Covid-19 vaccine: case report: https://www.ncbi.nlm.nih.gov//pmc/articles/PMC8324423/

June 24, 2021 Exacerbation of immune thrombocytopenia after COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34075578/

June 23, 2021 Immune thrombocytopenia following Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine: (download pdf to view Case Report) https://www.ima.org.il/MedicineIMAJ/viewarticle.aspx?year=2021&month=06&page=341

June 8, 2021 Spontaneous HIT syndrome: knee replacement, infection, and parallels with vaccine-induced immune thrombotic thrombocytopenia:  https://www.thrombosisresearch.com/article/S0049-3848(21)00357-1/fulltext

June 2, 2021 Immune thrombocytopenic purpura associated with COVID-19 mRNA vaccine Pfizer-BioNTech BNT16B2b2:  https://onlinelibrary.wiley.com/doi/10.1111/jdv.17444

May 31, 2021 Secondary immune thrombocytopenia putatively attributable to COVID-19 vaccination:  https://casereports.bmj.com/content/14/5/e242220.abstract

May 5, 2021 Newly diagnosed idiopathic thrombocytopenia after COVID-19 vaccine administration:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8176657/

May 1, 2021 Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8014568/

April 30, 2021 Thrombocytopenia, including immune thrombocytopenia after receiving COVID-19 mRNA vaccines reported to the Vaccine Adverse Event Reporting System (VAERS):  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8086806/

April 28, 2021 An observational study to identify the prevalence of thrombocytopenia and anti-PF4 / polyanion antibodies in Norwegian health care workers after COVID-19 vaccination:  https://onlinelibrary.wiley.com/doi/10.1111/jth.15352

April 28, 2021 Prothrombotic immune thrombocytopenia after COVID-19 vaccination:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8084604/

April 20, 2021 Thrombocytopenia with acute ischemic stroke and hemorrhage in a patient recently vaccinated with an adenoviral vector-based COVID-19 vaccine:.  https://onlinelibrary.wiley.com/doi/10.1111/jth.15347

April 9, 2021 Thrombocytopenia and intracranial venous sinus thrombosis after exposure to the “AstraZeneca COVID-19 vaccine”:  https://pubmed.ncbi.nlm.nih.gov/33918932/

April 6, 2021 Severe and refractory immune thrombocytopenia occurring after SARS-CoV-2 vaccination: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8040692/

March 25, 2021 Purpuric rash and thrombocytopenia after mRNA-1273 (Modern) COVID-19 vaccine:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996471/

March 9, 2021 Thrombocytopenia after Pfizer and Moderna SARS vaccination – CoV -2:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8014568/

March 1, 2021 Immune thrombocytopenic purpura after vaccination with COVID-19 vaccine (ChAdOx1 nCov-19):  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265330/

Feb 19, 2021 Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination.  https://onlinelibrary.wiley.com/doi/10.1002/ajh.26132

Feb 12, 2021 Idiopathic thrombocytopenic purpura and the Modern Covid-19 vaccine:  https://www.annemergmed.com/article/S0196-0644(21)00122-0/fulltext

Feb 11, 2021 Immune thrombocytopenia in a 22-year-old post Covid-19 vaccine:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8014773/

Thrombosis/Thromboembolism incl Venous Sinus Thrombosis (VST), Acute

Nov 29, 2021 COVID-19 Vaccine-Related Thrombosis: A Systematic Review and Exploratory Analysis: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8666479/

Nov 29, 2021 Major artery thrombosis and vaccination against ChAdOx1 nCov-19:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8627790/

Nov 15, 2021 Thrombotic adverse events reported for Moderna, Pfizer, and Oxford-AstraZeneca COVID-19 vaccines: comparison of occurrence and clinical outcomes in the EudraVigilance database: https://www.mdpi.com/2076-393X/9/11/1326

Nov 10, 2021 Thrombotic events after COVID-19 vaccination in over 50 years of age: results of a population-based study in Italy:  https://www.mdpi.com/2076-393X/9/11/1307

Nov 10, 2021 Thrombosis after adenovirus-vectored COVID-19 vaccination: a concern for underlying disease:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8586168/

Nov 8, 2021 New portal vein thrombosis in cirrhosis: is thrombophilia exacerbated by vaccine or COVID-19:  https://www.jcehepatology.com/article/S0973-6883(21)00545-4/fulltext

Oct 25, 2021 Potential risk of thrombotic events after COVID-19 vaccination with Oxford-AstraZeneca in women receiving estrogen:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8560237/

Oct 10,2021 Multiple sites of arterial thrombosis in a 35-year-old patient after vaccination with ChAdOx1 (AstraZeneca), which required emergency femoral and carotid surgical thrombectomy:  https://www.annalsofvascularsurgery.com/article/S0890-5096(21)00679-8/fulltext

Oct 12, 2021 Adenovirus-Vectored COVID-19 Vaccine–Induced Immune Thrombosis of Carotid Artery: https://n.neurology.org/content/97/15/716.long

Sept 30, 2021 Thrombosis formation after COVID-19 vaccination immunologic aspects: review article:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8489518/

Oct 6, 2021 Diffuse prothrombotic syndrome after administration of ChAdOx1 nCoV-19 vaccine: case report:  https://jmedicalcasereports.biomedcentral.com/articles/10.1186/s13256-021-03083-y

Sept 9, 2021 Autoimmunity roots of thrombotic events after vaccination with COVID-19:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8426137/

Sept 3, 2021 “Portal vein thrombosis occurring after the first dose of SARS-CoV-2 mRNA vaccine in a patient with antiphospholipid syndrome”: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8413101/

Sept 2, 2021 Thrombosis of the palmar digital vein after Oxford‐AstraZeneca COVID‐19 vaccination: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8652811/

Sept 1, 2021 Thrombosis in pre- and post-vaccination phase of COVID-19;  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8503327/

Aug 28, 2021 Thrombosis after COVID-19 vaccination: possible link to ACE pathways:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8397505/

Aug 20, 2021 Venous sinus thrombosis after vaccination with ChAdOx1 nCov-19:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8376560/

Aug 18, 2021 Immune complexes, innate immunity and NETosis in ChAdOx1 vaccine-induced thrombocytopenia:  https://academic.oup.com/eurheartj/article/42/39/4064/6354117

Aug 14, 2021 A case of acute pulmonary embolism after immunization with SARS-CoV-2 mRNA:  https://www.mdpi.com/2076-393X/9/8/903

Jul 26, 2021 Thromboembolic events in younger females exposed to Pfizer-BioNTech or Moderna COVID-19 vaccines:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8330010/

July 14, 2021 Case report Coeliac artery and splenic artery thrombosis complicated with splenic infarction 7 days following the first dose of Oxford vaccination, causal relationship or coincidence?:  https://casereports.bmj.com/content/14/7/e243799

July 2, 2021 Predicted and observed incidence of thromboembolic events among Koreans vaccinated with the ChAdOx1 nCoV-19 vaccine:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8275463/

June 16, 2021 Thromboaspiration infusion and fibrinolysis for portomesenteric thrombosis after administration of AstraZeneca COVID-19 vaccine:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8206184/

June 15, 2021 Comparison of vaccine-induced thrombotic episodes between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8204660/

June 8, 2021Portal vein thrombosis associated with ChAdOx1 nCov-19 vaccine:  https://www.thelancet.com/journals/langas/article/PIIS2468-1253(21)00197-7/

May 28, 2021 Antiphospholipid antibodies and risk of thrombophilia after COVID-19 vaccination: the straw that breaks the camel’s back?:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8159713/

May 19, 2021 Atypical thrombosis associated with the vaccine VaxZevria® (AstraZeneca): data from the French network of regional pharmacovigilance centers:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165560/

May 3, 2021 Acute thrombosis of the coronary tree after vaccination against COVID-19:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8092130/

Feb 1, 2021 Concerning the unexpected prothrombotic state following some coronavirus disease 2019 vaccines.  https://journals.lww.com/jcardiovascularmedicine/Fulltext/2022/02000/Concerning_the_unexpected_prothrombotic_state.1.aspx

Thrombotic Thrombocytopenia, VITT) or Thrombosis-Throbocytopenia

Jan 4, 2022  Post COVID-19 Vaccine Related Cerebral Venous Sinus Thrombosis and Thrombocytopenia: https://assets.cureus.com/uploads/case_report/pdf/81913/20220106-11592-i3k4v8.pdf

Dec 15, 2021 -Thrombosis with Thrombocytopenia Syndrome After Administration of AZD1222 or Ad26.COV2.S Vaccine for COVID-19: A Systematic Review: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8689609/

Dec 15, 2021 Comments on thrombosis after vaccination: spike protein leader sequence could be responsible for thrombosis and antibody-mediated thrombocytopenia:  https://www.liebertpub.com/doi/10.1089/vim.2021.0118?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed

Dec 2, 2021 Information on ChAdOx1 nCoV-19 vaccine-induced immune-mediated thrombotic thrombocytopenia:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8483989/

Nov 27, 2021 A case of unusual mild clinical presentation of COVID-19 vaccine-induced immune thrombotic thrombocytopenia with splanchnic vein thrombosis:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8626153/

Nov 23, 2021 Inflammation and platelet activation after COVID-19 vaccines: possible mechanisms behind vaccine-induced immune thrombocytopenia and thrombosis:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8649717/

Nov 17, 2021 Complicated case report of long-term vaccine-induced thrombotic immune thrombocytopenia A:  https://www.mdpi.com/2076-393X/9/11/1344

Nov 12, 2021 Case study of thrombosis and thrombocytopenia syndrome after administration of the AstraZeneca COVID-19 vaccine:  https://www1.racgp.org.au/ajgp/coronavirus/thrombosis-following-astrazeneca-vaccine/

Nov 9, 2021 Case series of vaccine-induced thrombotic thrombocytopenia in a London teaching hospital: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8652623/

Nov 3, 2021 VITT (vaccine-induced immune thrombotic thrombocytopenia) after vaccination with ChAdOx1 nCoV-19:  https://www.nejm.org/doi/10.1056/NEJMc2111026?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

Nov 1, 2021 Case report: vaccine-induced immune immune thrombotic thrombocytopenia in a patient with pancreatic cancer after vaccination with messenger RNA-1273:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8591100/

Oct 26, 2021 COVID-19 vaccine-associated thrombosis with thrombocytopenia syndrome (TTS): systematic review and post hoc analysis:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8552386/

Oct 26, 2021 Vaccine-associated thrombocytopenia and thrombosis: venous endotheliopathy leading to combined venous micro-macrothrombosis:  https://www.mdpi.com/1648-9144/57/11/1163

Oct 21, 2021 Refractory vaccine-induced immune thrombotic thrombocytopenia (VITT) treated with delayed therapeutic plasma exchange (TPE):  https://pubmed.ncbi.nlm.nih.gov/34672380/

Oct 21, 2021 Neuro-ophthalmic complications with thrombocytopenia and thrombosis induced by ChAdOx1 nCoV-19 vaccine: NO ABSTRACT PAYWALL FOR MAGONLINE: https://pubmed.ncbi.nlm.nih.gov/34726934/

Oct 20, 2021 Thrombosis and thrombocytopenia syndrome causing isolated symptomatic carotid occlusion after COVID-19 Ad26.COV2.S vaccine (Janssen):  https://www.thieme-connect.com/products/ejournals/html/10.1055/a-1674-0341

Oct 19, 2021 ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome: https://www.science.org/doi/10.1126/sciadv.abl8213

Oct 18, 2021 Vaccine-induced immune thrombosis and thrombocytopenia syndrome after adenovirus-vectored severe acute respiratory syndrome coronavirus 2 vaccination: a new hypothesis on mechanisms and implications for future vaccine development:  https://onlinelibrary.wiley.com/doi/10.1111/imcb.12505

Oct 14, 2021 Thrombosis in peripheral artery disease and thrombotic thrombocytopenia following adenoviral COVID-19 vaccination:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8524636/

Oct 13, 2021 Bilateral thalamic stroke: a case of COVID-19 (VITT) vaccine-induced immune thrombotic thrombocytopenia or a coincidence due to underlying risk factors:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8606181/

Oct 8, 2021 COVID-19 vaccine-induced immune thrombosis with thrombocytopenia thrombosis (VITT) and shades of gray in thrombus formation:  https://www.thieme-connect.com/products/ejournals/html/10.1055/s-0041-1735453

Oct 6, 2021 Successful treatment of vaccine-induced immune immune thrombotic thrombocytopenia in a 26-year-old female patient:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8678222/

Oct 1, 2021 Portal Vein Thrombosis due to Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) after Covid Vaccination with ChAdOx1 nCoV-19: https://www.thieme-connect.com/products/ejournals/html/10.1055/a-1579-9303

Sept 30,2021 Understanding the risk of thrombosis with thrombocytopenia syndrome following Ad26.COV2.S vaccination: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8482953/

Sept 27, 2021 Acute ST-segment elevation myocardial infarction secondary to vaccine-induced immune thrombosis with thrombocytopenia (VITT): https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8477249/

Sept 24, 2021 Cerebral venous sinus thrombosis, pulmonary embolism, and thrombocytopenia after COVID-19 vaccination in a Taiwanese man: a case report and review of the literature:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8498326/

Sept 21, 2021 Abdominal pain and bilateral adrenal hemorrhage from immune thrombotic thrombocytopenia induced by COVID-19 vaccine:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8500008/

Sept 21, 2021 Predictors of mortality in thrombotic thrombocytopenia after adenoviral COVID-19 vaccination: the FAPIC score:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8500026/

Sept 20,2021 Concerns for adverse effects of thrombocytopenia and thrombosis after adenovirus-vectored COVID-19 vaccination:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8642058/

Sept 17, 2021 A rare case of COVID-19 vaccine-induced thrombotic thrombocytopenia (VITT) affecting the venosplanchnic and pulmonary arterial circulation from a UK district general hospital:  https://casereports.bmj.com/content/14/9/e244223.long

Sept 15, 2021 Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis after covid-19 vaccination; a systematic review:  https://pubmed.ncbi.nlm.nih.gov/34365148/

Sept 10, 2021 COVID-19 vaccine-induced thrombotic thrombocytopenia: a case series:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8432416/

Sept 8, 2021 COVID-19 vaccine, immune thrombotic thrombocytopenia, jaundice, hyperviscosity: concern in cases with underlying hepatic problems:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8425075/

Sept 6, 2021 Australian and New Zealand approach to the diagnosis and treatment of vaccine-induced immune thrombosis and immune thrombocytopenia:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8661608/

Sept 2, 2021 Platelet activation and modulation in thrombosis with thrombocytopenia syndrome associated with the ChAdO × 1 nCov-19 vaccine:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8634168/

Aug 28, 2021 Treatment of acute ischemic stroke associated with ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8397593/

Aug 27, 2021 Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. https://www.bmj.com/content/374/bmj.n1931.long

Aug 27, 2021 The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune thrombotic immune thrombocytopenia (covid): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8390120/

Aug 26, 2021 Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and positive SARS-CoV-2 tests: self-controlled case series study:  https://pubmed.ncbi.nlm.nih.gov/34446426/

Aug 25, 2021 Vaccine-induced severe thrombotic thrombocytopenia following COVID-19 vaccination: a report of an autoptic case and review of the literature:  https://www.europeanreview.org/article/26464

Aug 19, 2021 Interactions of adenoviruses with platelets and coagulation and the vaccine-induced immune thrombotic thrombocytopenia syndrome:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8634187/

Aug 17, 2021 Imaging and hematologic findings in thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19 (AstraZeneca):  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8488810/

Aug 12, 2021 Venous thromboembolism and mild thrombocytopenia after vaccination with ChAdOx1 nCoV-19:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8632250/

Aug 11, 2021 Clinical features of vaccine-induced thrombocytopenia and immune thrombosis:  https://www.nejm.org/doi/10.1056/NEJMoa2109908?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

Aug 10,2021 Comparison of adverse drug reactions among four COVID-19 vaccines in Europe using the EudraVigilance database: Thrombosis in unusual sites:  https://onlinelibrary.wiley.com/doi/10.1111/jth.15493

Aug 3, 2021 Vaccine-induced immune immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis after vaccination with COVID-19; a systematic review:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330139/

Aug 2, 2021 Malignant cerebral infarction after vaccination with ChAdOx1 nCov-19: a catastrophic variant of vaccine-induced immune-mediated thrombotic thrombocytopenia:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8329262/

Aug 2, 2021 Three cases of acute venous thromboembolism in women after coronavirus 2019 vaccination:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8327605/

July 30,2021 Vaccine-induced immune thrombotic thrombocytopenia causing a severe form of cerebral venous thrombosis with high mortality rate: a case series:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8363077/

July 18,2021 Coronavirus (COVID-19) Vaccine-induced immune thrombotic thrombocytopenia (VITT):  (BOOK) https://www.ncbi.nlm.nih.gov/books/NBK570605/

July 15, 2021Thrombotic thrombocytopenic purpura: a new threat after COVID bnt162b2 vaccine:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8280631/

July 14, 2021 Pulmonary embolism, transient ischemic attack, and thrombocytopenia after Johnson & Johnson COVID-19 vaccine: https://casereports.bmj.com/content/14/7/e243975

July 10, 2021 Primary adrenal insufficiency associated with thrombotic immune thrombocytopenia induced by the Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine (VITT):  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8271354/

July 10, 2021  Thrombosis with thrombocytopenia syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination: risk-benefit analysis for persons <60 years in Australia: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270740/

July 10, 2021 Primary adrenal insufficiency associated with thrombotic immune thrombocytopena induced by Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine (VITT):  https://pubmed.ncbi.nlm.nih.gov/34256983/ OR https://www.ejinme.com/article/S0953-6205(21)00236-3/fulltext

July 8, 2021 Vaccine-induced thrombosis and thrombocytopenia with bilateral adrenal haemorrhage:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8444929/

July 7, 2021 Antibody epitopes in vaccine-induced immune immune thrombotic thrombocytopenia:  https://www.nature.com/articles/s41586-021-03744-4

July 5, 2021 First report of a de novo iTTP episode associated with a COVID-19 mRNA-based anti-COVID-19 vaccine:  https://onlinelibrary.wiley.com/doi/10.1111/jth.15418

July 3, 2021 Early Outcomes of Bivalirudin Therapy for Thrombotic Thrombocytopenia and Cerebral Venous Sinus Thrombosis After Ad26.COV2.S Vaccination: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8253724/

June 30, 2021 Vaccine-induced thrombotic thrombocytopenia: the elusive link between thrombosis and adenovirus-based SARS-CoV-2 vaccines:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8243058/

June 30, 2021 Thrombosis and SARS-CoV-2 vaccines: vaccine-induced immune thrombotic thrombocytopenia:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8342878/

June 30,2021 Renal vein thrombosis and pulmonary embolism secondary to vaccine-induced thrombotic immune thrombocytopenia (VITT):  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8276919/

June 29,2021 Vaccine-induced thrombotic thrombocytopenia, a rare but severe case of friendly fire in the battle against the COVID-19 pandemic: What pathogenesis?:  https://www.sciencedirect.com/science/article/pii/S0953620521002314

June 29, 2021 Thrombosis with thrombocytopenia after messenger RNA vaccine -1273:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251935/

June 24, 2021 Acute ischemic stroke revealing immune thrombotic thrombocytopenia induced by ChAdOx1 nCov-19 vaccine: impact on recanalization strategy:  https://www.strokejournal.org/article/S1052-3057(21)00345-1/fulltext

June 22, 2021 Vaccine-induced immune thrombotic thrombocytopenia (VITT): a new clinicopathologic entity with heterogeneous clinical presentations:  https://onlinelibrary.wiley.com/doi/10.1111/bjh.17613

June 18, 2021 Vaccine-induced thrombotic thrombocytopenia: the dark chapter of a success story:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217988/

June 17, 2021 A case of multiple thrombocytopenia and thrombosis following vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8219289/

June 15, 2021 Procoagulant microparticles: a possible link between vaccine-induced immune thrombocytopenia (VITT) and cerebral sinus venous thrombosis:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8204296/

June 9, 2021 First dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic, and hemorrhagic events in Scotland:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8282499/

June 9, 2021COVID‐19 vaccine‐associated immune thrombosis and thrombocytopenia (VITT): Diagnostic and therapeutic recommendations for a new syndrome:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8239516/

June 9, 2021 Immunoglobulin adjuvant for vaccine-induced immune thrombotic thrombocytopenia:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8362588/

June 8, 2021 Acquired thrombotic thrombocytopenic thrombocytopenic purpura: a rare disease associated with the BNT162b2 vaccine:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237075/

June 7, 2021 Management of a patient with a rare congenital limb malformation syndrome after SARS-CoV-2 vaccine-induced thrombosis and thrombocytopenia (VITT):  https://onlinelibrary.wiley.com/doi/10.1111/bjh.17619

June 7, 2021 Vaccine-induced thrombotic thrombocytopenia after Ad26.COV2.S vaccination in a man presenting as acute venous thromboembolism:  https://onlinelibrary.wiley.com/doi/10.1002/ajh.26265

May 31, 2021 Thrombocytopenia and splanchnic thrombosis after vaccination with Ad26.COV2.S successfully treated with transjugular intrahepatic intrahepatic portosystemic shunt and thrombectomy:  https://onlinelibrary.wiley.com/doi/10.1002/ajh.26258

May 28, 2021 Laboratory testing for suspicion of COVID-19 vaccine-induced thrombotic (immune) thrombocytopenia:  https://onlinelibrary.wiley.com/doi/pdf/10.1111/ijlh.13629

May 27, 2021 Thrombotic thrombocytopenia after vaccination with COVID-19: in search of the underlying mechanism:  https://www.mdpi.com/2076-393X/9/6/559/htm

May 25, 2021 Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8143907/

May 25, 2021 Thrombosis with thrombocytopenia syndrome associated with COVID-19 viral vector vaccines:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8148431/

May 24, 2021 Limb ischemia and pulmonary artery thrombosis after ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca): a case of vaccine-induced immune thrombotic thrombocytopenia:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8248449/

May 22, 2021 Immediate high-dose intravenous immunoglobulins followed by direct treatment with thrombin inhibitors is crucial for survival in vaccine-induced immune thrombotic thrombocytopenia Sars-Covid-19-vector adenoviral VITT with venous thrombosis of the cerebral sinus and portal vein: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8140563/

May 21, 2021 A case of vaccine-induced immune-immune thrombotic thrombocytopenia with massive arteriovenous thrombosis:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8297676/

May 20, 2021 Post-mortem findings in vaccine-induced thrombotic thrombocytopenia (covid-19):  https://haematologica.org/article/view/haematol.2021.279075

May 20, 2021 Procoagulant antibody-mediated procoagulant platelets in immune thrombotic thrombocytopenia associated with SARS-CoV-2 vaccination:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327736/

May 19, 2021 Mechanisms of immunothrombosis in vaccine-induced thrombotic thrombocytopenia (VITT) compared to natural SARS-CoV-2 infection:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8133385/

May 19, 2021 PF4 immunoassays in vaccine-induced thrombotic thrombocytopenia:  https://www.nejm.org/doi/full/10.1056/NEJMc2106383

May 18, 2021 Covid-19 vaccine- induced thrombosis and thrombocytopenia-a commentary on an important and practical clinical dilemma: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130591/

May 15, 2021 Hypothesis behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8123522/

May 4, 2021 Thrombotic thrombocytopenic purpura after vaccination with Ad26.COV2-S:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8095021/

April 30, 2021 COVID-19 vaccine-induced immune-immune thrombotic thrombocytopenia: an emerging cause of splanchnic vein thrombosis:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8086259/

April 30, 2021 Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS): https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8086806/

April 30,2021 U.S. case reports of cerebral venous sinus thrombosis with thrombocytopenia after vaccination with Ad26.COV2.S, March 2-April 21, 2021:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8087975/

April 29, 2021 Diagnosis and treatment of cerebral venous sinus thrombosis with vaccine-induced immune-immune thrombotic thrombocytopenia:
https://www.ahajournals.org/doi/full/10.1161/STROKEAHA.121.035564?rfr_dat=cr_pub++0pubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org

April 28, 2021 Arterial events, venous thromboembolism, thrombocytopenia and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population-based cohort study:  https://www.bmj.com/content/373/bmj.n1114.long

Apr 28, 2021 Images of immune thrombotic thrombocytopenia induced by Oxford / AstraZeneca® COVID-19 vaccine:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8080133/

April 20, 2021 - Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination: report of two cases in the United Kingdom:  https://www.sciencedirect.com/science/article/abs/pii/S088915912100163X

April 16, 2021 Thrombotic immune thrombocytopenia induced by SARS-CoV-2 vaccine:  https://www.nejm.org/doi/full/10.1056/nejme2106315

April 14, 2021 Bilateral superior ophthalmic vein thrombosis, ischemic stroke and immune thrombocytopenia after vaccination with ChAdOx1 nCoV-19:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046413/

April 13, 2021 Vaccine-induced immune thrombotic immune thrombocytopenia (VITT): targeting pathologic mechanisms with Bruton’s tyrosine kinase inhibitors:  https://www.thieme-connect.com/products/ejournals/html/10.1055/a-1481-3039

April 9, 2021 Thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19:  https://www.nejm.org/doi/full/10.1056/NEJMoa2104882?query=recirc_curatedRelated_article

March 29,2021 A prothrombotic thrombocytopenic disorder resembling heparin-induced thrombocytopenia after coronavirus-19 vaccination:  https://www.semanticscholar.org/paper/A-Prothrombotic-Thrombocytopenic-Disorder-Following-Greinacher-Thiele/8497f2726d66b0bc95a06395f823362f18f49fc2

March 1, 2021A rare case of thrombosis and thrombocytopenia of the superior ophthalmic vein after ChAdOx1 nCoV-19 vaccination against SARS-CoV-2:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8265377/

Thyroiditis 

May 27, 2021 Three cases of subacute thyroiditis after SARS-CoV-2 vaccination: post-vaccination ASIA syndrome:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8194612/

Tolosa-Hunt Syndrome (severe and unilateral headaches with orbital pain, along with weakness and paralysis of certain eye muscles)

July 31, 2021 Tolosa-Hunt syndrome occurring after COVID-19 vaccination:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8405240/

Transverse Myelitis (Acute, Cervical Vaccine Induced, etc)

Nov 25, 2021 Longitudinally extensive cervical myelitis after vaccination with inactivated virus based COVID-19 vaccine:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8614237/

Oct 12, 2021 Longitudinal extensive transverse myelitis following ChAdOx1 nCOV-19 vaccine: a case report https://bmcneurol.biomedcentral.com/articles/10.1186/s12883-021-02427-x

Oct 4, 2021 Acute-onset chronic inflammatory demyelinating polyneuropathy after COVID-19 infection and subsequent ChAdOx1 nCoV-19 vaccination: https://casereports.bmj.com/content/14/10/e245816

Sept 25, 2021 - Acute Transverse Myelitis after COVID-19 Vaccination https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8540274/

Sept 21, 2021 Extensive longitudinal transverse myelitis following AstraZeneca COVID-19 vaccination:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8439525/

Sept 10, 2021 Acute transverse myelitis after COVID-19 vaccination:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8470728/

Sept 5, 2021 Acute transverse myelitis after SARS-CoV-2 vaccination: case report and review of the literature:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8418691/

Aug 28, 2021 SARS-CoV-2 vaccination complicated by acute, disseminated encephalo-myelitis?: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8402996/

Aug 23, 2021 Post COVID-19 transverse myelitis; a case report with review of the literature: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8380545/

July 30, 2021 Acute transverse myelitis after inactivated COVID-19 vaccine https://elitmed.hu/en/publications/clinical-neuroscience/acute-transverse-myelitis-after-inactivated-covid-19-vaccine (you need an account) or https://pubmed.ncbi.nlm.nih.gov/34370410/

July 25, 2021 Transverse myelitis induced by SARS-CoV-2 vaccination: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8384391/

July 24, 2021  A case of longitudinally extensive transverse myelitis following vaccination against Covid-19: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8223023/

June 15, 2021 Acute bilateral bilateral optic neuritis/chiasm with longitudinal extensive transverse myelitis in long-standing stable multiple sclerosis after vector-based vaccination against SARS-CoV-2:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8205198/

April 26, 2021 Acute transverse myelitis (ATM): clinical review of 43 patients with COVID-19-associated ATM and 3 serious adverse events of post-vaccination ATM with ChAdOx1 nCoV-19 vaccine (AZD1222):  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107358/

Transient Cardiac Injury

June 2, 2021 Transient cardiac injury in adolescents receiving the BNT162b2 mRNA COVID-19 vaccine:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8443419/

Thymic hyperplasia 

Aug 26, 2021 Thymic hyperplasia after Covid-19 mRNA-based vaccination with Covid-19:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8387216/

Uveitis (inflammation of the Uvea)

Sept 30, 2021 Bilateral uveitis after inoculation with COVID-19 vaccine: a case report:  https://www.sciencedirect.com/science/article/pii/S1201971221007797

Variant Inducement

May 2021 Occurrence of COVID-19 variants among recipients of ChAdOx1 nCoV-19 vaccine (recombinant):  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8555616/

Vogt-Koyanagi-Harada Syndrome 

Aug 30, 2021 Vogt-Koyanagi-Harada syndrome after COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccination:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8404022/

July 5, 2021 Reactivation of Vogt-Koyanagi-Harada disease under control for more than 6 years, after anti-SARS-CoV-2 vaccination:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8256412/

Wow, these bioweapons sure look safe.
- said no rational human being ever!

Here’s the list of the 1,291 AESI’s that Pfizer tried, in vain, to hide from the world for 75 years..

APPENDIX 1. LIST OF ADVERSE EVENTS OF SPECIAL INTEREST

IP36 deletion syndrome; 2-Hydroxyglutaric aciduria;5'nucleotidase increased;Acoustic neuritis;Acquired C1 inhibitor deficiency;Acquired epidermolysis bullosa; Acquired epileptic aphasia;Acute cutaneous lupus erythematosus; Acute disseminated encephalomyelitis;Acute encephalitis with refractory, repetitive partial seizures;Acute febrile neutrophilic dermatosis; Acute flaccid myelitis; Acute haemorrhagic leukoencephalitis; Acute haemorrhagic oedema of infancy;Acute kidney injury;Acute macular outer retinopathy; Acute motor axonal neuropathy; Acute motor-sensory axonal neuropathy; Acute myocardial infarction;Acute respiratory distress syndrome;Acute respiratory failure;Addison's disease;Administration site thrombosis;Administration site vasculitis; Adrenal thrombosis;Adverse event following immunisation; Ageusia;Agranulocytosis;Air embolism;Alanine aminotransferase abnormal;Alanine aminotransferase increased;Alcoholic seizure;Allergic bronchopulmonary mycosis;Allergic oedema; Alloimmune hepatitis;Alopecia areata; Alpers disease;Alveolar proteinosis; Ammonia abnormal; Ammonia increased;Amniotic cavity infection; Amygdalohippocampectomy; Amyloid arthropathy; Amyloidosis; Amyloidosis senile; Anaphylactic reaction; Anaphylactic shock; Anaphylactic transfusion reaction; Anaphylactoid reaction;Anaphylactoid shock; Anaphylactoid syndrome of pregnancy; Angioedema; Angiopathic neuropathy; Ankylosing spondylitis; Anosmia; Antiacetylcholine receptor antibody positive;Anti-actin antibody positive; Anti-aquaporin-4 antibody positive;Anti-basal ganglia antibody positive;Anti-cyclic citrullinated peptide antibody positive;Anti-epithelial antibody positive;Anti-erythrocyte antibody positive; Anti-exosome complex antibody positive; AntiGAD antibody negative;Anti-GAD antibody positive;Anti-ganglioside antibody positive; Antigliadin antibody positive;Anti-glomerular basement membrane antibody positive;Anti-glomerular basement membrane disease; Anti-glycyl-tRNA synthetase antibody positive;Anti-HLA antibody test positive;Anti-IA2 antibody positive;Anti-insulin antibody increased;Anti-insulin antibody positive;Anti-insulin receptor antibody increased; Antiinsulin receptor antibody positive;Anti-interferon antibody negative;Anti-interferon antibody positive;Anti-islet cell antibody positive; Antimitochondrial antibody positive;Anti-muscle specific kinase antibody positive; Anti-myelin-associated glycoprotein antibodies positive;Anti-myelin-associated glycoprotein associated polyneuropathy; Antimyocardial antibody positive;Anti-neuronal antibody positive; Antineutrophil cytoplasmic antibody increased; Antineutrophil cytoplasmic antibody positive;Anti-neutrophil cytoplasmic antibody positive vasculitis; Anti-NMDA antibody positive;Antinuclear antibody increased; Antinuclear antibody positive; Antiphospholipid antibodies positive; Antiphospholipid syndrome; Anti-platelet antibody positive;Anti-prothrombin antibody positive; Antiribosomal P antibody positive;Anti-RNA polymerase III antibody positive; Anti-saccharomyces cerevisiae antibody test positive;Anti-sperm antibody positive;Anti-SRP antibody positive; Antisynthetase syndrome;Anti-thyroid antibody positive; Anti-transglutaminase antibody increased;Anti-VGCC antibody positive;AntiVGKC antibody positive; Anti-vimentin antibody positive; Antiviral prophylaxis; Antiviral treatment;Anti-zinc transporter 8 antibody positive;Aortic embolus;Aortic thrombosis; Aortitis; Aplasia pure red cell;Aplastic anaemia; Application site thrombosis;Application site vasculitis; Arrhythmia; Arterial bypass occlusion;Arterial bypass thrombosis; Arterial thrombosis; Arteriovenous fistula thrombosis; Arteriovenous graft site stenosis; Arteriovenous graft thrombosis; Arteritis; Arteritis coronary; Arthralgia; Arthritis; Arthritis enteropathic; Ascites; Aseptic cavernous sinus thrombosis; Aspartate aminotransferase abnormal; Aspartate aminotransferase increased; Aspartate-glutamate-transporter deficiency; AST to platelet ratio index increased;AST/ALT ratio abnormal;Asthma;Asymptomatic COVID19; Ataxia; Atheroembolism; Atonic seizures;Atrial thrombosis; Atrophic thyroiditis; Atypical benign partial epilepsy; Atypical pneumonia;Aura; Autoantibody positive;Autoimmune anaemia; Autoimmune aplastic anaemia;Autoimmune arthritis; Autoimmune blistering disease; Autoimmune cholangitis ; Autoimmune colitis; Autoimmune demyelinating disease;Autoimmune dermatitis;Autoimmune disorder;Autoimmune encephalopathy; Autoimmune endocrine disorder;Autoimmune enteropathy; Autoimmune eye disorder; Autoimmune haemolytic anaemia; Autoimmune heparin-induced thrombocytopenia; Autoimmune hepatitis; Autoimmune hyperlipidaemia; Autoimmune hypothyroidism; Autoimmune inner ear disease; Autoimmune lung disease; Autoimmune lymphoproliferative syndrome; Autoimmune myocarditis; Autoimmune myositis; Autoimmune nephritis;Autoimmune neuropathy; Autoimmune neutropenia; Autoimmune pancreatitis; Autoimmune pancytopenia; Autoimmune pericarditis; Autoimmune retinopathy; Autoimmune thyroid disorder; Autoimmune thyroiditis; Autoimmune uveitis; Autoinflammation with infantile enterocolitis; Autoinflammatory disease; Automatism epileptic; Autonomic nervous system imbalance;Autonomic seizure;Axial spondyloarthritis; Axillary vein thrombosis; Axonal and demyelinating polyneuropathy; Axonal neuropathy; Bacterascites; Baltic myoclonic epilepsy; Band sensation; Basedow's disease; Basilar artery thrombosis; Basophilopenia;B-cell aplasia; Behcet's syndrome;Benign ethnic neutropenia; Benign familial neonatal convulsions;Benign familial pemphigus; Benign rolandic epilepsy;Beta-2 glycoprotein antibody positive; Bickerstaff's encephalitis; Bile output abnormal; Bile output decreased; Biliary ascites; Bilirubin conjugated abnormal; Bilirubin conjugated increased;Bilirubin urine present; Biopsy liver abnormal; Biotinidase deficiency; Birdshot chorioretinopathy; Blood alkaline phosphatase abnormal; Blood alkaline phosphatase increased; Blood bilirubin abnormal; Blood bilirubin increased; Blood bilirubin unconjugated increased; Blood cholinesterase abnormal;Blood cholinesterase decreased; Blood pressure decreased;Blood pressure diastolic decreased;Blood pressure systolic decreased;Blue toe syndrome; Brachiocephalic vein thrombosis;Brain stem embolism; Brain stem thrombosis; Bromosulphthalein test abnormal; Bronchial oedema; Bronchitis;Bronchitis mycoplasmal; Bronchitis viral; Bronchopulmonary aspergillosis allergic; Bronchospasm;BuddChiari syndrome; Bulbar palsy; Butterfly rash;C1q nephropathy; Caesarean section;Calcium embolism; Capillaritis; Caplan's syndrome; Cardiac amyloidosis; Cardiac arrest; Cardiac failure; Cardiac failure acute; Cardiac sarcoidosis; Cardiac ventricular thrombosis; Cardiogenic shock; Cardiolipin antibody positive; Cardiopulmonary failure; Cardio-respiratory arrest; Cardio-respiratory distress; Cardiovascular insufficiency; Carotid arterial embolus; Carotid artery thrombosis; Cataplexy; Catheter site thrombosis; Catheter site vasculitis; Cavernous sinus thrombosis; CDKL5 deficiency disorder; CEC syndrome; Cement embolism; Central nervous system lupus; Central nervous system vasculitis; Cerebellar artery thrombosis; Cerebellar embolism; Cerebral amyloid angiopathy; Cerebral arteritis; Cerebral artery embolism; Cerebral artery thrombosis; Cerebral gas embolism; Cerebral microembolism; Cerebral septic infarct;Cerebral thrombosis;Cerebral venous sinus thrombosis; Cerebral venous thrombosis; Cerebrospinal thrombotic tamponade; Cerebrovascular accident; Change in seizure presentation; Chest discomfort; ChildPugh-Turcotte score abnormal; Child-Pugh-Turcotte score increased; Chillblains; Choking;Choking sensation; Cholangitis sclerosing; Chronic autoimmune glomerulonephritis; Chronic cutaneous lupus erythematosus; Chronic fatigue syndrome; Chronic gastritis;Chronic inflammatory demyelinating polyradiculoneuropathy; Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids; Chronic recurrent multifocal osteomyelitis; Chronic respiratory failure; Chronic spontaneous urticaria; Circulatory collapse; Circumoral oedema; Circumoral swelling; Clinically isolated syndrome; Clonic convulsion; Coeliac disease; Cogan's syndrome; Cold agglutinins positive; Cold type haemolytic anaemia; Colitis; Colitis erosive; Colitis herpes; Colitis microscopic; Colitis ulcerative; Collagen disorder; Collagen-vascular disease; Complement factor abnormal; Complement factor C1 decreased; Complement factor C2 decreased; Complement factor C3 decreased; Complement factor C4 decreased; Complement factor decreased; Computerised tomogram liver abnormal; Concentric sclerosis; Congenital anomaly; Congenital bilateral perisylvian syndrome; Congenital herpes simplex infection; Congenital myasthenic syndrome; Congenital varicella infection;Congestive hepatopathy; Convulsion in childhood; Convulsions local; Convulsive threshold lowered; Coombs positive haemolytic anaemia; Coronary artery disease; Coronary artery embolism; Coronary artery thrombosis; Coronary bypass thrombosis; Coronavirus infection; Coronavirus test; Coronavirus test negative; Coronavirus test positive; Corpus callosotomy; Cough; Cough variant asthma; COVID-19;COVID-19 immunisation; COVID-19 pneumonia; COVID-19 prophylaxis; COVID-19 treatment; Cranial nerve disorder; Cranial nerve palsies multiple; Cranial nerve paralysis;CREST syndrome; Crohn's disease; Cryofibrinogenaemia; Cryoglobulinaemia; CSF oligoclonal band present ;CSWS syndrome; Cutaneous amyloidosis; Cutaneous lupus erythematosus; Cutaneous sarcoidosis; Cutaneous vasculitis; Cyanosis; Cyclic neutropenia; Cystitis interstitial; Cytokine release syndrome; Cytokine storm; De novo purine synthesis inhibitors associated acute inflammatory syndrome; Death neonatal; Deep vein thrombosis; Deep vein thrombosis postoperative; Deficiency of bile secretion; Deja vu; Demyelinating polyneuropathy; Demyelination; Dermatitis; Dermatitis bullous; Dermatitis herpetiformis; Dermatomyositis; Device embolisation; Device related thrombosis; Diabetes mellitus; Diabetic ketoacidosis; Diabetic mastopathy; Dialysis amyloidosis; Dialysis membrane reaction; Diastolic hypotension; Diffuse vasculitis; Digital pitting scar; Disseminated intravascular coagulation;Disseminated intravascular coagulation in newborn; Disseminated neonatal herpes simplex; Disseminated varicella; Disseminated varicella zoster vaccine virus infection; Disseminated varicella zoster virus infection; DNA antibody positive;Double cortex syndrome; Double stranded DNA antibody positive; Dreamy state; Dressler's syndrome; Drop attacks; Drug withdrawal convulsions; Dyspnoea; Early infantile epileptic encephalopathy with burst-suppression; Eclampsia; Eczema herpeticum; Embolia cutis medicamentosa; Embolic cerebellar infarction; Embolic cerebral infarction; Embolic pneumonia; Embolic stroke; Embolism; Embolism arterial; Embolism venous; Encephalitis; Encephalitis allergic; Encephalitis autoimmune; Encephalitis brain stem; Encephalitis haemorrhagic; Encephalitis periaxialis diffusa; Encephalitis post immunisation; Encephalomyelitis; Encephalopathy; Endocrine disorder; Endocrine ophthalmopathy; Endotracheal intubation; Enteritis; Enteritis leukopenic; Enterobacter pneumonia; Enterocolitis; Enteropathic spondylitis; Eosinopenia;Eosinophilic fasciitis; Eosinophilic granulomatosis with polyangiitis; Eosinophilic oesophagitis; Epidermolysis; Epilepsy; Epilepsy surgery; Epilepsy with myoclonic-atonic seizures;Epileptic aura; Epileptic psychosis;Erythema; Erythema induratum; Erythema multiforme; Erythema nodosum; Evans syndrome; Exanthema subitum; Expanded disability status scale score decreased; Expanded disability status scale score increased; Exposure to communicable disease; Exposure to SARS-CoV-2;Eye oedema; Eye pruritus; Eye swelling; Eyelid oedema; Face oedema; Facial paralysis; Facial paresis; Faciobrachial dystonic seizure; Fat embolism; Febrile convulsion; Febrile infection-related epilepsy syndrome; Febrile neutropenia; Felty's syndrome; Femoral artery embolism; Fibrillary glomerulonephritis; Fibromyalgia; Flushing; Foaming at mouth; Focal cortical resection; Focal dyscognitive seizures; Foetal distress syndrome; Foetal placental thrombosis; Foetor hepaticus; Foreign body embolism; Frontal lobe epilepsy; Fulminant type 1 diabetes mellitus; Galactose elimination capacity test abnormal; Galactose elimination capacity test decreased; Gamma-glutamyltransferase abnormal; Gamma-glutamyltransferase increased; Gastritis herpes; Gastrointestinal amyloidosis; Gelastic seizure; Generalised onset non-motor seizure; Generalised tonic-clonic seizure; Genital herpes; Genital herpes simplex; Genital herpes zoster; Giant cell arteritis; Glomerulonephritis; Glomerulonephritis membranoproliferative; Glomerulonephritis membranous; Glomerulonephritis rapidly progressive; Glossopharyngeal nerve paralysis; Glucose transporter type 1 deficiency syndrome; Glutamate dehydrogenase increased; Glycocholic acid increased;GM2 gangliosidosis; Goodpasture's syndrome; Graft thrombosis; Granulocytopenia; Granulocytopenia neonatal; Granulomatosis with polyangiitis; Granulomatous dermatitis;Grey matter heterotopia; Guanase increased; GuillainBarre syndrome;Haemolytic anaemia; Haemophagocytic lymphohistiocytosis; Haemorrhage;Haemorrhagic ascites; Haemorrhagic disorder; Haemorrhagic pneumonia; Haemorrhagic varicella syndrome; Haemorrhagic vasculitis; Hantavirus pulmonary infection; Hashimoto's encephalopathy; Hashitoxicosis; Hemimegalencephaly; Henoch-Schonlein purpura; Henoch Schonlein purpura nephritis; Hepaplastin abnormal; Hepaplastin decreased; Heparin-induced thrombocytopenia; Hepatic amyloidosis; Hepatic artery embolism; Hepatic artery flow decreased; Hepatic artery thrombosis; Hepatic enzyme abnormal; Hepatic enzyme decreased; Hepatic enzyme increased; Hepatic fibrosis marker abnormal; Hepatic fibrosis marker increased; Hepatic function abnormal; Hepatic hydrothorax; Hepatic hypertrophy; Hepatic hypoperfusion; Hepatic lymphocytic infiltration; Hepatic mass;Hepatic pain;Hepatic sequestration; Hepatic vascular resistance increased; Hepatic vascular thrombosis; Hepatic vein embolism; Hepatic vein thrombosis; Hepatic venous pressure gradient abnormal; Hepatic venous pressure gradient increased; Hepatitis; Hepatobiliary scan abnormal; Hepatomegaly; Hepatosplenomegaly; Hereditary angioedema with C1 esterase inhibitor deficiency; Herpes dermatitis; Herpes gestationis;Herpes oesophagitis; Herpes ophthalmic; Herpes pharyngitis; Herpes sepsis;Herpes simplex; Herpes simplex cervicitis; Herpes simplex colitis; Herpes simplex encephalitis; Herpes simplex gastritis; Herpes simplex hepatitis; Herpes simplex meningitis; Herpes simplex meningoencephalitis; Herpes simplex meningomyelitis; Herpes simplex necrotising retinopathy; Herpes simplex oesophagitis; Herpes simplex otitis externa; Herpes simplex pharyngitis; Herpes simplex pneumonia; Herpes simplex reactivation; Herpes simplex sepsis;Herpes simplex viraemia; Herpes simplex virus conjunctivitis neonatal; Herpes simplex visceral; Herpes virus infection; Herpes zoster; Herpes zoster cutaneous disseminated; Herpes zoster infection neurological; Herpes zoster meningitis; Herpes zoster meningoencephalitis; Herpes zoster meningomyelitis; Herpes zoster meningoradiculitis; Herpes zoster necrotising retinopathy ;Herpes zoster oticus; Herpes zoster pharyngitis;Herpes zoster reactivation; Herpetic radiculopathy; Histone antibody positive; Hoigne's syndrome; Human herpesvirus 6 encephalitis;Human herpesvirus 6 infection; Human herpesvirus 6 infection reactivation; Human herpesvirus 7 infection; Human herpesvirus 8 infection; Hyperammonaemia; Hyperbilirubinaemia; Hypercholia; Hypergammaglobulinaemia benign monoclonal; Hyperglycaemic seizure; Hypersensitivity; Hypersensitivity vasculitis; Hyperthyroidism; Hypertransaminasaemia; Hyperventilation; Hypoalbuminaemia; Hypocalcaemic seizure; Hypogammaglobulinaemia; Hypoglossal nerve paralysis; Hypoglossal nerve paresis ;Hypoglycaemic seizure; Hyponatraemic seizure; Hypotension; Hypotensive crisis; Hypothenar hammer syndrome; Hypothyroidism; Hypoxia;Idiopathic CD4 lymphocytopenia; Idiopathic generalised epilepsy;Idiopathic interstitial pneumonia;Idiopathic neutropenia; Idiopathic pulmonary fibrosis; IgA nephropathy; IgM nephropathy; IIIrd nerve paralysis;IIIrd nerve paresis; Iliac artery embolism;Immune thrombocytopenia; Immunemediated adverse reaction; Immune-mediated cholangitis; Immune-mediated cholestasis;Immune-mediated cytopenia; Immune-mediated encephalitis;Immune-mediated encephalopathy; Immune-mediated endocrinopathy;Immune-mediated enterocolitis;Immunemediated gastritis;Immune-mediated hepatic disorder;Immune-mediated hepatitis; Immunemediated hyperthyroidism; Immune-mediated hypothyroidism; Immune-mediated myocarditis; Immune-mediated myositis;Immune-mediated nephritis; Immune-mediated neuropathy; Immune-mediated pancreatitis;Immune-mediated pneumonitis;Immune-mediated renal disorder;Immune-mediated thyroiditis;Immune-mediated uveitis; Immunoglobulin G4 related disease; Immunoglobulins abnormal; Implant site thrombosis; Inclusion body myositis; Infantile genetic agranulocytosis; Infantile spasms;Infected vasculitis; Infective thrombosis; Inflammation;Inflammatory bowel disease; Infusion site thrombosis; Infusion site vasculitis; Injection site thrombosis; Injection site urticaria;Injection site vasculitis; Instillation site thrombosis; Insulin autoimmune syndrome;I nterstitial granulomatous dermatitis; Interstitial lung disease; Intracardiac mass; Intracardiac thrombus;Intracranial pressure increased; Intrapericardial thrombosis; Intrinsic factor antibody abnormal;Intrinsic factor antibody positive; IPEX syndrome; Irregular breathing; IRVAN syndrome; IVth nerve paralysis ;IVth nerve paresis; JC polyomavirus test positive; JC virus CSF test positive; Jeavons syndrome; Jugular vein embolism;Jugular vein thrombosis; Juvenile idiopathic arthritis;Juvenile myoclonic epilepsy; Juvenile polymyositis; Juvenile psoriatic arthritis; Juvenile spondyloarthritis; Kaposi sarcoma inflammatory cytokine syndrome; Kawasaki's disease; Kayser-Fleischer ring; Keratoderma blenorrhagica;Ketosisprone diabetes mellitus; Kounis syndrome;Lafora's myoclonic epilepsy;Lambl's excrescences; Laryngeal dyspnoea; Laryngeal oedema; Laryngeal rheumatoid arthritis; Laryngospasm; Laryngotracheal oedema;Latent autoimmune diabetes in adults; LE cells present;Lemierre syndrome; Lennox-Gastaut syndrome; Leucine aminopeptidase increased; Leukoencephalomyelitis; Leukoencephalopathy; Leukopenia;Leukopenia neonatal; Lewis-Sumner syndrome; Lhermitte's sign;Lichen planopilaris; Lichen planus; Lichen sclerosus; Limbic encephalitis; Linear IgA disease;Lip oedema; Lip swelling; Liver function test abnormal;Liver function test decreased;Liver function test increased; Liver induration; Liver injury;Liver iron concentration abnormal; Liver iron concentration increased; Liver opacity;Liver palpable;Liver sarcoidosis; Liver scan abnormal;Liver tenderness; Low birth weight baby; Lower respiratory tract herpes infection; Lower respiratory tract infection; Lower respiratory tract infection viral; Lung abscess;Lupoid hepatic cirrhosis; Lupus cystitis;Lupus encephalitis;Lupus endocarditis; Lupus enteritis;Lupus hepatitis; Lupus myocarditis;Lupus myositis; Lupus nephritis;Lupus pancreatitis ;Lupus pleurisy;Lupus pneumonitis;Lupus vasculitis; Lupus-like syndrome; Lymphocytic hypophysitis;Lymphocytopenia neonatal; Lymphopenia; MAGIC syndrome;Magnetic resonance imaging liver abnormal; Magnetic resonance proton density fat fraction measurement; Mahler sign; Manufacturing laboratory analytical testing issue; Manufacturing materials issue;Manufacturing production issue; Marburg's variant multiple sclerosis; Marchiafava-Bignami disease; Marine Lenhart syndrome; Mastocytic enterocolitis; Maternal exposure during pregnancy; Medical device site thrombosis; Medical device site vasculitis; MELAS syndrome; Meningitis; Meningitis aseptic; Meningitis herpes; Meningoencephalitis herpes simplex neonatal; Meningoencephalitis herpetic; Meningomyelitis herpes;MERS-CoV test;MERS-CoV test negative;MERS-CoV test positive; Mesangioproliferative glomerulonephritis; Mesenteric artery embolism; Mesenteric artery thrombosis; Mesenteric vein thrombosis; Metapneumovirus infection; Metastatic cutaneous Crohn's disease; Metastatic pulmonary embolism; Microangiopathy;Microembolism;Microscopic polyangiitis; Middle East respiratory syndrome; Migraine-triggered seizure;Miliary pneumonia;Miller Fisher syndrome; Mitochondrial aspartate aminotransferase increased; Mixed connective tissue disease; Model for end stage liver disease score abnormal; Model for end stage liver disease score increased;Molar ratio of total branched-chain amino acid to tyrosine; Molybdenum cofactor deficiency; Monocytopenia; Mononeuritis; Mononeuropathy multiplex;Morphoea; Morvan syndrome;Mouth swelling;Moyamoya disease;Multifocal motor neuropathy; Multiple organ dysfunction syndrome;Multiple sclerosis; Multiple sclerosis relapse; Multiple sclerosis relapse prophylaxis; Multiple subpial transection; Multisystem inflammatory syndrome in children; Muscular sarcoidosis;Myasthenia gravis;Myasthenia gravis crisis; Myasthenia gravis neonatal;Myasthenic syndrome; Myelitis; Myelitis transverse; Myocardial infarction; Myocarditis; Myocarditis post infection; Myoclonic epilepsy; Myoclonic epilepsy and ragged-red fibres; Myokymia; Myositis; Narcolepsy; Nasal herpes; Nasal obstruction; Necrotising herpetic retinopathy; Neonatal Crohn's disease; Neonatal epileptic seizure; Neonatal lupus erythematosus; Neonatal mucocutaneous herpes simplex; Neonatal pneumonia; Neonatal seizure; Nephritis; Nephrogenic systemic fibrosis; Neuralgic amyotrophy; Neuritis; Neuritis cranial; Neuromyelitis optica pseudo relapse; Neuromyelitis optica spectrum disorder; Neuromyotonia; Neuronal neuropathy; Neuropathy peripheral; Neuropathy, ataxia, retinitis pigmentosa syndrome;Neuropsychiatric lupus; Neurosarcoidosis; Neutropenia; Neutropenia neonatal; Neutropenic colitis; Neutropenic infection; Neutropenic sepsis; Nodular rash; Nodular vasculitis; Noninfectious myelitis; Noninfective encephalitis; Noninfective encephalomyelitis; Noninfective oophoritis;Obstetrical pulmonary embolism; Occupational exposure to communicable disease; Occupational exposure to SARS-CoV-2; Ocular hyperaemia; Ocular myasthenia; Ocular pemphigoid; Ocular sarcoidosis; Ocular vasculitis; Oculofacial paralysis; Oedema; Oedema blister; Oedema due to hepatic disease; Oedema mouth; Oesophageal achalasia; Ophthalmic artery thrombosis; Ophthalmic herpes simplex; Ophthalmic herpes zoster; Ophthalmic vein thrombosis;Optic neuritis; Optic neuropathy; Optic perineuritis; Oral herpes; Oral lichen planus;Oropharyngeal oedema; Oropharyngeal spasm; Oropharyngeal swelling; Osmotic demyelination syndrome; Ovarian vein thrombosis; Overlap syndrome; Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection; Paget-Schroetter syndrome; Palindromic rheumatism; Palisaded neutrophilic granulomatous dermatitis;Palmoplantar keratoderma; Palpable purpura; Pancreatitis; Panencephalitis; Papillophlebitis; Paracancerous pneumonia;Paradoxical embolism; Parainfluenzae viral laryngotracheobronchitis; Paraneoplastic dermatomyositis; Paraneoplastic pemphigus; Paraneoplastic thrombosis; Paresis cranial nerve; Parietal cell antibody positive; Paroxysmal nocturnal haemoglobinuria; Partial seizures; Partial seizures with secondary generalisation; Patient isolation; Pelvic venous thrombosis; Pemphigoid;Pemphigus; Penile vein thrombosis; Pericarditis; Pericarditis lupus; Perihepatic discomfort; Periorbital oedema; Periorbital swelling; Peripheral artery thrombosis; Peripheral embolism; Peripheral ischaemia;Peripheral vein thrombus extension; Periportal oedema; Peritoneal fluid protein abnormal; Peritoneal fluid protein decreased; Peritoneal fluid protein increased;Peritonitis lupus; Pernicious anaemia; Petit mal epilepsy; Pharyngeal oedema; Pharyngeal swelling; Pityriasis lichenoides et varioliformis acuta; Placenta praevia; Pleuroparenchymal fibroelastosis; Pneumobilia; Pneumonia; Pneumonia adenoviral; Pneumonia cytomegaloviral; Pneumonia herpes viral; Pneumonia influenzal; Pneumonia measles; Pneumonia mycoplasmal;Pneumonia necrotising; Pneumonia parainfluenzae viral; Pneumonia respiratory syncytial viral; Pneumonia viral; POEMS syndrome; Polyarteritis nodosa; Polyarthritis; Polychondritis; Polyglandular autoimmune syndrome type I; Polyglandular autoimmune syndrome type II; Polyglandular autoimmune syndrome type III; Polyglandular disorder; Polymicrogyria; Polymyalgia rheumatica; Polymyositis; Polyneuropathy; Polyneuropathy idiopathic progressive; Portal pyaemia; Portal vein embolism; Portal vein flow decreased;Portal vein pressure increased;Portal vein thrombosis; Portosplenomesenteric venous thrombosis; Post procedural hypotension; Post procedural pneumonia;Post procedural pulmonary embolism; Post stroke epilepsy; Post stroke seizure; Post thrombotic retinopathy; Post thrombotic syndrome; Post viral fatigue syndrome; Postictal headache ;Postictal paralysis; Postictal psychosis; Postictal state; Postoperative respiratory distress; Postoperative respiratory failure; Postoperative thrombosis; Postpartum thrombosis; Postpartum venous thrombosis; Postpericardiotomy syndrome; Post-traumatic epilepsy; Postural orthostatic tachycardia syndrome; Precerebral artery thrombosis; Pre-eclampsia; Preictal state; Premature labour; Premature menopause; Primary amyloidosis; Primary biliary cholangitis; Primary progressive multiple sclerosis; Procedural shock;Proctitis herpes; Proctitis ulcerative; Product availability issue; Product distribution issue; Product supply issue; Progressive facial hemiatrophy; Progressive multifocal leukoencephalopathy; Progressive multiple sclerosis; Progressive relapsing multiple sclerosis; Prosthetic cardiac valve thrombosis; Pruritus; Pruritus allergic; Pseudovasculitis; Psoriasis; Psoriatic arthropathy;Pulmonary amyloidosis; Pulmonary artery thrombosis; Pulmonary embolism; Pulmonary fibrosis; Pulmonary haemorrhage; Pulmonary microemboli; Pulmonary oil microembolism; Pulmonary renal syndrome; Pulmonary sarcoidosis; Pulmonary sepsis; Pulmonary thrombosis; Pulmonary tumour thrombotic microangiopathy; Pulmonary vasculitis; Pulmonary veno-occlusive disease; Pulmonary venous thrombosis; Pyoderma gangrenosum; Pyostomatitis vegetans; Pyrexia; Quarantine; Radiation leukopenia; Radiculitis brachial; Radiologically isolated syndrome; Rash; Rash erythematous; Rash pruritic; Rasmussen encephalitis; Raynaud's phenomenon; Reactive capillary endothelial proliferation; Relapsing multiple sclerosis; Relapsing-remitting multiple sclerosis; Renal amyloidosis; Renal arteritis; Renal artery thrombosis; Renal embolism;Renal failure; Renal vascular thrombosis; Renal vasculitis; Renal vein embolism; Renal vein thrombosis; Respiratory arrest; Respiratory disorder; Respiratory distress;Respiratory failure; Respiratory paralysis; Respiratory syncytial virus bronchiolitis; Respiratory syncytial virus bronchitis; Retinal artery embolism; Retinal artery occlusion; Retinal artery thrombosis; Retinal vascular thrombosis; Retinal vasculitis; Retinal vein occlusion; Retinal vein thrombosis; Retinol binding protein decreased; Retinopathy; Retrograde portal vein flow; Retroperitoneal fibrosis; Reversible airways obstruction; Reynold's syndrome; Rheumatic brain disease; Rheumatic disorder; Rheumatoid arthritis; Rheumatoid factor increased; Rheumatoid factor positive; Rheumatoid factor quantitative increased; Rheumatoid lung; Rheumatoid neutrophilic dermatosis; Rheumatoid nodule; Rheumatoid nodule removal; Rheumatoid scleritis; Rheumatoid vasculitis; Saccadic eye movement ;SAPHO syndrome; Sarcoidosis; SARS-CoV-1 test; SARS-CoV-1 test negative; SARS-CoV-1 test positive; SARS-CoV-2 antibody test; SARS-CoV-2 antibody test negative; SARS-CoV-2 antibody test positive; SARS-CoV-2 carrier; SARS-CoV-2 sepsis; SARS-CoV-2 test;S ARSCoV-2 test false negative; SARS-CoV-2 test false positive; SARS-CoV-2 test negative; SARSCoV-2 test positive; SARS-CoV-2 viraemia; Satoyoshi syndrome; Schizencephaly; Scleritis; Sclerodactylia; Scleroderma; Scleroderma associated digital ulcer; Scleroderma renal crisis; Scleroderma-like reaction; Secondary amyloidosis; Secondary cerebellar degeneration; Secondary progressive multiple sclerosis; Segmented hyalinising vasculitis; Seizure; Seizure anoxic;Seizure cluster; Seizure like phenomena; Seizure prophylaxis; Sensation of foreign body;Septic embolus; Septic pulmonary embolism; Severe acute respiratory syndrome; Severe myoclonic epilepsy of infancy; Shock; Shock symptom; Shrinking lung syndrome; Shunt thrombosis; Silent thyroiditis; Simple partial seizures; Sjogren's syndrome; Skin swelling; SLE arthritis; Smooth muscle antibody positive; Sneezing; Spinal artery embolism; Spinal artery thrombosis; Splenic artery thrombosis; Splenic embolism; Splenic thrombosis; Splenic vein thrombosis; Spondylitis; Spondyloarthropathy; Spontaneous heparin-induced thrombocytopenia syndrome; Status epilepticus; Stevens-Johnson syndrome; Stiff leg syndrome; Stiff person syndrome; Stillbirth;Still's disease; Stoma site thrombosis; Stoma site vasculitis; Stress cardiomyopathy; Stridor; Subacute cutaneous lupus erythematosus; Subacute endocarditis; Subacute inflammatory demyelinating polyneuropathy; Subclavian artery embolism; Subclavian artery thrombosis; Subclavian vein thrombosis; Sudden unexplained death in epilepsy; Superior sagittal sinus thrombosis; Susac's syndrome; Suspected COVID19; Swelling; Swelling face; Swelling of eyelid; Swollen tongue; Sympathetic ophthalmia; Systemic lupus erythematosus; Systemic lupus erythematosus disease activity index abnormal; Systemic lupus erythematosus disease activity index decreased; Systemic lupus erythematosus disease activity index increased; Systemic lupus erythematosus rash;Systemic scleroderma; Systemic sclerosis pulmonary; Tachycardia; Tachypnoea; Takayasu's arteritis; Temporal lobe epilepsy; Terminal ileitis ;Testicular autoimmunity; Throat tightness; Thromboangiitis obliterans; Thrombocytopenia; Thrombocytopenic purpura; Thrombophlebitis; Thrombophlebitis migrans; Thrombophlebitis neonatal; Thrombophlebitis septic; Thrombophlebitis superficial; Thromboplastin antibody positive; Thrombosis; Thrombosis corpora cavernosa; Thrombosis in device; Thrombosis mesenteric vessel; Thrombotic cerebral infarction; Thrombotic microangiopathy; Thrombotic stroke; Thrombotic thrombocytopenic purpura; Thyroid disorder; Thyroid stimulating immunoglobulin increased; Thyroiditis; Tongue amyloidosis; Tongue biting;Tongue oedema; Tonic clonic movements; Tonic convulsion; Tonic posturing; Topectomy; Total bile acids increased; Toxic epidermal necrolysis; Toxic leukoencephalopathy; Toxic oil syndrome; Tracheal obstruction; Tracheal oedema; Tracheobronchitis; Tracheobronchitis mycoplasmal; Tracheobronchitis viral; Transaminases abnormal; Transaminases increased; Transfusion-related alloimmune neutropenia; Transient epileptic amnesia; Transverse sinus thrombosis; Trigeminal nerve paresis; Trigeminal neuralgia; Trigeminal palsy; Truncus coeliacus thrombosis; Tuberous sclerosis complex; Tubulointerstitial nephritis and uveitis syndrome; Tumefactive multiple sclerosis; Tumour embolism; Tumour thrombosis; Type 1 diabetes mellitus; Type I hypersensitivity; Type III immune complex mediated reaction; Uhthoff's phenomenon; Ulcerative keratitis; Ultrasound liver abnormal; Umbilical cord thrombosis; Uncinate fits; Undifferentiated connective tissue disease; Upper airway obstruction; Urine bilirubin increased; Urobilinogen urine decreased; Urobilinogen urine increased; Urticaria; Urticaria papular; Urticarial vasculitis; Uterine rupture; Uveitis; Vaccination site thrombosis; Vaccination site vasculitis; Vagus nerve paralysis; Varicella; Varicella keratitis; Varicella post vaccine; Varicella zoster gastritis; Varicella zoster oesophagitis; Varicella zoster pneumonia; Varicella zoster sepsis; Varicella zoster virus infection; Vasa praevia; Vascular graft thrombosis; Vascular pseudoaneurysm thrombosis; Vascular purpura; Vascular stent thrombosis;Vasculitic rash;Vasculitic ulcer; Vasculitis; Vasculitis gastrointestinal; Vasculitis necrotising; Vena cava embolism; Vena cava thrombosis; Venous intravasation; Venous recanalisation; Venous thrombosis; Venous thrombosis in pregnancy; Venous thrombosis limb; Venous thrombosis neonatal; Vertebral artery thrombosis; Vessel puncture site thrombosis; Visceral venous thrombosis; VIth nerve paralysis; VIth nerve paresis; Vitiligo; Vocal cord paralysis;Vocal cord paresis; Vogt-Koyanagi-Harada disease; Warm type haemolytic anaemia; Wheezing; White nipple sign; XIth nerve paralysis; X-ray hepatobiliary abnormal; Young's syndrome; Zika virus associated Guillain Barre syndrome.”

To all “health authorities” who have the cajoles to read this, I tried to warn you but this is what happens when you opted to deem me “non-essential”..

Feel free to share this and my other research with those who still have their heads buried in the sand. Maybe, just maybe, this will wake them from their slumber.

Thanks for reading and if you find any mistakes or find new studies or categories before I do? Add them in the comments below and I will update.

Remember,

I am not “anti-vaccine”, I am “anti-unsafe medical procedures of ANY KIND!”

Here’s my collection of the evidence regarding “Breathing Barriers”. If you are offended by the name change, don’t be as this is what they are.

Please note, in order to save some space, I’ve included the links embedded in the title headlines for your reference.

​Since the 1920 Kellogg Mask Study, I’ve read/reviewed every possible study/expert opinion/expert commentary and have come up with ones which you will never see on any of the Governments or Health Agencies which is a violation of “informed consent.”

The only masks which are effective in preventing upper respiratory viral transmission are full face respirators used in Bio Safety Labs.

or this which is used in BSL-4’s

Weird, how I never say anyone wear either one of these during “The Great Social Experiment of 2020”.

Moreover, as I will show below, we have a serious problem - the lack of Informed Consent when forcing people to cover their faces. Where there is harm or potential harm from a non-medical countermeasure, in this case - cloth masks, surgical masks, N-95’s, bandanas, plastic bags (yes, some dunderheads wore these), 5 gallon plastic water jugs (yes, some used these), even garbage bags lol - there must be Informed Consent.

AND.
You need to get FIT Tested and Spirometry Tested by a certified OSHA/CCOSH Hygienist. If you work in the medical, resource or construction sectors you are required to get these tests.

How many non-medical, construction and resource sector people had either of these important tests before covering your faces since 2020?

Complications from wearing face masks range from minor skin irritation to respiratory and cognitive effects, with severity often linked to mask type (e.g., N95 respirators pose higher risks than surgical masks) and duration of wear.

• Dermatological Issues: Prolonged use creates a warm, moist environment that damages the skin barrier, leading to acne (”maskne”), contact dermatitis, rashes, redness, and skin breakdown on pressure points like the nasal bridge and cheeks.

• Respiratory and Physical Discomfort: Wearers may experience increased breathing resistance, headaches (from tight straps or hypercapnia), dry eyes, sore throat, and ear pain. High-filtration masks can slightly reduce oxygen levels and increase carbon dioxide retention, though this is rarely dangerous for healthy individuals.

• Cognitive and Psychiatric Effects: Extended use can cause impaired cognition, confusion, anxiety, and panic attacks, particularly in healthcare workers or those with pre-existing respiratory conditions.

• Communication Barriers: Masks reduce speech clarity and volume, hindering communication for young children, older adults, and individuals with hearing impairments.

Wearing masks can exacerbate several health conditions, primarily through respiratory distress, skin irritation, and thermal dysregulation.

• Respiratory Conditions: Individuals with asthma or chronic obstructive pulmonary disease (COPD) may experience increased breathlessness, difficulty breathing, and reduced oxygen saturation. Studies indicate that N95 masks can significantly increase carbon dioxide retention and respiratory rate in advanced COPD patients, sometimes leading to discontinuation of use due to serious complaints.

• Skin Disorders: Masks can aggravate acne, dermatitis, and gingivitis (often termed “mask mouth”). The trapped moisture and friction cause sweat, rashes, and skin breakdown, while reduced saliva flow leads to dry mouth, halitosis, and fungal infections like candidiasis.

• Thermal and Anxiety Issues: People with obesity or conditions affecting temperature regulation may overheat, as masks trap body heat. Additionally, those with claustrophobia or anxiety disorders may experience panic, dizziness, and heightened stress responses when wearing face coverings.

• Neurological and Cardiovascular Effects: Prolonged use has been linked to headaches, fatigue, and increased heart rate. Some research suggests that elevated carbon dioxide levels from mask wear may contribute to high blood pressure and impaired cognitive performance.
  

Here is the brief summary of my findings from the above “informed consent violators”.

1. not one study they attempt to cite has "healthy people/populations" as a control group,

2. there are no peer reviewed studies for "healthy people/populations" wearing masks,

3. terms like “statistically significant” or “clinically relevant” are no where to be found in any of their literature. “may” or “could” are not good enough,

4. they cite 0 studies which have masks as the only form of source control (usually mixed with hand washing, sanitizer or distancing),

5. many of the references have no relevance to the actual study,

6. a majority of the above studies are based on anecdotal observations,

7. any study done during the summer as proof is ridiculous as upper respiratory viruses don’t like temps over 80°F

8. models or mannequins DO NOT provide a adequate substitute for humans.

Bottom Line? There is still no reliable or policy-grade evidence that face masks can reduce the risk from COVID-19.

Now I know there are some still “believing” their gov’t, health authorities and DOCTORS that these breathing barriers prevent upper respiratory viral transmission but they are full of it..

Let’s see what the leading expert, Dr. Steven Petty who has 45 years of experience on the topic of PPE.

Here’s the pdf version of his testimony which is only 65 pages and littered with actual facts and evidence - https://rebuildnh.com/wp-content/uploads/2022/03/1_Petty_New_Hampshire_Legislature_Presentation_January_27_2022.pdf

One of the take aways he mentions is proper “engineering controls”. Where are they?

Which brings me to the 2 elephants in the room - What about the negative effects or studies which show "no statistical difference" or actual studies which cite "statistical significance " or "clinical relevance"?

Studies/Expert Commentary/Expert Opinions from Non-Healthcare Related Settings

2025

May 2025 “Health outcomes attributed to inhalation of microplastic released from mask during COVID-19 pandemic: A systematic review”

“4. Conclusion

The widespread use of personal protective equipment during the Covid-19 pandemic has led to raise concerns about the inhalation of microplastics (MPs) released from masks. This review paper focused on recent studies regarding MPs and their analytical methods, specifically examining the health effects of inhaling MPs from face masks during the COVID-19 pandemic. The findings revealed that MPs released from masks, particularly those made of polypropylene and fibers, pose significant health risks due to their abundance and size. The increased use of masks during the pandemic has led to higher exposure to these particles, which can induce oxidative stress and trigger inflammatory responses in lung cells. Additionally, MPs can alter cellular morphology and disrupt normal functions. Mask-derived MPs may lead to gastrointestinal, respiratory, neurological, and reproductive health issues due to the transport of harmful substances that accumulate in the body.”

2023

Nov 13, 2023-Association between Face mask use and Risk of SARS-CoV-2 Infection – Cross-sectional study
”We examined the association between face masks and risk of infection with SARS-CoV-2 using cross-sectional data from 3,209 participants in a randomized trial of using glasses to reduce the risk of infection with SARS-CoV-2. Face mask use was based on participants’ response to the end-of-follow-up survey. We found that the incidence of self-reported COVID-19 was 33% (aRR 1.33; 95% CI 1.03 – 1.72) higher in those wearing face masks often or sometimes, and 40% (aRR 1.40; 95% CI 1.08 – 1.82) higher in those wearing face masks almost always or always, compared to participants who reported wearing face masks never or almost never.

The crude estimates show a higher incidence of testing positive for COVID-19 in the groups that used face masks more frequently, with 8.6% of participants who never or almost never used masks, 15.0% of participants who sometimes used masks, and 15.1% of participants who almost always or always used masks reporting a positive test result. The risk was 1.74 (1.38 to 2.18) times higher in those who wore face masks often or sometimes and 1.75 (1.39 to 2.21) times higher in those who wore face masks almost always or always, compared to participants who reported never or almost never wore masks.”

Feb 21, 2023 - Possible toxicity of chronic carbon dioxide exposure associated with face mask use, particularly in pregnant women, children and adolescents – A scoping review

“Fresh air has around 0.04% CO2, while wearing masks more than 5 min bears a possible chronic exposure to carbon dioxide of 1.41% to 3.2% of the inhaled air. Although the buildup is usually within the short-term exposure limits, long-term exceedances and consequences must be considered due to experimental data. US Navy toxicity experts set the exposure limits for submarines carrying a female crew to 0.8% CO2 based on animal studies which indicated an increased risk for stillbirths. Additionally, mammals who were chronically exposed to 0.3% CO2 the experimental data demonstrate a teratogenicity with irreversible neuron damage in the offspring, reduced spatial learning caused by brainstem neuron apoptosis and reduced circulating levels of the insulin-like growth factor-1. With significant impact on three readout parameters (morphological, functional, marker) this chronic 0.3% CO2 exposure has to be defined as being toxic. Additional data exists on the exposure of chronic 0.3% CO2 in adolescent mammals causing neuron destruction, which includes less activity, increased anxiety and impaired learning and memory. There is also data indicating testicular toxicity in adolescents at CO2 inhalation concentrations above 0.5%.”

Jan 30, 2023 Physical interventions to interrupt or reduce the spread of respiratory viruses

“Medical or surgical masks
Ten studies took place in the community, and two studies in healthcare workers. Compared with wearing no mask in the community studies only, wearing a mask may make little to no difference in how many people caught a flu‐like illness/COVID‐like illness (9 studies; 276,917 people); and probably makes little or no difference in how many people have flu/COVID confirmed by a laboratory test (6 studies; 13,919 people). Unwanted effects were rarely reported; discomfort was mentioned.

N95/P2 respirators
Four studies were in healthcare workers, and one small study was in the community. Compared with wearing medical or surgical masks, wearing N95/P2 respirators probably makes little to no difference in how many people have confirmed flu (5 studies; 8407 people); and may make little to no difference in how many people catch a flu‐like illness (5 studies; 8407 people), or respiratory illness (3 studies; 7799 people). Unwanted effects were not well‐reported; discomfort was mentioned.”

2022

Aug 23, 2022 - Unravelling the role of the mandatory use of face covering masks for the control of SARS-CoV-2 in schools: a quasi-experimental study nested in a population-based cohort in Catalonia (Spain)

“SARS-CoV-2 incidence was significantly lower in preschool than in primary education, and an increasing trend with age was observed. Six-year-old children showed higher incidence than 5 year olds (3.54% vs 3.1%; OR 1.15 (95% CI 1.08 to 1.22)) and slightly lower but not statistically significant SAR (4.36% vs 4.59%; incidence risk ratio 0.96 (95% CI 0.82 to 1.11)) and R* (0.9 vs 0.93; OR 0.96 (95% CI 0.87 to 1.09)).

We found no significant differences in SARS-CoV-2 transmission due to FCM mandates in Catalonian schools.”

July 18, 2022 - Bacterial and fungal isolation from face masks under the COVID-19 pandemic
”We surveyed 109 volunteers on their mask usage and lifestyles, and cultured bacteria and fungi from either the face-side or outer-side of their masks. The bacterial colony numbers were greater on the face-side than the outer-side; the fungal colony numbers were fewer on the face-side than the outer-side. A longer mask usage significantly increased the fungal colony numbers but not the bacterial colony numbers”

May 11, 2022 - Inhaled CO2 concentration while wearing face masks: a pilot study using capnography

“None of the available evaluations of the inhaled air carbon dioxide (CO2) concentration, while wearing face masks, used professional, real-time capnography with water-removal tubing. We measured the end-tidal CO2 using professional side-stream capnography, with water-removing tubing (Rad-97™ capnograph), at rest, (1) without masks, (2) wearing a surgical mask, and (3) wearing a FFP2 respirator, in 102 healthy volunteers aged 10-90 years, from the general population of Ferrara province, Italy.

The mean CO2 concentration was 4965±1047 ppm with surgical masks, and 9396±2254 ppm with FFP2 respirators. The proportion of the sample showing a CO2 concentration higher than the 5000 ppm acceptable exposure threshold recommended for workers was 40.2% while wearing surgical masks, 99.0% while wearing FFP2 respirators.

Adjusting for age, gender, BMI, and smoking, the inhaled air CO2 concentration significantly increased with increasing respiratory rate (with a mean of 10,143±2782 ppm among the participants taking 18 or more breaths per minute, while wearing FFP2 respirators), and was higher among the minors, who showed a mean CO2 concentration of 12,847±2898 ppm, while wearing FFP2 respirators.”

April 19, 2022 - Correlation Between Mask Compliance and COVID-19 Outcomes in Europe

“While no cause-effect conclusions could be inferred from this observational analysis, the lack of negative correlations between mask usage and COVID-19 cases and deaths suggest that the widespread use of masks at a time when an effective intervention was most needed, i.e., during the strong 2020-2021 autumn-winter peak, was not able to reduce COVID-19 transmission. Moreover, the moderate positive correlation between mask usage and deaths in Western Europe also suggests that the universal use of masks may have had harmful unintended consequences.”

Feb 15, 2022 Titanium dioxide particles frequently present in face masks intended for general use require regulatory control

“Although titanium dioxide (TiO2) is a suspected human carcinogen when inhaled, fiber-grade TiO2 (nano)particles were demonstrated in synthetic textile fibers of face masks intended for the general public. STEM-EDX analysis on sections of a variety of single use and reusable face masks visualized agglomerated near-spherical TiO2 particles in non-woven fabrics, polyester, polyamide and bi-component fibers. Median sizes of constituent particles ranged from 89 to 184 nm, implying an important fraction of nano-sized particles (< 100 nm). The total TiO2 mass determined by ICP-OES ranged from 791 to 152,345 µg per mask. The estimated TiO2 mass at the fiber surface ranged from 17 to 4394 µg, and systematically exceeded the acceptable exposure level to TiO2 by inhalation (3.6 µg), determined based on a scenario where face masks are worn intensively.”

2021

Nov 8, 2021 - Evidence for Community Cloth Face Masking to Limit the Spread of SARS-CoV-2: A Critical Review

“The primary mode of transmission (aerosol vs. droplet) for viral respiratory infections, including SARS-CoV-2, is controversial and remains unclear.40,41,42,43,44,45 If aerosol transmission plays a substantial role, the ability of masks to serve as a physical barrier to droplets becomes a less reliable surrogate of efficacy, since air expelled from the lungs necessarily penetrates the mask or flows around its edges, potentially advecting aerosols along with it.”

If aerosols can cause infection, however, then filtering capability is unlikely to be reliable surrogate for infection control, since exhaled air necessarily either leaks around a mask’s edges or passes through it.94,95,96 Such leakage has been shown to account for the vast majority (~5:1 ratio) of particle penetration of standardized surgical masks,97 and exhaled air easily passes around the edges of most cloth masks.98,99,100,101,102

Although high-quality evidence may eventually support recommendations to wear masks that are currently based on the precautionary principle or optimistic interpretations of observational data that have potentially important limitations, it is important to consider the an alternate possibility: that community masking may accelerate rather than reduce transmission of infectious disease. Although some evidence suggests masks may cause non-infection-related harms, such as breathing difficulties,269,270 psychological burdens,271 impaired communication,272,273 skin irritation or breakdown,274,275 and headaches,276 the most concerning potential harm to health is an increased rate of disease spread.

A number of studies have found higher point estimates of infection among mask wearers, some of which were statistically significant (Table 3).

Multiple household studies have found higher instances of respiratory sickness in masked intervention groups than in unmasked controls.

The World Health Organization has noted the possibility that mask wearing could accelerate disease spread by providing a false sense of security that induces individuals to forego standard sanitary measures,295

Recommendations to impose mask mandates based on the precautionary principle fail to account for the possibility that masks cause harm,318 or that masks may have varying benefits and risks in different settings.

…given the low quality of evidence, the absence of statistically significant benefit indicated by most randomized controlled trials, and the possible harm suggested by a few studies, scientists and public health officials must take care not to apply a double standard to available studies—emphasizing projections of lives saved when evidence suggests benefit, while focusing on study limitations rather than outcomes when the evidence suggests harm or the absence of benefit.

More than a century after the 1918 influenza pandemic, examination of the efficacy of masks has produced a large volume of mostly low- to moderate-quality evidence that has largely failed to demonstrate their value in most settings.”

Sept 16, 2021 Masks In Schools: Scientific American Fumbles Report On Childhood COVID Transmission

“Moreover, are the “multiple lines of evidence” strong enough to justify masks mandates in schools?

No, they're not. We can confirm this by looking more carefully at the research SciAm cited and bringing a few other studies into the discussion. SciAm in quotes, followed by my commentary:

"Researchers at the ABC Science Collaborative have collected data from more than a million K–12 students and staff members in North Carolina, which mandated masking in schools from August 2020 until July 2021. The scientists reported little in-school transmission over the fall, winter or summer months. Incidents remained low even as, in communities outside the schools, levels of COVID cases fluctuated and mitigation strategies shifted."

This study had no control group, as the authors themselves acknowledged, because every school in the state had a mask mandate in place. The researchers had no influence over North Carolina's masking policy, of course, but it's hard to investigate the efficacy of an intervention when you can't utilize the proper study design.

They tried to compensate by comparing their results to transmission rates at youth camps in Texas and Florida, as well as an unmasked school in Israel, but these numbers came from different studies; the researchers could only observe these settings from a distance. In any case, when you compare masked to unmasked settings, the outcomes aren't consistent. Many mandate-free schools around the world haven't experienced massive case surges.”

Sept 2021 - Nosocomial outbreak caused by the SARS-CoV-2 Delta variant in a highly vaccinated population, Israel, July 2021

“This nosocomial outbreak exemplifies the high transmissibility of the SARS-CoV-2 Delta variant among twice vaccinated and masked individuals.”

Aug 31, 2021 The Impact of Community Masking on COVID-19: A Cluster-Randomized Trial in Bangladesh:

“A cluster-randomized trial of community-level mask promotion in rural Bangladesh from November 2020 to April 2021 (N=600 villages, N=342,126 adults. Heneghan writes: “In a Bangladesh study, surgical masks reduced symptomatic COVID infections by between 0 and 22 percent, while the efficacy of cloth masks led to somewhere between an 11 percent increase to a 21 percent decrease. Hence, based on these randomized studies, adult masks appear to have either no or limited efficacy.”

Aug 25, 2021 CDC: Schools With Mask Mandates Didn’t See Statistically Significant Different Rates of COVID Transmission From Schools With Optional Policies

“The CDC did not include its finding that “required mask use among students was not statistically significant compared with schools where mask use was optional” in the summary of its report.

A recent New York magazine article states that the science on masks "remains uncertain," but noted the Centers for Disease Control and Prevention (CDC) in May published a large-scale study of COVID transmission in US schools.

The study, which analyzed some 90,000 elementary students in 169 Georgia schools from November 16 to December 11, found that there was no statistically significant difference in schools that required students to wear masks compared to schools where masks were optional.

“The 21% lower incidence in schools that required mask use among students was not statistically significant compared with schools where mask use was optional,” the CDC said. "This finding might be attributed to higher effectiveness of masks among adults, who are at higher risk for SARS-CoV-2 infection but might also result from differences in mask-wearing behavior among students in schools with optional requirements. CDC link

Conspicuously, there’s no evidence of more outbreaks in schools in those countries relative to schools in the U.S., where the solid majority of kids wore masks for an entire academic year and will continue to do so for the foreseeable future,” wrote Zweig. “These countries, along with the World Health Organization, whose child-masking guidance differs substantially from the CDC’s recommendations, have explicitly recognized that the decision to mask students carries with it potential academic and social harms for children and may lack a clear benefit.”

Aug 7, 2021 Mask mandate and use efficacy for COVID-19 containment in US States

“We did not observe association between mask mandates or use and reduced COVID-19 spread in US states.”

Aug 2021 - Mask mandate and use efficacy for COVID-19 containment in US States

“We did not observe association between mask mandates or use and reduced COVID-19 spread in US states. COVID-19 mitigation requires further research and use of existing efficacious strategies, most notably vaccination.”

July 29, 2021 An outbreak caused by the SARS-CoV-2 Delta variant (B.1.617.2) in a secondary care hospital in Finland, May 2021

“Both symptomatic and asymptomatic infections were found among vaccinated HCW, and secondary transmission occurred from those with symptomatic infections despite use of personal protective equipment (PPE).”

July 23, 2021 47 studies confirm ineffectiveness of masks for COVID and 32 more confirm their negative health effects

Read the article and corresponding studies. However, this one sticks out like a sore thumb.
“We included three trials, involving a total of 2106 participants. There was no statistically significant difference in infection rates between the masked and unmasked group in any of the trials”

May 1, 2021 Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study

“We observed no association of risk of transmission with reported mask usage by contacts, with the age or sex of the index case, or with the presence of respiratory symptoms in the index case at the initial study visit.”

March 31,2021 - "Is a Mask That Covers the Mouth and Nose Free from Undesirable Side Effects in Everyday Use and Free of Potential Hazards?

"Abstract - Many countries introduced the requirement to wear masks in public spaces for containing SARS-CoV-2 making it commonplace in 2020. Up until now, there has been no comprehensive investigation as to the adverse health effects masks can cause. The aim was to find, test, evaluate and compile scientifically proven related side effects of wearing masks. For a quantitative evaluation, 44 mostly experimental studies were referenced, and for a substantive evaluation, 65 publications were found. The literature revealed relevant adverse effects of masks in numerous disciplines. In this paper, we refer to the psychological and physical deterioration as well as multiple symptoms described because of their consistent, recurrent and uniform presentation from different disciplines as a Mask-Induced Exhaustion Syndrome (MIES). We objectified evaluation evidenced changes in respiratory physiology of mask wearers with significant correlation of O2 drop and fatigue (p < 0.05), a clustered co-occurrence of respiratory impairment and O2 drop (67%), N95 mask and CO2 rise (82%), N95 mask and O2 drop (72%), N95 mask and headache (60%), respiratory impairment and temperature rise (88%), but also temperature rise and moisture (100%) under the masks. Extended mask-wearing by the general population could lead to relevant effects and consequences in many medical fields."

March 2021 Effectiveness of Adding a Mask Recommendation to Other Public Health Measures to Prevent SARS-CoV-2 Infection in Danish Mask Wearers (RCT)
”Conclusion:
The recommendation to wear surgical masks to supplement other public health measures did not reduce the SARS-CoV-2 infection rate among wearers by more than 50% in a community with modest infection rates, some degree of social distancing, and uncommon general mask use. The data were compatible with lesser degrees of self-protection.”

Feb 18, 2021 Open Schools, Covid-19, and Child and Teacher Morbidity in Sweden

“Social distancing was encouraged in Sweden, but wearing face masks was not.3

No child with Covid-19 died.”

Feb 15, 2021 Using face masks in the community: first update Effectiveness in reducing transmission of COVID-19

“The evidence regarding the effectiveness of medical face masks for the prevention of COVID-19 in the community is compatible with a small to moderate protective effect, but there are still significant uncertainties about the size of this effect. Evidence for the effectiveness of non-medical face masks, face shields/visors and respirators in the community is scarce and of very low certainty.”

​Feb 11, 2021 - "Masks Can Be Detrimental to Babies' Speech and Language  Development". David J. Lewkowic. Scientific American. Cogntion, (Opinion)

"…the COVID pandemic has laid bare our fundamental need to see whole faces. Could it be that babies and young children, who must learn the meaning of the myriad communicative signals normally available in their social partners’ faces, are especially vulnerable to their degradation in partially visible faces? … in my lab … We discovered that babies begin lip- reading at around 8 months of age. …

Crucially, once lip-reading emerges in infancy, it becomes the default mode of speech processing whenever comprehension is difficult. …

​Overall, the research to date demonstrates that the visible articulations that babies normally see when others are talking play a key role in their acquisition of communication skills. Research also shows that babies who lip-read more have better language skills when they’re older. If so, this suggests that masks probably hinder babies’ acquisition of speech and language.”

Jan 23, 2021 Twenty Reasons Mandatory Face Masks are Unsafe, Ineffective and Immoral 9 potential dangers - “Cavities, Facial Deformities, Acne Vulgaris, Increased Risk of Covid-19, Bacterial Pneumonia, Immune Suppressing, Germophobia, Toxic, Psychologically Harmful.

6 proofs masks do not reduce infections - insubstantial, unreasonable, ineffective, unsanitary, no protection, unproven
5 ways forced masking is immoral - reckless, manipulative, fear-mongering, totalitarian and virtue signalling”

​January 5, 2021 - Corona children studies "Co-Ki": First results of a Germany-wide registry on mouth and nose covering (mask) in children:

“ABSTRACT. Background: Narratives about complaints in children and adolescents caused by wearing a mask are accumulating. There is, to date, no registry for side effects of masks.

Methods: At the University of Witten/Herdecke an online registry has been set up where parents, doctors, pedagogues and others can enter their observations. On 20.10.2020, 363 doctors were asked to make entries and to make parents and teachers aware of the registry.

Results: By 26.10.2020 the registry had been used by 20,353 people. In this publication we  report the results from the parents, who entered data on a total of 25,930 children. The average wearing time of the mask was 270 minutes per day. Impairments caused by wearing the mask  were reported by 68% of the parents. These included irritability (60%), headache (53%), difficulty concentrating (50%), less happiness (49%), reluctance to go to school/kindergarten (44%), malaise (42%) impaired learning (38%) and drowsiness or fatigue (37%).

Discussion: This world's first registry for recording the effects of wearing masks in children is dedicated to a new research question. Bias with respect to preferential documentation of children who are particularly severely affected or who are fundamentally critical of protective measures cannot be dismissed. The frequency of the registry’s use and the spectrum of  symptoms registry indicate the importance of the topic and call for representative surveys, randomized controlled trials with various masks and a renewed risk-benefit assessment for the  vulnerable group of children: adults need to collectively reflect the circumstances under which  they would be willing to take a residual risk upon themselves in favour of enabling children to have a higher quality of life without having to wear a mask.”

2020

​December 31, 2020 - The intersection of COVID‐19, school, and headaches: Problems and solutions" Headache: The Journal of Head and Face Pain, 61: 190-201
"Many common triggers such as dehydration, fasting, sleep problems, and stressors were discussed above. Here we highlight screen use and mask wearing as potential additional school‐related triggers.mm ,,, Pressure created by the mask or its straps against various contact points on the face or scalp could trigger headache"

Dec 17, 2020 SARS-CoV-2 Transmission among Marine Recruits during Quarantine
“Our study showed that in a group of predominantly young male military recruits, approximately 2% became positive for SARS-CoV-2, as determined by qPCR assay, during a 2-week, strictly enforced quarantine. Multiple, independent virus strain transmission clusters were identified…all recruits wore double-layered cloth masks at all times indoors and outdoors.”

Dec 7, 2020 - Masks, false safety and real dangers, Part 4: Proposed mechanisms by which masks increase risk of COVID-19 - PEER REVIEWED Jan 8, 2021
”Conclusion
Population studies show that the use of masks either resulted in an increased incidence of COVID-19 or had no impact. None of the examined jurisdictions experienced decreased incidence of COVID-19 after the introduction of mask mandates, except two that had already begun a sharp descent in COVID-19 cases weeks earlier. Two physical mechanisms are proposed to directly contribute to this finding, based on current available research. The first is scatter mechanics of dispersed respiratory droplets becoming aerosolized on collision with the mesh of a mask on outward exhalation and then lingering in air. The second is the pressurized and distant peripheral jets of unfiltered exhaled aerosol from the nozzled edges of a mask. These phenomena result in viral particles lingering longer and traveling farther in airspace from a masked person than exhaled respiratory droplets falling close to the body from the orifices of an unmasked person. There are also chemical mechanisms for increased COVID-19 cases in masked populations. This is likely due to immune suppression caused by hypoxic and hypercapnic conditions, as well as acidotic, immobilized cilia in the lungs, and reduced skin surface available to sunlight for Vitamin D production. Caution is therefore urged against use of masks among those who wish to reduce the risk, either for themselves or others, of infection with SARS-CoV-2 or COVID-19 disease.”

Nov 27, 2020 The Strangely Unscientific Masking of America

“As rapidly as mask use became a matter of ethics, the issue transformed into a political one, exemplified by an article printed on March 27 in the New York Times, entitled “More Americans Should Probably Wear Masks for Protection.” The piece was heavy on fear-mongering and light on evidence.  While acknowledging that “[t]here is very little data showing that flat surgical masks, in particular, have a protective effect for the general public,” the author went on to argue that they “may be better than nothing,” and cited a couple of studies in which surgical masks ostensibly reduced influenza transmission rates.  

One report reached its conclusion based on observations of a “dummy head attached to a breathing simulator.”  Another analyzed use of surgical masks on people experiencing at least two symptoms of acute respiratory illness. Incidentally, not one of these studies involved cloth masks or accounted for real-world mask usage (or misusage) among lay people, and none established efficacy of widespread mask-wearing by people not exhibiting symptoms.  There was simply no evidence whatsoever that healthy people ought to wear masks when going about their lives, especially outdoors.”

​Nov 22, 2020 - Facemasks in the COVID-19 era: A health hypothesis (link removed :( )

“Abstract: … Although, scientific evidence supporting facemasks’ efficacy is lacking, adverse physiological, psychological and health effects are established. Is has been hypothesized that facemasks have compromised safety and efficacy profile and should be avoided from use. The current article comprehensively summarizes scientific evidences with respect to wearing facemasks in the COVID-19 era. …

Long-Term health consequences of wearing facemasks: Long-term practice of wearing facemasks has strong potential for devastating health consequences. Prolonged hypoxic-hypercapnic state compromises normal physiological and psychological balance, deteriorating health and promotes the developing and progression of existing chronic diseases (10 refs).

Conclusion: … Wearing facemasks has been demonstrated to have substantial adverse physiological and psychological effects. These include hypoxia, hypercapnia, shortness of breath, increased acidity and toxicity, activation of fear and stress response, rise in stress hormones, immunosuppression, fatigue, headaches, decline in cognitive performance, predisposition for viral and infectious illnesses, chronic stress, anxiety and depression. Long-term consequences of wearing facemask can cause health deterioration, developing and progression of chronic diseases and premature death."

​Nov 18, 2020 - "Effectiveness of Adding a Mask Recommendation to Other Public Health Measures to Prevent SARS-CoV-2 Infection in Danish Mask Wearers: A Randomized Control Tiral

"the trial found no statistically significant benefit of wearing a face mask. The study used “high-quality surgical masks with a filtration rate of 98%”.

Nov 2, 2020 - Masks, false safety and real dangers, Part 3: Hypoxia, hypercapnia and physiological effects - PEER REVIEWED NOV 9, 2020
”Conclusion
This paper, the third in our series, focuses on physiological changes induced by hypoxia and hypercapnia. Our findings of reduced oxygen and increased carbon dioxide in a masked airspace are not inconsistent with previously reported data.82 83 Evidence of damage to multiple organ systems from the documented levels of [O2] and [CO2] in available airspace between a facemask and the airways are cited above and are abundant in the medical literature.

The pathological triad of micro-particles as long-term hazards, and bacterial and fungal infections as mid-term hazards, as well as injury from hypoxia and hypercapnia in the short- term, are expected to have synergistic results in endangering the health of masked people. Because of the extensive risk to mask wearers documented in these three papers, we urgently recommend that no adult or child be coerced to wear a mask under any circumstances. We further recommend that facemask hazards be published prominently and that masks only be worn by adults who choose to do so, and only with freely given informed consent, with full knowledge of their hazards, and that their use be prohibited for children, adult students and workers.

If on the other hand, widespread use of masks and mandating the same continue, then the question arises, from the data shown herein, whether morbidity and mortality from mask- wearing will exceed those of COVID-19 or other known infectious diseases. What will be the long-term effects of mask wearing if it continues? And will we be able to distinguish mask injury from COVID-19 or other pathologies? The evidence presented here, in summary of clinical data from around the world, show that masks can accelerate morbidity and mortality in those who are already ill, and that masks can sicken healthy people. Before masks are forced onto school children and workers, why are animal studies not being done with all-day masking, to investigate safety issues? How much of an increase in mask-related illnesses will we have to observe before mask “mandates” end?”

Nov 4, 2020 - That Mask Is Giving You Lung Cancer
Guy Crittenden was the editor for HazMat Management.

“I happen to know a thing or two about masks and safety. Why? Because for 25 years I was the editor of an award-winning trade magazine called HazMat Management that covered such topics as pollution prevention and compliance with health & safety laws. We routinely published articles on masks, gloves, respirators and other forms of personal protective equipment (PPE). Now let me tell you a few things about that mask you’re wearing. And please note that what I’m about to share was also stated in the most recent edition of Del Bigtree’s program The Highwire when two OSHA mask experts spoke to the fact that the kinds of masks people are wearing were never (never!) designed to be worn for long periods and doing so is very harmful.

The blue typical mask depicted in the photograph contain Teflon and other chemicals. A Facebook friend reminds us: 1. Masks are “sterilized” with Ethylene Oxide — a known carcinogen. Many teachers in various school boards have been experiencing significant symptoms as a direct result of the effects of this chemical. 2. The masks contain (not sprayed with) PTFE which makes up Teflon along with other chemicals. I found and have posted the US patent to allow manufacturers to use PTFE as a filter in commercial masks… “breathing these for extended periods can lead to lung cancer.”

Don’t agree? Argue with the experts at OSHA, which is the main US agency, i.e., its Occupational Health & Safety Agency. These masks are meant to be worn only for short periods, like say if you’re sanding a table for an hour and don’t want to inhale sawdust. They don’t do anything whatsoever to stop the spread of any virus, and the emerging science of virology now understands that viruses aren’t even passed person to person. I know that sounds incredible, but it’s the case that the virus is in the air, you breath it in, there’s no way to prevent that short of living in an oxygen tent, and if you have a strong immune system you’ll be fine, and if you have a weak immune system you may have to deal with the effects of your immune system working to restore balance within your metabolism.

So let’s say you don’t wear the blue packaged masks, and instead wear a homemade cloth mask — the kind people wear over and over and hang on their rearview mirror and so on. Those masks are completely useless against a virus, and are also very dangerous. OSHA would never condone a person wearing a mask of this kind for anything more than the shortest time. Re-breathing your own viral debris is dangerous to health, and the oxygen deprivation children suffer wearing such masks all day will certainly cause brain damage. I’m not making this up. Again, you might say, well, Guy, you’re not a doctor. True, but I did edit that magazine for 25 years. That’s a long time and many articles on masks and PPE. I’ve attended numerous OH&S conferences and listened to experts discussing these matters.

You may hear people saying that surgeons and nurses wear masks like this all day. Um, no. No they don’t. They’re trained in the proper use of masks, which is to wear them in the OR, then dispose of the mask when they leave that room. Are you aware that operating rooms are actually supplied extra oxygen, to compensate for the reduction in oxygen flow from mask wearing? To my mind, it’s criminal (not hyperbole) to force children to wear masks all day. Setting aside the very real psychological effects, we’re going to have a generation of brain damaged children. Ever heard the expression, “Not enough oxygen at birth?” That’s a joke at the expense of a mentally challenged person, but that’s literally what we’re doing. And we’re told it’s to “keep us safe”! We’re told this by doctors who actually don’t know about PPE and laypeople who have no clue.

So, you can choose to believe me or not, but I was the editor for a quarter century of a magazine that had a strong occupational health and safety mandate, and I can tell you that the mask wearing currently mandated by governments and private businesses offers no health benefit whatsoever, in no way protects you or anyone else from any virus, and actually does you damage beyond wearing it for a few minutes.Got that? Good. Now please share this message and get the conversation going with parents, who must end this masking of children immediately. This is a very serious matter. And related to that, let me just state this doesn’t end for me when the lockdown ends or the masking ends. No, this ends for me when every politician and bureaucrat who inflicted this travesty, this crime against humanity, on the population of Canada (and other affected countries) is in the dock, and faces their misdeeds in a court of law.

And as for those of you who have put masks on young children, I will have a long memory on that score. A very long memory.

END NOTE: The CDC and WHO have acknowledged that asymptomatic people do not spread the virus, so the case for masks for such people is moot in the first place.

​November 2020 - “Masks, false safety and real dangers, Part 2: Microbial challenges  from masks”. Primary Doctor Medical Journal. (Link removed :( )

In November 2020, Borovoy et al. [32] published an extensive review of biological and  medical knowledge that allowed them to infer a large potential for significant harms from masking, via microbial challenges from the masks. They rightly stress the known yet underplayed role of bacteria in viral pandemics, and also review respiratory diseases arising from oral bacteria, which can be induced by mask wearing to penetrate and infect the respiratory tract and lungs.

Oct 13, 2021 Facemask against viral respiratory infections among Hajj pilgrims: A challenging cluster-randomized trial

“Conclusion

This trial was unable to provide conclusive evidence on facemask efficacy against viral respiratory infections most likely due to poor adherence to protocol.”​

October 29, 2020 - "The implications of face masks for babies and families during the COVID-19 pandemic: A discussion paper"

“Abstract: … COVID-19 has changed the way that newborn babies are cared for within the neonatal setting due to the introduction of social distancing and wearing of face masks to limit the spread of the infection. Potential implications exist related to the normal development of bonding and connections with others. This paper discusses the importance of face to face interactions for early attachment between babies and parents within the context of relevant underpinning developmental theory. …”

​Oct 9, 2020. Masks, false safety and real dangers, Part 2: Microbial challenges from masks PEER REVIEWED OCT 15, 2020
Conclusion

Masks have been shown consistently over time and throughout the world to have no significant preventative impact against any known pathogenic microbes. Specifically, regarding COVID-19, we have shown in this paper that mask use is not correlated with lower death rates nor with lower positive PCR tests.

Masks have also been demonstrated historically to contribute to increased infections within the respiratory tract. We have examined the common occurrence of oral and nasal pathogens accessing deeper tissues and blood, and potential consequences of such events. We have demonstrated from the clinical and historical data cited herein, we conclude the use of face masks will contribute to far more morbidity and mortality than has occurred due to COVID-19.

October 6th - German Neurologist Warns Against Wearing Facemasks: 'Oxygen Deprivation Causes Permanent Neurological Damage'

Dr. Margarite Griesz-Brisson MD, PhD is a Consultant Neurologist and Neurophysiologist with a PhD in Pharmacology, with special interest in neurotoxicology, environmental medicine, neuroregeneration and neuroplasticity. This is what she has to say about facemasks and their effects on our brains: 

"The reinhalation of our exhaled air will without a doubt create oxygen deficiency and a flooding of carbon dioxide. We know that the human brain is very sensitive to oxygen deprivation. There are nerve cells for example in the hippocampus that can't be longer than 3 minutes without oxygen - they cannot survive.... However, when you have chronic oxygen deprivation, all of those symptoms disappear, because you get used to it. But your efficiency will remain impaired and the under-supply of oxygen in your brain continues to progress.... While you're thinking that you have gotten used to wearing your mask and rebreathing your own exhaled air, the degenerative processes in your brain are getting amplified as your oxygen deprivation continues.

The second problem is that the nerve cells in your brain are unable to divide themselves normally. So in case our governments will generously allow as to get rid of the masks and go back to breathing oxygen freely again in a few months, the lost nerve cells will no longer be regenerated. What is gone is gone. The acute warning symptoms are headaches, drowsiness, dizziness, issues in concentration, slowing down of reaction time - reactions of the cognitive system... 

There is no unfounded medical exemption from face masks because oxygen deprivation is dangerous for every single brain. It must be the free decision of every human being whether they want to wear a mask that is absolutely ineffective to protect themselves from a virus.

For children and adolescents, masks are an absolute no-no. Children and adolescents have an extremely active and adaptive immune system and they need a constant interaction with the microbiome of the Earth. Their brain is also incredibly active, as it is has so much to learn. The child's brain, or the youth's brain, is thirsting for oxygen. The more metabolically active the organ is, the more oxygen it requires. In children and adolescents every organ is metabolically active.

To deprive a child's or an adolescent's brain from oxygen, or to restrict it in any way, is not only dangerous to their health, it is absolutely criminal. Oxygen deficiency inhibits the development of the brain, and the damage that has taken place as a result CANNOT be reversed.

The child needs the brain to learn, and the brain needs oxygen to function. We don't need a clinical study for that. This is simple, indisputable physiology. Consciously and purposely induced oxygen deficiency is an absolutely deliberate health hazard, and an absolute medical contraindication.

An absolute medical contraindication in medicine means that this drug, this therapy, this method or measure should not be used, and is not allowed to be used. To coerce an entire population to use an absolute medical contraindication by force, there must be definite and serious reasons for this, and the reasons must be presented to competent interdisciplinary and independent bodies to be verified and authorized.

I know how damaging oxygen deprivation is for the brain, cardiologists know how damaging it is for the heart, pulmonologists know how damaging it is for the lungs. Oxygen deprivation damages every single organ.
Where are our health departments, our health insurance, our medical associations? It would have been their duty to be vehemently against the lockdown and to stop it and stop it from the very beginning.
Why do the medical boards issue punishments to doctors who give people exemptions? Does the person or the doctor seriously have to prove that oxygen deprivation harms people? What kind of medicine are our doctors and medical associations representing?

Sept 11, 2021 - Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities  

As a follow up to Fauci's 2008 findings, the CDC recently published data on hospital admissions which shows that those testing both positive and negative for the virus strain are presenting symptoms of covid-19, and that the vast majority of hospital admissions with severe respiratory symptoms are wearing face coverings.

​August 12, 2020 - Face masks: benefits and risks during the COVID-19 crisis

“If masks are not exchanged regularly (or washed properly when made of cloth), pathogens can accumulate in the mask. When improperly used, the risk of spreading the pathogen— including SARS-CoV-2—might be critically increased.” (p. 5)

​August 6, 2020 - "Masked education? The benefits and burdens of wearing face masks in schools during the current Corona pandemic. Trends in Neuroscience and  Education. 

“Abstract: … covering the lower half of the face reduces the ability to communicate, interpret, and mimic the expressions of those with whom we interact. Positive emotions become less recognizable, and negative emotions are amplified. Emotional mimicry, contagion, and  emotionality in general are reduced and (thereby) bonding between teachers and learners, group cohesion, and learning – of which emotions are a major driver.

1. Introduction: … along with other measures of physical distancing and economic lockdowns, school closures were implemented during March 2020 affecting more than 1.5 billion students (children and adolescents) around the globe (ref). These closures of schools lasted for a few weeks only (as in Denmark) up to several months (in Italy and many other countries; (ref)) and led to marked decreases in educational gains (ref), hunger (because school meals were no longer served), increases in child abuse (because children were no longer observed by school staff), and, in general, the risk of “scarring the life chances of a generation of young people”(ref) (because of the long-term psychological, physiological, educational and even economic burden (ref), that societies put on their most vulnerable members; (ref))…

• … wearing masks may have physical side effects.

• Face masks impair face recognition and face identification.

• Face masks impair verbal and non-verbal communication.

• Face masks block emotional signalling between teacher and learner.

Given these pros and cons, it is not clear whether face masks should play a major role in educational settings in times of the current viral pandemic. … This matter should be discussed urgently, since it globally affects more than 1.5 billion students, teachers, and school staff directly, and, in addition, their families indirectly.

6. Face masks block emotional signalling between teachers and students: … In sum, recognition of, and response to, the outward emotional displays of one's peers’ faces is a critical and necessary component of social interaction in schools. It helps pupils and teachers to modify  their behavior in order to align with social communication and behavioral norms. When these emotional displays are inhibited by face masks, our ability to communicate effectively with one another is reduced and we are primarily left with mimicking negative (frown) emotions. All of this happens primarily outside of conscious awareness, and hence, is hard to be consciously controlled or even corrected. Since emotions are a major driver of group cohesion, the decreased emotionality, and decreased positive emotionality in particular, may interfere with smooth classroom action. Given the fact that the very process of learning is facilitated by emotions (this is their main raison d´être), face masks are likely to cause some interference with pedagogy.” Coleen Huber

July 25, 2020 Does Universal Mask Wearing Decrease or Increase the Spread of COVID-19?

Additional Downsides of Wearing a Mask during the COVID-19 Outbreak

All masks make breathing more difficult, requiring more effort to inhale and exhale and potentially causing more viral load to be expelled into the air. Moreover, when a non-contagious person wears a cloth mask, his or her mask accumulates the coronavirus and other germs from the environment. If a contagious person wears a cloth mask, the mask also accumulates some viral load with each breath, and soon, it might discharge more viral load with each exhalation than the contagious person would otherwise exhale—and in more directions.

Masks cause heavier, deeper, and more forceful breathing as well as straining—all of the attributes believed to have caused exceptionally bad outcomes in the case of a church choir in Seattle (Read, “A choir decided to go ahead with rehearsal. Now dozens of members have COVID-19 and two are dead,” 2020). Deeper breathing allows the coronavirus to go deeper into the lungs, causing infection to take hold faster. The article explains:

“Jamie Lloyd-Smith, a UCLA infectious disease researcher, said it’s possible that the forceful breathing action of singing dispersed viral particles in the church room that were widely inhaled.”

As of now, hundreds of thousands of people are breathing similarly forcefully through masks in public spaces, and other people are inhaling what mask wearers expel. Read’s article contains another illustrative passage:

“Linsey Marr, an environmental engineer at Virginia Tech and an expert on airborne transmission of viruses, said some people happen to be especially good at exhaling fine material, producing 1,000 times more than others.”

This finding had been described in an unrelated study (Edwards et al., “Inhaling to mitigate exhaled bioaerosols,” 2004).

July 23, 2020 Masking lack of evidence with politics:

“It would appear that despite two decades of pandemic preparedness, there is considerable uncertainty as to the value of wearing masks. For instance, high rates of infection with cloth masks could be due to harms caused by cloth masks, or benefits of medical masks.  The numerous systematic reviews that have been recently published all include the same evidence base so unsurprisingly broadly reach the same conclusions.

The small number of trials and lateness in the pandemic cycle is unlikely to give us reasonably clear answers and guide decision-makers. This abandonment of the scientific modus operandi and lack of foresight has left the field wide open for the play of opinions, radical views and political influence.”  

July 17, 2020 Impact of non-pharmaceutical interventions against COVID-19 in Europe: a quasi-experimental study

“Face masks in public was not associated with reduced incidence. 

Relaxing stay-at-home orders and allowing reopening of non-essential businesses appeared to be the lowest risk measures to relax as part of plans to carefully lift COVID-19 lockdown measures. There is still even now relatively little unclear empirical evidence on the relative value of different interventions. And yet, the reasons to implement minimal control measures are compelling, given the social and economic harm linked to tight control measures. Hence, whilst we need to be cautious about using preliminary results, public health officials will have to use evidence as it emerges rather than expect to wait for a final full view to decide what might be (was) the best control strategy.”

July 6, 2020. Masks, false safety and real dangers, Part 1: PEER REVIEWED NOV 19, 2020
Conclusion: Friable mask particulate and lung vulnerabilitySurgical personnel are trained to never touch any part of a mask, except the loops and the nose bridge. Otherwise, the mask is considered useless and is to be replaced. Surgical personnel are strictly trained not to touch their masks otherwise. However, the general public may be seen touching various parts of their masks. Even the masks just removed from manufacturer packaging have been shown in the above photos to contain particulate and fiber that would not be optimal to inhale.

Both cotton and polymer clothing have been well-tolerated without pathology when covering any other part of the body, except over the only entry points/gateway to the respiratory system. Inhalation risks, such as the constant ventilation of the respiratory process, increased by the greater effort to attempt to fulfill bodily oxygen needs, with mostly and closely covered orifices are of great concern for those who would want to protect pulmonary health, without inhalation of unwanted particulate. When partial airway obstruction, i.e. masking, is added, deeper and more forceful breathing occurs. When this phenomenon is combined with the particles found herein on microscopic examination of the face side of newly unpackaged, never worn masks, there can arise the risk of a dangerous level of foreign material entering lung tissue. Furthermore, worn masks can only either lose these particles to lodge in the lungs of the wearer, or they would accumulate during use, to the burden (both biological and debris) of non-mask material carried on the inside of the mask.

Further concerns of macrophage response and other immune and inflammatory and fibroblast response to such inhaled particles specifically from facemasks should be the subject of more research.

If widespread masking continues, then the potential for inhaling mask fibers and environmental and biological debris continues on a daily basis for hundreds of millions of people. This should be alarming for physicians and epidemiologists knowledgeable in occupational hazards.

July 6, 2020 - Effects of surgical and FFP2/N95 face masks on cardiopulmonary exercise capacity
“Results - The pulmonary function parameters were significantly lower with mask (forced expiratory volume: 5.6 ± 1.0 vs 5.3 ± 0.8 vs 6.1 ± 1.0 l/s with sm, ffpm and nm, respectively; p = 0.001; peak expiratory flow: 8.7 ± 1.4 vs 7.5 ± 1.1 vs 9.7 ± 1.6 l/s; p < 0.001). The maximum power was 269 ± 45, 263 ± 42 and 277 ± 46 W with sm, ffpm and nm, respectively; p = 0.002; the ventilation was significantly reduced with both face masks (131 ± 28 vs 114 ± 23 vs 99 ± 19 l/m; p < 0.001). Peak blood lactate response was reduced with mask. Cardiac output was similar with and without mask. Participants reported consistent and marked discomfort wearing the masks, especially ffpm.

Conclusion - Ventilation, cardiopulmonary exercise capacity and comfort are reduced by surgical masks and highly impaired by FFP2/N95 face masks in healthy individuals. These data are important for recommendations on wearing face masks at work or during physical exercise.

​July 6, 2020 - Masks are neither effective nor safe: A summary of the science

In this meta-analysis, face masks were found to have no detectable effect against transmission of viral infections. (1)  It found: “Compared to no masks, there was no reduction of influenza-like illness cases or influenza for masks in the general population, nor in healthcare workers.” 

This 2020 meta-analysis found that evidence from randomized controlled trials of face masks did not support a substantial effect on transmission of laboratory-confirmed influenza, either when worn by infected persons (source control) or by persons in the general community to reduce their susceptibility. (2)

Another recent review found that masks had no effect specifically against Covid-19, although facemask use seemed linked to, in 3 of 31 studies, “very slightly reduced” odds of developing influenza-like illness. (3)

This 2019 study of 2862 participants showed that both N95 respirators and surgical masks “resulted in no significant difference in the incidence of laboratory confirmed influenza." (4)

This 2016 meta-analysis found that both randomized controlled trials and observational studies of N95 respirators and surgical masks used by healthcare workers did not show benefit against transmission of acute respiratory infections.  It was also found that acute respiratory infection transmission “may have occurred via contamination of provided respiratory protective equipment during storage and reuse of masks and respirators throughout the workday.” (5)

A 2011 meta-analysis of 17 studies regarding masks and effect on transmission of influenza found that “none of the studies established a conclusive relationship between mask/respirator use and protection against influenza infection.” (6)  However, authors speculated that effectiveness of masks may be linked to early, consistent and correct usage.

Face mask use was likewise found to be not protective against the common cold, compared to controls without face masks among healthcare workers. (7)"

June 19, 2020 - Downsides of face masks and possible mitigation strategies: a systematic review and meta-analysis

“There are insufficient data to quantify all of the adverse effects that might reduce the acceptability, adherence, and effectiveness of face masks. New research on facemasks should assess and report the harms and downsides. Urgent research is also needed on methods and designs to mitigate the downsides of facemask wearing, particularly the assessment of alternatives such as face shields.”

​June 18, 2020 - Can the Elastic of Surgical Face Masks Stimulate Ear Protrusion in Children? (Letter to the Editor)

“Abstract: … Among those on the market, surgical masks with elastic loops are the ones most chosen by parents for their children. These elastics cause constant compression on the skin and, consequently, on the cartilage of the auricle, leading to erythematous and painful lesions of the retroauricular skin when the masks are used for many hours a day. Pre- adolescent children have undeveloped auricular cartilage with less resistance to deformation; prolonged pressure from the elastic loops of the mask at the hollow or, even worse, at the anthelix level can influence the correct growth and angulation of the outer ear. In fact, unlike when using conservative methods for the treatment of protruding ears, this prolonged pressure can increase the cephaloauricular angle of the outer auricle. It is important for the authorities supplying the masks to be aware of this potential risk and for alternative solutions to be found …”

​June 2020 - “Exercise with facemask; Are we handling a devil's sword?” – A physiological hypothesis

"Straying away from a sedentary lifestyle is essential, especially in these troubled times of a global pandemic to reverse the ill effects associated with the health risks as mentioned earlier. In the view of anticipated effects on immune system and prevention against influenza and Covid-19, globally moderate to vigorous exercises are advocated wearing protective equipment such as facemasks. Though WHO supports facemasks only for Covid-19 patients, healthy “social exercisers” too exercise strenuously with customized facemasks or N95 which hypothesized to pose more significant health risks and tax various physiological systems especially pulmonary, circulatory and immune systems. Exercising with facemasks may reduce available Oxygen and increase air trapping preventing substantial carbon dioxide exchange. The hypercapnic hypoxia may potentially increase acidic environment, cardiac overload, anaerobic metabolism and renal overload, which may substantially aggravate the underlying pathology of established chronic diseases. Further contrary to the earlier thought, no evidence exists to claim the facemasks during exercise offer additional protection from the droplet transfer of the virus. Hence, we recommend social distancing is better than facemasks during exercise and optimal utilization rather than exploitation of facemasks during exercise."

May 20,2020 Assessment of Proficiency of N95 Mask Donning Among the General Public in Singapore

“These findings support ongoing recommendations against the use of N95 masks by the general public during the COVID-19 pandemic.5 N95 mask use by the general public may not translate into effective protection but instead provide false reassurance. Beyond N95 masks, proficiency among the general public in donning surgical masks needs to be assessed. Policy measures that encourage mask use in the general public must be coupled with effective training materials beyond instruction leaflets, which our study and a 2013 study by Harber et al 6 found to be inadequate.”

​MAY 8th 2020 - From the CDC itself which also follows the WHOs guidelines..

"If you are sick wear a cloth covering over your nose and mouth. You should wear a cloth face covering, over your nose and mouth if you must be around other people or animals, including pets (even at home). You don’t need to wear the cloth face covering if you are alone. If you can’t put on a cloth face covering (because of trouble breathing, for example), cover your coughs and sneezes in some other way. Try to stay at least 6 feet away from other people. This will help protect the people around you. Cloth face coverings should not be placed on young children under age 2 years, anyone who has trouble breathing, or anyone who is not able to remove the covering without help."

​April 2020 "The authors and CIDRAP have received requests in recent weeks to remove this article from the CIDRAP website.

Reasons have included: (1) we don’t truly know that cloth masks (face coverings) are not effective, since the data are so limited, (2) wearing a cloth mask or face covering is better than doing nothing, (3) the article is being used by individuals and groups to support non-mask wearing where mandated and (4) there are now many modeling studies suggesting that cloth masks or face coverings could be effective at flattening the curve and preventing many cases of infection.

​We do, however, have data from laboratory studies that indicate cloth masks or face coverings offer very low filter collection efficiency for the smaller inhalable particles we believe are largely responsible for transmission

The guidelines from the Centers for Disease Control and Prevention (CDC) for face coverings initially did not have any citations for studies of cloth material efficiency or fit, but some references have been added since the guidelines were first posted. We reviewed these and found that many employ very crude, non-standardized methods (Anfinrud 2020, Davies 2013, Konda 2020, Aydin 2020, Ma 2020) or are not relevant to cloth face coverings because they evaluate respirators or surgical masks (Leung 2020, Johnson 2009, Green 2012).

​The CDC failed to reference the National Academies of Sciences Rapid Expert Consultation on the Effectiveness of Fabric Masks for the COVID-19 Pandemic (NAS 2020), which concludes, “The evidence from…laboratory filtration studies suggests that such fabric masks may reduce the transmission of larger respiratory droplets. There is little evidence regarding the transmission of small aerosolized particulates of the size potentially exhaled by asymptomatic or presymptomatic individuals with COVID-19.

​Is wearing a face covering better than nothing?

Wearing a cloth mask or face covering could be better than doing nothing, but we simply don’t know at this point. We have observed an evolution in the messaging around cloth masks, from an initial understanding that they should not be seen as a replacement for physical distancing to more recent messaging that suggests cloth masks are equivalent to physical distancing. And while everyone appears to understand that this messaging suggests that a cloth mask is appropriate only for source control (ie, to protect others from infection), recent CDC and other guidance recommending their use by workers seems to imply that they offer some type of personal protection.

We know of workplaces in which employees are told they cannot wear respirators for the hazardous environments they work in, but instead need to wear a cloth mask or face covering. These are dangerous and inappropriate applications that greatly exceed the initial purpose of a cloth mask. We are concerned that many people do not understand the very limited degree of protection a cloth mask or face covering likely offers as source control for people located nearby.

​We know of workplaces in which employees are told they cannot wear respirators for the hazardous environments they work in, but instead need to wear a cloth mask or face covering. These are dangerous and inappropriate applications that greatly exceed the initial purpose of a cloth mask. We are concerned that many people do not understand the very limited degree of protection a cloth mask or face covering likely offers as source control for people located nearby."

Apr 2020 - Effectiveness of Surgical and Cotton Masks in Blocking SARS–CoV-2: A Controlled Comparison in 4 Patients.. This article has been retracted. See Notice of Retraction. 

"Whether face masks worn by patients with coronavirus disease 2019 (COVID-19) prevent contamination of the environment is uncertain (2, 3)

Objective: To evaluate the effectiveness of surgical and cotton masks in filtering SARS–CoV-2.

We compared disposable surgical masks (180 mm × 90 mm, 3 layers [inner surface mixed with polypropylene and polyethylene, polypropylene filter, and polypropylene outer surface], pleated, bulk packaged in cardboard; KM Dental Mask, KM Healthcare Corp) with reusable 100% cotton masks (160 mm × 135 mm, 2 layers, individually packaged in plastic; Seoulsa).

A petri dish... was placed approximately 20 cm from the patients' mouths. Patients were instructed to cough 5 times each onto a petri dish while wearing the following sequence of masks: no mask, surgical mask, cotton mask, and again with no mask.

All swabs from the outer mask surfaces of the masks were positive for SARS–CoV-2, whereas most swabs from the inner mask surfaces were negative" (no virus on the inside but lots on the outside from adjusting, touching, hanging on your rear view)

"Discussion: Neither surgical nor cotton masks effectively filtered SARS–CoV-2 during coughs by infected patients."

The consistent finding of virus on the outer mask surface is unlikely to have been caused by experimental error or artifact.

A turbulent jet due to air leakage around the mask edge could contaminate the outer surface." Basically the mask has to be fitted perfectly, otherwise, it will leak..

In conclusion, both surgical and cotton masks seem to be ineffective in preventing the dissemination of SARS–CoV-2 from the coughs of patients with COVID-19 to the environment and external mask surface."

The retraction on this was very questionable when you read it..

"LOD of the in-house reverse transcriptase polymerase chain reaction used in the study (2.63 log copies/mL), and we regret our failure to express the values below LOD as “<LOD (value).”

May19, 2020 from CDC - Nonpharmaceutical Measures for Pandemic Influenza in Nonhealthcare Settings—Personal Protective and Environmental Measures

"Although mechanistic studies support the potential effect of hand hygiene or face masks, evidence from 14 randomized controlled trials of these measures did not support a substantial effect on transmission of laboratory-confirmed influenza.

In pooled analysis, we found no significant reduction in influenza transmission with the use of face masks....

....None of the household studies reported a significant reduction in secondary laboratory-confirmed influenza virus infections in the face mask group (11–13,15,17,34,35)

There is limited evidence for their effectiveness in preventing influenza virus transmission either when worn by the infected person for source control or when worn by uninfected persons to reduce exposure. Our systematic review found no significant effect of face masks on transmission of laboratory-confirmed influenza.

We did not find evidence that surgical-type face masks are effective in reducing laboratory-confirmed influenza transmission, either when worn by infected persons (source control) or by persons in the general community to reduce their susceptibility (Figure 2)."

Moreover, why did the CDC choose to leave this out of their "research" or evidence? 

​(April 2020).. skip to chapter 16 if you like or read the whole thing.

"There are no studies of individuals wearing homemade fabric masks in the course of their typical activities. Therefore, we have only limited, indirect evidence regarding the effectiveness of such masks for protecting others, when made and worn by the general public on a regular basis. That evidence comes primarily from laboratory studies testing the effectiveness of different materials at capturing particles of different sizes.

The evidence from these laboratory filtration studies suggests that such fabric masks may reduce the transmission of larger respiratory droplets. There is little evidence regarding the transmission of small aerosolized particulates of the size potentially exhaled by asymptomatic or presymptomatic individuals with COVID-19."

Note the word "may" but they simply don't know at this point.. But the evidence doesn't support the narrative.. Weird..

Feb 3, 2020. Effectiveness of N95 respirators versus surgical masks against influenza: A systematic review and meta-analysis

Results: A total of six RCTs involving 9 171 participants were included. There were no statistically significant differences in preventing laboratory-confirmed influenza (RR = 1.09, 95% CI 0.92-1.28, P > .05), laboratory-confirmed respiratory viral infections (RR = 0.89, 95% CI 0.70-1.11),

laboratory-confirmed respiratory infection (RR = 0.74, 95% CI 0.42-1.29) and influenza-like illness (RR = 0.61, 95% CI 0.33-1.14) using N95 respirators and surgical masks. Meta-analysis indicated a protective effect of N95 respirators against laboratory-confirmed bacterial colonization (RR = 0.58, 95% CI 0.43-0.78).

Conclusion: The use of N95 respirators compared with surgical masks is not associated with a lower risk of laboratory-confirmed influenza. It suggests that N95 respirators should not be recommended for general public and non-high-risk medical staff those are not in close contact with influenza patients or suspected patients

Feb 2020 - The World Health Organization stated that viral transmission from asymptomatic people was likely "rare", based on information available at the time.

"Asymptomatic infection may be rare, and transmission from an asymptomatic person is very rare with other coronaviruses, as we have seen with Middle East Respiratory Syndrome coronavirus.Thus, transmission from asymptomatic cases is likely not a major driver of transmission.Persons who are symptomatic will spread the virus more readily through coughing and sneezing"

Pre-Covid

Sept 2019 - N95 Respirators vs Medical Masks for Preventing Influenza Among Health Care Personnel A Randomized Clinical Trial Findings

In this pragmatic, cluster randomized clinical trial involving 2862 health care personnel, there was no significant difference in the incidence of laboratory-confirmed influenza among health care personnel with the use of N95 respirators (8.2%) vs medical masks (7.2%).

June 2019 - Optical microscopic study of surface morphology and filtering efficiency of face masks.

" The PM10 filtering efficiency of four of the selected masks ranged from 63% to 84%. The poor filtering efficiency may have arisen from larger and open pores present in the masks. Interestingly, we found that efficiency dropped by 20% after the 4th washing and drying cycle."

Basically, after 4 washes the cloth masks are once again useless..

MARCH 2018 - Effect of a surgical mask on six minute walking distance

"Introduction: Six minutes walking test (6MWT) is regularly used in pulmonology. To minimize the risk of cross-infection, some patients must wear surgical mask at rest and sometimes during exercise.

Results: Distance was not modified by the mask (P=0.99). Dyspnea variation was significantly higher with surgical mask (+5.6 vs. +4.6; P<0.001) and the difference was clinically relevant. No difference was found for the variation of other parameters.

Conclusion: Wearing a surgical mask modifies significantly and clinically dyspnea without influencing walked distance.

2018 - Comparison of the Filter Efficiency of Medical Nonwoven Fabrics against Three Different Microbe Aerosols

“We conclude that the filter efficiency test using the phi-X174 phage aerosol may overestimate the protective performance of nonwoven fabrics with filter structure compared to that against real pathogens such as the influenza virus.”

​May 2016 - “The surgical mask is a bad fit for risk reduction” (perspective)

“I propose that the surgical mask is a symbol that protects from the perception of risk by offering nonprotection to the public while causing behaviours that project risk into the future … In an annex to the Canadian pandemic influenza preparedness plan covering public health measures, the Public Health Agency of Canada (PHAC) does not recommend the use of masks by well individuals in pandemic situations, acknowledging that the mask has not been shown to be effective in such circumstances … The same annex on public health measures refers to the “false sense of security” that a mask can psychologically provide, but the converse is the real risk posed to a government unable to mollify its population.”

​Nov 2014 Effects of long-duration wearing of N95 respirator and surgical facemask: a pilot study

“In conclusion, there is an increase of nasal resistance upon removal of N95 respirator and surgical facemask after 3hours wearing which potentially due to nasal physiological changes, instead of the size of nasal airways. The nasal resistance was not recovered even after 1.5hours removal of respirator/facemask. In addition, the N95 respirator caused higher post-wearing nasal resistance than surgical facemask with different recovery routines.”

Feb 2014 - Disposable surgical face masks for preventing surgical wound infection in clean surgery

Lipp and Edwards reviewed the surgical literature in 2014 and found “no statistically significant difference in infection rates between the masked and unmasked group in any of the trials.”

Vincent and Edwards updated this review in 2016 and the conclusion was the same.

June 2014  - Dubious effect of surgical masks during surgery.  

Based on four studies and 6,006 patients, wrote that “none of the four studies found a difference in the number of post-operative infections whether you used a surgical mask or not.”

​November 8, 2012 - “Need Satisfaction and Well-Being: Testing Self-Determination Theory in Eight Cultures”. Journal of Cross-Cultural Psychology. 

"Self-Determination Theory (SDT) proposes that certain evolved psychological needs must be satisfied if individuals are to develop to their fullest potential, in the same way that plants require key nutrients to thrive (refs). SDT posits three universal needs: autonomy, competence, and relatedness. Autonomy involves the need to experience one’s behavior as freely chosen and volitional, rather than imposed by external forces. Competence involves the need to feel capable and effective in one’s actions. Relatedness involves the need for belonging, intimacy, and connectedness to others. SDT theorists view these needs as broad motivational tendencies that operate across life domains and contend that satisfaction of all three needs, not just one or two, is essential for well-being. Although the expression or means of satisfying these needs may vary across cultures, their satisfaction is viewed as essential for well-being in all cultures.”

​June 2010 - From Oxford U Simple Respiratory Protection—Evaluation of the Filtration Performance of Cloth Masks and Common Fabric Materials Against 20–1000 nm Size Particles.

"A shortage of disposable filtering facepiece respirators can be expected during a pandemic...

... To address the filtration performance of common fabric materials against nano-size particles including viruses, five major categories of fabric materials including sweatshirts, T-shirts, towels, scarves, and cloth masks were tested for polydisperse and monodisperse aerosols (20–1000 nm) at two different face velocities (5.5 and 16.5 cm s−1) and compared with the penetration levels for N95 respirator filter media. The results showed that cloth masks and other fabric materials tested in the study had 40–90% instantaneous penetration levels against polydisperse NaCl aerosols employed in the National Institute for Occupational Safety and Health particulate respirator test protocol at 5.5 cm s (1)."

​Oct.  2008  - Predominant Role of Bacterial Pneumonia as a Cause of Death in Pandemic Influenza: Implications for Pandemic Influenza Preparedness

Fauci conducted a study in which the major finding was that the majority of deaths from the Spanish Flu Pandemic of 1918/1919 was not from the influenza virus, but from bacterial infection, which we are today seeing an alarming rise in due to the social use of face coverings. The recommendation to wear face coverings is therefore a deliberate act of harm which you can no longer plead ignorance to.

​April 2006 - Masks may cause hypoxia

".. [2][3][4] Third, the reproducibility of fi t testing over time has been questioned. 58 Fourth, prolonged use of N95 respirators has been shown to cause headaches, 59 facial discomfort, 60 and may result in hypoxia. 61 Therefore, we seriously question whether poor compliance would negate any potential benefi t that might be gained from their use. ..."

​May 26, 2005 - “Effects of wearing N95 and surgical  facemasks on heart rate, thermal stress and subjective sensations”

“Discussion: This first randomized cross-over study assessing the effects of surgical masks and FFP2/N95 masks on cardiopulmonary exercise capacity yields clear results. Both masks have a marked negative impact on exercise parameters such as maximum power output (Pmax)  and the maximum oxygen uptake (VO2max/kg). FFP2/N95 masks show consistently more pronounced negative effects compared to surgical masks. Both masks significantly reduce pulmonary parameters at rest (FVC, FEV1, PEF) and at maximum load (VE, BF, TV). …

Pulmonary function: … The data of this study are obtained in healthy young volunteers, the impairment is likely to be significantly greater, e.g., in patients with obstructive pulmonary diseases (ref). From our data, we conclude that wearing a medical face mask has a significant impact on pulmonary parameters both at rest and during maximal exercise in healthy adults. 13

Cardiac function: … These data suggest a myocardial [relating to the muscular tissue of the heart] compensation for the pulmonary limitation in the healthy volunteers. In patients with impaired myocardial function, this compensation may not be possible.”

​Aug.2004- The physiological impact of wearing an N95 mask during hemodialysis as a precaution against SARS in patients with end-stage renal disease.

"Most patients with end-stage renal disease (ERSD) visiting our hospital for hemodialysis treatment during the SARS outbreak wore an N95 mask. Data on the physiological stress imposed by the wearing of N95 masks remains limited. This study investigated the physiological impact of wearing an N95 mask during hemodialysis (HD) on patients with ESRD.

Each patient wore a new N95 mask (3M Model 8210) during HD (4 hours). Vital signs, clinical symptoms and arterial blood gas measured before and at the end of HD were compared.

Results - Thirty nine patients (23 men; mean age, 57.2 years or 70%) were recruited for participation in the study. Seventy percent of the patients showed a reduction in partial pressure of oxygen (PaO2), and 19% developed various degrees of hypoxemia. Wearing an N95 mask significantly reduced the PaO2 level.... increased the respiratory rate.... increased the occurrence of chest discomfort.... and respiratory distress

CONCLUSION- Wearing an N95 mask for 4 hours during HD significantly reduced PaO2 and increased respiratory adverse effects in ESRD patients"

Nov 2001 -  Patient surgical masks during regional anesthesia. Hygenic necessity or dispensable ritual?

Lahme et al., in 2001, wrote that “surgical face masks worn by patients during regional anaesthesia, did not reduce the concentration of airborne bacteria over the operation field in our study. Thus they are dispensable.”

Nov2001 -  Patient surgical masks during regional anesthesia. Hygenic necessity or dispensable ritual?

 In five years of doing peritoneal dialysis without masks, rates of peritonitis in their unit were no different than rates in hospitals where masks were worn.

MEDICAL RELATED

2021

​February 5, 2021, (preprint) - “Impact of personal protective equipment use on health care workers’ physical health during the COVID-19 pandemic: a  systematic review and meta-analysis”.

A systematic review and meta-analysis to “assess the impact of PPE use on HCWs’ physical health during the COVID19 pandemic”. Their “review included 14 studies with 11746 HCWs from 16 counties”:

“Results (Abstract): A total of 343 healthcare professionals on the COVID-19 front lines participated in this study [New York City]. 314 respondents reported adverse effects from prolonged mask use with headaches being the most common complaint (n = 245). Skin breakdown was experienced by 175 respondents, and acne was reported in 182 respondents. Impaired cognition was reported in 81 respondents. … Some respondents experienced resolved side effects once masks were removed, while others required physical or medical intervention.

Conclusion (Abstract): Prolonged use of N95 and surgical masks by healthcare professionals during COVID-19 has caused adverse effects such as headaches, rash, acne, skin breakdown, and impaired cognition in the majority of those surveyed. …”

Jan 27th, 2021- “Facemask headache: a new nosographic entity among healthcare providers in COVID-19 era”. Neurological  Sciences

“Conclusion (Abstract): (A total of 155 healthcare workers responded to the questionnaire [Morocco].) The increased use of PPE, especially high filtrating masks during the COVID-19 outbreak is responsible for generating headaches in healthcare workers on frontline (62%) either De novo (33%) or as an aggravation of pre-existing one (29%). Working conditions have the greater impact on generating these types of headaches more than any pre-existing comorbidity.”

2020

December 30, 2020 - Mask-associated ‘de novo’ headache in healthcare workers during the COVID-19 pandemic

“Results: … Out of 241 [Pakistan], 68 participants (28.2%) reported de novo headaches since the start of the pandemic, with majority describing the headache as bilateral in location ( n= 47, 69%), with pressure/heaviness in quality ( n = 31, 45.5%) and moderate in intensity ( n =45, 66%). … Out of the 68 participants with new-onset headaches, 16 (23.5%) stated that the headache started more than 2 hours after donning PPE, while 19 (27.9%) participants stated that the headache ended between 1-2 hours after doffing of PPE. Fifty-three respondents (77.9%) experienced the headaches for 4 or less days per month. …”

December 14, 2020 - “Association of Personal Protective Equipment with De Novo Headaches In Frontline Healthcare Workers during COVID-19 Pandemic: A Cross-Sectional Study”. (DENTAL)

“…Several dermatoses [skin defects or lesions on the skin] have been reported due to PPE, such as pressure injury, contact dermatitis, pressure urticaria [hives] and exacerbation of pre‐existing skin diseases, including seborrheic dermatitis [scales] and acne.(2 refs) We report a preliminary data of HCW who experienced facial dermatoses due to the use of PPE. From 24 March 2020 to 16 April 2020, we came across with 43 patients comprising physicians, nurses and paramedical staff who involved (directly/indirectly) in managing patients of COVID‐19 [India]. … The most commonly noted dermatoses were irritant contact dermatitis (ICD; 39.5%) followed by friction dermatitis (25.5%). Goggles were the most common culprit agent among all PPE causing any one of the dermatoses (51.92%), followed by N95 masks (30.77%) and face shields (17.31%). Nasal bridge (63%) was the commonest anatomical site affected due to dermatoses followed by cheeks and chin (26%). However, there was a considerable overlap of different dermatoses with affliction of multiple sites. The most common symptom experienced by patients was pruritus [itchiness] (67.44%), while erythema [redness] (53.49%) was the most common sign observed. Interestingly, we observed two distinct dermatoses, i.e. whole face erythema (suffusion; 21%) attributed to doffing after a long shift and lip lick dermatitis due to constant licking of lips, because of feeling of intense thirst due to restricted fluid intake after donning PPE. The duration of wearing the goggles and mask, excessive sweating and ill‐fitting  masks, all were associated with increased sensation of irritation. Most of these dermatoses responded well to topical moisturizer, calamine lotion and oral antihistamines. Overall, 21% patients suffered from work absenteeism due to one of the dermatoses. Personal protective equipment‐induced dermatoses occur mainly due to the occlusion and hyper‐hydration effect of PPE and friction leading breach in the epidermal integrity.(ref) Recently, in China, authors noted a very high prevalence, i.e. 97% of skin damages in first‐line HCW fighting COVID‐19.(ref)”

​December 12, 2020 - “Personal Protective Equipment and Headaches: Cross-Sectional Study Among Moroccan Healthcare Workers During COVID- 19 Pandemic”.

Results (Abstract): (315 participants, Turkey) … New-onset symptom rate was 66% (n=208).

The most common new-onset symptom was headache (n=115, 36.5%) followed by breathing difficulty-palpitation (n=79, 25.1%) and dermatitis (n=64, 20.3%). Extended use of PPE,  smoking, and overweight were independently associated with developing new-onset symptoms.  A clear majority of symptomatic participants pointed out impact on working performance (193/208, 92.7%).

November 19, 2020 - “Symptoms associated with personal protective equipment among frontline healthcare professionals during the COVID-19 pandemic”. Disaster Medicine and Public Health  Preparedness

“Results (Abstract): The subjects are n=306, 244 women (79.7%), with an average age of 43 years (range 23–65) [Spain]. Of the total, 129 (42.2%) were physicians, 112 (36.6%) nurses and 65 (21.2%) other health workers. 208 (79.7%) used surgical masks and 53 (20.3%) used filter masks. Of all those surveyed, 158 (51.6%) presented ‘de novo’ headache. The occurrence of a headache was independently associated with the use of a filter mask, OR 2.14 (95% CI 1.07 to 4.32); being a nurse, OR 2.09 (95% CI 1.18 to 3.72) or another health worker, OR 6.94 (95% CI 3.01 to 16.04); or having a history of asthma, OR 0.29 (95% CI 0.09 to 0.89). According to the type of mask used, there were differences in headache intensity, and the impact of a headache in the subjects who used a filter mask was worse in all the aspects evaluated.

Conclusion (Abstract): The appearance of ‘de novo’ headache is associated with the use of filter masks and is more frequent in certain healthcare workers, causing a greater occupational, family, personal and social impact.”

September 2020 - “Effects of Prolonged Use of Facemask on Healthcare Workers in Tertiary Care Hospital During COVID-19 Pandemic”. Indian J Otolaryngol Head Neck Surg 73, 59–65 (2021)

“Results (Abstract): A total of 158 healthcare workers participated in the study [Singapore].

 Out of 158 respondents, 128 (81.0%) respondents developed de novo PPE-associated headaches. A pre-existing primary headache diagnosis (OR = 4.20, 95% CI 1.48-15.40; P = .030) and combined PPE usage for >4 hours per day (OR 3.91, 95% CI 1.35-11.31; P = .012) were independently associated with de novo PPE-associated headaches. Since COVID-19 outbreak, 42/46 (91.3%) of respondents with pre-existing headache diagnosis either "agreed" or "strongly agreed" that the increased PPE usage had affected the control of their background headaches, which affected their level of work performance.

​Conclusion (Abstract): Most healthcare workers develop de novo PPE-associated headaches or exacerbation of their pre-existing headache disorders.

August 13, 2020 - “Personal protective equipment against COVID-19: Vital for surgeons, harmful for patients?”, The American Journal of Surgery.

On 13 August 2020, the surgeons Frountzas et al. warned that COVID-19 enthusiasm for imposing personal protective equipment (PPE) on surgeons could put surgery patients at risk (the equivalent can be said of train, tram, and bus drivers, and a large sector of workers servicing the public):

“Either in the case of a second lockdown or not, the safety of PPE use against COVID-19 for surgeons should be investigated. All parts of PPE increase surgeon's body temperature and sweating, leading to an impairment of surgeon's comfort, especially during prolonged and complicated surgical procedures. As mentioned above, PPE seems to be associated with important side effects, like dermatoses and headaches for healthcare workers. The PPE-associated discomfort and side effects during surgery may increase surgeons' anxiety and fatigue while performing difficult operations.”

July 30, 2020 - Headaches, Personal Protective Equipment, and Psychosocial Factors Associated With COVID‐19 Pandemic (Comments, Observations, and Rebuttals)

"The study carried out by Ong et al.1 is noteworthy for the high level of clinical detail and the originality of the observation. The topographical relationship between the points of skin contact of the N95 face mask as well as protective eyewear with headache is novel and suggestive, and could give indications for the technical improvement of the devices. However, this research has some weaknesses, which only subsequent investigations can clarify.

In workplaces, where no pollution problems are reported, a significant share of indoor workers (6% of males, 9% of females) suffer “often, at least once a week” from headaches attributed to the working environment.2 This symptom is significantly associated with occupational stress.3 The individual characteristics of workers, in particular anxiety and depression, significantly influence the reporting of headache.4 Among health care workers, headache is associated with occupational stress5 and with sleep problems,6 as well as with anxiety and depression that were significantly increased during the COVID‐19 pandemics.7

​This study did not take into account these variables. This may be a major limitation because the study population was drawn from high‐risk hospital areas such as isolation wards (designated as “pandemic wards”), the emergency rooms and medical intensive care unit. In these settings, workers are highly likely to experience emotional overload. The association between Personal Protective Equipment (PPE) and headache could be, therefore, spurious and the real factor should be sought among the psychosocial factors associated with the pandemic.

Furthermore, the study is entirely based on what workers remember of the situation before the epidemic, and this inevitably exposes to a possible recall bias.

​We are convinced that the association between PPE and headache is worthy of controlled longitudinal studies, which compare different types of PPE and take into account all confounding factors."

​June 1, 2020 - “Adverse Effects of Prolonged Mask Use among Healthcare Professionals during COVID-19”. Journal of Infectious Disease and  Epidemiology 

“Abstract:  … All participants wore either surgical masks or N95 respirators for a minimum of 4 h per day [India]. … A total of 250 healthcare workers participated in the study …  The acquired results were excessive sweating around the mouth accounting to 67.6%, difficulty in breathing on exertion 58.2%, acne 56.0% and itchy nose 52.0%. This study suggests that prolonged use of facemasks induces difficulty in breathing on exertion and excessive sweating around the mouth to the healthcare workers which results in poorer adherence and increased risk of susceptibility to infection.”

May 21, 2020 - Universal Masking in Hospitals in the Covid-19 Era

“We know that wearing a mask outside health care facilities offers little, if any, protection from infection. Public health authorities define a significant exposure to Covid-19 as face-to-face contact within 6 feet with a patient with symptomatic Covid-19 that is sustained for at least a few minutes (and some say more than 10 minutes or even 30 minutes). The chance of catching Covid-19 from a passing interaction in a public space is therefore minimal. In many cases, the desire for widespread masking is a reflexive reaction to anxiety over the pandemic.

It is also clear that masks serve symbolic roles. Masks are not only tools, they are also talismans that may help increase health care workers’ perceived sense of safety, well-being, and trust in their hospitals. Although such reactions may not be strictly logical, we are all subject to fear and anxiety, especially during times of crisis. One might argue that fear and anxiety are better countered with data and education than with a marginally beneficial mask, particularly in light of the worldwide mask shortage, but it is difficult to get clinicians to hear this message in the heat of the current crisis. Expanded masking protocols’ greatest contribution may be to reduce the transmission of anxiety, over and above whatever role they may play in reducing transmission of Covid-19. “

​May 12, 2020 - Personal protective equipment induced facial dermatoses in healthcare workers managing Coronavirus disease 2019 (Letter to the Editor)

“The most commonly noted dermatoses were irritant contact dermatitis (ICD; 39.5%) followed by friction dermatitis (25.5%). Goggles were the most common culprit agent among all PPE causing any one of the dermatoses (51.92%), followed by N95 masks (30.77%) and face shields (17.31%). Nasal bridge (63%) was the commonest anatomical site affected due to dermatoses followed by cheeks and chin (26%). However, there was a considerable overlap of different dermatoses with affliction of multiple sites. The most common symptom experienced by patients was pruritus (67.44%), while erythema (53.49%) was the most common sign observed. Interestingly, we observed two distinct dermatoses, i.e. whole face erythema (suffusion; 21%) attributed to doffing after a long shift and lip lick dermatitis due to constant licking of lips, because of feeling of intense thirst due to restricted fluid intake after donning PPE. The duration of wearing the goggles and mask, excessive sweating and ill-fitting masks, all were associated with increased sensation of irritation.”

May 2020 -  “Headaches Associated With Personal Protective Equipment - A Cross-Sectional Study Among Frontline Healthcare Workers During COVID-19”. Headache: The Journal of Head and Face Pain. 

“Conclusion: Most healthcare workers develop de novo PPE-associated headaches or exacerbation of their pre-existing headache disorders.”

Mar 2020 Adverse Effects of Prolonged Mask Use among Healthcare Professionals during COVID-19 (Survey)

"Results"

A total of 343 healthcare professionals on the COVID-19 front lines participated in this study. The majority were female (n = 315) and 227 were located in New York City. 225 respondents identified as White, 34 as Hispanic, 23 as African American, and 61 as "other" ethnicity. 314 respondents reported adverse effects from prolonged mask use with headaches being the most common complaint (n = 245). Skin breakdown was experienced by 175 respondents, and acne was reported in 182 respondents. Impaired cognition was reported in 81 respondents. Previous history of headaches (n = 98), skin sensitivity (n = 164), and acne (n = 121) were found in some respondents. Some respondents experienced resolved side effects once masks were removed, while others required physical or medical intervention.

"Conclusion"

Prolonged use of N95 and surgical masks by healthcare professionals during COVID-19 has caused adverse effects such as headaches, rash, acne, skin breakdown, and impaired cognition in the majority of those surveyed. As a second wave of COVID-19 is expected, and in preparation for future pandemics, it is imperative to identify solutions to manage these adverse effects. Frequent breaks, improved hydration and rest, skin care, and potentially newly designed comfortable masks are recommendations for future management of adverse effects related to prolonged mask use."

Pre-Covid

June 2015- As for surgeons wearing masks? Well, of course but the primary reason is to prevent blood splatter and not infection -

“Given that there is no evidence that they cause any harm either, proponents would rather err on the side of caution and encourage their continued use, stressing that there is no room for complacency when it comes to ensuring patient safety.25

Another unavoidable aspect of this debate is that of public perception. In the public psyche, facemasks have become so strongly associated with safe and proper surgical practice that their disposal could cause unnecessary patient distress. 

It is important not to construe an absence of evidence for effectiveness with evidence for the absence of effectiveness. While there is a lack of evidence supporting the effectiveness of facemasks, there is similarly a lack of evidence supporting their ineffectiveness. With the information currently available, it would be imprudent to recommend the removal of facemasks from surgery. Instead, in the medical field where common practice can so easily become dogma, it is necessary to recognzse the constant need to maintain a healthy scepticism towards established beliefs and to periodically re-evaluate and critically assess their scientific merit.”

June 17, 2015 - “Unmasking the surgeons: the evidence base behind the use of facemasks in surgery”

"overall there is a lack of substantial evidence to support claims that face masks protect either patient or surgeon from infectious contamination"

Sept 2013 -  Surgical attire and the operating room: role in infection prevention 

An investigated the necessity of scrubs, masks and head coverings in the operating room and concluded that “there is no evidence that these measures reduce the prevalence of surgical site infection.”

Mar 2010 - Use of face masks by non-scrubbed operating room staff: a randomized controlled trial

“Conclusion: Surgical site infection rates did not increase when non-scrubbed operating room personnel did not wear a face mask.”

​June 1, 2009 - Use of surgical face masks to reduce the incidence of the common cold among health care workers in Japan: a randomized controlled trial

“Results: Thirty-two health care workers completed the study, resulting in 2464 subject days. There were 2 colds during this time period, 1 in each group. Of the 8 symptoms recorded daily, subjects in the mask group were significantly more likely to experience headache during the study period (P < .05). Subjects living with children were more likely to have high cold severity scores over the course of the study.

Conclusion: Face mask use in health care workers has not been demonstrated to provide benefit in terms of cold symptoms or getting colds. A larger study is needed to definitively establish non-inferiority of no mask use.

​Apr-June 2009 - Does evidence based medicine support the effectiveness of surgical facemasks in preventing postoperative wound infections in elective surgery? 

 A systematic literature review in 2009 and found that “no significant difference in the incidence of postoperative wound infection was observed between masks groups and groups operated with no masks.”

May 2008 - Surgical mask filter and fit performance (DENTAL)

Methods: Filter penetration was measured for at least 3 replicates of 9 surgical masks using mono disperse latex sphere aerosols (0.895, 2.0, and 3.1 micron) at 6 L/min and 0.075-micron sodium chloride particles at 84 L/min. Facial fit was measured on 20 subjects for the 5 masks with lowest particle penetration, using both qualitative and quantitative fit tests.

Results: Masks typically used in dental settings collected particles with significantly lower efficiency than those typically used in hospital settings. All subjects failed the unassisted qualitative fit test on the first exercise (normal breathing). Eighteen subjects failed the assisted qualitative fit tests; 60% failed on the first exercise. Quantitative fit factors ranged from 2.5 to 9.6.

Conclusion: None of these surgical masks exhibited adequate filter performance and facial fit characteristics to be considered respiratory protection devices.

​July 1, 1991 - Surgical face masks in modern operating rooms—a costly and unnecessary ritual

“Oral microbial flora dispersed by unmasked male and female volunteers standing one metre from the table failed to contaminate exposed settle plates placed on the table. The wearing of face masks by non-scrubbed staff working in an operating room with forced ventilation seems to be unnecessary."

May 1991 - Postoperative wound infections and surgical face masks: A controlled study

“It has never been shown that wearing surgical face masks decreases postoperative wound infections. 'On the contrary, a 50% decrease has been reported after omitting face masks......

After 1,537 operations performed with face masks, 73 (4.7%) wound infections were recorded and, after 1,551 operations performed without face masks, 55 (3.5%) infections occurred. This difference was not statistically significant (p> 0.05) and the bacterial species cultured from the wound infections did not differ in any way, which would have supported the fact that the numerical difference was a statistically “missed” difference.

These results indicate that the use of face masks might be reconsidered. "

1981 - “Is a mask necessary in the operating theatre?”

(pg 391 first paragraph under Table 1)

"There was no increase in wound infections be interesting to see whether comparable results when masks were discarded in I980; in fact are obtained in emergency, orthopaedic, or designed only to see whether wound infection in- there was a significant (p<o.o5) decrease." Note, their references date back as far as 1905.

When looking at the data from the UK for  Week 42-51, Pfizer’s Claim of 95% efficacy actually demonstrates the complete opposite - negative efficacy.

First the preamble. Sorry about this but it’s important and contains some interesting facts and evidence which is lacking from our alleged un-elected“trusted” health shills.

Based on the Dec 30, 2020 study “Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine” from New England Journal of Medicine (NEJM) we were told: 

“A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6).” [1]

Here’s a little problem, the study that Pfizer lists as their landmark Phase 3 study enrolled 46,441 with a majority of the participants ranging from age 16-56.Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.”[2]

So what happened to the 2,983 people? It doesn’t look like a huge number but the reports coming out from various whistleblowers have stated that a statistically significant amount of the trial participants had an severe or serious adverse event aka, SAE. Were they excluded from the trials once they had an SAE with ZERO follow up which is a REQUIREMENT for the manufacturer and the manufacturers boast that they do rigorous follow ups. So what happened? Oh yeah, the trials turned out to be a disaster and they had to cover up their shortcomings.

Back to the NEJM “study”. In their conclusions, they later state that: 

“A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728 formerly known as C4591001, opens in new tab.)” [3]

Keep in mind that these trials were spread 166 different trial sites around the following countries exclusively to the US (38 states with California 13 , Florida 10, North Carolina 12, Ohio 10, Texas 17 trial sites respectively), Argentina (1), Brazil (2), Germany (6), South Africa (4) and Turkey(9). [4]. Ventavia is still on the list of approved CT sites.. Even after all of the bad pub they got from Brook Jackson [5]

These trials allegedly started recruiting April 30,2020 and the “Recruitment Status” is still set as “Recruiting” as of December 22,2021 [6].. Now I’m no genius or psychic but if they are still recruiting for the same trial which is already in the general populous.

They have 1 trial which has been completed. Allegedly. NCT04816669

“A PHASE 3, RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MULTIPLE FORMULATIONS OF THE VACCINE CANDIDATE BNT162B2 AGAINST COVID 19 IN HEALTHY ADULTS 18 THROUGH 55 YEARS OF AGE”
There are a few issues with this study:
1. Phase 3 trials are supposed to include thousands to 10’s of thousands of participants of all walks, shapes and sizes to ensure there are no complications from your Phase 1 (healthy people) or your Phase 2 (older and/or target populations). Instead, they had 629. Their original estimate was 1,100 participants. 

2. The previous length of the trials, excluding the USUAL, but blatantly skipped, Animal Trials (4-5 years) should’ve been at least 4 years, this was completed in approximately 8 months (April 1 - Dec 1, 2021). However, you also have to factor in the “recruiting period” which usually takes 2-3 months.

3. “Observer-Blind” is low on the totem pole (6th @ 0.62%) when it comes to clinical trials. Compare that to double blind (77.71% of single blind (9,29%) which can be found on page 25/47. [8]

4. Since the trials were unblinded 2x’s (Vantavia and Pfizer admitting to the FDA 2x’s that they were unblinding the trials last January 2021. The risk of bias is dangerous.

5. It was allegedly “randomized and they had a triple “masking” protocol in place (Participants, Care Provider and Investigator).. Oh boy, lets the germs spread from those useless “ritualistic shame muzzles”.

6. When you look at the trial “Outcome Measures”, they state in their “completed trial" that they are supposed to look for and report local reactions, systemic events, adverse events and serious adverse events for 7 days after both doses and not the 2nd dose, yet the data from what happened within 7 days of either dose is not reported. Why not?

Ok. Enough of the preamble.

If anyone reading this has listened to my bitchute channel recently, you would’ve found a couple of calls to both the Public Health Agency of Canada (PHAC) and to the BC Governments Covid-19 “complex questions line asking for the trial data for 5-11 year olds in Canada from trials actually preformed in CANADA. Neither group were able to answer my query or the other queries which I will add in another blog or whatever the hell this substack thingy is. ;)

The “Clinical Trials” info from Pfizer’s documentation show that Pfizer DID NOT PERFORM ANY CLINICAL TRIALS IN CANADA BEFORE THE DEC. 2020 ROLLOUT. This is paramount and also very dangerous for Health Canada and other countries which did not participate in the trials before unleashing these bio-weapons on society. Why? Easy. How can any “Health Agency” be able to prove that they were effective, or safe, or to ensure that sites were up to code (Brook Jackson - Ventavia Whistleblower for the Pfizer trials in Texas says hi), or if any SAE’s happened.

I wanted to do a breakdown of the Canadian data but I trust their “modelling data” as much as I trust a fat kid with a bowl of candy.. Or even Chunky Shoes Henry, Dr Goiter Tam, or any elected health official in this country. They are all corrupt shills and deserve to be sentenced to death without a trial as the taxpayers have footed the bill for too long. This may sound extreme and in no way am I supporting any violence against another human but 1 extreme deserves another. I digress no further.

Based on the data coming out of the UK from weeks 42-51, there is an elephant in the room when it comes to “efficacy”. The correct label should be “negative efficacy” as I will outline below. The CDC uses the term “Vaccine Efficacy” which looks something like this:

Risk among unvaccinated group − risk among vaccinated group —————————————————————————

Risk among unvaccinated group

OR: 1 − risk ratio

[9]. This is also called the “risk difference” or “excess risk”..

Hopefully, many of you have already looked into Absolute Risk Reduction (ARR) vs. Relative Risk Reduction (RRR) . What I’ve discovered makes RRR on it’s own look like a disaster especially after you see the results from the UK the RRR is no where close their 95% claim. 

Important note. The Current data sets below are over 2000x’s greater than the Vaccine Trial Data. In laymen terms? More people were involved than the trials.

 What about the actual case breakdown per age group? I briefly mentioned the 70+ group. Here’s the complete breakdown for all age groups over 18. 

So please tell me how on earth Pfizer can claim a 95% efficacy based on the data and evidence above? Short answer? They can not! Remember, in 2020, the jabs were designed for the still yet to be isolated or purified Alpha Variant. Delta allegedly appeared Summer of 2021 and the alleged Omicron Variant appeared December 2021. All of the jabs that people were getting were from 2020 and early 2021 stocks as we don’t have any of the alleged BLA approved experimental bio-weapons contrary to the massive “branding campaign”. The bio weapons were useless against the alleged Delta variant and are even worse than the alleged Omicron variant. LOL.

After reviewing the info above, RRR vs ARR is not worthy of discussion as RRR has imploded in the governments faces globally thanks to the actual data. The fact that immunity significantly wanes shortly after the jab compared to any jab pre-covid is laughable as are “Vaccine Passports”, “Mandatory Vaccination” and anything else they want to con us with. These jabs won’t limit the spread of anything related to SARS-CoV-2 but will assist in the spread of the synthetic self-replicating spike protein in conjunction with all of the crap in the various toxic test kits plus the erosion of your Rights. Once again, Natural Herd Immunity wins 1st place - again!!!!! As does common sense.

My concern from these experimental gene therapy bio weapons are all of the adverse effects which were blatantly ignored during the clinical trials under the guise that you need more shots to “protect” you from an alleged virus with a near 100% recovery rate. Ok, I lied, 2 more:

1. exacerbating existing conditions which have nothing to do with this alleged virus thanks to increased cortisol levels thanks to all of the constant fear porn from the Puppet Media, Puppet Governments and their respective unelected health shills,

2. numerous issues with wearing those useless “Ritualistic Shame Muzzles.”

I will leave you with 1 little bit of info I found in Pfizer’s  C45910001 trial. I’ve bolded the various issues.
“2.3. Benefit/Risk Assessment

There is an ongoing global pandemic of COVID-19 with no preventative or therapeutic options available. While there were no data available from clinical trials on the use of BNT162 vaccines in humans at the outset of this study, available nonclinical data with these vaccines, and data from nonclinical studies and clinical trials with the same or related RNA components, or antigens, supported a favorable risk/benefit profile. Anticipated AEs after vaccination were expected to be manageable using routine symptom-driven standard of care as determined by the investigators and, as a result, the profile of these vaccine candidates supported initiation of this Phase 1/2/3 clinical study."[11]

Ok. pretty much the entire paragraph is a complete joke. There are plenty of preventative or therapeutic options [12]available for this alleged virus but there is no money in cheap therapies which have been used for decades. They admitted that there was “no data available prior to the onset of this study”.. blah.. blah blah.. Yet, they blatantly ignored all of the important warning signs but still “support the trials. WTAF?

Now friends, family and other loved ones are getting severely injured or dying as a DIRECT result of these experimental gene therapy BIO WEAPONS.

When will enough be enough and what are YOU going to do about it to be the change?

References

[1] https://www.nejm.org/doi/full/10.1056/NEJMoa2034577 

[2] https://www.pfizer.com/science/coronavirus/vaccine/about-our-landmark-trial

[3] https://www.nejm.org/doi/full/10.1056/NEJMoa2034577

[4] https://clinicaltrials.gov/ct2/show/NCT04368728 

[5] https://www.bmj.com/content/375/bmj.n2635

[6] https://clinicaltrials.gov/ct2/show/NCT04368728 

[7]https://clinicaltrials.gov/ct2/show/NCT04816669term=C4591001&recrs=e&draw=2&r1

[8] http://www.biostatistici.it/wp-content/uploads/2018/12/05_GIACOMO_SIRI.pdf

[9] https://www.cdc.gov/csels/dsepd/ss1978/lesson3/section6.html

[10]https://www.gov.uk/government/publications/covid19vaccineweeklysurveillancereports 

[11] https://cdn.pfizer.com/pfizercom/2020-11/C4591001_Clinical_Protocol_Nov2020.pdf

[12] https://c19early.com/